0000917520-24-000061.txt : 20240506 0000917520-24-000061.hdr.sgml : 20240506 20240506160903 ACCESSION NUMBER: 0000917520-24-000061 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 93 CONFORMED PERIOD OF REPORT: 20240331 FILED AS OF DATE: 20240506 DATE AS OF CHANGE: 20240506 FILER: COMPANY DATA: COMPANY CONFORMED NAME: INTEGRA LIFESCIENCES HOLDINGS CORP CENTRAL INDEX KEY: 0000917520 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 510317849 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-26224 FILM NUMBER: 24917555 BUSINESS ADDRESS: STREET 1: 1100 CAMPUS ROAD CITY: PRINCETON STATE: NJ ZIP: 08540 BUSINESS PHONE: 6092750500 MAIL ADDRESS: STREET 1: 1100 CAMPUS ROAD CITY: PRINCETON STATE: NJ ZIP: 08540 FORMER COMPANY: FORMER CONFORMED NAME: INTEGRA LIFESCIENCES CORP DATE OF NAME CHANGE: 19950614 10-Q 1 iart-20240331.htm 10-Q iart-20240331
false2024Q10000917520December 310.0135739P6Y00009175202024-01-012024-03-3100009175202024-05-03xbrli:sharesiso4217:USD00009175202023-01-012023-03-31iso4217:USDxbrli:shares00009175202024-03-3100009175202023-12-3100009175202022-12-3100009175202023-03-310000917520us-gaap:CommonStockMember2023-12-310000917520us-gaap:TreasuryStockCommonMember2023-12-310000917520us-gaap:AdditionalPaidInCapitalMember2023-12-310000917520us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310000917520us-gaap:RetainedEarningsMember2023-12-310000917520us-gaap:RetainedEarningsMember2024-01-012024-03-310000917520us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310000917520us-gaap:CommonStockMember2024-01-012024-03-310000917520us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310000917520us-gaap:TreasuryStockCommonMember2024-01-012024-03-310000917520us-gaap:CommonStockMember2024-03-310000917520us-gaap:TreasuryStockCommonMember2024-03-310000917520us-gaap:AdditionalPaidInCapitalMember2024-03-310000917520us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310000917520us-gaap:RetainedEarningsMember2024-03-310000917520us-gaap:CommonStockMember2022-12-310000917520us-gaap:TreasuryStockCommonMember2022-12-310000917520us-gaap:AdditionalPaidInCapitalMember2022-12-310000917520us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000917520us-gaap:RetainedEarningsMember2022-12-310000917520us-gaap:RetainedEarningsMember2023-01-012023-03-310000917520us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310000917520us-gaap:CommonStockMember2023-01-012023-03-310000917520us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310000917520us-gaap:TreasuryStockCommonMember2023-01-012023-03-310000917520us-gaap:CommonStockMember2023-03-310000917520us-gaap:TreasuryStockCommonMember2023-03-310000917520us-gaap:AdditionalPaidInCapitalMember2023-03-310000917520us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310000917520us-gaap:RetainedEarningsMember2023-03-310000917520iart:AcclarentInc.Member2023-12-012023-12-310000917520iart:AcclarentInc.Member2023-12-310000917520iart:AcclarentInc.Memberus-gaap:SubsequentEventMember2024-04-01xbrli:pure0000917520iart:AcclarentInc.Memberus-gaap:SubsequentEventMember2024-04-012024-04-0100009175202024-04-012024-03-310000917520iart:CodmanSpecialtySurgicalMemberiart:NeurosurgeryMember2024-01-012024-03-310000917520iart:CodmanSpecialtySurgicalMemberiart:NeurosurgeryMember2023-01-012023-03-310000917520iart:CodmanSpecialtySurgicalMemberiart:InstrumentsMember2024-01-012024-03-310000917520iart:CodmanSpecialtySurgicalMemberiart:InstrumentsMember2023-01-012023-03-310000917520iart:CodmanSpecialtySurgicalMember2024-01-012024-03-310000917520iart:CodmanSpecialtySurgicalMember2023-01-012023-03-310000917520iart:TissueTechnologiesMemberiart:RegenerativeSkinAndWoundMember2024-01-012024-03-310000917520iart:TissueTechnologiesMemberiart:RegenerativeSkinAndWoundMember2023-01-012023-03-310000917520iart:TissueTechnologiesMemberiart:PrivateLabelMember2024-01-012024-03-310000917520iart:TissueTechnologiesMemberiart:PrivateLabelMember2023-01-012023-03-310000917520iart:TissueTechnologiesMember2024-01-012024-03-310000917520iart:TissueTechnologiesMember2023-01-012023-03-310000917520iart:CodmanSpecialtySurgicalMember2023-12-310000917520iart:TissueTechnologiesMember2023-12-310000917520iart:CodmanSpecialtySurgicalMember2024-03-310000917520iart:TissueTechnologiesMember2024-03-310000917520us-gaap:ValuationTechniqueDiscountedCashFlowMemberus-gaap:MeasurementInputLongTermRevenueGrowthRateMember2024-01-012024-03-310000917520us-gaap:MeasurementInputDiscountRateMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2024-01-012024-03-310000917520iart:TissueTechnologiesMember2024-03-310000917520iart:CompletedTechnologyMember2024-03-310000917520us-gaap:CustomerRelationshipsMember2024-03-310000917520iart:TrademarksBrandNamesMember2024-03-310000917520us-gaap:TradeNamesMember2024-03-310000917520iart:SupplierRelationShipsMember2024-03-310000917520iart:AllOtherMember2024-03-310000917520iart:CompletedTechnologyMember2023-12-310000917520us-gaap:CustomerRelationshipsMember2023-12-310000917520iart:TrademarksBrandNamesMember2023-12-310000917520us-gaap:TradeNamesMember2023-12-310000917520iart:SupplierRelationShipsMember2023-12-310000917520iart:AllOtherMember2023-12-310000917520iart:CompletedTechnologyMember2024-01-012024-03-310000917520us-gaap:CustomerRelationshipsMember2024-01-012024-03-310000917520iart:CompletedTechnologyMember2023-01-012023-03-310000917520iart:CompletedTechnologyMemberiart:CompletedTechnologySurgiMendMember2024-03-310000917520iart:CompletedTechnologyPriMatrixMemberiart:CompletedTechnologyMember2024-03-310000917520iart:SeniorCreditFacilityMember2023-03-240000917520iart:TermLoanFacilityMemberus-gaap:SecuredDebtMember2023-03-240000917520us-gaap:RevolvingCreditFacilityMember2023-03-240000917520us-gaap:StandbyLettersOfCreditMember2023-03-240000917520iart:SwinglineLoanMember2023-03-240000917520iart:DebtCovenantPeriod1Memberiart:SeniorCreditFacilityMember2023-03-240000917520iart:DebtCovenantPeriod2Memberiart:SeniorCreditFacilityMember2023-03-240000917520iart:DebtCovenantPeriod3Memberiart:SeniorCreditFacilityMember2023-03-240000917520us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberiart:SeniorCreditFacilityMember2024-01-012024-03-310000917520us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMembersrt:MinimumMemberiart:SeniorCreditFacilityMember2024-01-012024-03-310000917520srt:MaximumMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberiart:SeniorCreditFacilityMember2024-01-012024-03-310000917520us-gaap:FederalFundsEffectiveSwapRateMemberiart:SeniorCreditFacilityMember2024-01-012024-03-310000917520srt:MinimumMemberiart:SeniorCreditFacilityMember2024-01-012024-03-310000917520srt:MaximumMemberiart:SeniorCreditFacilityMember2024-01-012024-03-310000917520us-gaap:RevolvingCreditFacilityMember2024-03-310000917520us-gaap:RevolvingCreditFacilityMember2023-01-012023-03-310000917520us-gaap:RevolvingCreditFacilityMember2023-12-310000917520iart:TermLoanFacilityMemberus-gaap:SecuredDebtMember2024-03-310000917520iart:TermLoanFacilityMemberus-gaap:SecuredDebtMember2023-12-310000917520iart:TermLoanFacilityMemberus-gaap:SecuredDebtMemberus-gaap:FairValueInputsLevel2Member2024-03-310000917520us-gaap:StandbyLettersOfCreditMemberiart:SeniorCreditFacilityMember2024-03-310000917520us-gaap:StandbyLettersOfCreditMemberiart:SeniorCreditFacilityMember2023-12-310000917520us-gaap:ConvertibleDebtMemberiart:TwoThousandTwentyFiveSeniorConvertibleNotesMember2020-02-040000917520us-gaap:ConvertibleDebtMemberiart:TwoThousandTwentyFiveSeniorConvertibleNotesMember2020-02-042020-02-040000917520us-gaap:ConvertibleDebtMemberiart:TwoThousandTwentyFiveSeniorConvertibleNotesMember2020-12-090000917520us-gaap:CallOptionMemberus-gaap:ConvertibleDebtMemberiart:TwoThousandTwentyFiveSeniorConvertibleNotesMember2020-02-042020-02-040000917520us-gaap:ConvertibleDebtMemberiart:TwoThousandTwentyFiveSeniorConvertibleNotesMember2024-03-3100009175202023-12-150000917520us-gaap:FairValueInputsLevel2Member2024-03-310000917520iart:InterestRateSwapDesignatedDecember132017Tranche2Memberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-03-310000917520iart:InterestRateSwapDesignatedDecember132017Tranche2Memberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000917520us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberiart:InterestRateSwapDesignatedDecember132017Tranche3Member2024-03-310000917520us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberiart:InterestRateSwapDesignatedDecember132017Tranche3Member2023-12-310000917520us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberiart:InterestRateSwapDesignatedOctober102018Tranche1Member2024-03-310000917520us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberiart:InterestRateSwapDesignatedOctober102018Tranche1Member2023-12-310000917520us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberiart:InterestRateSwapDesignatedOctober102018Tranche2Member2024-03-310000917520us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberiart:InterestRateSwapDesignatedOctober102018Tranche2Member2023-12-310000917520iart:InterestRateSwapDesignatedOctober102018Tranche3Memberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-03-310000917520iart:InterestRateSwapDesignatedOctober102018Tranche3Memberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000917520us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberiart:InterestRateSwapDesignatedDecember182018Tranche1Member2024-03-310000917520us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberiart:InterestRateSwapDesignatedDecember182018Tranche1Member2023-12-310000917520us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberus-gaap:CashFlowHedgingMemberiart:InterestRateSwapDesignatedDecember182018Tranche2Memberus-gaap:DesignatedAsHedgingInstrumentMember2024-03-310000917520us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberus-gaap:CashFlowHedgingMemberiart:InterestRateSwapDesignatedDecember182018Tranche2Memberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000917520iart:InterestRateSwapDesignatedDecember152020Tranche1Memberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-03-310000917520iart:InterestRateSwapDesignatedDecember152020Tranche1Memberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000917520us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberus-gaap:CashFlowHedgingMemberiart:InterestRateSwapDesignatedDecember152020Tranche2Memberus-gaap:DesignatedAsHedgingInstrumentMember2024-03-310000917520us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberus-gaap:CashFlowHedgingMemberiart:InterestRateSwapDesignatedDecember152020Tranche2Memberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000917520iart:InterestRateSwapDesignatedMarch312023Memberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-03-310000917520iart:InterestRateSwapDesignatedMarch312023Memberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000917520us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-03-310000917520us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000917520us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2024-01-012024-03-310000917520us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2023-01-012023-03-310000917520us-gaap:InterestRateSwapMember2024-03-310000917520us-gaap:CrossCurrencyInterestRateContractMemberiart:CodmanMember2023-09-22iso4217:CHF0000917520us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:ShortMemberiart:CodmanMember2023-09-220000917520us-gaap:CrossCurrencyInterestRateContractMember2020-12-210000917520us-gaap:CrossCurrencyInterestRateContractMember2024-01-012024-03-310000917520iart:CrossCurrencyInterestRateContractOneMemberus-gaap:LongMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberiart:CodmanMember2024-03-310000917520iart:CrossCurrencyInterestRateContractOneMemberus-gaap:LongMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberiart:CodmanMember2023-12-310000917520iart:CrossCurrencyInterestRateContractOneMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberiart:CodmanMember2024-03-310000917520iart:CrossCurrencyInterestRateContractOneMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberiart:CodmanMember2023-12-310000917520iart:CrossCurrencyInterestRateContractOneMemberus-gaap:ShortMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberiart:CodmanMember2024-03-310000917520iart:CrossCurrencyInterestRateContractOneMemberus-gaap:ShortMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberiart:CodmanMember2023-12-310000917520iart:CrossCurrencyInterestRateContractTwoMemberus-gaap:LongMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberiart:CodmanMember2024-03-310000917520iart:CrossCurrencyInterestRateContractTwoMemberus-gaap:LongMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberiart:CodmanMember2023-12-310000917520iart:CrossCurrencyInterestRateContractTwoMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberiart:CodmanMember2024-03-310000917520iart:CrossCurrencyInterestRateContractTwoMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberiart:CodmanMember2023-12-310000917520iart:CrossCurrencyInterestRateContractTwoMemberus-gaap:ShortMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberiart:CodmanMember2024-03-310000917520iart:CrossCurrencyInterestRateContractTwoMemberus-gaap:ShortMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberiart:CodmanMember2023-12-310000917520us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberiart:CodmanMember2024-03-310000917520us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberiart:CodmanMember2023-12-310000917520us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-01-012024-03-310000917520us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-01-012023-03-310000917520us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-01-012024-03-310000917520us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-01-012023-03-310000917520us-gaap:CrossCurrencyInterestRateContractMember2023-01-012023-03-310000917520us-gaap:CrossCurrencyInterestRateContractMember2024-03-310000917520iart:CrossCurrencyInterestRateContractOneMemberus-gaap:NetInvestmentHedgingMemberus-gaap:LongMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-03-31iso4217:EUR0000917520iart:CrossCurrencyInterestRateContractOneMemberus-gaap:NetInvestmentHedgingMemberus-gaap:LongMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000917520iart:CrossCurrencyInterestRateContractOneMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-03-310000917520iart:CrossCurrencyInterestRateContractOneMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000917520iart:CrossCurrencyInterestRateContractOneMemberus-gaap:ShortMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-03-310000917520iart:CrossCurrencyInterestRateContractOneMemberus-gaap:ShortMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000917520iart:CrossCurrencyInterestRateContractTwoMemberus-gaap:NetInvestmentHedgingMemberus-gaap:LongMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-03-310000917520iart:CrossCurrencyInterestRateContractTwoMemberus-gaap:NetInvestmentHedgingMemberus-gaap:LongMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000917520iart:CrossCurrencyInterestRateContractTwoMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-03-310000917520iart:CrossCurrencyInterestRateContractTwoMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000917520iart:CrossCurrencyInterestRateContractTwoMemberus-gaap:ShortMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-03-310000917520iart:CrossCurrencyInterestRateContractTwoMemberus-gaap:ShortMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000917520us-gaap:NetInvestmentHedgingMemberus-gaap:LongMemberiart:CrossCurrencyInterestRateContractThreeMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-03-310000917520us-gaap:NetInvestmentHedgingMemberus-gaap:LongMemberiart:CrossCurrencyInterestRateContractThreeMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000917520us-gaap:NetInvestmentHedgingMemberiart:CrossCurrencyInterestRateContractThreeMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-03-310000917520us-gaap:NetInvestmentHedgingMemberiart:CrossCurrencyInterestRateContractThreeMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000917520us-gaap:ShortMemberus-gaap:NetInvestmentHedgingMemberiart:CrossCurrencyInterestRateContractThreeMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-03-310000917520us-gaap:ShortMemberus-gaap:NetInvestmentHedgingMemberiart:CrossCurrencyInterestRateContractThreeMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000917520us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-03-310000917520us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000917520us-gaap:InterestIncomeMemberus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-01-012024-03-310000917520us-gaap:InterestIncomeMemberus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-01-012023-03-310000917520us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-01-012024-03-310000917520us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-01-012023-03-310000917520us-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:SubsequentEventMember2024-05-020000917520us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-03-310000917520us-gaap:CostOfSalesMemberus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-01-012024-03-310000917520us-gaap:CashFlowHedgingMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2024-03-310000917520us-gaap:CashFlowHedgingMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2023-12-310000917520us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-03-310000917520us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000917520us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-03-310000917520us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000917520us-gaap:OtherAssetsMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2024-03-310000917520us-gaap:OtherAssetsMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2023-12-310000917520us-gaap:OtherAssetsMemberus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-03-310000917520us-gaap:OtherAssetsMemberus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000917520us-gaap:OtherAssetsMemberus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-03-310000917520us-gaap:OtherAssetsMemberus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000917520us-gaap:DesignatedAsHedgingInstrumentMember2024-03-310000917520us-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000917520iart:AccruedExpensesAndOtherCurrentLiabilitiesMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2024-03-310000917520iart:AccruedExpensesAndOtherCurrentLiabilitiesMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2023-12-310000917520us-gaap:CrossCurrencyInterestRateContractMemberiart:AccruedExpensesAndOtherCurrentLiabilitiesMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-03-310000917520us-gaap:CrossCurrencyInterestRateContractMemberiart:AccruedExpensesAndOtherCurrentLiabilitiesMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000917520iart:AccruedExpensesAndOtherCurrentLiabilitiesMemberus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-03-310000917520iart:AccruedExpensesAndOtherCurrentLiabilitiesMemberus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000917520us-gaap:CrossCurrencyInterestRateContractMemberiart:AccruedExpensesAndOtherCurrentLiabilitiesMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-03-310000917520us-gaap:CrossCurrencyInterestRateContractMemberiart:AccruedExpensesAndOtherCurrentLiabilitiesMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000917520us-gaap:OtherLiabilitiesMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2024-03-310000917520us-gaap:OtherLiabilitiesMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2023-12-310000917520us-gaap:OtherLiabilitiesMemberus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-03-310000917520us-gaap:OtherLiabilitiesMemberus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000917520us-gaap:OtherLiabilitiesMemberus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-03-310000917520us-gaap:OtherLiabilitiesMemberus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000917520us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2023-12-310000917520us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2024-03-310000917520us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:InterestExpenseMember2023-12-310000917520us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:InterestExpenseMember2024-01-012024-03-310000917520us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:InterestExpenseMember2024-03-310000917520us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000917520us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-03-310000917520us-gaap:CostOfSalesMemberus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000917520us-gaap:CostOfSalesMemberus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-03-310000917520us-gaap:InterestIncomeMemberus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000917520us-gaap:InterestIncomeMemberus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-03-310000917520us-gaap:AccumulatedOtherComprehensiveIncomeMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000917520us-gaap:DesignatedAsHedgingInstrumentMember2024-01-012024-03-310000917520us-gaap:AccumulatedOtherComprehensiveIncomeMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-03-310000917520us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:InterestExpenseMember2022-12-310000917520us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:InterestExpenseMember2023-01-012023-03-310000917520us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:InterestExpenseMember2023-03-310000917520us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-12-310000917520us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-03-310000917520us-gaap:CostOfSalesMemberus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-01-012023-03-310000917520us-gaap:CostOfSalesMemberus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-03-310000917520us-gaap:InterestIncomeMemberus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-12-310000917520us-gaap:InterestIncomeMemberus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-03-310000917520us-gaap:AccumulatedOtherComprehensiveIncomeMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-12-310000917520us-gaap:DesignatedAsHedgingInstrumentMember2023-01-012023-03-310000917520us-gaap:AccumulatedOtherComprehensiveIncomeMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-03-310000917520us-gaap:CurrencySwapMemberus-gaap:NondesignatedMember2021-06-300000917520us-gaap:CurrencySwapMemberus-gaap:NondesignatedMember2024-03-310000917520us-gaap:CurrencySwapMemberus-gaap:NondesignatedMember2023-12-310000917520us-gaap:CurrencySwapMember2024-01-012024-03-310000917520us-gaap:CurrencySwapMember2023-01-012023-03-310000917520srt:MaximumMemberus-gaap:EmployeeStockOptionMember2024-01-012024-03-310000917520srt:DirectorMemberus-gaap:EmployeeStockOptionMember2024-01-012024-03-310000917520iart:EmployeeMemberus-gaap:EmployeeStockOptionMember2024-01-012024-03-310000917520srt:MinimumMemberus-gaap:EmployeeStockOptionMemberiart:DirectorsandCertainExecutiveOfficersMember2024-01-012024-03-310000917520srt:MaximumMemberus-gaap:EmployeeStockOptionMemberiart:DirectorsandCertainExecutiveOfficersMember2024-01-012024-03-310000917520us-gaap:RestrictedStockMember2024-01-012024-03-310000917520us-gaap:EmployeeStockOptionMember2024-03-310000917520us-gaap:EmployeeStockOptionMember2024-01-012024-03-310000917520iart:PerformanceStockAndRestrictedStockAwardsMember2024-01-012024-03-310000917520us-gaap:RestrictedStockMember2024-03-310000917520us-gaap:PerformanceSharesMember2024-01-012024-03-310000917520srt:ChiefExecutiveOfficerMember2024-01-012024-03-310000917520srt:ChiefExecutiveOfficerMembersrt:ScenarioForecastMember2024-01-012024-12-31iart:renewalOption0000917520us-gaap:RelatedPartyMember2023-01-012023-03-310000917520us-gaap:RelatedPartyMember2024-01-012024-03-310000917520us-gaap:BuildingMember2024-03-310000917520us-gaap:BuildingMember2023-12-310000917520us-gaap:VehiclesMember2024-03-310000917520us-gaap:VehiclesMember2023-12-310000917520iart:RelatedPartiesMember2024-03-310000917520iart:ThirdPartiesMember2024-03-310000917520us-gaap:RelatedPartyMemberiart:FiveYearOptionLeasePeriodOneMember2024-03-310000917520us-gaap:RelatedPartyMemberiart:FiveYearOptionLeasePeriodOneMember2024-01-012024-03-310000917520us-gaap:RelatedPartyMemberiart:FiveYearOptionLeasePeriodTwoMember2024-03-310000917520us-gaap:RelatedPartyMemberiart:FiveYearOptionLeasePeriodTwoMember2024-01-012024-03-3100009175202023-01-012023-12-3100009175202023-08-1500009175202023-10-1800009175202023-01-2600009175202023-06-300000917520iart:A2023ShareRepurchaseProgramMember2023-07-180000917520iart:A2022ShareRepurchaseProgramMember2022-04-260000917520iart:A2022ShareRepurchaseProgramMember2023-07-180000917520iart:A2023ShareRepurchaseProgramMember2024-03-3100009175202024-03-312024-03-3100009175202023-03-312023-03-310000917520us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-12-310000917520us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-12-310000917520us-gaap:AccumulatedTranslationAdjustmentMember2023-12-310000917520us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-01-012024-03-310000917520us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-01-012024-03-310000917520us-gaap:AccumulatedTranslationAdjustmentMember2024-01-012024-03-310000917520us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-03-310000917520us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-03-310000917520us-gaap:AccumulatedTranslationAdjustmentMember2024-03-310000917520us-gaap:OtherIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-01-012024-03-310000917520us-gaap:InterestIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-01-012024-03-31iart:Segmentiart:product0000917520us-gaap:OperatingSegmentsMemberiart:CodmanSpecialtySurgicalMember2024-01-012024-03-310000917520us-gaap:OperatingSegmentsMemberiart:CodmanSpecialtySurgicalMember2023-01-012023-03-310000917520us-gaap:OperatingSegmentsMemberiart:TissueTechnologiesMember2024-01-012024-03-310000917520us-gaap:OperatingSegmentsMemberiart:TissueTechnologiesMember2023-01-012023-03-310000917520us-gaap:OperatingSegmentsMember2024-01-012024-03-310000917520us-gaap:OperatingSegmentsMember2023-01-012023-03-310000917520us-gaap:CorporateNonSegmentMember2024-01-012024-03-310000917520us-gaap:CorporateNonSegmentMember2023-01-012023-03-310000917520country:US2024-01-012024-03-310000917520country:US2023-01-012023-03-310000917520srt:EuropeMember2024-01-012024-03-310000917520srt:EuropeMember2023-01-012023-03-310000917520srt:AsiaPacificMember2024-01-012024-03-310000917520srt:AsiaPacificMember2023-01-012023-03-310000917520iart:RestOfWorldMember2024-01-012024-03-310000917520iart:RestOfWorldMember2023-01-012023-03-310000917520us-gaap:FairValueInputsLevel3Memberiart:ArkisBioSciencesInc.Memberiart:ContingentConsiderationLiabilityMember2023-12-310000917520us-gaap:FairValueInputsLevel3Memberiart:DermaSciencesMemberiart:ContingentConsiderationLiabilityMember2023-12-310000917520us-gaap:FairValueInputsLevel3Memberiart:ACellMemberiart:ContingentConsiderationLiabilityMember2023-12-310000917520us-gaap:FairValueInputsLevel3Memberiart:SurgicalInnovationAssociatesIncMemberiart:ContingentConsiderationLiabilityMember2023-12-310000917520us-gaap:FairValueInputsLevel3Memberiart:ArkisBioSciencesInc.Memberiart:ContingentConsiderationLiabilityMember2024-01-012024-03-310000917520us-gaap:FairValueInputsLevel3Memberiart:DermaSciencesMemberiart:ContingentConsiderationLiabilityMember2024-01-012024-03-310000917520us-gaap:FairValueInputsLevel3Memberiart:ACellMemberiart:ContingentConsiderationLiabilityMember2024-01-012024-03-310000917520us-gaap:FairValueInputsLevel3Memberiart:SurgicalInnovationAssociatesIncMemberiart:ContingentConsiderationLiabilityMember2024-01-012024-03-310000917520us-gaap:FairValueInputsLevel3Memberiart:ArkisBioSciencesInc.Memberiart:ContingentConsiderationLiabilityMember2024-03-310000917520us-gaap:FairValueInputsLevel3Memberiart:DermaSciencesMemberiart:ContingentConsiderationLiabilityMember2024-03-310000917520us-gaap:FairValueInputsLevel3Memberiart:ACellMemberiart:ContingentConsiderationLiabilityMember2024-03-310000917520us-gaap:FairValueInputsLevel3Memberiart:SurgicalInnovationAssociatesIncMemberiart:ContingentConsiderationLiabilityMember2024-03-310000917520us-gaap:FairValueInputsLevel3Memberiart:ArkisBioSciencesInc.Memberus-gaap:OtherCurrentLiabilitiesMemberiart:ContingentConsiderationLiabilityMember2024-03-310000917520us-gaap:FairValueInputsLevel3Memberiart:DermaSciencesMemberus-gaap:OtherCurrentLiabilitiesMemberiart:ContingentConsiderationLiabilityMember2024-03-310000917520us-gaap:FairValueInputsLevel3Memberiart:ACellMemberus-gaap:OtherCurrentLiabilitiesMemberiart:ContingentConsiderationLiabilityMember2024-03-310000917520us-gaap:FairValueInputsLevel3Memberus-gaap:OtherCurrentLiabilitiesMemberiart:SurgicalInnovationAssociatesIncMemberiart:ContingentConsiderationLiabilityMember2024-03-310000917520us-gaap:FairValueInputsLevel3Memberiart:ArkisBioSciencesInc.Memberiart:ContingentConsiderationLiabilityMemberus-gaap:OtherNoncurrentLiabilitiesMember2024-03-310000917520us-gaap:FairValueInputsLevel3Memberiart:DermaSciencesMemberiart:ContingentConsiderationLiabilityMemberus-gaap:OtherNoncurrentLiabilitiesMember2024-03-310000917520us-gaap:FairValueInputsLevel3Memberiart:ACellMemberiart:ContingentConsiderationLiabilityMemberus-gaap:OtherNoncurrentLiabilitiesMember2024-03-310000917520us-gaap:FairValueInputsLevel3Memberiart:SurgicalInnovationAssociatesIncMemberiart:ContingentConsiderationLiabilityMemberus-gaap:OtherNoncurrentLiabilitiesMember2024-03-310000917520us-gaap:FairValueInputsLevel3Memberiart:ArkisBioSciencesInc.Memberiart:ContingentConsiderationLiabilityMember2022-12-310000917520us-gaap:FairValueInputsLevel3Memberiart:DermaSciencesMemberiart:ContingentConsiderationLiabilityMember2022-12-310000917520us-gaap:FairValueInputsLevel3Memberiart:ACellMemberiart:ContingentConsiderationLiabilityMember2022-12-310000917520us-gaap:FairValueInputsLevel3Memberiart:SurgicalInnovationAssociatesIncMemberiart:ContingentConsiderationLiabilityMember2022-12-310000917520us-gaap:FairValueInputsLevel3Memberiart:ArkisBioSciencesInc.Memberiart:ContingentConsiderationLiabilityMember2023-01-012023-03-310000917520us-gaap:FairValueInputsLevel3Memberiart:DermaSciencesMemberiart:ContingentConsiderationLiabilityMember2023-01-012023-03-310000917520us-gaap:FairValueInputsLevel3Memberiart:ACellMemberiart:ContingentConsiderationLiabilityMember2023-01-012023-03-310000917520us-gaap:FairValueInputsLevel3Memberiart:SurgicalInnovationAssociatesIncMemberiart:ContingentConsiderationLiabilityMember2023-01-012023-03-310000917520us-gaap:FairValueInputsLevel3Memberiart:ArkisBioSciencesInc.Memberiart:ContingentConsiderationLiabilityMember2023-03-310000917520us-gaap:FairValueInputsLevel3Memberiart:DermaSciencesMemberiart:ContingentConsiderationLiabilityMember2023-03-310000917520us-gaap:FairValueInputsLevel3Memberiart:ACellMemberiart:ContingentConsiderationLiabilityMember2023-03-310000917520us-gaap:FairValueInputsLevel3Memberiart:SurgicalInnovationAssociatesIncMemberiart:ContingentConsiderationLiabilityMember2023-03-310000917520us-gaap:FairValueInputsLevel3Memberiart:ArkisBioSciencesInc.Memberus-gaap:OtherCurrentLiabilitiesMemberiart:ContingentConsiderationLiabilityMember2023-03-310000917520us-gaap:FairValueInputsLevel3Memberiart:DermaSciencesMemberus-gaap:OtherCurrentLiabilitiesMemberiart:ContingentConsiderationLiabilityMember2023-03-310000917520us-gaap:FairValueInputsLevel3Memberiart:ACellMemberus-gaap:OtherCurrentLiabilitiesMemberiart:ContingentConsiderationLiabilityMember2023-03-310000917520us-gaap:FairValueInputsLevel3Memberus-gaap:OtherCurrentLiabilitiesMemberiart:SurgicalInnovationAssociatesIncMemberiart:ContingentConsiderationLiabilityMember2023-03-310000917520us-gaap:FairValueInputsLevel3Memberiart:ArkisBioSciencesInc.Memberiart:ContingentConsiderationLiabilityMemberus-gaap:OtherNoncurrentLiabilitiesMember2023-03-310000917520us-gaap:FairValueInputsLevel3Memberiart:DermaSciencesMemberiart:ContingentConsiderationLiabilityMemberus-gaap:OtherNoncurrentLiabilitiesMember2023-03-310000917520us-gaap:FairValueInputsLevel3Memberiart:ACellMemberiart:ContingentConsiderationLiabilityMemberus-gaap:OtherNoncurrentLiabilitiesMember2023-03-310000917520us-gaap:FairValueInputsLevel3Memberiart:SurgicalInnovationAssociatesIncMemberiart:ContingentConsiderationLiabilityMemberus-gaap:OtherNoncurrentLiabilitiesMember2023-03-310000917520iart:ArkisBioSciencesInc.Member2019-07-290000917520iart:ArkisBioSciencesInc.Memberiart:MilestonePaymentOneMember2019-07-290000917520iart:ArkisBioSciencesInc.Memberiart:MilestonePaymentTwoMember2019-07-290000917520iart:DermaSciencesMemberiart:BioDEarnoutPaymentsandMedihoneyEarnoutPaymentsMember2024-01-012024-03-310000917520iart:DermaSciencesMember2024-03-31iart:liability0000917520iart:ACellIncMember2021-01-200000917520iart:SurgicalInnovationAssociatesIncMember2022-12-060000917520iart:SurgicalInnovationAssociatesIncMember2022-12-062022-12-06iart:payment0000917520iart:SurgicalInnovationAssociatesIncMemberiart:RevenueBasedPerformanceMilestonesMember2022-12-060000917520iart:SurgicalInnovationAssociatesIncMemberiart:FDAApprovalOfPremarketApprovalMember2022-12-06

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 10-Q
 
(Mark One)
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2024
or
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from              to             
COMMISSION FILE NUMBER 000-26224
 
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
 
Delaware 51-0317849
(STATE OR OTHER JURISDICTION OF
INCORPORATION OR ORGANIZATION)		 (I.R.S. EMPLOYER
IDENTIFICATION NO.)
1100 Campus Road 08540
Princeton,New Jersey(ZIP CODE)
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES) 
Registrant's Telephone Number, Including Area Code: (609) 275-0500
Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report:
Securities registered pursuant to Section 12(b) of the Act:
TITLE OF EACH CLASSTRADING SYMBOLNAME OF EACH EXCHANGE ON WHICH REGISTERED
Common Stock, Par Value $.01 Per ShareIARTNasdaq Global Select Market
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).   Yes  ☒    No  ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer", "accelerated filer", "smaller reporting company", and "emerging growth company" in Rule 12b-2 of the Exchange Act.




Large accelerated filer☒Accelerated filer☐
Non-accelerated filer
☐  
Smaller reporting company☐
Emerging growth company☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ☐    No  ☒
The number of shares of the registrant’s Common Stock, $0.01 par value, outstanding as of May 3, 2024 was 78,799,694.
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
INDEX

 
 Page
Number


PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

INTEGRA LIFESCIENCES HOLDINGS CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
AND COMPREHENSIVE INCOME
(UNAUDITED)
(Dollars in thousands, except per share amounts)
 Three Months Ended March 31,
 20242023
Total revenue, net$368,872 $380,846 
Costs and expenses:
Cost of goods sold162,038 147,975 
Research and development26,965 26,724 
Selling, general and administrative165,798 166,657 
Intangible asset amortization10,107 3,108 
Total costs and expenses364,908 344,464 
Operating income3,964 36,382 
Interest income5,040 4,107 
Interest expense(13,624)(12,100)
Other (expense) income, net(610)1,389 
(Loss) income before income taxes(5,230)29,778 
(Benefit) provision for income taxes(1,949)5,552 
Net (loss) income$(3,281)$24,226 
Net (loss) income per share
Basic$(0.04)$0.30 
Diluted$(0.04)$0.29 
Weighted average common shares outstanding (See Note 13):
Basic77,735 81,871 
Diluted77,735 82,323 
Comprehensive income (See Note 14)
1,179 $21,028 

The accompanying unaudited notes are an integral part of these condensed consolidated financial statements.
3
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
(Dollars in thousands, except per share amounts)
March 31, 2024December 31, 2023
ASSETS
Current assets:
Cash and cash equivalents$591,906 $276,402 
Short-term investments71,194 32,694 
Trade accounts receivable, net of allowances of $5,050 and $4,879
241,092 259,327 
Inventories, net403,422 389,608 
Prepaid Expenses72,667 67,362 
Other Current Assets35,369 32,643 
Total current assets1,415,650 1,058,036 
Property, plant and equipment, net345,356 340,199 
Right of use asset - operating leases151,834 156,184 
Intangible assets, net1,022,609 1,067,833 
Goodwill1,040,235 1,055,462 
Deferred tax assets, net34,175 46,080 
Other assets68,365 58,194 
Total assets$4,078,224 $3,781,988 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Current portion of borrowings under senior credit facility$19,375 $14,531 
Current portion of lease liability - operating leases16,303 15,284 
Accounts payable, trade94,397 92,326 
Contract liabilities7,841 8,540 
Accrued compensation52,582 75,455 
Accrued expenses and other current liabilities111,896 100,844 
Total current liabilities302,394 306,980 
Long-term borrowings under senior credit facility1,171,036 825,563 
Long-term borrowings under securitization facility94,600 89,200 
Long-term convertible securities570,984 570,255 
Lease liability - operating leases170,082 166,849 
Deferred tax liabilities31,431 35,317 
Other liabilities139,745 199,940 
Total liabilities2,480,272 2,194,104 
Stockholders’ equity:
Preferred stock; no par value; 15,000 authorized shares; none outstanding
— — 
Common stock; $0.01 par value; 240,000 authorized shares; 91,484 and 90,920 issued at March 31, 2024 and December 31, 2023, respectively
915 909 
Additional paid-in capital1,310,527 1,302,484 
Treasury stock, at cost; 12,735 shares and 12,751 shares at March 31, 2024 and December 31, 2023, respectively
(646,422)(647,262)
Accumulated other comprehensive loss(10,646)(15,106)
Retained earnings943,578 946,859 
Total stockholders’ equity1,597,952 1,587,884 
Total liabilities and stockholders’ equity$4,078,224 $3,781,988 
The accompanying unaudited notes are an integral part of these condensed consolidated financial statements.
4

INTEGRA LIFESCIENCES HOLDINGS CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
(Dollars in thousands)
 Three Months Ended March 31,
 20242023
OPERATING ACTIVITIES:
Net (Loss) Income$(3,281)$24,226 
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization30,566 31,143 
Non-cash impairment charges$7,064 — 
Deferred income tax provision (benefit)(2,856)1,953 
Share-based compensation5,599 3,620 
Amortization of debt issuance costs and expenses associated with debt refinancing1,398 1,890 
Non-cash lease expense149 1,260 
Loss (gain) on disposal of property and equipment12 (23)
Change in fair value of contingent consideration and others456 4,699 
Changes in assets and liabilities:
Accounts receivable16,827 10,041 
Inventories(19,021)(25,423)
Prepaid expenses and other current assets(2,676)(2,164)
Other non-current assets339 (6,009)
Accounts payable, accrued expenses and other current liabilities(19,210)(4,984)
Contract liabilities(1,498)430 
Other non-current liabilities1,888 (14,503)
Net cash provided by operating activities15,756 26,156 
INVESTING ACTIVITIES:
Purchases of property and equipment(15,465)(13,704)
Purchases of Investments(38,500)— 
Net cash used in investing activities(53,965)(13,704)
FINANCING ACTIVITIES:
Proceeds from borrowings of long-term indebtedness370,500 10,200 
Payments on debt(15,100)(12,400)
Payment of debt issuance costs— (7,578)
Purchases of treasury stock— (150,000)
Proceeds from exercised stock options6,398 2,326 
Cash taxes paid in net equity settlement(3,122)(5,231)
Net cash provided by (used in) financing activities358,676 (162,683)
Effect of exchange rate changes on cash and cash equivalents(4,963)937 
Net increase (decrease) in cash and cash equivalents315,504 (149,294)
Cash and cash equivalents at beginning of period276,402 456,661 
Cash and cash equivalents at end of period$591,906 $307,367 
The accompanying unaudited notes are an integral part of these condensed consolidated financial statements.
5
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY
(UNAUDITED)
(Dollars in thousands)
Three Months Ended March 31, 2024
Common StockTreasury StockAdditional Paid-In CapitalAccumulated Other Comprehensive LossRetained EarningsTotal Equity
SharesAmountSharesAmount
Balance, January 1, 202490,920 $909 (12,751)$(647,262)$1,302,484 $(15,106)$946,859 $1,587,884 
Net loss— — — — — — (3,281)(3,281)
Other comprehensive income (loss), net of tax— — — — — 4,460 — 4,460 
Issuance of common stock through employee stock purchase plan23 — — — 965 — — 965 
Issuance of common stock for vesting of share based awards, net of shares withheld for taxes541 2 16 840 1,470 — — 2,312 
Share-based compensation— 4 — — 5,608 — — 5,612 
Accelerated shares repurchased— $— — — — $— — — 
Balance, March 31, 202491,484 $915 (12,735)$(646,422)$1,310,527 $(10,646)$943,578 $1,597,952 
Three Months Ended March 31, 2023
Common StockTreasury StockAdditional Paid-In CapitalAccumulated Other Comprehensive LossRetained EarningsTotal Equity
SharesAmountSharesAmount
Balance, January 1, 2023
90,476 $905 (6,823)$(362,862)$1,276,977 $10,265 $879,118 $1,804,403 
Net income— — — — — — 24,226 24,226 
Other comprehensive income (loss), net of tax— — — — — (3,198)— (3,198)
Issuance of common stock through employee stock purchase plan21 — — — 1,107 — — 1,107 
Issuance of common stock for vesting of share based awards, net of shares withheld for taxes316 1 16 846 (4,858)— — (4,011)
Share-based compensation— 2 — — 3,609 — — 3,611 
Accelerated shares repurchased— — (2,111)(119,662)(31,538)— — (151,200)
Balance, March 31, 2023
90,813 $908 (8,918)$(481,678)$1,245,297 $7,067 $903,344 $1,674,938 
The accompanying unaudited notes are an integral part of these condensed consolidated financial statements.
6
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

1. BASIS OF PRESENTATION
General
The terms “we,” “our,” “us,” “Company” and “Integra” refer to Integra LifeSciences Holdings Corporation, a Delaware corporation, and its subsidiaries unless the context suggests otherwise.
In the opinion of management, the March 31, 2024 unaudited condensed consolidated financial statements contain all adjustments (consisting only of normal recurring adjustments) necessary for a fair statement of the financial position, statement of changes in shareholders’ equity, results of operations and cash flows of the Company. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) have been condensed or omitted in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements for the year ended December 31, 2023 included in the Company’s Annual Report on Form 10-K. The December 31, 2023 consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by GAAP. Operating results for the three-month period ended March 31, 2024 are not necessarily indicative of the results to be expected for the entire year.
The preparation of consolidated financial statements is in conformity with GAAP, which requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, the disclosure of contingent liabilities, and the reported amounts of revenues and expenses. Significant estimates affecting amounts reported or disclosed in the condensed consolidated financial statements include allowances for doubtful accounts receivable and sales returns and allowances, net realizable value of inventories, valuation of intangible assets including amortization periods for acquired intangible assets, discount rates and estimated projected cash flows used to value and test impairments of long-lived assets and goodwill, estimates of projected cash flows and depreciation and amortization periods for long-lived assets, computation of taxes, valuation allowances recorded against deferred tax assets, the valuation of stock-based compensation, valuation of derivative instruments, valuation of contingent liabilities, the fair value of debt instruments and loss contingencies. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the current circumstances. Actual results could differ from these estimates.
Recent Accounting Pronouncements
In March 2020, the Financial Accounting Standards Board (“FASB”) issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting, and, in January 2021, subsequently amended the initial guidance in: ASU 2021-01, Reference Rate Reform (Topic 848): Scope (collectively, “Topic 848”). Topic 848 provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments apply only to contracts, hedging relationships, and other transactions that reference London Inter-Bank Offered Rate (“LIBOR”) or another reference rate expected to be discontinued because of reference rate reform. In December 2022, the FASB issued ASU 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848, which delayed the effective date from December 31, 2022 to December 31, 2024. The Alternative Reference Rates Committee, a group of private-market participants convened by the U.S. Federal Reserve Board and the New York Federal Reserve, has recommended the use of the Secured Overnight Financing Rate (“SOFR”) as a more robust reference rate alternative to LIBOR. On March 24, 2023, the Company entered into the seventh amendment and restatement (the “March 2023 Amendment”) of its Senior Credit Facility (the “Senior Credit Facility”) with a syndicate of lending banks with Bank of America, N.A., as Administrative Agent. In connection with the March 2023 Amendment, the Company replaced all LIBOR-based contracts with SOFR, which is calculated based on overnight transactions under repurchase agreements backed by Treasury securities. In addition, on April 17, 2023 the Company entered into an amendment (the “April 2023 Amendment”) of the Securitization Facility (as defined below) and amended the interest rate from LIBOR to SOFR indexed rate. (See Note 6, Debt). In March 2023, the Company entered into a basis swap where the Company receives Term SOFR and pays LIBOR to convert the portfolio of interest rate swaps from LIBOR to SOFR. Integra has elected to adopt the optional expedient under Topic 848, which will allow the interest rate swap hedging relationship to continue, without de-designation, due to the change in the indexed rate from LIBOR to SOFR.
7
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures which enhances the transparency of income tax disclosures by expanding annual disclosure requirements related to the rate reconciliation and income taxes paid. The amendments are effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company does not plan to early adopt and is currently evaluating this ASU to determine its impact on the Company’s disclosures.
In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which updates reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. The amendments are effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company does not plan to early adopt and is currently evaluating this ASU to determine its impact on the Company’s disclosures.
There are no other recently issued accounting pronouncements that are expected to have any significant effect on the Company’s financial position, results of operations or cash flows.
2. ACQUISITIONS AND DIVESTITURES
Acquisition of Acclarent Inc.
In December 2023, the Company entered into a definitive agreement to acquire Acclarent, Inc. (“Acclarent”) from Ethicon, Inc., a subsidiary of Johnson & Johnson, for $275.0 million in cash at closing, subject to customary purchase price adjustments, and an additional $5.0 million contingent upon the achievement of a regulatory milestone, which was achieved prior to closing. Acclarent is a developer and marketer of medical devices used in Ear, Nose, Throat (“ENT”) procedures. Acclarent’s results of operations will be reported in the Company’s Codman Specialty Surgical reportable segment from the date of acquisition.
On April 1, 2024, the Company successfully completed the acquisition of 100% of Acclarent for approximately $282.0 million in cash, subject to customary adjustments set forth in the purchase agreement related to working capital balances transferred to the Company. To facilitate the completion of the acquisition of Acclarent, the Company drew from the revolving portion of the Senior Credit Facility during the three months ended March 31, 2024. For further detail on the Company’s additional borrowings, see Note 6. Debt.
3. REVENUES FROM CONTRACTS WITH CUSTOMERS
Summary of Accounting Policies on Revenue Recognition
Revenue is recognized upon the transfer of control of promised products or services to the customers in an amount that reflects the consideration the Company expects to receive in exchange for those products and services.
Performance Obligations
The Company’s performance obligations consist mainly of transferring control of goods and services identified in the contracts, purchase orders, or invoices. The Company has no significant multi-element contracts with customers.
Significant Estimates
Usage-based royalties and licenses are estimated based on the provisions of contracts with customers and recognized in the same period that the royalty-based products are sold by the Company’s strategic partners. The Company estimates and recognizes royalty revenue based upon communication with licensees, historical information, and expected sales trends. Differences between actual reported licensee sales and those that were estimated are adjusted in the period in which they become known, which is typically the following quarter. Historically, such adjustments have not been significant.
The Company estimates returns, price concessions, and discount allowances using the expected value method based on historical trends and other known factors. Rebate allowances are estimated using the most likely method based on each customer contract.
The Company’s return policy, as set forth in its product catalogs and sales invoices, requires review and authorization in advance prior to the return of product. Upon the authorization, a credit will be issued for the goods returned within a set amount of days from the shipment, which is generally 90 days.
8
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
In 2023, due to the voluntary recall of all products manufactured at the Boston facility, including PriMatrix®, SurgiMend®, Revize™, and TissueMend™ (the “Boston recall”), the Company recorded a total of $18.7 million provision for product returns. As of March 31, 2024, the Company has credited $16.7 million to customers and holds a remaining return reserve of $2.0 million.
The Company disregards the effects of a financing component if the Company expects, at contract inception, that the period between the transfer and customer payment for the goods or services will be one year or less. The Company has no significant revenues recognized on payments expected to be received more than one year after the transfer of control of products or services to customers.
Contract Asset and Liability
Revenues recognized from the Company’s private label business that are not invoiced to the customers as a result of recognizing revenue over time are recorded as a contract asset included in the other current assets account in the consolidated balance sheets.
Other operating revenues may include fees received under service agreements. Non-refundable fees received under multiple-period service agreements are recognized as revenue as the Company satisfies the performance obligations to the other party. A portion of the transaction price allocated to the performance obligations to be satisfied in the future periods is recognized as contract liability.
The following table summarizes the changes in the contract asset and liability balances for the three months ended March 31, 2024:
Dollars in thousandsTotal
Contract Asset
Contract asset, January 1, 2024
$9,233 
Transferred to trade receivable from contract asset included in beginning of the year contract asset(9,233)
Contract asset, net of transferred to trade receivables on contracts during the period7,478 
Contract asset, March 31, 2024
$7,478 
Contract Liability
Contract liability, January 1, 2024
$16,252 
Recognition of revenue included in beginning of year contract liability(3,523)
Contract liability, net of revenue recognized on contracts during the period2,017 
Foreign currency translation(63)
Contract liability, March 31, 2024
$14,683 
At March 31, 2024, the short-term portion of the contract liability of $7.8 million and the long-term portion of $6.9 million are included in current liabilities and other liabilities, respectively, in the consolidated balance sheets.
As of March 31, 2024, the Company is expected to recognize revenue of approximately 53% of unsatisfied (or partially unsatisfied) performance obligations as revenue within 12 months, with the remaining balance to be recognized thereafter.
Shipping and Handling Fees
The Company elected to account for shipping and handling activities as a fulfillment cost rather than a separate performance obligation. Amounts billed to customers for shipping and handling are included as part of the transaction price and recognized as revenue when control of underlying products is transferred to the customer. The related shipping and freight charges incurred by the Company are included in the cost of goods sold.
Product Warranties
Certain of the Company’s medical devices, including monitoring systems and neurosurgical systems, are designed to operate over long periods of time. These products are sold with warranties which may extend for up to two years from the date of purchase. The warranties are not considered a separate performance obligation. The Company estimates its product warranties using the expected value method based on historical trends and other known factors. The Company includes them in accrued expenses and other current liabilities in the consolidated balance sheet.
9
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
Taxes Collected from Customers
The Company elected to exclude from the measurement of the transaction price all taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction and collected by the entity from a customer.
Disaggregated Revenue
The following table presents revenues disaggregated by the major sources of revenues for the three months ended March 31, 2024 and 2023 (dollar amounts in thousands):
Three Months Ended March 31, 2024Three Months Ended March 31, 2023
Neurosurgery$202,268 $192,870 
Instruments54,166 55,266 
Total Codman Specialty Surgical256,434 248,136 
Wound Reconstruction and Care80,877 100,940 
Private Label31,561 31,770 
Total Tissue Technologies112,438 132,710 
Total revenue$368,872 $380,846 
See Note 15, Segment and Geographical Information, for details of revenues based on the location of the customer.
4. INVENTORIES
Inventories, net consisted of the following:
Dollars in thousandsMarch 31, 2024December 31, 2023
Finished goods$192,287 $196,402 
Work in process83,334 74,035 
Raw materials127,801 119,171 
Total inventories, net$403,422 $389,608 
5. GOODWILL AND OTHER INTANGIBLE ASSETS
Goodwill
Changes in the carrying amount of goodwill for the three-month period ended March 31, 2024 were as follows:
Dollars in thousandsCodman Specialty
Surgical		Tissue TechnologiesTotal
Goodwill at December 31, 2023$666,937 $388,525 $1,055,462 
Foreign currency translation(9,622)(5,605)(15,227)
Goodwill at March 31, 2024
$657,315 $382,920 $1,040,235 
The Company tests goodwill and intangible assets with indefinite lives for impairment annually in the third quarter in accordance with FASB ASC Topic 350, Intangibles—Goodwill and Other (“ASC 350”). Additionally, the Company may perform interim tests if an event occurs or circumstances change that could potentially reduce the fair value of a reporting unit or indefinite lived intangible asset below its carrying amount. The carrying value of each reporting unit is determined by assigning the assets and liabilities, including the existing goodwill and intangible assets, to those reporting units.
The Company tests for impairment by either performing a qualitative evaluation or a quantitative test. The qualitative evaluation is an assessment of factors, including reporting unit specific operating results as well as industry, market and general economic conditions, to determine whether it is more likely than not that the fair values of a reporting unit is less than its carrying amount, including goodwill. The Company may elect to bypass this qualitative evaluation for some or all of its reporting units and perform a quantitative test. The quantitative test estimates the fair value of the reporting unit using a
10
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
discounted cash flow model, which incorporates significant estimates and assumptions made by management which, by their nature, are characterized by uncertainty.
Due to third-party audit findings and an update to the estimated timeframe to resume the commercial distribution of products manufactured in the Boston facility, the Company elected to perform a quantitative analysis of its Tissue Technologies reporting unit in the first quarter of 2024 in accordance with ASC 350. The quantitative test estimates the fair value of the reporting unit using a discounted cash flow model, which incorporates significant estimates and assumptions made by management with respect to future revenue and expense growth rates and discount rates which, by their nature, are characterized by uncertainty. An impairment loss is recognized when the reporting unit’s carrying amount exceeds its estimated fair value. The quantitative test utilized a terminal growth rate of 2%, a discount rate of 15%, and a range and application of the company guideline multiples. The Company determined, after performing the quantitative analysis, that the fair value of the Tissue Technologies reporting unit was not less than its carrying amount, with 20% headroom.
Other Intangible Assets
The components of the Company’s identifiable intangible assets were as follows:
 March 31, 2024
Dollars in thousandsWeighted
Average
Life		CostAccumulated
Amortization		Net
Completed technology18 years$1,209,921 $(460,545)$749,376 
Customer relationships12 years$167,360 $(134,587)$32,773 
Trademarks/brand names28 years$97,668 $(39,330)$58,338 
Codman tradenameIndefinite$168,678 $— $168,678 
Supplier relationships30 years$30,211 $(18,393)$11,818 
All other11 years$6,052 $(4,426)$1,626 
$1,679,890 $(657,281)$1,022,609 
 December 31, 2023
Dollars in thousandsWeighted
Average
Life		CostAccumulated
Amortization		Net
Completed technology18 years$1,226,128 $(448,519)$777,609 
Customer relationships12 years193,895 (152,160)41,735 
Trademarks/brand names28 years98,892 (38,754)60,138 
Codman tradenameIndefinite174,531 — 174,531 
Supplier relationships30 years30,211 (18,148)12,063 
All other11 years6,180 (4,423)1,757 
$1,729,837 $(662,004)$1,067,833 
Total amortization of intangible assets for the three months ended March 31, 2024 was $27.7 million. Of these amounts, $17.6 million was related to amortization of technology based intangibles and included in cost of goods sold. $7.1 million related to the impairment of a customer relationship intangible and the remainder were included in intangible amortization in the statement of operations.
Total amortization of intangible assets for the three months ended March 31, 2023 was $20.6 million. Of these amounts, $17.5 million was related to amortization of technology based intangibles and included in cost of goods sold, with the remainder included in intangible amortization in the statement of operations.
Based on quarter-end exchange rates, amortization expense (including amounts reported in cost of goods sold) is expected to be approximately $60.1 million for the remainder of 2024, $80.2 million in 2025, $80.0 million in 2026, $79.1 million in 2027, $78.7 million in 2028, $74.9 million in 2029 and $403.5 million thereafter.
The Company periodically performs testing for impairment on certain long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.
11
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
Due to third-party audit findings and an update to the estimated timeframe to resume the commercial distribution of products manufactured in the Boston facility, the Company elected to perform impairment testing on certain definite-lived intangible assets including completed technology and customer relationships in accordance with FASB ASC Topic 360, Property, Plant and Equipment. For the three months ended March 31, 2024, the Company recorded an impairment charge related to the definite-lived intangible asset associated with the customer relationships of $7.1 million in intangible asset amortization in the consolidated statement of operations. With respect to the definite-lived intangible assets associated with the completed technology of SurgiMend® and PriMatrix®, the carrying values are $38.3 million and $27.7 million, respectively, as of March 31, 2024. We determined that the carrying amount of these definite-lived intangible assets were recoverable and, therefore, the intangible assets were not deemed to be impaired.
6. DEBT
Amendment to the Seventh Amended and Restated Senior Credit Agreement
On March 24, 2023, the Company entered into the seventh amendment and restatement (the “March 2023 Amendment”) of the Senior Credit Facility (the “Senior Credit Facility”) with a syndicate of lending banks with Bank of America, N.A., as Administrative Agent. The March 2023 Amendment extended the maturity date to March 24, 2028, amended the contractual repayments of the term loan component, and amended the interest rate from LIBOR to SOFR-indexed interest. The Company continues to have the aggregate principal amount of up to approximately $2.1 billion available to it through the following facilities: (i) a $775.0 million term loan facility, and (ii) a $1.3 billion revolving credit facility, which includes a $60 million sublimit for the issuance of standby letters of credit and a $60 million sublimit for swingline loans.
The Company’s maximum consolidated total leverage ratio in the financial covenants (as defined in the Senior Credit Facility) was modified to the following:
Fiscal Quarter EndingMaximum Consolidated Total Leverage Ratio
March 31, 2023 through December 31, 2024
4.50 to 1.00
March 31, 2025 through June 30, 2026
4.25 to 1.00
September 30, 2026 and the last day of each fiscal quarter thereafter
4.00 to 1.00
Borrowings under the Senior Credit Facility bear interest, at the Company’s option, at a rate equal to the following:
i.Term SOFR in effect from time to time plus 0.10% plus the applicable rate (ranging from 1.00% to 1.75%), or
ii.The highest of:
1.the weighted average overnight Federal funds rate, as published by the Federal Reserve Bank of New York, plus 0.50%;
2.the prime lending rate of Bank of America, N.A.; or
3.the one-month Term SOFR plus 1.00%.
The applicable rates are based on the Company’s consolidated total leverage ratio (defined as the ratio of (a) consolidated funded indebtedness as of such date less cash that is not subject to any restriction on the use or investment thereof to (b) consolidated EBITDA (as defined by the amended Seventh Amended and Restated Credit Agreement (the “Credit Agreement”)), for the period of four consecutive fiscal quarters ending on such date).
The Company will pay an annual commitment fee (ranging from 0.15% to 0.30%), based on the Company’s consolidated total leverage ratio, on the amount available for borrowing under the revolving credit facility.
The Senior Credit Facility is collateralized by substantially all of the assets of the Company’s U.S. subsidiaries, excluding intangible assets. The Senior Credit Facility is subject to various financial and negative covenants and, at March 31, 2024, the Company was in compliance with all such covenants. The Company capitalized $7.6 million in deferred financing costs in connection with the modification of the Senior Credit Facility and wrote off $0.2 million of previously capitalized financing costs during the first quarter of 2023.
At March 31, 2024 and December 31, 2023 there was $420.0 million and $70.0 million, respectively, outstanding under the revolving portion of the Senior Credit Facility. At March 31, 2024 and December 31, 2023, there was $775.0 million outstanding under the term loan component of the Senior Credit Facility at a weighted average interest rate of 6.8% and 6.8%, respectively. As of March 31, 2024 and December 31, 2023 there was $19.4 million and $14.5 million, respectively, of the term loan component of the Senior Credit Facility classified as current on the condensed consolidated balance sheet.
12
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
The fair value of outstanding borrowings of the Senior Credit Facility’s term loan component at March 31, 2024 was $765.5 million. This fair value was determined by using a discounted cash flow model based on current market interest rates available to the Company. These inputs are corroborated by observable market data for similar liabilities and therefore classified within Level 2 of the fair value hierarchy. Level 2 inputs represent inputs that are observable for the asset or liability, either directly or indirectly, and are other than active market observable inputs that reflect unadjusted quoted prices for identical assets or liabilities.
Letters of credit outstanding as of March 31, 2024 and December 31, 2023 totaled $1.7 million. There were no amounts drawn under the letters of credit outstanding as of March 31, 2024.
Contractual repayments of the term loan component of the Senior Credit Facility are due as follows:
As of March 31, 2024
Principal Repayment
Dollars in thousands
Remainder of 2024
$14,531 
2025
33,906 
2026
38,750 
2027
53,281 
Thereafter634,532 
$775,000 
Future interest payments on the term loan component of the Senior Credit Facility based on current interest rates are expected to approximate $39.3 million for the remainder of 2024, $50.8 million in 2025, $48.1 million in 2026, $45.0 million in 2027, and $10.0 million thereafter. Interest is calculated on the term loan portion of the Senior Credit Facility based on SOFR plus the certain amounts set forth in the Credit Agreement. As the revolving credit facility and Securitization Facility (defined below) can be repaid at any time, no interest has been included in the calculation.
Any outstanding borrowings on the revolving credit component of the Senior Credit Facility are due on March 24, 2028.
Convertible Senior Notes
On February 4, 2020, the Company issued $575.0 million aggregate principal amount of its 0.5% Convertible Senior Notes due 2025 (the “2025 Notes”). The 2025 Notes will mature on August 15, 2025 and bear interest at a rate of 0.5% per annum payable semi-annually in arrears, unless earlier converted, repurchased or redeemed in accordance with the terms of the 2025 Notes. In connection with this offering, the Company capitalized $13.2 million of financing fees.
The 2025 Notes are senior, unsecured obligations of the Company, and are convertible into cash and shares of its common stock based on an initial conversion rate, subject to adjustment of 13.5739 shares per $1,000 principal amounts of the 2025 Notes (which represents an initial conversion price of $73.67 per share). The 2025 Notes convert only in the following circumstances: (1) if the closing price of the Company’s common stock has been at least 130% of the conversion price during the period; (2) if the average trading price per $1,000 principal amount of the 2025 Notes is less than or equal to 98% of the average conversion value of the 2025 Notes during a period as defined in the indenture; (3) if the Company calls the notes for optional redemption as defined in the indenture; or (4) if specified corporate transactions occur. As of March 31, 2024, none of these conditions existed and the 2025 Notes are classified as long term obligations.
On December 9, 2020, the Company entered into the First Supplemental Indenture to the original indenture dated as of February 4, 2020 (the “Indenture”) between the Company and Citibank, N.A., as trustee, governing the Company’s outstanding 2025 Notes. The Company irrevocably elected (1) to eliminate the Company’s option to choose physical settlement on any conversion of the 2025 Notes that occurs on or after the date of the First Supplemental Indenture and (2) with respect to any Combination Settlement (as defined in the indenture) for a conversion of the 2025 Notes, the Specified Dollar Amount (as defined in the indenture) that will be settled in cash per $1,000 principal amount of the 2025 Notes shall be no lower than $1,000.
Holders of the 2025 Notes will have the right to require the Company to repurchase for cash all or a portion of their 2025 Notes at 100% of their principal amount, plus any accrued and unpaid interest, upon the occurrence of a fundamental change (as defined in the indenture relating to the 2025 Notes). The Company will also be required to increase the conversion rate for holders who convert their 2025 Notes in connection with certain fundamental changes occurring prior to the maturity date or following delivery by the Company of a notice of redemption.
13
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
In connection with the issuance of the 2025 Notes, the Company entered into call transactions and warrant transactions, primarily with affiliates of the initial purchasers of the 2025 Notes (the “hedge participants”). The cost of the call transactions was $104.2 million for the 2025 Notes. The Company received $44.5 million of proceeds from the warrant transactions for the 2025 Notes. The call transactions involved purchasing call options from the hedge participants, and the warrant transactions involved selling call options to the hedge participants with a higher strike price than the purchased call options. The initial strike price of the call transactions was $73.67, subject to anti-dilution adjustments substantially similar to those in the 2025 Notes. The initial strike price of the warrant transactions was $113.34 for the 2025 Notes, subject to customary anti-dilution adjustments.
At March 31, 2024, the carrying amount of the liability was $575.0 million. The fair value of the 2025 Notes at March 31, 2024 was $549.7 million. Factors that the Company considered when estimating the fair value of the 2025 Notes included recent quoted market prices or dealer quotes. The 2025 Notes are valued based on Level 1 measurements in the fair value hierarchy.
Securitization Facility
In 2018, the Company entered into an accounts receivable securitization facility (the “Securitization Facility”) under which accounts receivable of certain domestic subsidiaries are sold on a non-recourse basis to a special purpose entity (“SPE”), which is a bankruptcy-remote, consolidated subsidiary of the Company. Accordingly, the assets of the SPE are not available to satisfy the obligations of the Company or any of its subsidiaries. From time to time, the SPE may finance such accounts receivable with a revolving loan facility secured by a pledge of such accounts receivable. The amount of outstanding borrowings on the Securitization Facility at any one time is limited to $150.0 million. The Securitization Facility Agreement (“Securitization Agreement”) governing the Securitization Facility contains certain covenants and termination events. An occurrence of an event of default or a termination event under this Securitization Agreement may give rise to the right of its counterparty to terminate this facility. As of March 31, 2024, the Company was in compliance with the covenants and none of the termination events had occurred.
On December 15, 2023, the Company entered into an amendment (the “December 2023 Amendment”) of the Securitization Facility which extended the maturity date from May 28, 2024 to December 15, 2026. The Company incurred approximately $0.3 million of new issuance costs associated with the December Amendment which will be amortized over 3 years, the length of the Securitization Agreement as amended by the December 2023 Amendment. Due to the increase in borrowing capacity, the remaining $0.1 million of unamortized costs from the previous agreement will also be amortized over the length of the amended agreement, 3 years. In addition, on April 17, 2023 the Company entered into an amendment (the “April 2023 Amendment”) of the Securitization Facility and amended the interest rate from LIBOR to SOFR-indexed rate. The December 2023 Amendment and April 2023 Amendment did not increase the Company’s total indebtedness.
At March 31, 2024 and December 31, 2023, the Company had $94.6 million and $89.2 million, respectively, of outstanding borrowings under its Securitization Facility at a weighted average interest rate of 6.5% and 5.9%, respectively. The fair value of the outstanding borrowing of the Securitization Facility at March 31, 2024 was $92.7 million. These fair values were determined by using a discounted cash flow model based on current market interest rates available to the Company. These inputs are corroborated by observable market data for similar liabilities and therefore classified within Level 2 of the fair value hierarchy. Level 2 inputs represent inputs that are observable for the asset or liability, either directly or indirectly, and are other than active market observable inputs that reflect unadjusted quoted prices for identical assets or liabilities.
14
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
7. DERIVATIVE INSTRUMENTS
Interest Rate Hedging
The Company’s interest rate risk relates to U.S. dollar denominated variable interest rate borrowings. The Company uses interest rate swap derivative instruments to manage earnings and cash flow exposure resulting from changes in interest rates. These interest rate swaps apply a fixed interest rate on a portion of the Company’s expected SOFR-indexed borrowings. In March 2023, the Company entered into a basis swap where the Company receives Term SOFR and pays daily compounded SOFR to convert the portfolio of swaps from daily compounded SOFR to term SOFR.
The Company held the following interest rate swaps as of March 31, 2024 and December 31, 2023 (dollar amounts in thousands):
March 31, 2024December 31, 2023March 31, 2024December 31, 2023
Hedged ItemNotional AmountDesignation DateEffective DateTermination DateFixed Interest RateEstimated Fair Value
Asset (Liability)
1-month Term SOFR Loan150,000 150,000 December 13, 2017July 1, 2019June 30, 20242.423 %1,125 2,105 
1-month Term SOFR Loan200,000 200,000 December 13, 2017January 1, 2018December 31, 20242.313 %4,341 4,978 
1-month Term SOFR Loan75,000 75,000 October 10, 2018July 1, 2020June 30, 20253.220 %1,556 1,349 
1-month Term SOFR Loan75,000 75,000 October 10, 2018July 1, 2020June 30, 20253.199 %1,548 1,312 
1-month Term SOFR Loan75,000 75,000 October 10, 2018July 1, 2020June 30, 20253.209 %1,548 1,346 
1-month Term SOFR Loan100,000 100,000 December 18, 2018December 30, 2022December 31, 20272.885 %4,512 3,015 
1-month Term SOFR Loan100,000 100,000 December 18, 2018December 30, 2022December 31, 20272.867 %4,519 3,052 
1-month Term SOFR Loan575,000 575,000 December 15, 2020July 31, 2025December 31, 20271.415 %29,267 22,965 
1-month Term SOFR Loan125,000 125,000 December 15, 2020July 1, 2025December 31, 20271.404 %6,770 5,263 
Basis Swap (1)
—— March 31, 2023March 24, 2023December 31, 2027N/A(2,127)0(1,829)
$1,475,000 $1,475,000 $53,059 $43,556 
(1) The notional of the basis swap amortizes to match the total notional of the interest rate swap portfolio over time
The interest rate swaps were carried on the consolidated balance sheet at fair value and changes in the fair values were recorded as unrealized gains or losses in accumulated other comprehensive income (“AOCI”). For the three months ended March 31, 2024 and 2023, the Company recorded a gain of $14.7 million and a loss of $10.5 million, respectively, in AOCI related to the change in fair value of the interest rate swaps.
For the three months ended March 31, 2024 and 2023, the Company recorded gains of $5.2 million and $3.5 million, respectively, in the consolidated statements of operations related to the interest rate differential of the interest rate swaps. The estimated gain that is expected to be reclassified to interest income from AOCI as of March 31, 2024 within the next twelve months is $13.6 million.
The Company has designated these derivative instruments as cash flow hedges. The Company assesses the effectiveness of these derivative instruments and has recorded the changes in the fair value of the derivative instrument designated as a cash flow hedge as unrealized gains or losses in AOCI, net of tax, until the hedged item affected earnings, at which point any gain or loss was reclassified to earnings. If the hedged cash flow does not occur, or if it becomes probable that it will not occur, the Company will reclassify the remaining amount of any gain or loss on the related cash flow hedge recorded in AOCI to interest expense at that time.
15
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
Foreign Currency Hedging
From time to time, the Company enters into foreign currency hedge contracts intended to protect the U.S. dollar value of certain forecasted foreign currency denominated transactions. The Company assesses the effectiveness of the contracts that are designated as hedging instruments. The changes in fair value of foreign currency cash flow hedges are recorded in AOCI, net of tax. Those amounts are subsequently reclassified to earnings from AOCI as impacted by the hedged item when the hedged item affects earnings. If the hedged forecasted transaction does not occur or if it becomes probable that it will not occur, the Company will reclassify the amount of any gain or loss on the related cash flow hedge to earnings at that time. For contracts not designated as hedging instruments, the changes in fair value of the contracts are recognized in other income, net in the consolidated statements of operation, along with the offsetting foreign currency gain or loss on the underlying assets or liabilities.
The success of the Company’s hedging anticipated currency exchange gains or losses to the extent that there are differences between forecasted and actual activities during periods of currency volatility. In addition, changes in currency exchange rates related to any unhedged transactions may affect earnings and cash flows.
Cross-Currency Rate Swaps
The objective of these cross-currency swaps is to reduce volatility of earnings and cash flows associated with changes in the foreign currency exchange rate. Under the terms of these contracts, which have been designated as cash flow hedges, the Company will make interest payments in Swiss francs (“CHFs”) and receive interest in U.S. dollars. Upon the maturity of these contracts, the Company will pay the principal amount of the loans in CHFs and receive U.S. dollars from the counterparties.
On September 22, 2023, the Company amended the Swiss franc denominated intercompany loan to partially settle CHF 20.0 million and extend the termination date to September 2024 and as a result, the Company terminated the cross-currency swap designated as cash flow hedge of an intercompany loan with aggregate notional amount of $48.5 million. Simultaneously, the Company entered into a cross-currency swap agreement to hedge a notional amount of CHF 28.5 million equivalent to $31.5 million of this amended intercompany loan into U.S. dollars. The loss recorded by the Company upon the settlement of the swap was not material for the period.
On December 21, 2020, the Company entered into cross-currency swap agreements to convert a notional amount of $471.6 million equivalent to 420.1 million of a CHF-denominated intercompany loan into U.S. dollars. The CHF-denominated intercompany loan was the result of an intra-entity transfer of certain intellectual property rights to a subsidiary in Switzerland completed during the fourth quarter of 2020. The intercompany loan requires quarterly payments of CHF 5.8 million plus accrued interest. As a result, the aggregate notional amount of the related cross-currency swaps will decrease by a corresponding amount.
The Company held the following cross-currency rate swaps as of March 31, 2024 and December 31, 2023 (dollar amounts in thousands):
March 31, 2024December 31, 2023March 31, 2024December 31, 2023
Effective DateTermination DateFixed RateAggregate Notional AmountFair Value
Asset (Liability)
Pay CHFDecember 21, 2020December 22, 20253.00%CHF333,887 351,137 (9,902)(38,324)
Receive U.S.$3.98%$374,817 394,183 
Pay CHFSeptember 22, 2023September 29, 20242.40%CHF28,500 28,500 (2,578)(2,348)
Receive U.S.$6.27%$31,457 31,457 
Total$(12,480)$(40,672)
16
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
The cross-currency swaps are carried on the consolidated balance sheet at fair value, and changes in the fair values are recorded as unrealized gains or losses in AOCI. For the three months ended March 31, 2024 the Company recorded a gain of $30.1 million in other income, net related to change in fair value related to the foreign currency rate translation to offset the losses recognized on the intercompany loans. For the three months ended March 31, 2023, the Company recorded a loss of $4.9 million in other income, net related to change in fair value related to the foreign currency rate translation to offset the losses recognized on the intercompany loans.
For the three months ended March 31, 2024, the Company recorded a gain of $29.5 million in AOCI related to change in fair value of the cross-currency swaps. For the three months ended March 31, 2023, the Company recorded a gain of $2.2 million in AOCI related to change in fair value of the cross-currency swaps.
For the three months ended March 31, 2024, the Company recorded a gain of $1.3 million in other income, net included in the consolidated statements of operations related to the interest rate differential of the cross-currency swaps. For the three months ended March 31, 2023, the Company recorded a gain of $1.5 million in other income, net included in the consolidated statements of operations related to the interest rate differential of the cross-currency swaps.
The estimated loss that is expected to be reclassified to other income (expense), net from AOCI as of March 31, 2024 within the next twelve months is $1.9 million. As of March 31, 2024, the Company does not expect any gains or losses will be reclassified into earnings because the original forecasted transactions will not occur.
Net Investment Hedges
The Company manages certain foreign exchange risks through a variety of strategies, including hedging. The Company is exposed to foreign exchange risk from its international operations through foreign currency purchases, net investments in foreign subsidiaries, and foreign currency assets and liabilities created in the normal course of business. On October 1, 2018 May 24, 2022, and November 17, 2023, the Company entered into cross-currency swap agreements designated as net investment hedges to partially offset the effects of foreign currency on foreign subsidiaries.
The Company held the following cross-currency rate swaps designated as net investment hedges as of March 31, 2024 and December 31, 2023, respectively (dollar amounts in thousands):
March 31, 2024December 31, 2023
March 31, 2024
December 31, 2023
Effective DateTermination DateFixed RateAggregate Notional AmountFair Value
Asset (Liability)
Pay EUROctober 3, 2018September 30, 2025—%EUR38,820 38,820 3,459 2,475 
Receive U.S.$2.19%$45,000 45,000 
Pay CHFMay 26, 2022December 16, 2028—%CHF288,210 288,210 (29,614)(48,047)
Receive U.S.$1.94%$300,000 300,000 
Pay CHFNovember 21, 2023December 17, 2029—%CHF66,525 66,525 (736)(4,037)
Receive U.S.$2.54%$75,000 75,000 
Total$(26,891)$(49,609)
The cross-currency swaps were carried on the consolidated balance sheet at fair value and changes in the fair values were recorded as unrealized gains or losses in AOCI. For the three months ended March 31, 2024, the Company recorded a gain of $24.9 million in AOCI related to the change in fair value of the cross-currency swaps. For the three months ended March 31, 2023, the Company recorded a gain of $1.0 million in AOCI related to change in fair value of the cross-currency swaps.
For the three months ended March 31, 2024, the Company recorded a gain of $2.2 million in interest income included in the consolidated statements of operations related to the interest rate differential of the cross-currency swaps. For the three months ended March 31, 2023, the Company recorded a gain of $2.1 million in interest income included in the consolidated statements of operations related to the interest rate differential of the cross-currency swaps.
The estimated gain that is expected to be reclassified to interest income from AOCI as of March 31, 2024 within the next twelve months is $4.1 million.
17
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
On May 2, 2024, the Company entered into a cross-currency swap agreement with a notional amount of CHF 68.5 million, equivalent to $75.0 million, where the Company agreed with third-parties to sell Swiss francs in exchange for U.S. dollars at a specified rate at the maturity of the contract. The new cross-currency swap agreement was designated as a net investment hedge to partially offset the effects of foreign currency on foreign subsidiaries.
Foreign Currency Forward Contracts
The Company has entered into a hedge for forecasted intercompany purchases denominated in foreign currencies through the use of forward contracts designated as cash flow hedges. To the extent these forward contracts meet hedge accounting criteria, changes in their fair value are not included in accumulated comprehensive loss. These changes in fair value will be recognized into earnings as a component of cost of sales when the forecasted-transaction occurs.
In the first quarter of 2024, the Company entered into foreign currency forwards to mitigate the exchange rate risk of Swiss franc denominated intercompany purchases. These contracts typically settle at various dates within twelve months of execution. As of March 31, 2024 the notional amount of foreign currency forward contracts was CHF13.3 million. For the three months ended March 31, 2024 the Company recorded a loss of $0.6 million in AOCI related to the change in fair value of the foreign currency forward contracts and a loss of $0.1 million in cost of goods sold included in the consolidated statements of operations.
Counterparty Credit Risk
The Company manages its concentration of counterparty credit risk on its derivative instruments by limiting acceptable counterparties to a group of major financial institutions with investment grade credit ratings, and by actively monitoring their credit ratings and outstanding positions on an ongoing basis. Therefore, the Company considers the credit risk of the counterparties to be low. Furthermore, none of the Company’s derivative transactions are subject to collateral or other security arrangements, and none contain provisions that depend upon the Company’s credit ratings from any credit rating agency.
Fair Value of Derivative Instruments
The Company has classified all of its derivative instruments within Level 2 of the fair value hierarchy because observable inputs are available for substantially the full term of the derivative instruments. The fair values of the interest rate swaps and cross-currency swaps were developed using a market approach based on publicly available market yield curves and the terms of the swap. The Company performs ongoing assessments of counterparty credit risk.
18
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
The following table summarizes the fair value for derivatives designated as hedging instruments in the condensed consolidated balance sheets as of March 31, 2024 and December 31, 2023:
Fair Value as of
Location on Balance Sheet (1):
March 31, 2024December 31, 2023
Dollars in thousands
Derivatives designated as hedges — Assets:
Prepaid expenses and other current assets
Cash Flow Hedges
Interest rate swap(2)
$14,188 $14,675 
Cross-currency swap680 537 
Net Investment Hedges
Cross-currency swap4,084 2,938 
Other assets
Cash Flow Hedges
Interest rate swap(2)
40,998 30,710 
Cross-currency swap— — 
Net Investment Hedges
Cross-currency swap2,454 1,470 
Total derivatives designated as hedges — Assets$62,404 $50,330 
Derivatives designated as hedges — Liabilities:
Accrued expenses and other current liabilities
Cash Flow Hedges
Interest rate swap(2)
$540 $579 
Cross-currency swap2,578 4,813 
Foreign currency forward contracts629 — 
Net Investment Hedges
Cross-currency swap— 2,903 
Other liabilities
Cash Flow Hedges
Interest rate swap(2)
1,586 1,250 
Cross-currency swap10,582 36,396 
Net Investment Hedges
Cross-currency swap33,427 51,114 
Total derivatives designated as hedges — Liabilities$49,342 $97,055 
(1) The Company classifies derivative assets and liabilities as current based on the cash flows expected to be incurred within the following 12 months.
(2) At March 31, 2024 and December 31, 2023, the total notional amounts related to the Company’s interest rate swaps were $1.5 billion.
19
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
The following presents the effect of derivative instruments designated as cash flow hedges and net investment hedges on the accompanying condensed consolidated statement of operations during the three months ended March 31, 2024 and 2023:
Dollars in thousandsBalance in AOCI
Beginning of
Quarter		Amount of
Gain (Loss)
Recognized in
AOCI		Amount of Gain (Loss)
Reclassified from
AOCI into
Earnings		Balance in AOCI
End of Quarter		Location in
Statements of
Operations
Three Months Ended March 31, 2024
Cash Flow Hedges
Interest rate swap$43,556 $14,723 $5,219 $53,060 Interest expense
Cross-currency swap(15,763)29,532 31,473 (17,704)Other income (expense), net
Foreign currency forward contract— (629)(110)(519)Cost of sales
Net Investment Hedges
Cross-currency swap(45,498)24,920 2,202 (22,780)Interest income
$(17,705)$68,546 $38,784 $12,057 
Three Months Ended March 31, 2023
Cash Flow Hedges
Interest rate swap$56,712 $(10,534)$3,500 $42,678 Interest expense
Cross-currency swap(20,271)2,191 (3,504)(14,576)Other income (expense), net
Foreign currency forward contract$(69)$(69)
Net Investment Hedges
Cross-currency swap(6,914)950 2,096 (8,060)Interest income
$29,527 $(7,462)$2,092 $19,973 
Derivative Instruments not Designated Hedges:
During the second quarter of 2021, the Company entered into a foreign currency swap, with a notional amount of $7.3 million to mitigate the risk from fluctuations in foreign currency exchange rates associated with an intercompany loan denominated in Japanese yen. In a foreign currency swap transaction, the Company agrees with another party to exchange, at specified intervals, the difference between one currency and another currency at a fixed exchange rate, generally set at inception, calculated by reference to an agreed upon notional amount. The notional amount of each currency is exchanged at the inception and termination of the currency swap by each party. The Company subsequently paid down a portion of this swap, bringing the notional amount down to $5.5 million as of March 31, 2024.
The fair value of the foreign currency swaps not designated as hedges was $1.5 million and $1.2 million as of March 31, 2024 and December 31, 2023, respectively. The following table summarizes the gains (losses) on derivative instruments not designated as hedges on the condensed consolidated statements of income, which was included in other income:
Dollars in thousandsThree Months Ended March 31,
20242023
Foreign currency swaps273 55 
Total$273 $55 
8. STOCK-BASED COMPENSATION
As of March 31, 2024, the Company had stock options, restricted stock awards, performance stock awards, contract stock awards and restricted stock unit awards outstanding under the Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan (the “2003 Plan”).
20
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
Stock options issued under the 2003 Plan become exercisable over specified periods, generally within four years from the date of grant for officers and employees, within one year from date of grant for directors which generally expire eight years from the grant date for employees, and from six to ten years for directors and certain executive officers, except in certain instances that result in accelerated vesting due to death, disability, retirement age or change in-control provisions within their grant agreements. The Company values stock option grants using the binomial distribution model. Restricted stock issued under the 2003 Plan vests over specified periods, generally three years after the date of grant. The vesting of performance stock issued under the 2003 Plan is subject to service and performance conditions.
Stock Options
As of March 31, 2024, there were approximately $4.9 million of total unrecognized compensation costs related to unvested stock options. These costs are expected to be recognized over a weighted-average period of approximately three years. There were 243,964 stock options granted during the three months ended March 31, 2024. For the three months ended March 31, 2024, the weighted average grant date fair value for stock options granted was $15.68 per option.
Awards of Restricted Stock and Performance Stock
Performance stock and restricted stock awards generally have requisite service periods of three years, except in certain instances that result in accelerated vesting due to death, disability, retirement age provision or change in-control provisions in their grant agreements. Performance stock units are subject to graded vesting conditions based on revenue goals of the Company. The Company expenses the fair value of restricted stock awards on a straight-line basis over the requisite service period. As of March 31, 2024, there was approximately $48.6 million of total unrecognized compensation costs related to these unvested awards. The Company expects to recognize these costs over a weighted-average period of approximately two years. The Company granted 532,379 restricted stock awards and 263,350 performance stock awards during the three months ended March 31, 2024. For the three months ended March 31, 2024, the weighted average grant date fair value for restricted stock awards and performance stock units granted was $36.46 and $36.22 per award, respectively.
The Company also maintains an Employee Stock Purchase Plan (the “ESPP”), which provides eligible employees with the opportunity to acquire shares of common stock at periodic intervals by means of accumulated payroll deductions. The ESPP is a non-compensatory plan based on its terms.
CEO Separation
On February 27th, 2024, the Company announced that Mr. De Witte would retire from his position as President and Chief Executive Officer and director of the Company following the completion of a succession process and entered into a letter agreement with Mr. De Witte to modify his current employment agreement and put forth the form of a post-employment consulting agreement. The Company applied modification accounting to the outstanding equity-based awards granted to Mr. De Witte as of that date, which revalued and accelerated stock-based compensation associated with equity-based awards granted to him over his expected service period to the Company. Pursuant to this letter agreement, Mr. De Witte’s unvested equity-based awards will continue to vest during his continued service period to the Company and vested stock options were modified such that they will remain exercisable until the lesser of (a) the stated term of the stock options and (b) six months following his cessation of continued service to the Company. As a result of the modifications, the Company recorded incremental stock-based compensation expense of $0.2 million during the three months ended March 31, 2024. The Company will record a total of $1.9 million in accelerated stock-based compensation expenses for the twelve months ended 2024 that would not have been recognized if Mr. De Witte had not announced his retirement from Integra.
9. RETIREMENT PLANS
The Company maintains defined benefit pension plans that cover certain employees in France, Japan, Germany and Switzerland.
Net periodic benefit costs for the Company’s defined benefit pension plans for the three months ended March 31, 2024 were $0.4 million. The components of the net periodic benefit costs other than the service cost component of $0.8 million for the three months ended March 31, 2024 are included in other income, net in the consolidated statements of operations.
Net periodic benefit costs for the Company’s defined benefit pension plans for the three months ended March 31, 2023 were $0.3 million. The components of the net periodic benefit costs other than the service cost component of $0.5 million for the three months ended March 31, 2023 are included in other income, net in the consolidated statements of operations.
21
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
The estimated fair values of plan assets were $40.4 million and $45.7 million as of March 31, 2024 and December 31, 2023, respectively. The net plan assets of the pension plans are invested in common trusts as of March 31, 2024 and December 31, 2023. Common trusts are classified as Level 2 in the fair value hierarchy. The fair value of common trusts is valued at the net asset value based on the fair values of the underlying investments of the trusts as determined by the sponsor of the trusts. The investment strategy of the Company’s defined benefit plans is both to meet the liabilities of the plans as they fall due and to maximize the return on invested assets within an appropriate risk profile.
Deferred Compensation Plan
The Company maintains a Deferred Compensation Plan in which certain employees of the Company may defer the payment and taxation of up to 75% of their base salary and up to 100% of bonus amounts and other eligible cash compensation.
This deferred compensation is invested in funds offered under this plan and is valued based on Level 1 measurements in the fair value hierarchy. Assets of the Company’s deferred compensation plan are included in other current assets and recorded at fair value based on their quoted market prices. The fair value of these assets were $5.7 million and $6.1 million as of March 31, 2024 and December 31, 2023, respectively. Offsetting liabilities relating to the deferred compensation plan are included in other liabilities.
10. LEASES AND RELATED PARTY LEASES
The Company leases administrative, manufacturing, research and distribution facilities, and vehicles through operating lease agreements. The Company has no finance leases as of March 31, 2024. Many of the Company’s leases include both lease (e.g., fixed payments including rent) and non-lease components (e.g., common-area or other maintenance costs). For vehicles, the Company has elected the practical expedient to group lease and non-lease components.
Most facility leases include one or more options to renew. The exercise of lease renewal options is typically at the Company’s sole discretion, therefore, the majority of renewals to extend the lease terms are not included in the Right of Use (“ROU”) assets and lease liabilities as they are not reasonably certain of exercise. The Company regularly evaluates renewal options and when they are reasonably certain of exercise, the renewal period is included in the lease term.
As most of the Company’s leases do not provide an implicit rate, the Company uses a collateralized incremental borrowing rate based on the information available at the lease commencement date in determining the present value of the lease payments.
Total operating lease expense for the three months ended March 31, 2024 and March 31, 2023 was $6.3 million and $6.0 million, respectively, which includes $0.3 million, in related party operating lease expense.
Supplemental balance sheet information related to operating leases were as follows:
Dollars in thousands, except lease term and discount rateMarch 31, 2024
December 31, 2023
ROU assets$151,834 $156,184 
Current lease liabilities16,303 15,284 
Non-current lease liabilities170,082 166,849 
Total lease liabilities$186,385 $182,133 
Weighted average remaining lease term (in years):
Leased facilities16.5 years16.3 years
Leased vehicles2.1 years1.9 years
Weighted average discount rate:
Leased facilities5.7 %5.9 %
Leased vehicles2.7 %2.7 %
22
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
Supplemental cash flow information related to leases for the three months ended March 31, 2024 and 2023 were as follows:
Dollars in thousandsMarch 31, 2024
March 31, 2023
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$5,734 $4,319 
ROU assets obtained in exchange for lease liabilities:
Operating leases$746 $1,721 
Future minimum lease payments under operating leases at March 31, 2024 were as follows:
Dollars in thousandsRelated PartiesThird PartiesTotal
Remainder of 2024
$222 $17,884 $18,106 
2025296 22,859 23,155 
2026296 20,210 20,506 
2027296 18,892 19,188 
2028296 16,603 16,899 
2029246 15,771 16,017 
Thereafter— 163,479 163,479 
Total minimum lease payments$1,652 $275,698 $277,350 
Less: Imputed interest90,965 
Total lease liabilities186,385 
Less: Current lease liabilities16,303 
Long-term lease liabilities170,082 
There were no future minimum lease payments under finance leases at March 31, 2024.
Related Party Leases
The Company leases its manufacturing facility in Plainsboro, New Jersey, from a general partnership that is 50% owned by a principal stockholder of the Company. The term of the current lease agreement is through October 31, 2029 at an annual rate of approximately $0.3 million. The current lease agreement also provides (i) a 5-year renewal option for the Company to extend the lease from November 1, 2029 through October 31, 2034 at the fair market rental rate of the premises, and (ii) another 5-year renewal option to extend the lease from November 1, 2034 through October 31, 2039 at the fair market rental rate of the premises.
11. TREASURY STOCK
As of March 31, 2024 and December 31, 2023, there were 12.7 million and 12.8 million shares of treasury stock outstanding with a cost of $646.4 million and $647.3 million, at a weighted average cost per share of $50.76 and $50.76, respectively.
On August 15, 2023, the Company entered into a $125 million accelerated share repurchase (“August 2023 ASR”) and received 2.3 million shares of common stock at inception of the August 2023 ASR, which represented approximately 80% of the expected total shares under the August 2023 ASR. On October 18, 2023 the early exercise provision was exercised by the August 2023 ASR counterparty. The Company received an additional 0.9 million shares determined using the volume-weighted average price of the Company’s common stock during the term of the August 2023 ASR.
23
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
On January 26, 2023, the Company entered into a $150 million accelerated share repurchase (“January 2023 ASR”) and received 2.1 million shares of common stock at inception of the January 2023 ASR, which represented approximately 80% of the expected total shares under the January 2023 ASR. The settlement of the January 2023 ASR agreement was completed in the second quarter of 2023, where the Company received 0.6 million shares, determined using the volume-weighted average price of the Company’s common stock during the term of the January 2023 ASR.
On August 16, 2022, the Inflation Reduction Act of 2022 (the “Inflation Act”) was signed into law. The Inflation Act implements a new excise tax of 1% on the net share repurchases made by the Company effective for share repurchases performed January 1, 2023, or after.
On July 18, 2023, the Board of Directors authorized a new $225 million share repurchase program, replacing the existing $225 million program authorized in April 2022, under which $75 million remained authorized at the time of its replacement. As of March 31, 2024, $100 million remained authorized. The program authorized in July 2023 allows the Company to repurchase its shares opportunistically from time to time. The Company may utilize various methods to effect any repurchases, including open market transactions, privately negotiated transactions, transactions structured through investment banking institutions, including accelerated share repurchases, or a combination of the foregoing, some of which may be effected through Rule 10b5-1 plans. The price and timing of any future purchases under the share repurchase program will depend on factors such as levels of cash generation from operations, the volume of stock option exercises by employees, cash requirements for acquisitions, dividends, economic and market conditions and stock price, and such repurchases may be discontinued at any time.
12. INCOME TAXES
The following table provides a summary of the Company’s effective tax rate:
 Three Months Ended March 31,
 20242023
Reported tax rate37.3 %18.6 %
The Company’s effective income tax rates for the three months ended March 31, 2024 and 2023 were 37.3% and 18.6%, respectively. For the three months ended March 31, 2024, the higher tax rate is attributable to a $1.5 million shortfall from stock based compensation, offset by a tax benefit for the intangible asset impairment, as compared to previous year. The Company does not have tax basis in the impaired intangible asset and has treated the tax impact as a discrete event in this quarter.
Changes to income tax laws and regulations, in any of the tax jurisdictions in which the Company operates, could impact the effective tax rate. Various governments, both U.S. and non-U.S., are increasingly focused on tax reform and revenue-raising legislation. On August 16, 2022, the Inflation Act was signed into law. The Company did not experience a material impact on the Company’s effective tax rate under the Inflation Act. Further, legislation in foreign jurisdictions may be enacted, in continued response to the base erosion and profit-sharing (“BEPS”) project begun by the Organization for Economic Cooperation and Development (“OECD”).
The OECD released model rules related to a new 15% global minimum tax regime (“Pillar 2”). Several of the jurisdictions that the Company operates in have already adopted some form of the model rules, which could impact the amount of taxes that the Company pays after 2023. However, the rules are complex and provide for delays for implementing the tax during the early transition years, if certain conditions are met. At this time, the Company is projecting an immaterial amount related to Pillar 2 tax liability for the 2024 year. Such changes in U.S. and Non-U.S. jurisdictions could have an adverse effect on the Company’s effective tax rate.
24
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
13. NET INCOME PER SHARE
Basic and diluted net income per share was as follows:
 Three Months Ended March 31,
 Dollars in thousands, except per share amounts20242023
Basic net (loss) income per share:
Net (loss) income$(3,281)$24,226 
Weighted average common shares outstanding77,735 81,871 
Basic net (loss) income per common share$(0.04)$0.30 
Diluted net (loss) income per share:
Net (loss) income$(3,281)$24,226 
Weighted average common shares outstanding — Basic77,735 81,871 
Effect of dilutive securities:
Stock options and restricted stock— 452 
Weighted average common shares for diluted earnings per share77,735 82,323 
Diluted net (loss) income per common share$(0.04)$0.29 
Basic earnings per share is computed by dividing net income by the weighted-average common shares outstanding during the period. Diluted earnings per share is computed based on the weighted-average common shares outstanding plus the effect of dilutive potential common shares outstanding during the period calculated using the treasury stock method. Dilutive potential common shares include employee equity share options, non-vested shares, and similar equity instruments granted by the Company. Potential common share equivalents have been excluded where their inclusion would be anti-dilutive.
Common stock of approximately 1.3 million and 0.3 million shares at March 31, 2024, and 2023, respectively, were not included in the computation of diluted net (loss) income per share because their effect would have been anti-dilutive.
14. ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)
Comprehensive income for the three months ended March 31, 2024 and 2023:
 Three Months Ended March 31,
Dollars in thousands20242023
Net (loss) income$(3,281)$24,226 
Foreign currency translation adjustment730 3,192 
Change in unrealized loss/(gain) on derivatives, net of tax3,735 (6,493)
Pension liability adjustment, net of tax(5)103 
Comprehensive income, net$1,179 $21,028 
25
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
Changes in accumulated other comprehensive income by component between December 31, 2023 and March 31, 2024 are presented in the table below, net of tax:
Dollars in thousandsGains and Losses on DerivativesDefined Benefit Pension ItemsForeign Currency ItemsTotal
Balance at January 1, 2024
$21,489 $2,712 $(39,307)$(15,106)
Other comprehensive gain (loss)34,939 (5)2,425 37,359 
Less: Amounts reclassified from accumulated other comprehensive income, net31,204 — 1,695 32,899 
Net current-period other comprehensive gain (loss)3,735 (5)730 4,460 
Balance at March 31, 2024
$25,224 $2,707 $(38,577)$(10,646)
For the three months ended March 31, 2024, the Company reclassified a gain of $27.2 million and $5.7 million from accumulated other comprehensive income to other income, net and interest income, respectively.
15. SEGMENT AND GEOGRAPHIC INFORMATION
The Company internally manages two global reportable segments and reports the results of its businesses to its chief operating decision maker. The two reportable segments and their activities are described below.
•The Codman Specialty Surgical segment includes (i) the Neurosurgery business, which sells a full line of products for neurosurgery and neuro critical care such as tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment and (ii) the Instruments business, which sells more than 40,000 instrument patterns and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices.
•The Tissue Technologies segment includes such offerings as skin and wound repair, plastics & surgical reconstruction products, bone grafts, and nerve and tendon repair products.
The Corporate and other category includes (i) various executive, finance, human resource, information systems and legal functions, (ii) brand management, and (iii) share-based compensation costs.
The operating results of the various reportable segments as presented are not comparable to one another because (i) certain operating segments are more dependent than others on corporate functions for unallocated general and administrative and/or operational manufacturing functions, and (ii) the Company does not allocate certain manufacturing costs and general and administrative costs to the operating segment results. Net sales and profit by each reportable segment for the three months ended March 31, 2024 and 2023 are as follows:
Three Months Ended March 31,
Dollars in thousands20242023
Segment Net Sales
Codman Specialty Surgical$256,434 $248,136 
Tissue Technologies
112,438 132,710 
Total revenues$368,872 $380,846 
Segment Profit
Codman Specialty Surgical$103,492 $110,933 
Tissue Technologies
30,66652,281 
Segment profit134,158 163,214 
Amortization(10,107)(3,108)
Corporate and other(120,087)(123,724)
Operating income$3,964 $36,382 
26
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
The Company does not allocate any assets to the reportable segments. No asset information is reported to the chief operating decision maker and disclosed in the financial information for each segment. The Company attributes revenues to geographic areas based on the location of the customer. Total revenue by major geographic area consisted of the following:
 Three Months Ended March 31,
Dollars in thousands20242023
United States$256,229 $271,002 
Europe41,596 41,064 
Asia Pacific49,545 50,473 
Rest of World21,502 18,307 
Total Revenues$368,872 $380,846 
16. COMMITMENTS AND CONTINGENCIES
In consideration for certain technology, manufacturing, distribution, and selling rights and licenses granted to the Company, the Company has agreed to pay royalties on sales of certain products that it sells. The royalty payments that the Company made under these agreements were not significant for any of the periods presented.
In the ordinary course of its business, the Company is involved in, from time to time, various legal actions, including any matters described below, involving product liability, employment, intellectual property and commercial disputes, shareholder related matters, environmental proceedings, tax disputes, and governmental proceedings and investigations, some of which have been settled by the Company. In the opinion of management, such matters are either adequately covered by insurance or otherwise indemnified, or are not expected, individually or in the aggregate, to result in a material, adverse effect on the Company’s financial condition. However, it is possible that the Company’s results of operations, financial position and cash flows in a particular period could be materially affected by these contingencies.
The Company accrues for loss contingencies when it is deemed probable that a loss has been incurred and that loss is estimable. The amounts accrued are based on the full amount of the estimated loss before considering insurance proceeds and do not include an estimate for legal fees expected to be incurred in connection with the loss contingency. The Company consistently accrues legal fees expected to be incurred in connection with loss contingencies as those fees are incurred by outside counsel as a period cost.
On December 21, 2023, Fortis Advisors, LLC (representative of the security holders of ACell, Inc. (“ACell”)) filed for arbitration against Integra Life Sciences claiming breach of contract related to the earnout consideration from the 2021 acquisition of ACell. Refer below for additional information on the ACell contingent considerations. The Company believes that it has strong defenses to the allegations in the arbitration and intends to defend the matter vigorously.
On September 12, 2023, a securities class action complaint, captioned Pembroke Pines Firefighters & Police Officers Pension Fund v. Integra LifeSciences Holdings Corporation, No. 23-cv-20321 (D.N.J.), was filed by a purported stockholder of the Company in the United States District Court for the District of New Jersey (the “Pembroke Litigation”) against the Company and certain of the Company’s current and former executive officers. The Pembroke Litigation, filed on behalf of a putative class of stockholders who purchased or acquired the Company’s common stock between March 11, 2019 and May 22, 2023, inclusive, alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder, on the basis of purportedly materially false and misleading statements and omissions relating to certain quality systems issues identified by the U.S. Food and Drug Administration at the Company’s Boston, Massachusetts manufacturing facility, the Company’s efforts to remediate those issues, and the Company’s forecasts for certain products in its Tissue Technologies segment. The complaint seeks, among other things, compensatory damages, attorneys’ fees, expert fees, and other costs. The Company believes that it has strong defenses to the allegations in the Pembroke Litigation, and intends to defend the matter vigorously.
Contingent Consideration
The Company determined the fair value of contingent consideration during the three month period ended March 31, 2024 and March 31, 2023 to reflect the change in estimate, additions, payments, transfers and the time value of money during the period.
27
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
A reconciliation of the opening balances to the closing balances of these Level 3 measurements for the three months ended March 31, 2024 and March 31, 2023 is as follows (in thousands):
Three Months Ended March 31, 2024Contingent Consideration Liability Related to Acquisition of:
ArkisLocation in Financial StatementsDerma SciencesACellSurgical Innovations Associates (SIA), Inc.Location in Financial Statements
Balance as of January 1, 2024
$15,755 $2,557 $300 68,700 
Change in fair value of contingent consideration liabilities (83)Research and development39 — 500 Selling, general and administrative
Balance as of March 31, 202415,672 2,596 300 69,200 
Short-Term $7,562 $— $— $29,300 Accrued expenses and other current liabilities
Long-Term8,110 2,596 300 39,900 Other liabilities
Total15,672 2,596 300 69,200 
Three Months Ended March 31, 2023Contingent Consideration Liability Related to Acquisition of:
Arkis Location in Financial StatementsDerma SciencesACellSurgical Innovations Associates (SIA), Inc.Location in Financial Statements
Balance as of January 1, 2023
$12,895 $230 $3,700 $57,607 
Change in fair value of contingent consideration liabilities3,299 Research and development— (2,200)3,600 Selling, general and administrative
Balance as of March 31, 2023
$16,194 $230 $1,500 $61,207 
Short-Term $4,388 $— $— $12,500 Accrued expenses and other current liabilities
Long-Term11,806 230 1,500 48,707 Other liabilities
Total16,194 230 1,500 61,207 
Arkis BioSciences Inc.
As part of the acquisition of Arkis BioSciences Inc. (“Arkis”), the Company is required to pay the former shareholders of Arkis up to $25.5 million based on the timing of certain development milestones of $10.0 million and commercial sales milestones of $15.5 million, respectively. The Company used a probability weighted income approach to calculate the fair value of the contingent consideration that considered the possible outcomes of scenarios related to each specified milestone. The Company estimated the fair value of the contingent consideration to be $13.1 million at the acquisition date.
Derma Sciences, Inc.
The Company assumed contingent consideration incurred by Derma Sciences, Inc. (“Derma Sciences”) related to its acquisitions of BioD, LLC and the intellectual property related to Medihoney® products. The Company accounted for the contingent liabilities by recording the fair value on the date of the acquisition based on a probability weighted income approach. The Company has already paid $33.3 million related to the aforementioned contingent liabilities. One contingent milestone remains which relates to net sales of Medihoney®™ products exceeding certain amounts defined in the agreement between the Company and Derma Sciences. The potential maximum undiscounted payment amounts to $3.0 million.
28
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
ACell, Inc.
As part of the acquisition of ACell, the Company is required to make payments to the former shareholders of ACell up to $100 million in total for years 2022, 2023, and 2025 based on the achievement by the Company of certain revenue-based performance milestones. The 2022 and 2023 milestones were not achieved, leaving only one contingent milestone remaining. The Company used iterations of the Monte Carlo simulation to calculate the fair value of the contingent consideration that considered the possible outcomes of scenarios related to each specific milestone. The Company estimated the fair value of the contingent consideration to be $23.9 million at the acquisition date.
Surgical Innovations Associates, Inc.
As part of the acquisition of Surgical Innovations Associates, Inc. (“SIA”), the Company is required to pay to the former shareholders of SIA up to $90.0 million for two separate payments, which are dependent on 1) achieving certain revenue-based performance milestones in 2023, 2024, and 2025 (up to $50.0 million in additional payments), as well as 2) the approval by the FDA of the PMA for DuraSorb for certain uses by certain timing targets (up to $40.0 million in additional payments). The Company used iterations of the Monte Carlo simulation to calculate the fair value of the contingent consideration for the revenue-based milestone that considered the possible outcomes of scenarios related to each specific milestone for the revenue based performance milestone. The Company used probabilities of achieving the conditions to calculate the fair value of the contingent consideration for the PMA approval milestone. The Company estimated the fair value of the contingent consideration for the revenue based milestone to be $32.6 million at the acquisition date and $25.0 million for the PMA approval milestone at the acquisition date.


29
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion and analysis of the Company’s financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and the related notes thereto appearing elsewhere in this Quarterly Report on Form 10-Q (this “Quarterly Report”) and our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2023.
We have made statements in this Quarterly Report that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”). All statements other than statements of historical fact contained in this Quarterly Report, including, but not limited to, statements regarding our business strategy and plans, growth and growth strategies, developments in the markets for our products and services, financial results, development launches and effectiveness, research and development strategy, regulatory approvals, competitive strengths, the potential or anticipated direct or indirect impact of the Coronavirus pandemic on our business, results of operations, and/or financial condition, objectives of management for future operations and current expectations or forecasts of future results, our expectations regarding the Boston facility; restructuring and cost-saving initiatives, intellectual property rights, litigation and tax matters, governmental proceedings and investigations, mergers and acquisitions, divestitures, market acceptance of our products and services, accounting estimates, financing activities, ongoing contractual obligations, working capital adequacy, value of our investments, our effective tax rate, our expected returns to shareholders, and sales efforts, are forward-looking statements. In some cases, these forward-looking statements may be identified by forward-looking words such as “believe,” “may,” “might,” “could,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “seek,” “plan,” “expect,” “should,” “would” or the negative version of these words or other similar words and expressions in this Quarterly Report.
These forward-looking statements are subject to a number of risks, uncertainties and assumptions about the Company and other matters that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. We believe these risks include but are not limited to those described under the headings “Risk Factors” and “Special Note Regarding Forward-Looking Statements” in our Annual Report on Form 10-K for the year ended December 31, 2023 and in this Quarterly Report, as such factors may be updated from time to time in our periodic filings with the Securities and Exchange Commission (the “SEC”), which are accessible on the SEC’s website at https://www.sec.gov. Such risks and uncertainties include, but are not limited, to the following: the ongoing and possible future effects of global challenges, including macroeconomic uncertainties, inflation, supply chain disruptions, trade regulation and tariffs, other economic disruptions and U.S. and global recession concerns, on the Company’s customers and on the Company’s business, financial condition, results of operations and cash flows; the Company's ability to execute its operating plan effectively; the Company’s ability to successfully integrate acquired businesses; the Company’s ability to achieve sales growth in a timely fashion; the Company’s ability to manufacture and ship sufficient quantities of its products to meet its customers’ demands; the ability of third-party suppliers to supply us with raw materials and finished products; global macroeconomic and political conditions, including the war in Ukraine and the conflict in Israel and Gaza; the Company’s ability to manage its direct sales channels effectively; the sales performance of third-party distributors on whom the Company relies to generate revenue for certain products and geographic regions; the Company’s ability to access and maintain relationships with customers of acquired entities and businesses; physicians’ willingness to adopt and third-party payors’ willingness to provide or maintain reimbursement for the Company’s recently launched, planned and existing products; initiatives launched by the Company's competitors; downward pricing pressures from customers; the Company's ability to secure regulatory approval for products in development; the Company’s ability to remediate quality systems violations; fluctuations in hospitals’ spending for capital equipment; the Company’s ability to comply with regulations regarding products of human origin and products containing materials derived from animal source; difficulties in controlling expenses, including costs to procure and manufacture our products; the impact of changes in management or staff levels; the impact of goodwill and intangible asset impairment charges if future operating results of acquired businesses are significantly less than the results anticipated at the time of the acquisitions, the Company’s ability to leverage its existing selling organizations and administrative infrastructure; the Company’s ability to increase product sales and gross margins, and control non-product costs; the Company’s ability to achieve anticipated growth rates, margins and scale and execute its strategy generally; the amount and timing of divestiture, acquisition and integration-related costs; the geographic distribution of where the Company generates its taxable income; new U.S. and foreign government laws and regulations, and changes in existing laws, regulations and enforcement guidance, which affect areas of our operations including, but not limited to, those affecting the health care industry, including the EU Medical Devices Regulation; the scope, duration and effect of additional U.S. and international governmental, regulatory, fiscal, monetary and public health responses to public health crises; fluctuations in foreign currency exchange rates; the amount of our bank borrowings outstanding and other factors influencing liquidity; potential negative impacts resulting from environmental, social and governance matters; and the potential impact of our compliance with governmental regulations and accounting guidance.
30
We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, results of operations, financial condition, and/or cash flows. These forward-looking statements speak only as of the date of this Quarterly Report and we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by applicable law. You should carefully consider forward-looking statements and understand that such forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and involve a variety of risks and uncertainties.
GENERAL
We are a leading global medical technology company innovating treatment pathways in surgical, neurologic and regenerative care to advance patient outcomes and set new standards of surgical, neurologic and regenerative care. Founded in 1989 with the acquisition of an engineered collagen technology platform used to repair and regenerate tissue, our common stock trades on the Nasdaq Global Select Market (“Nasdaq”) under the symbol “IART.” We have developed numerous product lines from this technology for applications ranging from burn and deep tissue wounds to the repair of dura mater in the brain, as well as nerves and tendons. We have expanded our base regenerative technology business to include surgical instruments, neurosurgical products and advanced wound care through global acquisitions and product development to meet the evolving needs of our customers and enhance patient care.
Our products are sold in more than 120 countries through a direct sales force as well as distributors and wholesalers. We manufacture and sell medical technologies and products in two reportable business segments: Codman Specialty Surgical (“CSS”) and Tissue Technologies (“TT”). The CSS segment, which represents approximately two-thirds of our total revenue, consists of market-leading technologies and instrumentation used for a wide range of specialties, such as neurosurgery, neurocritical care and otolaryngology. We are the world leader in neurosurgery and one of the top three providers in instruments used in precision, specialty, and general surgical procedures. Our TT segment generates about one-third of our overall revenue and focuses on three main areas: complex wound surgery, surgical reconstruction, and peripheral nerve repair.
We have key manufacturing and research facilities located in California, Maryland, Massachusetts, New Jersey, Ohio, Puerto Rico, Tennessee, Utah, France, Germany, Ireland and Switzerland. We source most of our handheld surgical instruments and dural sealant products through specialized third-party vendors.
Our strategies are focused around five pillars. Of these five pillars, we have identified three core growth drivers: (1) innovating for outcomes, (2) growing internationally, and (3) broadening our impact on care pathways. Our execution of the core growth drivers is enabled by two key levers: (4) driving operational and customer excellence and (5) cultivating a high-performance culture. As outlined in greater detail below, we believe these five pillars will enable us to realize and advance our integrated growth strategy.
To this end, our executive leadership team has established the following key priorities aligned to the following five pillars:
Innovating for Outcomes. An important part of Integra’s growth strategy is introducing new products to strengthen and expand our portfolio, including via acquisitions. For example, On April 1, 2024, the Company successfully completed the acquisition of Acclarent from Ethicon, Inc., a subsidiary of Johnson & Johnson. Acclarent is an innovator and market leader in ear, nose and throat (“ENT”) procedures and we believe that the acquisition of Acclarent will provide Integra with the opportunity to become a leading provider of ENT products and technologies. Furthermore, we believe that, owing to the ENT segment being an anatomical adjacency to neurosurgery, the acquisition will allow Integra to deliver future innovation both within the ENT segment and across our other CSS technology platforms. Additionally, we seek clinical evidence to support regulatory approval and strong reimbursement of our product portfolio around the world, including new indications for existing technologies. For example, in 2021, we filed a pre-market approval (“PMA”) application for a specific indication for Surgimend® in the use of post-mastectomy breast reconstruction. In 2022, we acquired SIA, which is also pursuing a PMA for DuraSorb for use in implant-based breast reconstruction (“IBBR”), and in June 2023 we completed enrollment in the DuraSorb U.S. investigational device exemption clinical study for two-stage breast reconstruction; the primary follow-up period is one year after device implantation. We hope to have approval for DuraSorb in 2025. For SurgiMend, we are not currently able to predict an approval date because of the delays in remediating our Boston manufacturing site. We also continued to advance the development of pioneering neurosurgical technologies with the expansion of our product offerings. In 2023 we launched the CUSA® Clarity Tips for use in surgical procedures requiring the controlled fragmentation, emulsification and aspiration of bone as well as in laparoscopic liver surgery.
Growing Internationally: Over the years, we have been significantly expanding our global footprint through investments in our commercial and manufacturing organizations, the expansion and development of international markets and new product introductions. As part of our In-China-For-China strategy, we continue the build out of our assembly capabilities in our new facility in Suzhou, China. Several new products were introduced in select international markets in 2023, including MicroMatrix® and Certas Plus® Programmable Valve which were launched in Europe, and CUSA Clarity Laparoscopic tip
31
which was launched in Australia, New Zealand, Japan, Canada, South Africa and Israel. In addition, DuraGen Secure, received approval in Japan, while DuraGen Plus, an absorbable and sutureless collagen onlay indicated as a dura substitute for the repair of dura mater, was approved in China.
Broadening Impact on Care Pathways. We seek ways to develop products and technologies that impact the lives of patients, starting with the journey that a patient takes from diagnosis and treatment planning to surgery and postoperative care. We are well-established in acute care in the hospital setting and continue to leverage that strong position to grow in this segment and shape treatment pathways into preoperative care and additional sites of care.
Driving Operations and Customer Excellence. We have been making investments to build more responsive and scalable processes, enhance the reliability of our supply chain, and drive productivity initiatives to further supply and lower costs. Additionally, we continue to invest in technologies, systems and processes to enhance the customer experience. We continue to invest in our capacity expansion. This includes ongoing projects of transferring our Boston manufacturing to a new location in Braintree, Massachusetts, validating manufacturing processes in our manufacturing facility in Plainsboro, New Jersey and increasing cleanroom capacity in our Memphis, Tennessee location.
Cultivating a High-Performance Culture. In seeking to sustain a culture of excellence and accountability, we have focused on employee empowerment and agility and building a diverse and inclusive workplace. These efforts resulted in our being named in several best workplace lists globally in 2023. Additionally, we have been making further strides in advancing our environmental, social and governance (“ESG”) agenda to drive sustainability across the organization and recently published our second annual ESG report in the third quarter of 2023. For more information on our ESG strategy, goals, performance, and achievements, please visit “Our Company—ESG Report” at https://www.integralife.com/esg-report. Information on our website is not incorporated by reference herein and is not part of this Quarterly Report.
New Product Introductions and Research and Development Updates
We continue to invest in collecting clinical evidence to support our existing products and new product launches, and to ensure that we obtain market access for broader and more cost-effective solutions.
Electromechanical Technologies and Instrumentation. The CSS business consists of a broad portfolio of market-leading brands, such as Codman®, DuraGen®, DuraSeal®, CUSA®, Mayfield®, Bactiseal®, and Certas® Plus, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. The growth in this business in recent years has been fueled by geographic expansion and new product registrations in markets, such as China, Japan, and Europe, which we expect to continue in the near-to-long term. Because our electromechanical products and instruments address significant needs in surgical procedures and limit uncertainty for surgeons, we continue to invest in registrations, clearances, and approvals for new indications and next generation improvements to our market-leading products. We have several active programs focused on life cycle management and innovation for capital and disposable products in our portfolio. Our product development efforts are focused on core clinical applications in cerebrospinal fluid (“CSF”) management, neuro-critical care monitoring, minimally invasive instruments and electrosurgery and ultrasonic medical technologies, as well as our ambition to transform the standard of care in neurosurgery with product advancements in minimally invasive surgery (“MIS”) and the surgical management of intracerebral hemorrhage (“ICH”). Our lighting franchise is among the most dynamic in the industry.
We are focused on the development of core clinical applications in our electromechanical technologies portfolio. We continue to update our CUSA Clarity platform by incorporating new ultrasonic handpiece and integrated electrosurgical capabilities. We have made several enhancements to our CUSA Clarity Tissue Ablation System. The extended laparoscopic tip was launched in the U.S. to enhance laparoscopic liver procedures. In addition, a single-sided bone tip received 510(k) clearance from the FDA. Commercial launch was completed successfully in early 2023. In August 2023, we launched a modified 23 kHz CUSA Electrosurgery Module (“CEM”) for Clarity handpieces that can be used with additional electrosurgery generators. We continue to work with several instrument partners to bring new surgical instrument platforms to the market.
We also continued to advance the early-stage technology platforms we acquired in 2019. Through the acquisition of Arkis Biosciences, Inc. (“Arkis”) we added a platform technology, CerebroFlo® external ventricular drainage (“EVD”), a catheter with Endexo® technology, a permanent additive designed to reduce the potential for catheter obstruction due to thrombus formation. The CerebroFlo EVD catheter has demonstrated an average of 99% less thrombus accumulation onto its surface, in vitro, compared to a market leading EVD catheter. Our work to combine our Bactiseal® antimicrobial technology with the Endexo anti-occlusive technology continues to progress for both a silicone-based hydrocephalus and EVD project.
We also continued to advance our innovation from the Rebound Therapeutics Corporation (“Rebound Therapeutics”), which was acquired in 2019. Rebound Therapeutics specializes in a single-use medical device, known as the Aurora Surgiscope, which is the only tubular retractor system designed for cranial surgery with an integrated access channel, camera and lighting. The 9mm Surgiscope received 510(k) clearance from the FDA in the fourth quarter of 2023.
32
On August 18, 2022, the Company, after consultation with the FDA and other regulatory authorities outside of the United States, initiated an immediate voluntary global product removal of all CereLink® intracranial pressure monitors. Shipments of CereLink monitors to international markets resumed in the third quarter of 2023 and shipments in the U.S. resumed in the first quarter of 2024.
Regenerative Technologies. We were the first company to receive an FDA claim for regeneration of dermal tissue and are a world leader in regenerative technology. Our regenerative technology development program applies our expertise in bioengineering to a range of biomaterials including natural materials such as purified collagen, intact human or animal tissues, honey as well as resorbable synthetic polymers with our DuraSorb and DuraSeal product lines. These unique product designs are used for neurosurgical and reconstructive surgical applications, as well as dermal regeneration, including the healing of chronic and acute wounds, tendon and nerve repair. Our regenerative technology platform includes our legacy Integra® Dermal Regeneration Template (“IDRT”) products and complementary technologies that we have acquired. Our collagen manufacturing capability, combined with our history of innovation, including our launch of NeuraGen 3D, provides us with strong platform technologies for multiple indications.
In the second quarter of 2023, after consultation with the FDA, The Company initiated a voluntary global recall of all products manufactured at the Boston facility, including PriMatrix®, SurgiMend®, Revize™, and TissueMend™, distributed between March 1, 2018 and May 22, 2023.
In the third quarter of 2021, we filed a PMA application for a specific indication for Surgimend® in the use of post-mastectomy breast reconstruction. In 2022, we acquired SIA, which has also submitted a PMA application for DuraSorb with IBBR, and in June 2023 we completed enrollment in the DuraSorb U.S. IDE clinical study for two-stage breast reconstruction; the primary follow-up period is one year after device implantation. By offering two distinct product solutions, we believe we have the opportunity to build a leading position in the IBBR market. We hope to have approval for DuraSorb in 2025. For SurgiMend, we are not currently able to predict an approval date because of the delays in remediating our Boston manufacturing site.
Additionally, in 2022 we launched NeuraGen 3D Nerve Guide Matrix, a resorbable implant for repair of peripheral nerve discontinuities and engineered to create an optimized environment for nerve regeneration. Following the completion of design control activities in 2022, we launched both Cytal and MicroMatrix in Europe in 2023. In 2023, the Company received 510(k) clearance from the FDA for MicroMatrix® Flex, which is now commercially available in the U.S. as of March 2024.
As part of our ongoing efforts to remain compliant, the Company continues to work towards European Union Medical Device Regulation (“EU MDR”) certifications. In 2023 the Company received EU MDR certification in the CSS segment for Hakim Programmable Valves, Certas Plus without Bactiseal catheters, and DuraSeal Dural. Additionally, the Company received EU MDR certification in the TT segment for IDRT and BioPatch in 2023, and MicroMatrix and Cytal in 2024.
FDA Matters
On March 7, 2019, TEI Biosciences, Inc. (“TEI”), one of our wholly-owned subsidiaries, received a Warning Letter (the “2019 Warning Letter”), dated March 6, 2019, from the FDA. The 2019 Warning Letter related to quality systems issues at TEI’s manufacturing facility located in Boston, Massachusetts. The Boston facility manufactures extracellular bovine matrix products in our TT segment that are sold both in wound reconstruction and care and in private label channels. The letter resulted from an inspection held at that facility in October and November 2018 and did not identify any new observations that were not already provided in the Form 483 that followed the inspection. We submitted our initial response to the 2019 Warning Letter on March 28, 2019 and provide regular progress reports to the FDA as to its corrective actions. On October 28, 2021, the FDA initiated an inspection of the facility and at the conclusion of the inspection, issued an FDA Form 483 on November 12, 2021 (the “2021 Form 483”). We provided an initial response to the inspection observations. On March 1, 2023, the FDA commenced an inspection of the Boston facility, and issued an FDA Form 483 at the conclusion of this inspection (the “2023 Form 483”). In May 2023, after consultation with the FDA, the Company initiated a voluntary recall of products manufactured in the Boston facility distributed between March 1, 2018 and May 22, 2023, and extended the temporary halt of manufacturing at the facility to implement additional detection and quality controls. On July 19, 2023, TEI received a Warning Letter, dated July 17, 2023, from the FDA related to quality system issues at the Boston facility (the “2023 Warning Letter”). The 2023 Warning Letter did not identify any new observations that had not already been provided in the 2023 Form 483. The Company has submitted periodic responses to the FDA for both the 2023 Form 483 and the 2023 Warning Letter. We are committed to resolving the matters identified in the Warning Letters and Form 483s and are continuing our significant efforts to remediate the observations.
Although the Warning Letters do not restrict the Company’s ability to seek FDA 510(k) clearance of products, PMAs for Class III devices to which the quality system regulation violations are reasonably related will not be approved until the violations have been addressed. We cannot give any assurances that the FDA will be satisfied with our response to the issues identified by the FDA or as to the expected date of the resolution of such issues. Until the issues cited by the FDA are resolved to the FDA’s satisfaction, the FDA may initiate additional regulatory action without further notice. Any adverse regulatory
33
action, depending on its magnitude, may restrict us from effectively manufacturing, marketing and selling our products and could have a material adverse effect on our business, financial condition and results of operations.
As required by the 2023 Warning Letter, we retained an outside expert consultant to perform an audit of the Boston facility in March 2024. While we anticipated this audit would yield findings and there would be remaining work to be completed, the audit yielded more findings than we anticipated. We are still determining the full scope of the work required to address these additional findings and resume commercial distribution. Based on a preliminary assessment of the work to be done, we no longer expect to resume commercial distribution in 2024. As a result, the Company elected to perform impairment testing on certain definite-lived intangibles and goodwill. For further detail on the impairment testing, see Note 5. Goodwill and Other Intangible Assets.
We continue to work with our customers in wound reconstruction and care as we move toward commercialization. Revenues of products manufactured in the Boston facility for the year ended December 31, 2022 were approximately 5.3% of consolidated revenues.
On August 18, 2022, we, after consultation with the FDA and other regulatory authorities outside of the United States, initiated an immediate voluntary global product removal of all CereLink intracranial pressure monitors as a result of customer reports about monitors whose pressure readings were out of range. We submitted a traditional 510(k) premarket notification to the FDA on September 15, 2023 and received 510(k) clearance on February 4, 2024 from the FDA. The submission included design changes to remedy the out-of-range readings. Shipments of CereLink monitors in the U.S. resumed in the first quarter of 2024 and shipments to international markets resumed in the third quarter of 2023.
Optimization and Integration Activities
As a result of our ongoing acquisition strategy and significant growth in recent years, we have undertaken cost-saving initiatives to consolidate manufacturing operations, distribution facilities and transfer activities, eliminate duplicative positions, realign various sales and marketing activities, and expand and upgrade production capacity for our regenerative technology products. These efforts are expected to continue and while we expect a positive impact from ongoing restructuring, integration, and manufacturing transfer and expansion activities, such results remain uncertain.
RESULTS OF OPERATIONS
Executive Summary
Net loss for the three months ended March 31, 2024 was $3.3 million, or $0.04 per diluted share, as compared to net income of $24.2 million or $0.29 per diluted share for the three months ended March 31, 2023. The decrease in net income for the three months ended March 31, 2024, was driven by higher manufacturing costs and impairment charges of $7.1 million, primarily related to our Boston facility.
34
Special Charges
Income before taxes includes the following special charges:
Three Months Ended March 31,
Dollars in thousands20242023
Acquisition, divestiture and integration-related charges$4,723 $8,776 
Structural optimization charges6,505 4,335 
EU medical device regulation12,023 11,404 
Boston recall expenses(1)
6,979 — 
Total$30,230 $24,515 
(1) This primarily includes idle capacity charges and inventory write offs.
The items reported above are reflected in the condensed consolidated statements of operations as follows:
Three Months Ended March 31,
Dollars in thousands20242023
Cost of goods sold $13,021 $6,066 
Research and development5,843 4,218 
Selling, general and administrative11,411 14,730 
Other income(45)(499)
 Total$30,230 $24,515 
We typically define special charges as items for which the amounts and/or timing of such expenses may vary significantly from period to period, depending upon our acquisition, divestiture, integration and restructuring activities, and for which the amounts are non-cash in nature, and for which the amounts are not expected to recur at the same magnitude. We believe that given our ongoing strategy of seeking acquisitions, our continuing focus on rationalizing our existing manufacturing and distribution infrastructure and our continuing review of various product lines in relation to our current business strategy, some of the special charges discussed above could recur with similar materiality in the future.
We believe that the separate identification of these special charges provides important supplemental information to investors regarding financial and business trends relating to our financial condition and results of operations. Investors may find this information useful in assessing the comparability of our operating performance from period to period, against the business model objectives that management has established, and against other companies in our industry. We provide this information to investors so that they can analyze our operating results in the same way that management does and to use this information in their assessment of our core business and valuation of the Company.
Revenues and Gross Margin
The Company’s revenues and gross margin on product revenues were as follows:
 Three Months Ended March 31,
Dollars in thousands20242023
Segment Net Sales
Codman Specialty Surgical$256,434$248,136
Tissue Technologies112,438132,710
Total revenues$368,872380,846
Cost of goods sold162,038147,975
Gross margin on total revenues$206,834$232,871
Gross margin as a percentage of total revenues56.1 %61.1 %
35
Three Months Ended March 31, 2024 as Compared to Three Months Ended March 31, 2023
Revenues
For the three months ended March 31, 2024, total revenues decreased by $12.0 million to $368.9 million from $380.8 million for the same period in 2023. This decrease was primarily driven by the impact of the Boston recall of $15.2 million. The decrease was also inclusive of an unfavorable foreign currency impact of $2.4 million on revenues. Excluding the impacts of these items, domestic revenues decreased by $1.3 million, or 0.5% compared to the same period in the prior year. International revenues increased by $8.7 million or 8.1% as compared to the prior period. The increase in international revenues was primarily driven by increases in our APAC region, including China and Taiwan.
In the CSS segment, revenues were $256.4 million which was an increase of $8.3 million, or 3.3% as compared to the prior-year period, inclusive of a $2.4 million unfavorable foreign currency impact on revenue. Excluding the impact of foreign exchange, the Neurosurgery portfolio grew mid-single digits primarily due to increased sales in Neuro Monitoring and CSF Management.
In the TT segment, revenues were $112.4 million which was a decrease of $20.3 million, or 15.3% from the prior-year period. This decrease is primarily driven by the impact of the Boston recall of $15.2 million decline in revenue. Excluding the impact of these items, the TT segment showed a decrease in sales as compared to the same period in the prior year, primarily attributable to Integra Skin MediHoney® and MicroMatrix®
Gross Margin
Gross margin was $206.8 million for the three months ended March 31, 2024, a decrease of $26.0 million from $232.9 million for the same period in 2023. Gross margin as a percentage of revenues was 56.1% for the three months ended March 31, 2024 and 61.1% for the same period in 2023. The decrease in gross margin percentage was primarily associated with higher costs related to idle capacity at our Boston facility, as well as additional manufacturing expenses across our manufacturing sites.
Operating Expenses
The following is a summary of operating expenses as a percent of total revenues:
 Three Months Ended March 31,
 20242023
Research and development7.3 %7.0 %
Selling, general and administrative44.9 %43.8 %
Intangible asset amortization2.7 %0.8 %
Total operating expenses54.9 %51.6 %
Total operating expenses, which consist of research and development, selling, general and administrative, and amortization expenses, increased by $6.4 million, or 3.3% to $202.9 million in the three months ended March 31, 2024, compared to $196.5 million in the same period in 2023, mainly driven by intangible amortization.
Research and Development
Research and development expenses for the three months ended March 31, 2024 increased by $0.2 million as compared to the same period in the prior year.
Selling, General and Administrative
Selling, general and administrative costs for the three months ended March 31, 2024 decreased by $0.9 million as compared to the same period in the prior year.
Intangible Asset Amortization
Amortization expense (excluding amounts reported in cost of product revenues for technology-based intangible assets) for the three months ended March 31, 2024 was $10.1 million compared to $3.1 million for the same period in the prior year. The increase is driven by the impairment of customer relationship intangible related to our Boston facility.
36
Non-Operating Income and Expenses
The following is a summary of non-operating income and expenses:
 Three Months Ended March 31,
Dollars in thousands20242023
Interest income$5,040 $4,107 
Interest expense(13,624)(12,100)
Other income, net(610)1,389 
Total non-operating income and expense$(9,194)$(6,604)
Interest Income
Interest income for the three months ended March 31, 2024 increased by $0.9 million as compared to the same period in the prior year primarily due to higher interest rates.
Interest Expense
Interest expense for the three months ended March 31, 2024 increased by $1.5 million as compared to the same period in the prior year primarily due incremental borrowing and higher interest rates.
Other Income, net
Other income, net for the three months ended March 31, 2024 decreased by $2.0 million compared to the same period in the prior year. The decrease is primarily driven by lower Transition Service Agreement (“TSA”) income from our divestitures.
Income Taxes
 Three Months Ended March 31,
Dollars in thousands20242023
Income before income taxes$(5,230)$29,778 
Income tax (benefit) expense(1,949)5,552 
Effective tax rate37.3 %18.6 %
Our effective income tax rates for the three months ended March 31, 2024 and 2023 were 37.3% and 18.6%, respectively.
For the three months ended March 31, 2024, the primary drivers of the higher tax rate relates to a $1.5 million expense due to a shortfall from stock based compensation, offset by a tax benefit for the intangible asset impairment, as compared to previous year. The Company does not have tax basis in the impaired intangible asset and has treated the tax impact as a discrete event in this quarter.
The effective tax rate may vary from period to period depending on, among other factors, the geographic and business mix of taxable earnings and losses, tax planning and settlements with various taxing authorities. We consider these factors and others, including the Company’s history of generating taxable earnings, in assessing our ability to realize tax assets on a quarterly basis.
Additionally, changes to income tax laws and regulations, in any of the tax jurisdictions in which the Company operates, could impact the effective tax rate. Various governments, both U.S. and non-U.S., are increasingly focused on tax reform and revenue-raising legislation. The current U.S. administration has proposed tax reform which, if enacted, may increase the Company’s U.S. federal income tax liability. Further, legislation in foreign jurisdictions may be enacted, in response to the base erosion and profit-shifting project begun by the Organization for Economic Cooperation and Development (“OECD”). Such changes in the U.S. and non-U.S. jurisdictions could have an adverse effect on the Company's effective tax rate.
The OECD released model rules related to a new 15% global minimum tax regime (“Pillar 2”). Several of the jurisdictions in which we operate have already adopted some form of the model rules, which could impact the amount of taxes that the Company pays during 2024 and future taxable periods. The rules are complex and provide for delays of implementing the tax during the early transition years, if certain conditions are met. At this time, the Company is projecting an immaterial amount related to Pillar 2 tax liability for the 2024 year. The Company will continue to analyze the new Pillar 2 laws and any related guidance to determine potential impacts. Such changes in U.S. and non-U.S. jurisdictions could have an adverse effect on the Company’s effective tax rate.
37
As discussed previously, the Company recorded a total impairment charge of $7.1 million in intangible asset amortization during the first quarter of 2024. The Company does not have tax basis in the impaired customer relationship, therefore the charge resulted in a $1.6 million reduction of the Company’s deferred tax liability related to such intangible.
While it is often difficult to predict the outcome or the timing of the resolution of a particular matter with the various federal, state, and foreign tax authorities, we believe that our reserves reflect the most probable outcome of known tax contingencies. Settlement of a particular issue would usually require the use of cash. A favorable resolution would be recognized as a reduction to our annual effective tax rate in the year of resolution. The Company’s tax reserves are presented in the balance sheet within other liabilities, except for amounts relating to items that we expect to pay in the coming year, which would be classified as current income taxes payable.
GEOGRAPHIC PRODUCT REVENUES AND OPERATIONS
We attribute revenues to geographic areas based on the location of the customer. Total revenue by major geographic area consisted of the following:
Three Months Ended March 31,
Dollars in thousands20242023
United States$256,229 $271,002 
Europe41,596 41,064 
Asia Pacific49,545 50,473 
Rest of World21,502 18,307 
Total Revenues$368,872 $380,846 
We generate significant revenues outside the U.S., a portion of which are U.S. dollar-denominated transactions conducted with customers that generate revenue in currencies other than the U.S. dollar. As a result, currency fluctuations between the U.S. dollar and the currencies in which those customers do business could have an impact on the demand for our products in foreign countries. Local economic conditions, regulatory compliance or political considerations, the effectiveness of our sales representatives and distributors, local competition and changes in local medical practice all may combine to affect our sales into markets outside the U.S.
Domestic revenues decreased by $14.8 million for the three months ended March 31, 2024 compared to the same period last year. European sales increased by $0.5 million for the three months ended March 31, 2024 compared to the same period last year. Sales to customers in Asia Pacific decreased by $0.9 million for the three months ended March 31, 2024. Sales to customers in the the Rest of World for the three months ended March 31, 2024 increased by $3.2 million compared to the same period last year. The international revenues were impacted by $2.4 million of unfavorable foreign exchange impact, with the larger impact in Asia. The decrease in global revenues is primarily the result of the Boston recall which affected both domestic and international markets.
LIQUIDITY AND CAPITAL RESOURCES
Working Capital
The Company’s working capital as of March 31, 2024 and December 31, 2023 was $1,113.3 million and $751.1 million, respectively. Working capital consists of total current assets less total current liabilities as presented in the consolidated balance sheets.
Cash and Marketable Securities
The Company had cash and cash equivalents totaling approximately $591.9 million and $276.4 million at March 31, 2024 and December 31, 2023 respectively, which are valued based on Level 1 measurements in the fair value hierarchy. At March 31, 2024, our non-U.S. subsidiaries held approximately $210.6 million of cash and cash equivalents that are available for use outside the U.S. The Company asserts that it has the ability and intends to indefinitely reinvest the undistributed earnings from its foreign operations unless there is no material tax cost to remit the earnings into the U.S.
Short Term Investments
The Company had short term investments, primarily consisting of time deposits, totaling approximately $71.2 million at March 31, 2024 compared to $32.7 million at December 31, 2023.

38
Cash Flows
 Three Months Ended March 31,
Dollars in thousands20242023
Net cash provided by operating activities$15,756 $26,156 
Net cash used in investing activities(53,965)(13,704)
Net cash provided by (used in) financing activities358,676 (162,683)
Effect of exchange rate fluctuations on cash(4,963)937 
Cash Flows Provided by Operating Activities
Operating cash flows for the three months ended March 31, 2024 decreased by $10.4 million compared to the same period in 2023. Within operating cash flows, net income less non-cash adjustments decreased for the three months ended March 31, 2024 by approximately $29.7 million as compared to the same period in 2023 primarily due to lower revenues attributable to the Boston recall, as well as additional manufacturing expenses across our manufacturing sites.
The changes in assets and liabilities for the three months ended March 31, 2024, net of business acquisitions, decreased cash flows by $23.4 million, mainly attributable to increases in inventory, and decreases in other current liabilities and accounts receivable.
The changes in assets and liabilities for the three months ended March 31, 2023, net of business acquisitions, decreased cash flows by $42.6 million, primarily due to increases in inventory.
Cash Flows Used in Investing Activities
Uses of cash from investing activities for the three months ended March 31, 2024 related to $38.5 million related to short term investments, and $15.5 million paid for capital expenditures to support operations improvement initiatives at a number of our manufacturing facilities and other information technology investments.
There were no sources of cash from investing activities during the three months ended March 31, 2024.
Uses of cash from investing activities during the three months ended March 31, 2023 related to $13.7 million paid for capital expenditures to support operations improvement initiatives at a number of our manufacturing facilities and other information technology investments.
There were no sources of cash from investing activities during the three months ended March 31, 2023.
Cash Flows Provided by or Used in Financing Activities
Uses of cash from financing activities in the three months ended March 31, 2024 related to the repayments of $15.1 million under our Senior Credit Facility and Securitization Facility. In addition, the Company had $3.1 million in cash taxes paid for net equity settlements.
Sources of cash from financing activities for the three months ended March 31, 2024 were $370.5 million proceeds from borrowings of long-term indebtedness and $6.4 million proceeds from the exercise of stock options.
Uses of cash from financing activities in the three months ended March 31, 2023 related to the repurchase of treasury stock of $150.0 million under the share repurchase agreements, repayments of $12.4 million under our Senior Credit Facility and Securitization Facility. In addition, we had $7.6 million attributable to debt issuance costs, as well as $5.2 million in cash taxes paid for net equity settlements.
Sources of cash from financing activities for the three months ended March 31, 2023 were $10.2 million borrowing under our Senior Credit Facility and Securitization Facility and $2.3 million proceeds from the exercise of stock options.
Amended and Restated Senior Credit Agreement, Convertible Senior Notes, Securitization and Related Hedging Activities
See Note 6. Debt, to the Notes to Unaudited Condensed Consolidated Financial Statements (Part I, Item 1 of this Quarterly Report) for a discussion of our Amended and Restated Senior Credit Agreement, the 2025 Notes and Securitization Facility and Note 7, Derivative Instruments, to the Notes to Unaudited Condensed Consolidated Financial Statements (Part I, Item 1 of this Quarterly Report) for discussion of our hedging activities.
39
Share Repurchase Plan
See Note 11, Treasury Stock, to the Notes to Unaudited Condensed Consolidated Financial Statements (Part I, Item 1 of this Quarterly Report) for further details of our share repurchase programs.
Dividend Policy
We have not paid any cash dividends on our common stock since our formation. Our Senior Credit Facility limits the amount of dividends that we may pay. Any future determinations to pay cash dividends on our common stock will be at the discretion of the Board of Directors and will depend upon our financial condition, results of operations, cash flows and other factors deemed relevant by the Board of Directors.
Capital Resources
We believe that our cash and available borrowings under the Senior Credit Facility are sufficient to finance our operations and capital expenditures for the next 12 months and foreseeable future. Our future capital requirements will depend on many factors, including the growth of our business, the timing and introduction of new products and investments, strategic plans and acquisitions, among others. Additional sources of liquidity available to us include short term borrowings and the issuance of long term debt and equity securities.
Off-Balance Sheet Arrangements
We do not have any off–balance sheet financing arrangements during the three months ended March 31, 2024 that have or are reasonably likely to have, a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to our interests.
Contractual Obligations and Commitments
We will continue to have cash requirements to support seasonal working capital needs and capital expenditures, to pay interest, to service debt, and to fund acquisitions. As part of our ongoing operations, we enter into contractual arrangements that obligate us to make future cash payments.
Our primary obligations include principal and interest payments on the revolving portion and term loan component of the Senior Credit Facility, Securitization Facility and 2025 Notes. See Note 6. Debt, to the Notes to Unaudited Condensed Consolidated Financial Statements (Part I, Item 1 of this Quarterly Report) for details. We also lease some of our manufacturing facilities and office buildings which have future minimum lease payments. See Note 10. Leases and Related Party Leases, to the Notes to Unaudited Condensed Consolidated Financial Statements (Part I, Item 1 of this Quarterly Report) for a schedule of our future minimum lease payments. Amounts related to our other obligations, including employment agreements and purchase obligations were not material.
The Company has contingent consideration obligations related to prior and current year acquisitions and future pension contribution obligations. See Note 9. Retirement Plans, and Note 16. Commitments and Contingencies, to the Notes to Unaudited Condensed Consolidated Financial Statements (Part I, Item 1 of this Quarterly Report) for details. The associated obligations are not fixed. We also have a liability for uncertain tax benefits including interest and penalties. We cannot make a reliable estimate of the period in which the uncertain tax benefits may be realized.

OTHER MATTERS
Critical Accounting Estimates
We based the discussion and analysis of our financial condition and results of operations upon our consolidated financial statements, which have been prepared in conformity with GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amount of assets and liabilities, the disclosure of contingent liabilities, and the reported amounts of revenues and expenses. The critical accounting estimates discussed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 did not materially change in the three months ended March 31, 2024.
Recently Issued Accounting Standards
Information regarding new accounting pronouncements is included in Note 1. Basis of Presentation, to the Notes to Unaudited Condensed Consolidated Financial Statements (Part I, Item 1 of this Quarterly Report), and is applicable to the current period’s unaudited condensed consolidated financial statements.
40
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We are exposed to various market risks, including changes in foreign currency exchange rates and interest rates that could adversely affect our results of operations and financial condition. To manage the volatility relating to these typical business exposures, we may enter into various derivative transactions when appropriate. We do not hold or issue derivative instruments for trading or other speculative purposes.
Foreign Currency Exchange and Other Rate Risks
We operate on a global basis and are exposed to the risk that changes in foreign currency exchange rates could adversely affect our financial condition, results of operations and cash flows. We are primarily exposed to foreign currency exchange rate risk with respect to transactions and net assets denominated in Euros, British pounds, Swiss francs, Canadian dollars, Japanese yen, Mexican pesos, Brazilian reais, Australian dollars, and Chinese yuan. We manage the foreign currency exposure centrally, on a combined basis, which allows us to net exposures and to take advantage of any natural offsets. To mitigate the impact of currency fluctuations on transactions denominated in nonfunctional currencies, we periodically enter into derivative financial instruments in the form of foreign currency exchange forward contracts with major financial institutions. We temporarily record realized and unrealized gains and losses on these contracts that qualify as cash flow hedges in other comprehensive income, and then recognize them in other income or expense when the hedged item affects net earnings.
From time to time, we enter into foreign currency forward exchange contracts to manage currency exposures for transactions denominated in a currency other than an entity’s functional currency. As a result, the impact of foreign currency gains/losses recognized in earnings are partially offset by gains/losses on the related foreign currency forward exchange contracts in the same reporting period. Refer to Note 7. Derivative Instruments, to Notes to Unaudited Condensed Consolidated Financial Statements (Part I, Item 1 of this Quarterly Report) for further information.
We maintain written policies and procedures governing our risk management activities. With respect to derivatives, changes in hedged items are generally expected to be completely offset by changes in the fair value of hedge instruments. Consequently, foreign currency exchange contracts would not subject us to material risk due to exchange rate movements, because gains and losses on these contracts offset gains and losses on the assets, liabilities or transactions being hedged.
The results of operations discussed herein have not been materially affected by inflation.
Interest Rate Risk
Cash and Cash Equivalents - We are exposed to the risk of interest rate fluctuations on the interest income earned on our cash and cash equivalents. A hypothetical 100 basis points movement in interest rates applicable to our cash and cash equivalents outstanding at March 31, 2024 would impact interest income by approximately $5.9 million on an annual basis. We are subject to foreign currency exchange risk with respect to cash balances maintained in foreign currencies.
Debt - Our interest rate risk relates primarily to U.S. dollar SOFR-indexed borrowings. We use interest rate swap derivative instruments to manage our earnings and cash flow exposure to changes in interest rates. These interest rate swaps fix the interest rate on a portion of our expected SOFR-indexed floating-rate borrowings. These interest rate swaps were designated as cash flow hedges as of March 31, 2024. The total notional amounts related to the Company's interest rate swaps were $1.5 billion with $775.0 million effective as of March 31, 2024. Based on our outstanding borrowings at March 31, 2024, a 100 basis points change in interest rates would have impacted interest expense on the unhedged portion of the debt by $5.1 million on an annualized basis. See Note 7. Derivative Instruments, to the Notes to Unaudited Condensed Consolidated Financial Statements (Part I, Item 1 of this Quarterly Report) for further information regarding interest rate swaps.
ITEM 4. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
We maintain disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. Disclosure controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Management has designed our disclosure controls and procedures to provide reasonable assurance of achieving the desired control objectives.
41
As required by Exchange Act Rule 13a-15(b), we have carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of March 31, 2024. Based upon this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective as of March 31, 2024 to provide such reasonable assurance.
Changes in Internal Control Over Financial Reporting
There were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that occurred during the quarter ended March 31, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
In response to business integration activities, we have and will continue to further align and streamline the design and operation of the financial control environment to be responsive to the changing business model.
PART II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
Please refer to Note 16, Commitments and Contingencies, to the Notes to Unaudited Condensed Consolidated Financial Statements (Part I, Item 1 of this Quarterly Report) for further details on current legal proceedings.
ITEM 1A. RISK FACTORS
There have been no material changes in our risk factors included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and subsequent periodic reports filed with the Securities and Exchange Commission pursuant to the Exchange Act.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
Recent Sale of Unregistered Securities:
None.
Purchase of Equity Securities
None.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
Not applicable.
ITEM 4. MINE SAFETY DISCLOSURES
Not applicable.
ITEM 5. OTHER INFORMATION
Rule 10b5-1 Trading Plans
During the quarter ended March 31, 2024, none of the Company’s directors or officers adopted or terminated any contract, instruction or written plan for the purchase or sale of Company securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement.”
42
ITEM 6. EXHIBITS
Exhibits
3.1(a)
3.1(b)
3.1(c)
3.1(d)
3.2
10.1*
10.2*+
31.1+ 
31.2+ 
32.1+ 
32.2+ 
101.INS+# XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH+# XBRL Taxonomy Extension Schema Document
101.CAL+# XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF+# XBRL Definition Linkbase Document
101.LAB+# XBRL Taxonomy Extension Labels Linkbase Document
101.PRE+# XBRL Taxonomy Extension Presentation Linkbase Document
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
 
*Indicates a management contract or compensatory plan or arrangement.
+Indicates this document is filed as an exhibit herewith.
#
The financial information of Integra LifeSciences Holdings Corporation Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 filed on 05/06/2024 formatted in XBRL (Extensible Business Reporting Language): (i) the Condensed Consolidated Statements of Operations and Comprehensive Income, (ii) the Condensed Consolidated Balance Sheets, (iii) Parenthetical Data to the Condensed Consolidated Balance Sheets, (iv) the Condensed Consolidated Statements of Cash Flows, and (v) Notes to Condensed Consolidated Financial Statements, is furnished electronically herewith.
43
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 INTEGRA LIFESCIENCES HOLDINGS CORPORATION
Date:May 6, 2024/s/ Jan De Witte
 Jan De Witte
 President and Chief Executive Officer
(Principal Executive Officer)
Date:May 6, 2024/s/ Lea Knight
Lea Knight
Executive Vice President and Chief Financial Officer
(Principal Financial Officer)
Date:May 6, 2024/s/ Jeffrey A. Mosebrook
 Jeffrey A. Mosebrook
 Senior Vice President, Finance
(Principal Accounting Officer)

44
 EX-10.2 2 iart-20240331xexx102.htm EX-10.2 Document

Exhibit 10.2
    INTEGRA LIFESCIENCES HOLDINGS CORPORATION
    2003 EQUITY INCENTIVE PLAN
    NON-QUALIFIED STOCK OPTION AGREEMENT

    NON-QUALIFIED STOCK OPTION AGREEMENT (together with the attached Notice of Grant of Stock Options and Option Agreement (“Notice of Grant”), the “Option Agreement”) made as of the date (the “Grant Date”) set forth in Notice of Grant, between Integra LifeSciences Holdings Corporation, a Delaware corporation (the “Company”), and the named Key Employee of the Company, a Related Corporation, or an affiliate (the “Employee”).

    WHEREAS, the Company desires to afford the Employee an opportunity to purchase shares of common stock of the Company, par value $.01 per share (“Common Stock”), as hereinafter provided, in accordance with the provisions of the Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan, as amended (the “Plan”). Requests for hardcopies of the “Plan” should be directed to Mythili Seshan at the New Jersey Corporate Office.

    NOW, THEREFORE, in consideration of the mutual covenants hereinafter set forth and for other good and valuable consideration the legal sufficiency of which is hereby acknowledged, the parties hereto, intending to be legally bound hereby, agree as follows:

    Capitalized terms not otherwise defined below shall have the meaning set forth in the Plan. The masculine pronoun shall include the feminine and neuter, and the singular the plural, where the context so indicates.

Grant of Option. Effective                      , the Company hereby grants to the Employee a non-qualified stock option (the “Option”) to purchase all or any part of an aggregate of the number of shares of Common Stock as set forth in the attached Notice of Grant, subject to adjustment in accordance with Section 8 of the Plan.
Purchase Price. The purchase price per share of the shares of Common Stock covered by the Option shall be that set forth in the attached Notice of Grant, subject to adjustment in accordance with Section 8 of the Plan. It is the determination of the Company’s Compensation Committee (the “Committee”) that on the Grant Date the per share Option exercise price was not less than the greater of one hundred percent (100%) of the fair market value of the Common Stock, or the par value thereof.
Term. Unless earlier terminated pursuant to any provision of this Option Agreement, this Option shall expire on                        (the “Expiration Date”). Notwithstanding anything herein to the contrary, this Option shall not be exercisable after the Expiration Date.


Exhibit 10.2
Exercise of Option. Twenty Five percent (25%) of the shares of Stock Options shall become vested each of the first and second, third and fourth anniversaries of the grant date. Any portion of the Option that becomes exercisable in accordance with the foregoing shall remain exercisable, subject to the provisions contained in this Option Agreement, until the expiration of the term of this Option as set forth above or until other termination of the Option as set forth in this Option Agreement.
        Notwithstanding anything contained herein, no portion of the Option which has not become vested and exercisable as of the Employee’s Termination of Service or in connection with Employee’s Termination of Service shall thereafter become vested or exercisable.

        For purposes of this Agreement, “Termination of Service” shall mean the time when the Employee ceases to provide services to the Company and its Related Corporations and Affiliates as an employee or Associate for any reason with or without Cause, including, but not by way of limitation, a termination by resignation, discharge, death, or disability. A Termination of Service shall not include a termination where the Employee is simultaneously reemployed by, or remains employed by, or continues to provide services to, the Company and/or one or more of its Related Corporations and Affiliates or a successor entity thereto.

Method of Exercising Option. Subject to the terms and conditions of this Option Agreement, the Option may be exercised in whole or in part by written notice to the Company, at its principal office, which currently is located at 1100 Campus Road, Princeton, New Jersey 08540. Such notice shall state the election to exercise the Option, and the number of shares with respect to which it is being exercised; shall be signed by the person or persons so exercising the Option; shall, unless the Company otherwise notifies the Employee, be accompanied by the investment certificate referred to below; and shall be accompanied by payment of the full Option price of such shares.
        The Option price shall be paid to the Company: (i) in cash; (ii) in cash equivalent; (iii) in Common Stock of the Company, in accordance with Section 7.1(f)(ii) of the Plan (as in effect on the date of this Option Agreement); (iv) by delivering a properly executed notice of exercise of the Option, in accordance with Section 7.1(f)(iii) of the Plan (as in effect on the date of this Option Agreement); (v) in Common Stock of the Company issuable pursuant to the exercise of the Option or otherwise withheld in net settlement of the Option, in accordance with Section 7.1(f)(iv) of the Plan (as in effect on the date of this Option Agreement); or (vi) by any combination of (i)-(v).
        Upon receipt of such notice and payment, the Company, as promptly as practicable, shall deliver or cause to be delivered a certificate or certificates representing the shares with respect to which the Option is so exercised. Such certificate(s) shall be registered in the name of the person or persons so exercising the Option (or, if the Option is exercised by the Employee and if the Employee so requests in the notice exercising the Option, shall be registered in the name of the Employee and the Employee’s spouse,


Exhibit 10.2
jointly, with right of survivorship) and shall be delivered as provided above to or upon the written order of the person or persons exercising the Option. In the event the Option is exercised by any person or persons after the legal disability or death of the Employee, such notice shall be accompanied by appropriate proof of the right of such person or persons to exercise the Option. All shares that are purchased upon the exercise of the Option as provided herein shall be fully paid and not assessable by the Company.
Shares to be Purchased for Investment. Unless the Company has theretofore notified the Employee that a registration statement covering the shares to be acquired upon the exercise of the Option has become effective under the Securities Act of 1933 and the Company has not thereafter notified the Employee that such registration statement is no longer effective, it shall be a condition to any exercise of this Option that the shares acquired upon such exercise be acquired for investment and not with a view to distribution, and the person effecting such exercise shall submit to the Company a certificate of such investment intent, together with such other evidence supporting the same as the Company may request. The Company shall be entitled to delay the transferability of the shares issued upon any such exercise to the extent necessary to avoid a risk of violation of the Securities Act of 1933 (or of any rules or regulations promulgated thereunder) or of any state laws or regulations. Such restrictions may, at the option of the Company, be noted or set forth in full on the share certificates.
Non-Transferability of Option. This Option is not assignable or transferable, in whole or in part, by the Employee other than by will or by the laws of descent and distribution, and during the lifetime of the Employee the Option shall be exercisable only by the Employee or by his or her guardian or legal representative.
Termination of Service. If the Employee experiences a Termination of Service prior to the Expiration Date for any reason other than by (i) death or disability or (ii) a Qualifying Termination upon a Change in Control as further described below, this Option may be exercised, to the extent of the number of shares with respect to which the Employee could have exercised it on the date of such Termination of Service, or to any greater extent permitted by the Committee, by the Employee at any time prior to the earlier of (i) the Expiration Date or (ii) six (6) months after such Termination of Service.
Death. Notwithstanding anything contained in this Option Agreement to the contrary, if the Employee dies during his service with the Company and Related Corporations and prior to the Expiration Date, the Option shall become fully vested and exercisable and such Option upon such death can be exercised by the Employee’s estate, personal representative or beneficiary who acquired the right to exercise such Option by bequest or inheritance or by reason of the Employee’s death, at any time prior to the earlier of (i) the Expiration Date or (ii) one year after the date of the Employee’s death.
Disability. Notwithstanding anything contained in this Option Agreement to the contrary, if the Employee incurs a disability, as defined in the Plan, during his service with the Company and Related Corporations and, prior to the Expiration Date, the Employee experiences a Termination of Service as a consequence of such disability, this


Exhibit 10.2
Option shall become fully vested and exercisable and such Option upon such termination due to such Disability can be exercised by the Employee, or in the event of the Employee’s legal disability, by the Employee’s legal representative, at any time prior to the earlier of (i) the Expiration Date or (ii) one year after the date of such termination of service due to such Disability.
Double Trigger Change in Control. Notwithstanding anything contained in this Option Agreement to the contrary, if during the Employee’s service with the Company and Related Corporations and prior to the Expiration Date, a Change in Control occurs and the Employee incurs a Qualifying Termination on or within twelve (12) months following the date of such Change in Control, this Option shall become fully vested and exercisable and such Option upon such Qualifying Termination can be exercised by the Employee at any time prior to the Expiration Date.
Clawback Notwithstanding anything contained in the Plan or the Option Agreement to the contrary, the Option shall be subject to the provisions of any clawback, repayment or recapture policy implemented by the Company, including any such policy adopted to comply with applicable law (including without limitation the Dodd-Frank Wall Street Reform and Consumer Protection Act) or securities exchange listing standards and any rules or regulations promulgated thereunder, to the extent set forth in such policy and/or in any notice or agreement relating to the Option under the Plan.
Withholding of Taxes. The obligation of the Company to deliver shares of Common Stock upon the exercise of the Option shall be subject to applicable federal, state and local tax withholding requirements. If the exercise of any Option is subject to the withholding requirements of applicable federal, state or local tax laws, the Committee, in its discretion, may permit the Employee, subject to the provisions of the Plan and such additional withholding rules (the “Withholding Rules”) as shall be adopted by the Committee, to satisfy the withholding tax, in whole or in part, by electing to have the Company withhold (or by returning to the Company) shares of Common Stock, which shares shall be valued, for this purpose, at their fair market value on the date of exercise of the Option (or, if later, the date on which the Employee recognizes ordinary income with respect to such exercise). An election to use shares of Common Stock to satisfy tax withholding requirements must be made in compliance with and subject to the Withholding Rules. The Committee may not withhold shares in excess of the number necessary to satisfy the minimum tax withholding requirements.
Construction. This Option Agreement is made under and subject to the provisions of the Plan as in effect on the Grant Date, and all of the provisions of the Plan as in effect on the Grant Date are hereby incorporated herein as provisions of this Option Agreement.
Governing Law. This Non-Qualified Stock Option Agreement shall be governed by applicable federal law and otherwise by the laws of the State of Delaware.


Exhibit 10.2

[Remainder of Page Intentionally Blank]



Exhibit 10.2

    IN WITNESS WHEREOF, this Option Agreement has been executed and delivered by the parties hereto.

THE PARTICIPANT    



                
INTEGRA LIFESCIENCES
HOLDINGS CORPORATION

        
By                    
Name:
Title:


EX-31.1 3 iart-20240331xexx311.htm EX-31.1 Document

Exhibit 31.1
Certification of Principal Executive Officer
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
I, Jan De Witte, certify that:
1.I have reviewed this quarterly report on Form 10-Q of Integra LifeSciences Holdings Corporation;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:
(a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
 
Date:May 6, 2024/s/ Jan De Witte
Jan De Witte
President and Chief Executive Officer


 EX-31.2 4 iart-20240331xexx312.htm EX-31.2 Document

Exhibit 31.2
Certification of Principal Financial Officer
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
I, Lea Knight, certify that:
1.I have reviewed this quarterly report on Form 10-Q of Integra LifeSciences Holdings Corporation;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:
(a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date:May 6, 2024/s/ Lea Knight
Lea Knight
Executive Vice President and Chief Financial Officer


 EX-32.1 5 iart-20240331xexx321.htm EX-32.1 Document

Exhibit 32.1
Certification of Principal Executive Officer
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report of Integra LifeSciences Holdings Corporation (the “Company”) on Form 10-Q for the quarter ended March 31, 2024 as filed with the Securities Exchange Commission on the date hereof (the “Report”), I, Jan De Witte, President and Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

1.The Report fully complies with the requirement of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date:May 6, 2024/s/ Jan De Witte
Jan De Witte
President and Chief Executive Officer


 EX-32.2 6 iart-20240331xexx322.htm EX-32.2 Document

Exhibit 32.2
Certification of Principal Financial Officer
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report of Integra LifeSciences Holdings Corporation (the “Company”) on Form 10-Q for the quarter ended March 31, 2024 as filed with the Securities Exchange Commission on the date hereof (the “Report”), I, Lea Knight, Executive Vice President and Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

1.The Report fully complies with the requirement of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date:May 6, 2024/s/ Lea Knight
Lea Knight
Executive Vice President and Chief Financial Officer


 EX-101.SCH 7 iart-20240331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 0000007 - Disclosure - BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - ACQUISITIONS AND DIVESTITURES link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - INVENTORIES link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - DEBT link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - DERIVATIVE INSTRUMENTS link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - RETIREMENT PLANS link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - LEASES AND RELATED PARTY LEASES link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - TREASURY STOCK link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - NET INCOME PER SHARE link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - BASIS OF PRESENTATION (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - INVENTORIES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - DEBT (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - DERIVATIVE INSTRUMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - LEASES AND RELATED PARTY LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - NET INCOME PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION (Tables) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - ACQUISITIONS AND DIVESTITURES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS - Schedule of Changes in Contract Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS - Narrative, Revenue Remaining Performance Obligation (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS - Narrative, Revenue Remaining Performance Obligation (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS - Schedule of Revenues Disaggregated by Major Source (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - INVENTORIES - Schedule of Net Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Schedule of Changes in Carrying Amount of Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Components of Company's Identifiable Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - DEBT - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - DEBT - Maximum Total Leverage Ratio Table (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - DEBT - Contractual Maturity Table (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - DERIVATIVE INSTRUMENTS - Schedule of Derivative Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - DERIVATIVE INSTRUMENTS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - DERIVATIVE INSTRUMENTS - Schedule of Cross Currency Swap Derivatives (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - DERIVATIVE INSTRUMENTS - Schedule of Net Investment Hedges Derivatives (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - DERIVATIVE INSTRUMENTS - Fair Value of Derivative Instruments By Balance Sheet Location (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - DERIVATIVE INSTRUMENTS - Effect of Derivative Instruments Designated Cash Flow Hedges on Statements of Operations (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - DERIVATIVE INSTRUMENTS - Schedule of Derivatives Not Designated as Hedging Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - RETIREMENT PLANS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - LEASES AND RELATED PARTY LEASES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - LEASES AND RELATED PARTY LEASES - Supplemental Balance Sheet Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - LEASES AND RELATED PARTY LEASES - Supplemental Cash Flow Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - LEASES AND RELATED PARTY LEASES - Future Minimum Lease Payment Under Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - LEASES AND RELATED PARTY LEASES - Future Minimum Lease Payment Under Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - TREASURY STOCK - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - INCOME TAXES - Summary of Effective Tax Rate (Details) link:presentationLink link:calculationLink link:definitionLink 9954510 - Disclosure - INCOME TAXES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954511 - Disclosure - NET INCOME PER SHARE - Basic and Diluted Net Income Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954512 - Disclosure - NET INCOME PER SHARE - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954513 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Schedule of Comprehensive Income (Details) link:presentationLink link:calculationLink link:definitionLink 9954514 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Schedule of Changes in Accumulated Other Comprehensive Income by Component (Details) link:presentationLink link:calculationLink link:definitionLink 9954515 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954516 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954517 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Net Sales and Profit by Reportable Segment (Details) link:presentationLink link:calculationLink link:definitionLink 9954518 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Total Revenue by Major Geographic Area (Details) link:presentationLink link:calculationLink link:definitionLink 9954519 - Disclosure - COMMITMENTS AND CONTINGENCIES - Fair Value Contingent Consideration, Balance Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954520 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 iart-20240331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 iart-20240331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 iart-20240331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Operating Leased Assets [Line Items] Operating Leased Assets [Line Items] Taxes Collected from Customers Revenue, Transaction Price Measurement, Tax Exclusion [Policy Text Block] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Change in fair value of contingent consideration liabilities Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Variable Rate [Domain] Variable Rate [Domain] Pay vs Performance Disclosure [Line Items] Accrued expenses and other current liabilities Accrued Liabilities, Current Other Long-term Liabilities Other Noncurrent Liabilities [Member] Statistical Measurement [Domain] Statistical Measurement [Domain] Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Changes in assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Expiration period Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Award Type [Domain] Award Type [Domain] Transferor's interests in transferred financial assets, unamortized issuance costs Transferor's Interests In Transferred Financial Assets, Unamortized Issuance Costs Transferor's Interests In Transferred Financial Assets, Unamortized Issuance Costs Contract Liability Change In Contract With Customer, Liability [Roll Forward] Change In Contract With Customer, Liability [Roll Forward] Fair Value as of Grant Date Award Grant Date Fair Value Performance obligations expected to be satisfied, expected timing Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period DEBT Debt Disclosure [Text Block] Other Current Liabilities Other Current Liabilities [Member] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Supplemental Balance Sheet Information Assets And Liabilities, Lessee [Table Text Block] Assets And Liabilities, Lessee [Table Text Block] Debt Covenant Period [Axis] Debt Covenant Period [Axis] Debt Covenant Period [Axis] Cross-currency swap Cross Currency Interest Rate Contract [Member] Revolving Credit Facility Revolving Credit Facility [Member] Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations FDA Approval Of Premarket Approval FDA Approval Of Premarket Approval [Member] FDA Approval Of Premarket Approval Number of renewal options (or more) Lessee, Operating Lease, Number Of Renewal Options Lessee, Operating Lease, Number Of Renewal Options Non-cash impairment charges Impairment of Intangible Assets, Finite-Lived Deferred tax liabilities Deferred Income Tax Liabilities, Net MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Performance Stock Performance Shares [Member] Segment Reporting [Abstract] Segment Reporting [Abstract] Prepaid expenses and other current assets Prepaid Expenses and Other Current Assets [Member] Restatement Determination Date: Restatement Determination Date [Axis] Derivatives Not Designated as Hedging Instruments Derivatives Not Designated as Hedging Instruments [Table Text Block] Purchases of Investments Payments to Acquire Investments Other non-current liabilities Increase (Decrease) in Other Noncurrent Liabilities Insider Trading Policies and Procedures [Line Items] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] 2029 Lessee, Operating Lease, Liability, to be Paid, Year Five Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Reporting unit, measurement input Reporting Unit, Measurement Input Reporting Unit, Measurement Input Schedule of Operating Leased Assets [Table] Schedule of Operating Leased Assets [Table] Tissue Technologies Tissue Technologies [Member] Orthopedics and Tissue Technologies [Member] Schedule of Goodwill [Table] Schedule of Goodwill [Table] Geographical [Axis] Geographical [Axis] Requisite service periods of awards Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period INCOME TAXES Income Tax Disclosure [Text Block] Contract liabilities Increase (Decrease) in Contract with Customer, Liability Segment Net Sales Segment Reporting Information, Operating Income (Loss) [Abstract] Reporting Unit [Domain] Reporting Unit [Domain] Directors Director [Member] Current liabilities: Liabilities, Current [Abstract] Employees Employee [Member] Employee [Member] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred stock; no par value; 15,000 authorized shares; none outstanding Preferred Stock, Value, Issued Business Acquisition [Line Items] Business Acquisition [Line Items] Securitization program outstanding borrowings, maximum limit Transferor's Interests In Transferred Financial Assets, Maximum Investment Limit Transferor's Interests In Transferred Financial Assets, Maximum Investment Limit Subsequent Event Type [Domain] Subsequent Event Type [Domain] Payment for contingent consideration Payment for Contingent Consideration Liability, Financing Activities Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Diluted (in dollars per share) Diluted net (loss) income per common share (in dollars per share) Earnings Per Share, Diluted Total derivatives designated as hedges — Liabilities Derivative Liability, Subject to Master Netting Arrangement, before Offset PEO Total Compensation Amount PEO Total Compensation Amount Hedging Relationship [Axis] Hedging Relationship [Axis] Trade accounts receivable, net of allowances of $5,050 and $4,879 Accounts Receivable, after Allowance for Credit Loss, Current Amount of Gain (Loss) Reclassified from AOCI into Earnings Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax Goodwill [Roll Forward] Goodwill [Roll Forward] Change in unrealized loss/(gain) on derivatives, net of tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Fair Value, Inputs, Level 3 Fair Value, Inputs, Level 3 [Member] Treasury stock (in shares) Balance, beginning of period, treasury stock (in shares) Balance, beginning of period, treasury stock (in shares) Treasury Stock, Common, Shares Accelerated stock based compensation expenses Share-Based Payment Arrangement, Accelerated Cost Trading Symbol Trading Symbol Letters of credit outstanding Letters of Credit Outstanding, Amount Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Instruments Instruments [Member] Instruments [Member] Options, weighted average grant date fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Net (loss) income Net (Loss) Income Net (loss) income Net Income (Loss) Expected annual amortization expense, thereafter Finite-Lived Intangible Asset, Expected Amortization, after Year Five Total current liabilities Liabilities, Current Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] Derivative Contract [Domain] Derivative, Name [Domain] Derivative Contract [Domain] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] LEASES AND RELATED PARTY LEASES Lessee, Operating Leases [Text Block] Rest of World Rest Of World [Member] Revenues from rest of the world. Acquired Finite-Lived Intangible Assets [Line Items] Acquired Finite-Lived Intangible Assets [Line Items] Balance, beginning of period, (in shares) Balance, end of period (in shares) Shares, Issued LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Accelerated shares repurchased Stock Repurchased During Period, Value Overnight Federal Funds Fed Funds Effective Rate Overnight Index Swap Rate [Member] Derivative Instruments, Gain (Loss) by Hedging Relationship, by Income Statement Location, by Derivative Instrument Risk [Table] Derivative Instruments, Gain (Loss) [Table] Stockholders’ equity: Equity, Attributable to Parent [Abstract] Less: Amounts reclassified from accumulated other comprehensive income, net Gain (loss) reclassified from AOCI Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent Contract liability, beginning of period Contract liability, end of period Contract with Customer, Liability Gain (loss) recorded in AOCI, change in fair value Amount of Gain (Loss) Recognized in AOCI Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Interest payments, year one Interest Payments, Year One Interest Payments, Year One Basic and Diluted Net Income (Loss) Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Cost of goods sold Cost of Goods and Services Sold Service cost component Defined Benefit Plan, Service Cost Stock options exercisable, vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Executive Category: Executive Category [Axis] Schedule of Indefinite-Lived Intangible Assets Schedule of Indefinite-Lived Intangible Assets [Table Text Block] Pension liability adjustment, net of tax Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent Name Measure Name Name Forgone Recovery, Individual Name Goodwill Beginning of period End of period Goodwill Equity Components [Axis] Equity Components [Axis] Warrant strike price (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Hedging Relationship [Domain] Hedging Relationship [Domain] Notional amount terminated Derivative, Notional Amount, Terminated Derivative, Notional Amount, Terminated Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] 2026 Long-Term Debt, Maturity, Year Two Underlying Securities Award Underlying Securities Amount Smaller Reporting Company Entity Small Business Expected annual amortization expense, in 2028 Finite-Lived Intangible Asset, Expected Amortization, Year Four Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Cross Currency Interest Rate Swap Two Cross Currency Interest Rate Contract Two [Member] Cross Currency Interest Rate Contract Two [Member] ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) Comprehensive Income (Loss) Note [Text Block] Local Phone Number Local Phone Number Accounts receivable Increase (Decrease) in Accounts Receivable Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Forecast Forecast [Member] Interest Rate Swap Designated October 10, 2018 Tranche 2 Interest Rate Swap Designated October 10, 2018 Tranche 2 [Member] Interest Rate Swap Designated October 10, 2018 Tranche 2 [Member] Third Parties Third Parties [Member] Third Parties [Member] Arkis Arkis BioSciences Inc. [Member] Arkis BioSciences Inc. [Member] Notional Amount Current notional amount Aggregate Notional Amount Derivative, Notional Amount Remainder of 2024 Long-Term Debt, Maturity, Remainder of Fiscal Year Derma Sciences Derma Sciences [Member] Derma Sciences [Member] Lease liability - operating leases Non-current lease liabilities Long-term lease liabilities Operating Lease, Liability, Noncurrent Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Retirement Benefits [Abstract] Retirement Benefits [Abstract] Payment of debt issuance costs Payments of Debt Issuance Costs Revenue Based Performance Milestones Revenue Based Performance Milestones [Member] Revenue Based Performance Milestones 2022 Share Repurchase Program 2022 Share Repurchase Program [Member] 2022 Share Repurchase Program Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Interest payments, year two Interest Payments, Year Two Interest Payments, Year Two Income Statement Location [Axis] Income Statement Location [Axis] Schedule of Long-term Debt Maximum Leverage Ratios Schedule of Long-Term Debt Instruments [Table Text Block] Research and development Research and Development Expense (Excluding Acquired in Process Cost) Schedule of Operating Lease Maturities Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Foreign currency forward contracts Foreign Exchange Forward [Member] Europe Europe [Member] Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Product and Service [Domain] Product and Service [Domain] Other Performance Measure, Amount Other Performance Measure, Amount Interest Rate Swap Designated December 13, 2017 Tranche 3 Interest Rate Swap Designated December 13, 2017 Tranche 3 [Member] Interest Rate Swap Designated December 13, 2017 Tranche 3 [Member] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Inventories Increase (Decrease) in Inventories Standby Letters of Credit Standby Letters of Credit [Member] INVESTING ACTIVITIES: Net Cash Provided by (Used in) Investing Activities [Abstract] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Shares excluded from computation as their effect would be antidilutive (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Award Type [Axis] Award Type [Axis] Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Awards granted during the period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Document Quarterly Report Document Quarterly Report Interest expense Interest Expense Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Hedging Designation [Axis] Hedging Designation [Axis] Current portion of borrowings under senior credit facility Term loan component of senior credit facility Secured Debt, Current Goodwill [Line Items] Goodwill [Line Items] Operating leases Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Expected annual amortization expense, remainder of 2024 Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year Trading Arrangement: Trading Arrangement [Axis] Less: Imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Derivatives, Fair Value [Line Items] Derivatives, Fair Value [Line Items] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Secured long-term debt, securitization program Secured Long-Term Debt, Securitization Program Secured Long-Term Debt, Securitization Program Fair value in excess of carrying amount, percent Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount Entity File Number Entity File Number Loss Contingencies [Table] Loss Contingencies [Table] Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Measurement Input, Discount Rate Measurement Input, Discount Rate [Member] Current portion of lease liability - operating leases Current lease liabilities Less: Current lease liabilities Operating Lease, Liability, Current Prepaid Expenses Prepaid Expense, Current 2027 Long-Term Debt, Maturity, Year Three Raw materials Inventory, Raw Materials and Purchased Parts, Net of Reserves Issuance of common stock through employee stock purchase plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Intangible asset amortization Amortization Amortization of Intangible Assets Entity Shell Company Entity Shell Company 2027 Lessee, Operating Lease, Liability, to be Paid, Year Three Interest rate adjustment Debt Instrument, Basis Spread Adjustment On Variable Rate Debt Instrument, Basis Spread Adjustment On Variable Rate Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Other comprehensive gain (loss) OCI, before Reclassifications, Net of Tax, Attributable to Parent Product warranty period (up to) Revenue, Product Warranty Period Revenue, Product Warranty Period Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Restatement Determination Date Restatement Determination Date Treasury stock, average cost per share (in dollars per share) Shares Acquired, Average Cost Per Share Interest Rate Swap Designated March 31, 2023 Interest Rate Swap Designated March 31, 2023 [Member] Interest Rate Swap Designated March 31, 2023 Counterparty Name [Domain] Counterparty Name [Domain] Directors and Certain Executive Officers Directors and Certain Executive Officers [Member] Directors and Certain Executive Officers [Member] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization 2026 Lessee, Operating Lease, Liability, to be Paid, Year Two Fair value Debt Instrument, Fair Value Disclosure Acclarent Inc. Acclarent Inc. [Member] Acclarent Inc. Interest income Investment Income, Interest Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Common stock, issued shares (in shares) Common Stock, Shares, Issued Purchase price of business combination Business Combination, Consideration Transferred Line of credit, commitment fee percentage Line of Credit Facility, Commitment Fee Percentage Option Indexed to Issuer's Equity, Type [Domain] Option Indexed to Issuer's Equity, Type [Domain] Contract liabilities Short-term portion of contract liability Contract with Customer, Liability, Current Treasury stock, at cost; 12,735 shares and 12,751 shares at March 31, 2024 and December 31, 2023, respectively Treasury stock Treasury Stock, Common, Value Security Exchange Name Security Exchange Name Income tax benefit, tax credit, research and development Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount Total long-term debt Long-Term Debt Selling, general and administrative Selling, General and Administrative Expense Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Foreign Currency Items Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Stock Options Employee Stock Option [Member] DERIVATIVE INSTRUMENTS Derivative Instruments and Hedging Activities Disclosure [Text Block] Weighted-average period for cost recognition Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Total costs and expenses Costs and Expenses Maximum Maximum [Member] Comprehensive income (See Note 14) Comprehensive income, net Comprehensive Income (Loss), Net of Tax, Attributable to Parent Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] Total unrecognized compensation costs Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Document Type Document Type Number of days from shipment to issue a credit Return Policy, Issue Of Credit, Number Of Days From Shipment Return Policy, Issue of Credit, Number of Days from Shipment Tabular List, Table Tabular List [Table Text Block] Foreign currency swaps Currency Swap [Member] Entity Address Entity Address, Address Line One Chief Executive Officer Chief Executive Officer [Member] STOCK-BASED COMPENSATION Share-Based Payment Arrangement [Text Block] Basis Of Presentation Basis of Accounting, Policy [Policy Text Block] Development Milestones Milestone Payment One [Member] Milestone Payment One [Member] Business Acquisition [Axis] Business Acquisition [Axis] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Number of contingent liabilities remaining Business Combination, Contingent Consideration, Number Of Liabilities Business Combination, Contingent Consideration, Number Of Liabilities Estimated Fair Value Fair Value Asset (Liability) Derivative, Fair Value, Net Expected performance obligation, percentage Revenue, Remaining Performance Obligation, Percentage Long-term convertible securities Convertible Debt, Noncurrent Trade accounts receivable, allowance Accounts Receivable, Allowance for Credit Loss, Current Subsequent Event Subsequent Event [Member] Long-term borrowings under securitization facility Secured Long-Term Debt, Securitization Program, Noncurrent Secured Long-Term Debt, Securitization Program, Noncurrent Derivative [Table] Derivative [Table] Schedule of Finite-Lived Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Variable Rate [Axis] Variable Rate [Axis] Accounts payable, accrued expenses and other current liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Income Statement [Abstract] Income Statement [Abstract] Costs and expenses: Costs and Expenses [Abstract] Title of 12(b) Security Title of 12(b) Security Valuation Approach and Technique [Axis] Valuation Approach and Technique [Axis] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Related Party [Domain] Related Party, Type [Domain] Plan modification, compensation expense Share-Based Payment Arrangement, Plan Modification, Incremental Cost Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Operating Segments Operating Segments [Member] Issuance of common stock for vesting of share based awards, net of shares withheld for taxes Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Other Current Assets Other Assets, Current Class of Stock [Line Items] Class of Stock [Line Items] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Fixed Interest Rate Fixed Rate Derivative, Fixed Interest Rate Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Diluted net (loss) income per share: Earnings Per Share, Diluted [Abstract] Interest payments, year three Interest Payments, Year Three Interest Payments, Year Three Defer payment and taxation, base salary, percentage (up to) Defined Benefit Plan, Defer Payment And Taxation, Base Salary, Percentage Defined Benefit Plan, Defer Payment And Taxation, Base Salary, Percentage Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Neurosurgery Neurosurgery [Member] Neurosurgery [Member] Entity Tax Identification Number Entity Tax Identification Number Foreign currency translation Goodwill, Foreign Currency Translation Gain (Loss) Inventories, net Inventories, net Inventory, Net Product Warranties Extended Product Warranty, Policy [Policy Text Block] Statistical Measurement [Axis] Statistical Measurement [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Entity Interactive Data Current Entity Interactive Data Current Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Product returns, payments Revenue From Contract With Customer, Product Returns, Payments Revenue From Contract With Customer, Product Returns, Payments Total Shareholder Return Amount Total Shareholder Return Amount Purchases of treasury stock Payments for Repurchase of Common Stock Accelerated share repurchases, additional shares received (in shares) Accelerated Share Repurchases, Additional Shares Received Accelerated Share Repurchases, Additional Shares Received Entity Common Stock, Shares Outstanding (in shares) Entity Common Stock, Shares Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] ACQUISITIONS AND DIVESTITURES Mergers, Acquisitions and Dispositions Disclosures [Text Block] Supplier relationships Supplier Relation Ships [Member] Supplier Relation Ships [Member] Inventory Disclosure [Abstract] Other assets Other Assets [Member] Segments [Domain] Segments [Domain] Deferred compensation plan, fair value of assets Deferred Compensation Plan Assets Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Operating Activities [Domain] Consolidation Items [Domain] Measurement Input, Long-Term Revenue Growth Rate Measurement Input, Long-Term Revenue Growth Rate [Member] Retained earnings Retained Earnings (Accumulated Deficit) Measure: Measure [Axis] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Name Outstanding Recovery, Individual Name Summary of Accounting Policies on Revenue Recognition and Shipping and Handling Fees Revenue from Contract with Customer [Policy Text Block] Convertible notes, maximum borrowing capacity Debt Instrument, Face Amount Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Product returns provision Revenue From Contract With Customer, Product Returns, Provision Revenue From Contract With Customer, Product Returns, Provision Current assets: Assets, Current [Abstract] Leases [Abstract] Leases [Abstract] Entity State Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Counterparty Name [Axis] Counterparty Name [Axis] Short Short [Member] Unusual or Infrequent Item, or Both [Domain] Unusual or Infrequent Item, or Both [Domain] Wound Reconstruction and Care Regenerative Skin And Wound [Member] Regenerative Skin And Wound [Member] OPERATING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities [Abstract] Expected annual amortization expense, in 2025 Finite-Lived Intangible Asset, Expected Amortization, Year One Operating cash flows from operating leases Operating Lease, Payments Initial conversion price (in dollars per share) Debt Instrument, Convertible, Conversion Price Initial conversion rate Debt Instrument, Convertible, Conversion Ratio Cross Currency Interest Rate Swap One Cross Currency Interest Rate Contract One [Member] Cross Currency Interest Rate Contract One [Member] Basic net (loss) income per share: Earnings Per Share, Basic [Abstract] Gain (loss) reclassified into other income Gain (Loss) on Derivative Instruments, Net, Pretax PEO PEO [Member] Schedule of Comprehensive Income (Loss) Comprehensive Income (Loss) [Table Text Block] RETIREMENT PLANS Retirement Benefits [Text Block] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Related Parties Related Parties [Member] Related Parties [Member] Total derivatives designated as hedges — Assets Derivative Asset, Subject to Master Netting Arrangement, before Offset Call Option Call Option [Member] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Schedule of Inventories, Net Schedule of Inventory, Current [Table Text Block] Interest Rate Swap Interest rate swap Interest Rate Swap [Member] Debt Instrument [Axis] Debt Instrument [Axis] Interest payments, after year three Interest Payments, After Year Three Interest Payments, After Year Three Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Reported tax rate Effective income tax rate Effective Income Tax Rate Reconciliation, Percent Total lease liabilities Total lease liabilities Operating Lease, Liability Measurement Input Type [Domain] Measurement Input Type [Domain] Credit Facility [Axis] Credit Facility [Axis] Schedule of Contractual Repayments of Long-Term Debt Schedule of Maturities of Long-Term Debt [Table Text Block] Total liabilities Liabilities Contract Asset Change In Contract With Customer, Asset [Roll Forward] Change In Contract With Customer, Asset [Roll Forward] BASIS OF PRESENTATION Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Accumulated Other Comprehensive Loss Total AOCI Attributable to Parent [Member] Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] All Executive Categories All Executive Categories [Member] Long-term portion of contract liability Contract with Customer, Liability, Noncurrent Title of Individual [Axis] Title of Individual [Axis] Commercial Sales Milestones Milestone Payment Two [Member] Milestone Payment Two [Member] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Defined Benefit Pension Items Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Contract asset, net of transferred to trade receivables on contracts during the period Contract With Customer, Asset, Net Of Reclassified To Receivable Contract With Customer, Asset, Net Of Reclassified To Receivable Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Number of reportable segments Number of Reportable Segments Net (loss) income per share Earnings Per Share [Abstract] Earnings Per Share [Abstract] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Annual rate of lease agreement Annual Rate Of Lease Agreement Annual rate of lease agreement. Common stock; $0.01 par value; 240,000 authorized shares; 91,484 and 90,920 issued at March 31, 2024 and December 31, 2023, respectively Common Stock, Value, Issued Redemption price, percentage Debt Instrument, Redemption Price, Percentage Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Codman tradename Trade Names [Member] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Total current assets Assets, Current Net periodic benefit costs Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Contingent consideration, cash payments due upon achievement of certain revenue-based performance milestones (up to) Contingent consideration, estimated fair value Business Combination, Contingent Consideration, Liability Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] All Individuals All Individuals [Member] Amortization Amortization Other (expense) income, net Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Proceeds from borrowings of long-term indebtedness Proceeds from Issuance of Secured Debt Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Statement [Table] Statement [Table] Long-term borrowings under senior credit facility Secured Long-Term Debt, Noncurrent Current Fiscal Year End Date Current Fiscal Year End Date Stock repurchase program, authorized amount Stock Repurchase Program, Authorized Amount GOODWILL AND OTHER INTANGIBLE ASSETS Goodwill and Intangible Assets Disclosure [Text Block] Accelerated shares repurchased (shares) Stock Repurchased During Period, Shares Accounts payable, trade Accounts Payable, Trade, Current Transferred to trade receivable from contract asset included in beginning of the year contract asset Contract with Customer, Asset, Reclassified to Receivable Schedule of Effective Income Tax Rate Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] PEO Name PEO Name Balance, Beginning of Period Balance, End of Period Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Asia Pacific Asia Pacific [Member] Schedule of Changes in Accumulated Other Comprehensive Loss by Component Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Preferred stock, authorized shares (in shares) Preferred Stock, Shares Authorized Other than options, weighted average grant date fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Expected annual amortization expense, in 2029 Finite-Lived Intangible Asset, Expected Amortization, Year Five Leased facilities Building [Member] Debt instrument, securitization facility, agreement term Debt Instrument, Securitization Facility, Agreement Term Debt Instrument, Securitization Facility, Agreement Term Schedule of Changes in Carrying Amount of Goodwill Schedule of Goodwill [Table Text Block] Preferred stock, outstanding shares (in shares) Preferred Stock, Shares Outstanding Interest Rate Swap Designated December 13, 2017 Tranche 2 Interest Rate Swap Designated December 13, 2017 Tranche 2 [Member] Interest Rate Swap Designated December 13, 2017 Tranche 2 Swingline Loans Swingline Loan [Member] Swingline Loan [Member] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Other Income Other Income [Member] Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Corporate and other Corporate, Non-Segment [Member] 2025 Notes Two Thousand Twenty Five Senior Convertible Notes [Member] Two Thousand Twenty Five Senior Convertible Notes [Member] Cross Currency Interest Rate Swap Three Cross Currency Interest Rate Contract Three [Member] Cross Currency Interest Rate Contract Three [Member] Convertible notes, interest rate Debt Instrument, Interest Rate, Stated Percentage Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Lease Contractual Term [Domain] Lease Contractual Term [Domain] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Total stockholders’ equity Balance, beginning of period Balance, end of period Equity, Attributable to Parent Consolidation Items [Axis] Consolidation Items [Axis] Accelerated share repurchases, shares received at inception (in shares) Accelerated Share Repurchases, Shares Received at Inception Accelerated Share Repurchases, Shares Received at Inception Interest Rate Swap Designated October 10, 2018 Tranche 1 Interest Rate Swap Designated October 10, 2018 Tranche 1 [Member] Interest Rate Swap Designated October 10, 2018 Tranche 1 [Member] Restricted Stock Restricted Stock [Member] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Reporting Unit [Axis] Reporting Unit [Axis] Contract liability, net of revenue recognized on contracts during the period Contract with Customer, Liability, Revenue Recognized TREASURY STOCK Treasury Stock [Text Block] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Term Loan Facility Term Loan Facility [Member] Term Loan Facility [Member] Gains and Losses on Derivatives Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Notional amount settled Derivative, Notional Amount, Settled Derivative, Notional Amount, Settled (Loss) income before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Not Designated as Hedging Instrument Not Designated as Hedging Instrument [Member] Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Hedging Designation [Domain] Hedging Designation [Domain] Fair Value, Inputs, Level 2 Fair Value, Inputs, Level 2 [Member] Net Investment Hedges Net Investment Hedging [Member] Emerging Growth Company Entity Emerging Growth Company Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Recognition of revenue included in beginning of year contract liability Contract With Customer, Liability, Net Of Revenue Recognized Contract With Customer, Liability, Net Of Revenue Recognized Debt issuance costs capitalized Debt Issuance Costs, Net Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Contingent consideration Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability Performance Stock and Restricted Stock Awards Performance Stock And Restricted Stock Awards [Member] Performance Stock And Restricted Stock Awards [Member] Effect of Derivative Instruments Designated as Cash Flow Hedges on Statements of Operations Derivative Instruments, Gain (Loss) [Table Text Block] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Document Fiscal Period Focus Document Fiscal Period Focus 2025 Lessee, Operating Lease, Liability, to be Paid, Year One Weighted Average Life Finite-Lived Intangible Asset, Useful Life Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] 2028 Lessee, Operating Lease, Liability, to be Paid, Year Four Title Trading Arrangement, Individual Title Operating lease expense Operating Lease, Expense Option Indexed to Issuer's Equity [Axis] Option Indexed to Issuer's Equity [Axis] Share-based compensation Share-Based Payment Arrangement, Noncash Expense Codman Specialty Surgical Codman Specialty Surgical Codman Specialty Surgical [Member] Codman Specialty Surgical [Member] 2023 Share Repurchase Program 2023 Share Repurchase Program [Member] 2023 Share Repurchase Program Position [Domain] Position [Domain] Common Stock Common Stock [Member] Non-cash lease expense Noncash Lease Expense Noncash Lease Expense Cost Cost Of Definite And Indefinite Lived Intangible Assets Gross Excluding Goodwill Cost Of Definite And Indefinite Lived Intangible Assets Gross Excluding Goodwill. Grants in period, net of forfeitures (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures Individual: Individual [Axis] City Area Code City Area Code Entity Postal Zip Code Entity Address, Postal Zip Code Product and Service [Axis] Product and Service [Axis] NET INCOME PER SHARE Earnings Per Share [Text Block] ROU assets obtained in exchange for lease liabilities: Right Of Use Asset Obtained In Exchange For Lease Liability [Abstract] Right Of Use Asset Obtained In Exchange For Lease Liability [Abstract] Income Statement Location [Domain] Income Statement Location [Domain] Valuation Technique, Discounted Cash Flow Valuation Technique, Discounted Cash Flow [Member] Payments on debt Repayments of Secured Debt Schedule of Contingent Consideration Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Geographical [Domain] Geographical [Domain] Weighted average interest rate on debt Debt, Weighted Average Interest Rate Accelerated share repurchase program, receipt (payment) Accelerated Share Repurchases, Settlement (Payment) or Receipt Accelerated share repurchases, percentage of expected total repurchased Accelerated Share Repurchases, Percentage Of Expected Total Repurchased Accelerated Share Repurchases, Percentage Of Expected Total Repurchased Five Year Option Lease From November 1, 2034 Through October 31, 2039 Five Year Option Lease Period Two [Member] Five-Year Option Lease Period Two Minimum Minimum [Member] Property, plant and equipment, net Property, Plant and Equipment, Net Weighted average common shares outstanding (See Note 13): Weighted Average Number of Shares Outstanding, Diluted [Abstract] Share Repurchase Program [Domain] Share Repurchase Program [Domain] Weighted average interest rate, accounts receivable securitization revolving loan facility Debt, Weighted Average Interest Rate, From Securitization Debt, Weighted Average Interest Rate, From Securitization Completed Technology, Surgimend Completed Technology, SurgiMend [Member] Completed Technology, SurgiMend Exercise Price Award Exercise Price Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Derivative instruments not designated as hedging instruments, gain (loss), net Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net Contingent consideration, maximum undiscounted payment amount Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] ASSETS Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Minimum settled in cash per principal amount Debt Instrument, Combination Settlement For Debt Conversion, Minimum Settled In Cash Per Principal Amount Debt Instrument, Combination Settlement For Debt Conversion, Minimum Settled In Cash Per Principal Amount Schedule of Fair Value and Presentation of Derivatives Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Cash taxes paid in net equity settlement Payment, Tax Withholding, Share-Based Payment Arrangement Incremental financing costs capitalized Debt Issuance Costs, Gross Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities Deferred tax assets, net Deferred Income Tax Assets, Net Number of products offered (more than) Segment Reporting Information, Number Of Products Offered Number of products sold by a segment ACell ACell [Member] ACell Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Defer payment and taxation, bonus and other eligible cash compensation, percentage (up to) Defined Benefit Plan, Defer Payment And Taxation, Bonus And Other Compensation, Percentage Defined Benefit Plan, Defer Payment And Taxation, Bonus And Other Compensation, Percentage Percentage of shares acquired Business Acquisition, Percentage of Voting Interests Acquired Unusual or Infrequent Item, or Both [Axis] Unusual or Infrequent Item, or Both [Axis] Retained Earnings Retained Earnings [Member] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Total liabilities and stockholders’ equity Liabilities and Equity Other assets Other Assets, Noncurrent Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification and tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax Right of use asset - operating leases ROU assets Operating Lease, Right-of-Use Asset Basic (in dollars per share) Basic net (loss) income per common share (in dollars per share) Earnings Per Share, Basic Completed Technology, PriMatrix Completed Technology, PriMatrix [Member] Completed Technology, PriMatrix Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Issuance of common stock through employee stock purchase plan Stock Issued During Period, Value, Employee Stock Purchase Plan Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Estimated fair value of plan assets Defined Benefit Plan, Plan Assets, Amount Remainder of 2024 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Maximum average conversion value of notes Debt Instrument, Maximum Average Conversion Value Of Notes Debt Instrument, Maximum Average Conversion Value Of Notes Arrangement Duration Trading Arrangement Duration Entity City Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Trademarks/brand names Trademarks Brand Names [Member] Trademarks Brand Names. Related Party Related Party [Member] Schedule of Net Sales and Profit by Segments Schedule of Geographic Revenue by Area Schedule of Segment Reporting Information, by Segment [Table Text Block] Completed technology Completed Technology [Member] Completed technology. BioD Earnout Payments and Medihoney Earnout Payments BioD Earnout Payments and Medihoney Earnout Payments [Member] BioD Earnout Payments and Medihoney Earnout Payments [Member] Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Interest expense Interest Expense [Member] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Remaining amount under share repurchase Stock Repurchase Program, Remaining Authorized Repurchase Amount Termination Date Trading Arrangement Termination Date Common stock, authorized shares (in shares) Common Stock, Shares Authorized Depreciation and amortization Other Depreciation and Amortization Codman Codman [Member] Codman [Member] ACell, Inc. ACell, Inc. [Member] ACell, Inc. Indefinite-lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets [Axis] Interest payments, remainder of fiscal year Interest Payments, Reminder Of Fiscal Year Interest Payments, Reminder Of Fiscal Year Derivative Instrument [Axis] Derivative, by Nature [Axis] Derivative Instrument [Axis] Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Liability Class [Axis] Liability Class [Axis] All Trading Arrangements All Trading Arrangements [Member] Measurement Input Type [Axis] Measurement Input Type [Axis] Transferor's interests in transferred financial assets, issuance costs Transferor's Interests In Transferred Financial Assets, Issuance Costs Transferor's Interests In Transferred Financial Assets, Issuance Costs Gain expected to be reclassified to earnings in the next twelve months Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net All Adjustments to Compensation All Adjustments to Compensation [Member] Derivative [Line Items] Derivative [Line Items] Award Timing Disclosures [Line Items] Title of Individual [Domain] Title of Individual [Domain] Compensation Amount Outstanding Recovery Compensation Amount Interest Rate Swap Designated October 10, 2018 Tranche 3 Interest Rate Swap Designated October 10, 2018 Tranche 3 [Member] Interest Rate Swap Designated October 10, 2018 Tranche 3 [Member] Cost of call transactions Payments For Option Index To Issuers Equity Payments For Options Indexed to Issuer's Equity Deferred income tax provision (benefit) Deferred Income Tax Expense (Benefit) Subsequent Event Type [Axis] Subsequent Event Type [Axis] Proceeds from exercised stock options Proceeds from Stock Options Exercised Percent of manufacturing facility owned by corporation whose shareholders are trusts whose beneficiaries include family members of company's former director Percent Of Manufacturing Facility Owned By Corporation Whose Shareholders Are Trusts, Whose Beneficiaries Include Family Members Of Company's Former Director Percent Of Manufacturing Facility Owned By Corporation Whose Shareholders Are Trusts, Whose Beneficiaries Include Family Members Of Company's Former Director Loss (gain) on disposal of property and equipment Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property Convertible Debt Convertible Debt [Member] Supplemental Cash Flow Information Cash Flow, Lessee [Table Text Block] Cash Flow, Lessee [Table Text Block] Expected annual amortization expense, in 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Three Securitization facility, outstanding borrowings, fair value Securitization Facility, Fair Value Of Amount Outstanding Securitization Facility, Fair Value Of Amount Outstanding Number of contingent liabilities Business Acquisition, Number Of Contingent Liabilities Business Acquisition, Number Of Contingent Liabilities Insider Trading Arrangements [Line Items] Derivative Instruments, Gain (Loss) [Roll Forward] Accumulated Other Comprehensive Income (Loss) [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] 2025 Long-Term Debt, Maturity, Year One Related Party [Axis] Related Party, Type [Axis] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Issuance of common stock for vesting of share based awards, net of shares withheld for taxes (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Entity Registrant Name Entity Registrant Name Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] Stock options and restricted stock (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Other non-current assets Increase (Decrease) in Other Operating Assets Expected annual amortization expense, in 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Two Adjustment to Compensation, Amount Adjustment to Compensation Amount Cost of Sales Cost of Sales [Member] Change in fair value of contingent consideration and others Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Lease Contractual Term [Axis] Lease Contractual Term [Axis] Thereafter Long-Term Debt, Maturity, after Year Three Long-Term Debt, Maturity, after Year Three Document Period End Date Document Period End Date Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Adoption Date Trading Arrangement Adoption Date Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Treasury Stock Treasury Stock, Common [Member] Entity Central Index Key Entity Central Index Key Line of credit facility, fair value of amount outstanding Line of Credit Facility, Fair Value of Amount Outstanding Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Effect of dilutive securities: Dilutive Securities, Effect on Basic Earnings Per Share [Abstract] (Benefit) provision for income taxes Income Tax Expense (Benefit) Finished goods Inventory, Finished Goods, Net of Reserves Designated as Hedging Instrument Designated as Hedging Instrument [Member] Accrued compensation Employee-related Liabilities, Current Valuation Approach and Technique [Domain] Valuation Approach and Technique [Domain] Contingent Consideration Liability Contingent Consideration Liability [Member] Contingent Consideration Liability [Member] Name Trading Arrangement, Individual Name Other comprehensive income (loss), net of tax Net current-period other comprehensive gain (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Write off of debt issuance costs Deferred Debt Issuance Cost, Writeoff Foreign currency translation Contract With Customer, Liability, Increase (Decrease) From Foreign Currency Translation Contract With Customer, Liability, Increase (Decrease) From Foreign Currency Translation Schedule of Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Net Definite And Indefinite Lived Intangible Assets Net Excluding Goodwill Definite And Indefinite Lived Intangible Assets Net Excluding Goodwill. Maximum Consolidated Total Leverage Ratio Debt Instrument, Covenant, Maximum Leverage Ratio Debt Instrument, Covenant, Maximum Leverage Ratio Debt Covenant Period [Domain] Debt Covenant Period [Domain] [Domain] for Debt Covenant Period [Axis] Cost, amortization Cost, Amortization Equity [Abstract] Equity [Abstract] INVENTORIES Inventory Disclosure [Text Block] Weighted average remaining lease term (in years) Operating Lease, Weighted Average Remaining Lease Term Maximum selling price of the company's common stock of the conversion price Debt Instrument, Maximum Selling Price Of Common Stock Of The Conversion Price During Period Debt Instrument, Maximum Selling Price Of Common Stock Of The Conversion Price During Period Total revenue, net Total Revenues Revenue from Contract with Customer, Excluding Assessed Tax Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Amendment Flag Amendment Flag Plan modification, expiration period (in months) Share-Based Payment Arrangement, Plan Modification, Expiration Period Share-Based Payment Arrangement, Plan Modification, Expiration Period Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Weighted average discount rate Operating Lease, Weighted Average Discount Rate, Percent Intercompany loan quarterly payments Intercompany Loan, Quarterly Payment Intercompany Loan, Quarterly Payment Credit Facility [Domain] Credit Facility [Domain] Interest rates available Debt Instrument, Basis Spread on Variable Rate Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] March 31, 2023 through December 31, 2024 Debt Covenant Period 1 [Member] Debt Covenant Period 1 Initial strike price (in dollars per share) Option Indexed to Issuer's Equity, Strike Price Diluted (in shares) Weighted average common shares for diluted earnings per share (in shares) Weighted Average Number of Shares Outstanding, Diluted Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Schedule of Changes in Contract Assets and Contract Liabilities Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Five Year Option Lease From November 1, 2029 Through October 31, 2034 Five Year Option Lease Period One [Member] Five-Year Option Lease Period One REVENUES FROM CONTRACTS WITH CUSTOMERS Revenue from Contract with Customer [Text Block] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Company Selected Measure Amount Company Selected Measure Amount Interest Rate Swap Designated December 15, 2020 Tranche 2 Interest Rate Swap Designated December 15, 2020 Tranche 2 [Member] Interest Rate Swap Designated December 15, 2020 Tranche 2 Additional paid-in capital Additional Paid in Capital, Common Stock Interest income Interest Income [Member] Additional Paid-In Capital Additional Paid-in Capital [Member] Period for extended lease Lessee, Operating Lease, Option to Extend Mergers, Acquisitions and Dispositions [Abstract] Mergers, Acquisitions and Dispositions Leased vehicles Vehicles [Member] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Total assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Share Repurchase Program [Axis] Share Repurchase Program [Axis] Other liabilities Other Liabilities [Member] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Cover [Abstract] Cover [Abstract] Position [Axis] Position [Axis] Surgical Innovation Associates, Inc. Surgical Innovation Associates Inc [Member] Surgical Innovation Associates Inc Proceeds from warrant transactions Proceeds from Issuance of Warrants Share-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition United States UNITED STATES Product returns, reserve Revenue From Contract With Customer, Product Returns, Reserve Revenue From Contract With Customer, Product Returns, Reserve Interest Rate Swap Designated December 18, 2018 Tranche 1 Interest Rate Swap Designated December 18, 2018 Tranche 1 [Member] Interest Rate Swap Designated December 18, 2018 Tranche 1 [Member] Other liabilities Other Liabilities, Noncurrent Non-NEOs Non-NEOs [Member] Total minimum lease payments Lessee, Operating Lease, Liability, to be Paid September 30, 2026 and the last day of each fiscal quarter thereafter Debt Covenant Period 3 [Member] Debt Covenant Period 3 [Member] Short-term investments Short-Term Investments Other income, net Other Nonoperating Income (Expense) [Member] Private Label Private Label [Member] Private Label [Member] All other All Other [Member] All Other [Member] Cash Flow Hedges Cash Flow Hedging [Member] Accrued expenses and other current liabilities Accrued Expenses And Other Current Liabilities [Member] Accrued expenses and other current liabilities. SEGMENT AND GEOGRAPHIC INFORMATION Segment Reporting Disclosure [Text Block] Net increase (decrease) in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect FINANCING ACTIVITIES: Net Cash Provided by (Used in) Financing Activities [Abstract] Secured Debt Secured Debt [Member] Non-PEO NEO Non-PEO NEO [Member] Option to extend lease, years Lessee, Operating Lease, Renewal Term Interest Rate Swap Designated December 15, 2020 Tranche 1 Interest Rate Swap Designated December 15, 2020 Tranche 1 [Member] Interest Rate Swap Designated December 15, 2020 Tranche 1 Equity Component [Domain] Equity Component [Domain] Adjustment to Compensation: Adjustment to Compensation [Axis] Interest Rate Swap Designated December 18, 2018 Tranche 2 Interest Rate Swap Designated December 18, 2018 Tranche 2 [Member] Interest Rate Swap Designated December 18, 2018 Tranche 2 [Member] Work in process Inventory, Work in Process, Net of Reserves Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Scenario [Axis] Scenario [Axis] Debt Instrument [Line Items] Debt Instrument [Line Items] Contract asset, Beginning of period Contract asset, End of Period Contract with Customer, Asset, after Allowance for Credit Loss Basic (in shares) Weighted average common shares outstanding - basic (in shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Operating income Operating income Operating Income (Loss) Long Long [Member] March 31, 2025 through June 30, 2026 Debt Covenant Period 2 [Member] Debt Covenant Period 2 Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Cash paid for amounts included in the measurement of lease liabilities: Cash Flow, Lessee [Abstract] Cash Flow, Lessee [Abstract] Segments [Axis] Segments [Axis] Statement [Line Items] Statement [Line Items] Scenario [Domain] Scenario [Domain] Schedule of Derivative Instruments Schedule of Derivative Instruments [Table Text Block] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Segment Profit Segment Reporting Information, Profit (Loss) [Abstract] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Line of credit facility outstanding Long-Term Line of Credit Customer relationships Customer Relationships Customer Relationships [Member] Amortization of debt issuance costs and expenses associated with debt refinancing Amortization Of Debt Issuance Costs And Debt Refinanced Fees Amortization Of Debt Issuance Costs And Debt Refinanced Fees Senior Credit Facility Senior Credit Facility [Member] Senior Credit Facility. EX-101.PRE 11 iart-20240331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 13 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Cover - shares
 3 Months Ended
Mar. 31, 2024
May 03, 2024
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2024  
Document Transition Report false  
Entity File Number 000-26224  
Entity Registrant Name INTEGRA LIFESCIENCES HOLDINGS CORP  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 51-0317849  
Entity Address 1100 Campus Road  
Entity City Princeton  
Entity State NJ  
Entity Postal Zip Code 08540  
City Area Code 609  
Local Phone Number 275-0500  
Title of 12(b) Security Common Stock, Par Value $.01 Per Share  
Trading Symbol IART  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Smaller Reporting Company false  
Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding (in shares)   78,799,694
Amendment Flag false  
Document Fiscal Year Focus 2024  
Document Fiscal Period Focus Q1  
Entity Central Index Key 0000917520  
Current Fiscal Year End Date --12-31  
XML 14 R2.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (UNAUDITED) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]    
Total revenue, net $ 368,872 $ 380,846
Costs and expenses:    
Cost of goods sold 162,038 147,975
Research and development 26,965 26,724
Selling, general and administrative 165,798 166,657
Intangible asset amortization 10,107 3,108
Total costs and expenses 364,908 344,464
Operating income 3,964 36,382
Interest income 5,040 4,107
Interest expense (13,624) (12,100)
Other (expense) income, net (610) 1,389
(Loss) income before income taxes (5,230) 29,778
(Benefit) provision for income taxes (1,949) 5,552
Net (loss) income $ (3,281) $ 24,226
Net (loss) income per share    
Basic (in dollars per share) $ (0.04) $ 0.30
Diluted (in dollars per share) $ (0.04) $ 0.29
Weighted average common shares outstanding (See Note 13):    
Basic (in shares) 77,735 81,871
Diluted (in shares) 77,735 82,323
Comprehensive income (See Note 14) $ 1,179 $ 21,028
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 591,906 $ 276,402
Short-term investments 71,194 32,694
Trade accounts receivable, net of allowances of $5,050 and $4,879 241,092 259,327
Inventories, net 403,422 389,608
Prepaid Expenses 72,667 67,362
Other Current Assets 35,369 32,643
Total current assets 1,415,650 1,058,036
Property, plant and equipment, net 345,356 340,199
Right of use asset - operating leases 151,834 156,184
Intangible assets, net 1,022,609 1,067,833
Goodwill 1,040,235 1,055,462
Deferred tax assets, net 34,175 46,080
Other assets 68,365 58,194
Total assets 4,078,224 3,781,988
Current liabilities:    
Current portion of borrowings under senior credit facility 19,375 14,531
Current portion of lease liability - operating leases 16,303 15,284
Accounts payable, trade 94,397 92,326
Contract liabilities 7,841 8,540
Accrued compensation 52,582 75,455
Accrued expenses and other current liabilities 111,896 100,844
Total current liabilities 302,394 306,980
Long-term borrowings under senior credit facility 1,171,036 825,563
Long-term borrowings under securitization facility 94,600 89,200
Long-term convertible securities 570,984 570,255
Lease liability - operating leases 170,082 166,849
Deferred tax liabilities 31,431 35,317
Other liabilities 139,745 199,940
Total liabilities 2,480,272 2,194,104
Stockholders’ equity:    
Preferred stock; no par value; 15,000 authorized shares; none outstanding 0 0
Common stock; $0.01 par value; 240,000 authorized shares; 91,484 and 90,920 issued at March 31, 2024 and December 31, 2023, respectively 915 909
Additional paid-in capital 1,310,527 1,302,484
Treasury stock, at cost; 12,735 shares and 12,751 shares at March 31, 2024 and December 31, 2023, respectively (646,422) (647,262)
Accumulated other comprehensive loss (10,646) (15,106)
Retained earnings 943,578 946,859
Total stockholders’ equity 1,597,952 1,587,884
Total liabilities and stockholders’ equity $ 4,078,224 $ 3,781,988
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Statement of Financial Position [Abstract]    
Trade accounts receivable, allowance $ 5,050 $ 4,879
Preferred stock, par value (in dollars per share) $ 0 $ 0
Preferred stock, authorized shares (in shares) 15,000,000 15,000,000
Preferred stock, outstanding shares (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, authorized shares (in shares) 240,000,000 240,000,000
Common stock, issued shares (in shares) 91,484,000 90,920,000
Treasury stock (in shares) 12,735,000 12,751,000
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
OPERATING ACTIVITIES:    
Net (Loss) Income $ (3,281) $ 24,226
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 30,566 31,143
Non-cash impairment charges 7,064 0
Deferred income tax provision (benefit) (2,856) 1,953
Share-based compensation 5,599 3,620
Amortization of debt issuance costs and expenses associated with debt refinancing 1,398 1,890
Non-cash lease expense 149 1,260
Loss (gain) on disposal of property and equipment 12 (23)
Change in fair value of contingent consideration and others 456 4,699
Changes in assets and liabilities:    
Accounts receivable 16,827 10,041
Inventories (19,021) (25,423)
Prepaid expenses and other current assets (2,676) (2,164)
Other non-current assets 339 (6,009)
Accounts payable, accrued expenses and other current liabilities (19,210) (4,984)
Contract liabilities (1,498) 430
Other non-current liabilities 1,888 (14,503)
Net cash provided by operating activities 15,756 26,156
INVESTING ACTIVITIES:    
Purchases of property and equipment (15,465) (13,704)
Purchases of Investments (38,500) 0
Net cash used in investing activities (53,965) (13,704)
FINANCING ACTIVITIES:    
Proceeds from borrowings of long-term indebtedness 370,500 10,200
Payments on debt (15,100) (12,400)
Payment of debt issuance costs 0 (7,578)
Purchases of treasury stock 0 (150,000)
Proceeds from exercised stock options 6,398 2,326
Cash taxes paid in net equity settlement (3,122) (5,231)
Net cash provided by (used in) financing activities 358,676 (162,683)
Effect of exchange rate changes on cash and cash equivalents (4,963) 937
Net increase (decrease) in cash and cash equivalents 315,504 (149,294)
Cash and cash equivalents at beginning of period 276,402 456,661
Cash and cash equivalents at end of period $ 591,906 $ 307,367
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (UNAUDITED) - USD ($)
$ in Thousands
Total
Common Stock
Treasury Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Loss
Retained Earnings
Balance, beginning of period, (in shares) at Dec. 31, 2022   90,476,000        
Balance, beginning of period at Dec. 31, 2022 $ 1,804,403 $ 905 $ (362,862) $ 1,276,977 $ 10,265 $ 879,118
Balance, beginning of period, treasury stock (in shares) at Dec. 31, 2022     (6,823,000)      
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net (Loss) Income 24,226         24,226
Other comprehensive income (loss), net of tax (3,198)       (3,198)  
Issuance of common stock through employee stock purchase plan (in shares)   21,000        
Issuance of common stock through employee stock purchase plan 1,107     1,107    
Issuance of common stock for vesting of share based awards, net of shares withheld for taxes (in shares)   316,000 16,000      
Issuance of common stock for vesting of share based awards, net of shares withheld for taxes (4,011) $ 1 $ 846 (4,858)    
Share-based compensation 3,611 $ 2   3,609    
Accelerated shares repurchased (shares)     (2,111,000)      
Accelerated shares repurchased (151,200)   $ (119,662) (31,538)    
Balance, end of period (in shares) at Mar. 31, 2023   90,813,000        
Balance, end of period at Mar. 31, 2023 1,674,938 $ 908 $ (481,678) 1,245,297 7,067 903,344
Balance, beginning of period, treasury stock (in shares) at Mar. 31, 2023     (8,918,000)      
Balance, beginning of period, (in shares) at Dec. 31, 2023   90,920,000        
Balance, beginning of period at Dec. 31, 2023 $ 1,587,884 $ 909 $ (647,262) 1,302,484 (15,106) 946,859
Balance, beginning of period, treasury stock (in shares) at Dec. 31, 2023 (12,751,000)   (12,751,000)      
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net (Loss) Income $ (3,281)         (3,281)
Other comprehensive income (loss), net of tax 4,460       4,460  
Issuance of common stock through employee stock purchase plan (in shares)   23,000        
Issuance of common stock through employee stock purchase plan 965     965    
Issuance of common stock for vesting of share based awards, net of shares withheld for taxes (in shares)   541,000 16,000      
Issuance of common stock for vesting of share based awards, net of shares withheld for taxes 2,312 $ 2 $ 840 1,470    
Share-based compensation 5,612 $ 4   5,608    
Accelerated shares repurchased 0          
Balance, end of period (in shares) at Mar. 31, 2024   91,484,000        
Balance, end of period at Mar. 31, 2024 $ 1,597,952 $ 915 $ (646,422) $ 1,310,527 $ (10,646) $ 943,578
Balance, beginning of period, treasury stock (in shares) at Mar. 31, 2024 (12,735,000)   (12,735,000)      
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.24.1.u1
BASIS OF PRESENTATION
 3 Months Ended
Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
BASIS OF PRESENTATION BASIS OF PRESENTATION
General
The terms “we,” “our,” “us,” “Company” and “Integra” refer to Integra LifeSciences Holdings Corporation, a Delaware corporation, and its subsidiaries unless the context suggests otherwise.
In the opinion of management, the March 31, 2024 unaudited condensed consolidated financial statements contain all adjustments (consisting only of normal recurring adjustments) necessary for a fair statement of the financial position, statement of changes in shareholders’ equity, results of operations and cash flows of the Company. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) have been condensed or omitted in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements for the year ended December 31, 2023 included in the Company’s Annual Report on Form 10-K. The December 31, 2023 consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by GAAP. Operating results for the three-month period ended March 31, 2024 are not necessarily indicative of the results to be expected for the entire year.
The preparation of consolidated financial statements is in conformity with GAAP, which requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, the disclosure of contingent liabilities, and the reported amounts of revenues and expenses. Significant estimates affecting amounts reported or disclosed in the condensed consolidated financial statements include allowances for doubtful accounts receivable and sales returns and allowances, net realizable value of inventories, valuation of intangible assets including amortization periods for acquired intangible assets, discount rates and estimated projected cash flows used to value and test impairments of long-lived assets and goodwill, estimates of projected cash flows and depreciation and amortization periods for long-lived assets, computation of taxes, valuation allowances recorded against deferred tax assets, the valuation of stock-based compensation, valuation of derivative instruments, valuation of contingent liabilities, the fair value of debt instruments and loss contingencies. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the current circumstances. Actual results could differ from these estimates.
Recent Accounting Pronouncements
In March 2020, the Financial Accounting Standards Board (“FASB”) issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting, and, in January 2021, subsequently amended the initial guidance in: ASU 2021-01, Reference Rate Reform (Topic 848): Scope (collectively, “Topic 848”). Topic 848 provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments apply only to contracts, hedging relationships, and other transactions that reference London Inter-Bank Offered Rate (“LIBOR”) or another reference rate expected to be discontinued because of reference rate reform. In December 2022, the FASB issued ASU 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848, which delayed the effective date from December 31, 2022 to December 31, 2024. The Alternative Reference Rates Committee, a group of private-market participants convened by the U.S. Federal Reserve Board and the New York Federal Reserve, has recommended the use of the Secured Overnight Financing Rate (“SOFR”) as a more robust reference rate alternative to LIBOR. On March 24, 2023, the Company entered into the seventh amendment and restatement (the “March 2023 Amendment”) of its Senior Credit Facility (the “Senior Credit Facility”) with a syndicate of lending banks with Bank of America, N.A., as Administrative Agent. In connection with the March 2023 Amendment, the Company replaced all LIBOR-based contracts with SOFR, which is calculated based on overnight transactions under repurchase agreements backed by Treasury securities. In addition, on April 17, 2023 the Company entered into an amendment (the “April 2023 Amendment”) of the Securitization Facility (as defined below) and amended the interest rate from LIBOR to SOFR indexed rate. (See Note 6, Debt). In March 2023, the Company entered into a basis swap where the Company receives Term SOFR and pays LIBOR to convert the portfolio of interest rate swaps from LIBOR to SOFR. Integra has elected to adopt the optional expedient under Topic 848, which will allow the interest rate swap hedging relationship to continue, without de-designation, due to the change in the indexed rate from LIBOR to SOFR.
In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures which enhances the transparency of income tax disclosures by expanding annual disclosure requirements related to the rate reconciliation and income taxes paid. The amendments are effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company does not plan to early adopt and is currently evaluating this ASU to determine its impact on the Company’s disclosures.
In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which updates reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. The amendments are effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company does not plan to early adopt and is currently evaluating this ASU to determine its impact on the Company’s disclosures.
There are no other recently issued accounting pronouncements that are expected to have any significant effect on the Company’s financial position, results of operations or cash flows.
XML 20 R8.htm IDEA: XBRL DOCUMENT v3.24.1.u1
ACQUISITIONS AND DIVESTITURES
 3 Months Ended
Mar. 31, 2024
Mergers, Acquisitions and Dispositions [Abstract]  
ACQUISITIONS AND DIVESTITURES ACQUISITIONS AND DIVESTITURES
Acquisition of Acclarent Inc.
In December 2023, the Company entered into a definitive agreement to acquire Acclarent, Inc. (“Acclarent”) from Ethicon, Inc., a subsidiary of Johnson & Johnson, for $275.0 million in cash at closing, subject to customary purchase price adjustments, and an additional $5.0 million contingent upon the achievement of a regulatory milestone, which was achieved prior to closing. Acclarent is a developer and marketer of medical devices used in Ear, Nose, Throat (“ENT”) procedures. Acclarent’s results of operations will be reported in the Company’s Codman Specialty Surgical reportable segment from the date of acquisition.
On April 1, 2024, the Company successfully completed the acquisition of 100% of Acclarent for approximately $282.0 million in cash, subject to customary adjustments set forth in the purchase agreement related to working capital balances transferred to the Company. To facilitate the completion of the acquisition of Acclarent, the Company drew from the revolving portion of the Senior Credit Facility during the three months ended March 31, 2024. For further detail on the Company’s additional borrowings, see Note 6. Debt.
XML 21 R9.htm IDEA: XBRL DOCUMENT v3.24.1.u1
REVENUES FROM CONTRACTS WITH CUSTOMERS
 3 Months Ended
Mar. 31, 2024
Revenue from Contract with Customer [Abstract]  
REVENUES FROM CONTRACTS WITH CUSTOMERS REVENUES FROM CONTRACTS WITH CUSTOMERS
Summary of Accounting Policies on Revenue Recognition
Revenue is recognized upon the transfer of control of promised products or services to the customers in an amount that reflects the consideration the Company expects to receive in exchange for those products and services.
Performance Obligations
The Company’s performance obligations consist mainly of transferring control of goods and services identified in the contracts, purchase orders, or invoices. The Company has no significant multi-element contracts with customers.
Significant Estimates
Usage-based royalties and licenses are estimated based on the provisions of contracts with customers and recognized in the same period that the royalty-based products are sold by the Company’s strategic partners. The Company estimates and recognizes royalty revenue based upon communication with licensees, historical information, and expected sales trends. Differences between actual reported licensee sales and those that were estimated are adjusted in the period in which they become known, which is typically the following quarter. Historically, such adjustments have not been significant.
The Company estimates returns, price concessions, and discount allowances using the expected value method based on historical trends and other known factors. Rebate allowances are estimated using the most likely method based on each customer contract.
The Company’s return policy, as set forth in its product catalogs and sales invoices, requires review and authorization in advance prior to the return of product. Upon the authorization, a credit will be issued for the goods returned within a set amount of days from the shipment, which is generally 90 days.
In 2023, due to the voluntary recall of all products manufactured at the Boston facility, including PriMatrix®, SurgiMend®, Revize™, and TissueMend™ (the “Boston recall”), the Company recorded a total of $18.7 million provision for product returns. As of March 31, 2024, the Company has credited $16.7 million to customers and holds a remaining return reserve of $2.0 million.
The Company disregards the effects of a financing component if the Company expects, at contract inception, that the period between the transfer and customer payment for the goods or services will be one year or less. The Company has no significant revenues recognized on payments expected to be received more than one year after the transfer of control of products or services to customers.
Contract Asset and Liability
Revenues recognized from the Company’s private label business that are not invoiced to the customers as a result of recognizing revenue over time are recorded as a contract asset included in the other current assets account in the consolidated balance sheets.
Other operating revenues may include fees received under service agreements. Non-refundable fees received under multiple-period service agreements are recognized as revenue as the Company satisfies the performance obligations to the other party. A portion of the transaction price allocated to the performance obligations to be satisfied in the future periods is recognized as contract liability.
The following table summarizes the changes in the contract asset and liability balances for the three months ended March 31, 2024:
Dollars in thousandsTotal
Contract Asset
Contract asset, January 1, 2024
$9,233 
Transferred to trade receivable from contract asset included in beginning of the year contract asset(9,233)
Contract asset, net of transferred to trade receivables on contracts during the period7,478 
Contract asset, March 31, 2024
$7,478 
Contract Liability
Contract liability, January 1, 2024
$16,252 
Recognition of revenue included in beginning of year contract liability(3,523)
Contract liability, net of revenue recognized on contracts during the period2,017 
Foreign currency translation(63)
Contract liability, March 31, 2024
$14,683 
At March 31, 2024, the short-term portion of the contract liability of $7.8 million and the long-term portion of $6.9 million are included in current liabilities and other liabilities, respectively, in the consolidated balance sheets.
As of March 31, 2024, the Company is expected to recognize revenue of approximately 53% of unsatisfied (or partially unsatisfied) performance obligations as revenue within 12 months, with the remaining balance to be recognized thereafter.
Shipping and Handling Fees
The Company elected to account for shipping and handling activities as a fulfillment cost rather than a separate performance obligation. Amounts billed to customers for shipping and handling are included as part of the transaction price and recognized as revenue when control of underlying products is transferred to the customer. The related shipping and freight charges incurred by the Company are included in the cost of goods sold.
Product Warranties
Certain of the Company’s medical devices, including monitoring systems and neurosurgical systems, are designed to operate over long periods of time. These products are sold with warranties which may extend for up to two years from the date of purchase. The warranties are not considered a separate performance obligation. The Company estimates its product warranties using the expected value method based on historical trends and other known factors. The Company includes them in accrued expenses and other current liabilities in the consolidated balance sheet.
Taxes Collected from Customers
The Company elected to exclude from the measurement of the transaction price all taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction and collected by the entity from a customer.
Disaggregated Revenue
The following table presents revenues disaggregated by the major sources of revenues for the three months ended March 31, 2024 and 2023 (dollar amounts in thousands):
Three Months Ended March 31, 2024Three Months Ended March 31, 2023
Neurosurgery$202,268 $192,870 
Instruments54,166 55,266 
Total Codman Specialty Surgical256,434 248,136 
Wound Reconstruction and Care80,877 100,940 
Private Label31,561 31,770 
Total Tissue Technologies112,438 132,710 
Total revenue$368,872 $380,846 
See Note 15, Segment and Geographical Information, for details of revenues based on the location of the customer.
XML 22 R10.htm IDEA: XBRL DOCUMENT v3.24.1.u1
INVENTORIES
 3 Months Ended
Mar. 31, 2024
Inventory Disclosure [Abstract]  
INVENTORIES INVENTORIES
Inventories, net consisted of the following:
Dollars in thousandsMarch 31, 2024December 31, 2023
Finished goods$192,287 $196,402 
Work in process83,334 74,035 
Raw materials127,801 119,171 
Total inventories, net$403,422 $389,608 
XML 23 R11.htm IDEA: XBRL DOCUMENT v3.24.1.u1
GOODWILL AND OTHER INTANGIBLE ASSETS
 3 Months Ended
Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL AND OTHER INTANGIBLE ASSETS GOODWILL AND OTHER INTANGIBLE ASSETS
Goodwill
Changes in the carrying amount of goodwill for the three-month period ended March 31, 2024 were as follows:
Dollars in thousandsCodman Specialty
Surgical		Tissue TechnologiesTotal
Goodwill at December 31, 2023$666,937 $388,525 $1,055,462 
Foreign currency translation(9,622)(5,605)(15,227)
Goodwill at March 31, 2024
$657,315 $382,920 $1,040,235 
The Company tests goodwill and intangible assets with indefinite lives for impairment annually in the third quarter in accordance with FASB ASC Topic 350, Intangibles—Goodwill and Other (“ASC 350”). Additionally, the Company may perform interim tests if an event occurs or circumstances change that could potentially reduce the fair value of a reporting unit or indefinite lived intangible asset below its carrying amount. The carrying value of each reporting unit is determined by assigning the assets and liabilities, including the existing goodwill and intangible assets, to those reporting units.
The Company tests for impairment by either performing a qualitative evaluation or a quantitative test. The qualitative evaluation is an assessment of factors, including reporting unit specific operating results as well as industry, market and general economic conditions, to determine whether it is more likely than not that the fair values of a reporting unit is less than its carrying amount, including goodwill. The Company may elect to bypass this qualitative evaluation for some or all of its reporting units and perform a quantitative test. The quantitative test estimates the fair value of the reporting unit using a
discounted cash flow model, which incorporates significant estimates and assumptions made by management which, by their nature, are characterized by uncertainty.
Due to third-party audit findings and an update to the estimated timeframe to resume the commercial distribution of products manufactured in the Boston facility, the Company elected to perform a quantitative analysis of its Tissue Technologies reporting unit in the first quarter of 2024 in accordance with ASC 350. The quantitative test estimates the fair value of the reporting unit using a discounted cash flow model, which incorporates significant estimates and assumptions made by management with respect to future revenue and expense growth rates and discount rates which, by their nature, are characterized by uncertainty. An impairment loss is recognized when the reporting unit’s carrying amount exceeds its estimated fair value. The quantitative test utilized a terminal growth rate of 2%, a discount rate of 15%, and a range and application of the company guideline multiples. The Company determined, after performing the quantitative analysis, that the fair value of the Tissue Technologies reporting unit was not less than its carrying amount, with 20% headroom.
Other Intangible Assets
The components of the Company’s identifiable intangible assets were as follows:
 March 31, 2024
Dollars in thousandsWeighted
Average
Life		CostAccumulated
Amortization		Net
Completed technology18 years$1,209,921 $(460,545)$749,376 
Customer relationships12 years$167,360 $(134,587)$32,773 
Trademarks/brand names28 years$97,668 $(39,330)$58,338 
Codman tradenameIndefinite$168,678 $— $168,678 
Supplier relationships30 years$30,211 $(18,393)$11,818 
All other11 years$6,052 $(4,426)$1,626 
$1,679,890 $(657,281)$1,022,609 
 December 31, 2023
Dollars in thousandsWeighted
Average
Life		CostAccumulated
Amortization		Net
Completed technology18 years$1,226,128 $(448,519)$777,609 
Customer relationships12 years193,895 (152,160)41,735 
Trademarks/brand names28 years98,892 (38,754)60,138 
Codman tradenameIndefinite174,531 — 174,531 
Supplier relationships30 years30,211 (18,148)12,063 
All other11 years6,180 (4,423)1,757 
$1,729,837 $(662,004)$1,067,833 
Total amortization of intangible assets for the three months ended March 31, 2024 was $27.7 million. Of these amounts, $17.6 million was related to amortization of technology based intangibles and included in cost of goods sold. $7.1 million related to the impairment of a customer relationship intangible and the remainder were included in intangible amortization in the statement of operations.
Total amortization of intangible assets for the three months ended March 31, 2023 was $20.6 million. Of these amounts, $17.5 million was related to amortization of technology based intangibles and included in cost of goods sold, with the remainder included in intangible amortization in the statement of operations.
Based on quarter-end exchange rates, amortization expense (including amounts reported in cost of goods sold) is expected to be approximately $60.1 million for the remainder of 2024, $80.2 million in 2025, $80.0 million in 2026, $79.1 million in 2027, $78.7 million in 2028, $74.9 million in 2029 and $403.5 million thereafter.
The Company periodically performs testing for impairment on certain long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.
XML 24 R12.htm IDEA: XBRL DOCUMENT v3.24.1.u1
DEBT
 3 Months Ended
Mar. 31, 2024
Debt Disclosure [Abstract]  
DEBT DEBT
Amendment to the Seventh Amended and Restated Senior Credit Agreement
On March 24, 2023, the Company entered into the seventh amendment and restatement (the “March 2023 Amendment”) of the Senior Credit Facility (the “Senior Credit Facility”) with a syndicate of lending banks with Bank of America, N.A., as Administrative Agent. The March 2023 Amendment extended the maturity date to March 24, 2028, amended the contractual repayments of the term loan component, and amended the interest rate from LIBOR to SOFR-indexed interest. The Company continues to have the aggregate principal amount of up to approximately $2.1 billion available to it through the following facilities: (i) a $775.0 million term loan facility, and (ii) a $1.3 billion revolving credit facility, which includes a $60 million sublimit for the issuance of standby letters of credit and a $60 million sublimit for swingline loans.
The Company’s maximum consolidated total leverage ratio in the financial covenants (as defined in the Senior Credit Facility) was modified to the following:
Fiscal Quarter EndingMaximum Consolidated Total Leverage Ratio
March 31, 2023 through December 31, 2024
4.50 to 1.00
March 31, 2025 through June 30, 2026
4.25 to 1.00
September 30, 2026 and the last day of each fiscal quarter thereafter
4.00 to 1.00
Borrowings under the Senior Credit Facility bear interest, at the Company’s option, at a rate equal to the following:
i.Term SOFR in effect from time to time plus 0.10% plus the applicable rate (ranging from 1.00% to 1.75%), or
ii.The highest of:
1.the weighted average overnight Federal funds rate, as published by the Federal Reserve Bank of New York, plus 0.50%;
2.the prime lending rate of Bank of America, N.A.; or
3.the one-month Term SOFR plus 1.00%.
The applicable rates are based on the Company’s consolidated total leverage ratio (defined as the ratio of (a) consolidated funded indebtedness as of such date less cash that is not subject to any restriction on the use or investment thereof to (b) consolidated EBITDA (as defined by the amended Seventh Amended and Restated Credit Agreement (the “Credit Agreement”)), for the period of four consecutive fiscal quarters ending on such date).
The Company will pay an annual commitment fee (ranging from 0.15% to 0.30%), based on the Company’s consolidated total leverage ratio, on the amount available for borrowing under the revolving credit facility.
The Senior Credit Facility is collateralized by substantially all of the assets of the Company’s U.S. subsidiaries, excluding intangible assets. The Senior Credit Facility is subject to various financial and negative covenants and, at March 31, 2024, the Company was in compliance with all such covenants. The Company capitalized $7.6 million in deferred financing costs in connection with the modification of the Senior Credit Facility and wrote off $0.2 million of previously capitalized financing costs during the first quarter of 2023.
At March 31, 2024 and December 31, 2023 there was $420.0 million and $70.0 million, respectively, outstanding under the revolving portion of the Senior Credit Facility. At March 31, 2024 and December 31, 2023, there was $775.0 million outstanding under the term loan component of the Senior Credit Facility at a weighted average interest rate of 6.8% and 6.8%, respectively. As of March 31, 2024 and December 31, 2023 there was $19.4 million and $14.5 million, respectively, of the term loan component of the Senior Credit Facility classified as current on the condensed consolidated balance sheet.
The fair value of outstanding borrowings of the Senior Credit Facility’s term loan component at March 31, 2024 was $765.5 million. This fair value was determined by using a discounted cash flow model based on current market interest rates available to the Company. These inputs are corroborated by observable market data for similar liabilities and therefore classified within Level 2 of the fair value hierarchy. Level 2 inputs represent inputs that are observable for the asset or liability, either directly or indirectly, and are other than active market observable inputs that reflect unadjusted quoted prices for identical assets or liabilities.
Letters of credit outstanding as of March 31, 2024 and December 31, 2023 totaled $1.7 million. There were no amounts drawn under the letters of credit outstanding as of March 31, 2024.
Contractual repayments of the term loan component of the Senior Credit Facility are due as follows:
As of March 31, 2024
Principal Repayment
Dollars in thousands
Remainder of 2024
$14,531 
2025
33,906 
2026
38,750 
2027
53,281 
Thereafter634,532 
$775,000 
Future interest payments on the term loan component of the Senior Credit Facility based on current interest rates are expected to approximate $39.3 million for the remainder of 2024, $50.8 million in 2025, $48.1 million in 2026, $45.0 million in 2027, and $10.0 million thereafter. Interest is calculated on the term loan portion of the Senior Credit Facility based on SOFR plus the certain amounts set forth in the Credit Agreement. As the revolving credit facility and Securitization Facility (defined below) can be repaid at any time, no interest has been included in the calculation.
Any outstanding borrowings on the revolving credit component of the Senior Credit Facility are due on March 24, 2028.
Convertible Senior Notes
On February 4, 2020, the Company issued $575.0 million aggregate principal amount of its 0.5% Convertible Senior Notes due 2025 (the “2025 Notes”). The 2025 Notes will mature on August 15, 2025 and bear interest at a rate of 0.5% per annum payable semi-annually in arrears, unless earlier converted, repurchased or redeemed in accordance with the terms of the 2025 Notes. In connection with this offering, the Company capitalized $13.2 million of financing fees.
The 2025 Notes are senior, unsecured obligations of the Company, and are convertible into cash and shares of its common stock based on an initial conversion rate, subject to adjustment of 13.5739 shares per $1,000 principal amounts of the 2025 Notes (which represents an initial conversion price of $73.67 per share). The 2025 Notes convert only in the following circumstances: (1) if the closing price of the Company’s common stock has been at least 130% of the conversion price during the period; (2) if the average trading price per $1,000 principal amount of the 2025 Notes is less than or equal to 98% of the average conversion value of the 2025 Notes during a period as defined in the indenture; (3) if the Company calls the notes for optional redemption as defined in the indenture; or (4) if specified corporate transactions occur. As of March 31, 2024, none of these conditions existed and the 2025 Notes are classified as long term obligations.
On December 9, 2020, the Company entered into the First Supplemental Indenture to the original indenture dated as of February 4, 2020 (the “Indenture”) between the Company and Citibank, N.A., as trustee, governing the Company’s outstanding 2025 Notes. The Company irrevocably elected (1) to eliminate the Company’s option to choose physical settlement on any conversion of the 2025 Notes that occurs on or after the date of the First Supplemental Indenture and (2) with respect to any Combination Settlement (as defined in the indenture) for a conversion of the 2025 Notes, the Specified Dollar Amount (as defined in the indenture) that will be settled in cash per $1,000 principal amount of the 2025 Notes shall be no lower than $1,000.
Holders of the 2025 Notes will have the right to require the Company to repurchase for cash all or a portion of their 2025 Notes at 100% of their principal amount, plus any accrued and unpaid interest, upon the occurrence of a fundamental change (as defined in the indenture relating to the 2025 Notes). The Company will also be required to increase the conversion rate for holders who convert their 2025 Notes in connection with certain fundamental changes occurring prior to the maturity date or following delivery by the Company of a notice of redemption.
In connection with the issuance of the 2025 Notes, the Company entered into call transactions and warrant transactions, primarily with affiliates of the initial purchasers of the 2025 Notes (the “hedge participants”). The cost of the call transactions was $104.2 million for the 2025 Notes. The Company received $44.5 million of proceeds from the warrant transactions for the 2025 Notes. The call transactions involved purchasing call options from the hedge participants, and the warrant transactions involved selling call options to the hedge participants with a higher strike price than the purchased call options. The initial strike price of the call transactions was $73.67, subject to anti-dilution adjustments substantially similar to those in the 2025 Notes. The initial strike price of the warrant transactions was $113.34 for the 2025 Notes, subject to customary anti-dilution adjustments.
At March 31, 2024, the carrying amount of the liability was $575.0 million. The fair value of the 2025 Notes at March 31, 2024 was $549.7 million. Factors that the Company considered when estimating the fair value of the 2025 Notes included recent quoted market prices or dealer quotes. The 2025 Notes are valued based on Level 1 measurements in the fair value hierarchy.
Securitization Facility
In 2018, the Company entered into an accounts receivable securitization facility (the “Securitization Facility”) under which accounts receivable of certain domestic subsidiaries are sold on a non-recourse basis to a special purpose entity (“SPE”), which is a bankruptcy-remote, consolidated subsidiary of the Company. Accordingly, the assets of the SPE are not available to satisfy the obligations of the Company or any of its subsidiaries. From time to time, the SPE may finance such accounts receivable with a revolving loan facility secured by a pledge of such accounts receivable. The amount of outstanding borrowings on the Securitization Facility at any one time is limited to $150.0 million. The Securitization Facility Agreement (“Securitization Agreement”) governing the Securitization Facility contains certain covenants and termination events. An occurrence of an event of default or a termination event under this Securitization Agreement may give rise to the right of its counterparty to terminate this facility. As of March 31, 2024, the Company was in compliance with the covenants and none of the termination events had occurred.
On December 15, 2023, the Company entered into an amendment (the “December 2023 Amendment”) of the Securitization Facility which extended the maturity date from May 28, 2024 to December 15, 2026. The Company incurred approximately $0.3 million of new issuance costs associated with the December Amendment which will be amortized over 3 years, the length of the Securitization Agreement as amended by the December 2023 Amendment. Due to the increase in borrowing capacity, the remaining $0.1 million of unamortized costs from the previous agreement will also be amortized over the length of the amended agreement, 3 years. In addition, on April 17, 2023 the Company entered into an amendment (the “April 2023 Amendment”) of the Securitization Facility and amended the interest rate from LIBOR to SOFR-indexed rate. The December 2023 Amendment and April 2023 Amendment did not increase the Company’s total indebtedness.
At March 31, 2024 and December 31, 2023, the Company had $94.6 million and $89.2 million, respectively, of outstanding borrowings under its Securitization Facility at a weighted average interest rate of 6.5% and 5.9%, respectively. The fair value of the outstanding borrowing of the Securitization Facility at March 31, 2024 was $92.7 million. These fair values were determined by using a discounted cash flow model based on current market interest rates available to the Company. These inputs are corroborated by observable market data for similar liabilities and therefore classified within Level 2 of the fair value hierarchy. Level 2 inputs represent inputs that are observable for the asset or liability, either directly or indirectly, and are other than active market observable inputs that reflect unadjusted quoted prices for identical assets or liabilities.
XML 25 R13.htm IDEA: XBRL DOCUMENT v3.24.1.u1
DERIVATIVE INSTRUMENTS
 3 Months Ended
Mar. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
DERIVATIVE INSTRUMENTS DERIVATIVE INSTRUMENTS
Interest Rate Hedging
The Company’s interest rate risk relates to U.S. dollar denominated variable interest rate borrowings. The Company uses interest rate swap derivative instruments to manage earnings and cash flow exposure resulting from changes in interest rates. These interest rate swaps apply a fixed interest rate on a portion of the Company’s expected SOFR-indexed borrowings. In March 2023, the Company entered into a basis swap where the Company receives Term SOFR and pays daily compounded SOFR to convert the portfolio of swaps from daily compounded SOFR to term SOFR.
The Company held the following interest rate swaps as of March 31, 2024 and December 31, 2023 (dollar amounts in thousands):
March 31, 2024December 31, 2023March 31, 2024December 31, 2023
Hedged ItemNotional AmountDesignation DateEffective DateTermination DateFixed Interest RateEstimated Fair Value
Asset (Liability)
1-month Term SOFR Loan150,000 150,000 December 13, 2017July 1, 2019June 30, 20242.423 %1,125 2,105 
1-month Term SOFR Loan200,000 200,000 December 13, 2017January 1, 2018December 31, 20242.313 %4,341 4,978 
1-month Term SOFR Loan75,000 75,000 October 10, 2018July 1, 2020June 30, 20253.220 %1,556 1,349 
1-month Term SOFR Loan75,000 75,000 October 10, 2018July 1, 2020June 30, 20253.199 %1,548 1,312 
1-month Term SOFR Loan75,000 75,000 October 10, 2018July 1, 2020June 30, 20253.209 %1,548 1,346 
1-month Term SOFR Loan100,000 100,000 December 18, 2018December 30, 2022December 31, 20272.885 %4,512 3,015 
1-month Term SOFR Loan100,000 100,000 December 18, 2018December 30, 2022December 31, 20272.867 %4,519 3,052 
1-month Term SOFR Loan575,000 575,000 December 15, 2020July 31, 2025December 31, 20271.415 %29,267 22,965 
1-month Term SOFR Loan125,000 125,000 December 15, 2020July 1, 2025December 31, 20271.404 %6,770 5,263 
Basis Swap (1)
—— March 31, 2023March 24, 2023December 31, 2027N/A(2,127)0(1,829)
$1,475,000 $1,475,000 $53,059 $43,556 
(1) The notional of the basis swap amortizes to match the total notional of the interest rate swap portfolio over time
The interest rate swaps were carried on the consolidated balance sheet at fair value and changes in the fair values were recorded as unrealized gains or losses in accumulated other comprehensive income (“AOCI”). For the three months ended March 31, 2024 and 2023, the Company recorded a gain of $14.7 million and a loss of $10.5 million, respectively, in AOCI related to the change in fair value of the interest rate swaps.
For the three months ended March 31, 2024 and 2023, the Company recorded gains of $5.2 million and $3.5 million, respectively, in the consolidated statements of operations related to the interest rate differential of the interest rate swaps. The estimated gain that is expected to be reclassified to interest income from AOCI as of March 31, 2024 within the next twelve months is $13.6 million.
The Company has designated these derivative instruments as cash flow hedges. The Company assesses the effectiveness of these derivative instruments and has recorded the changes in the fair value of the derivative instrument designated as a cash flow hedge as unrealized gains or losses in AOCI, net of tax, until the hedged item affected earnings, at which point any gain or loss was reclassified to earnings. If the hedged cash flow does not occur, or if it becomes probable that it will not occur, the Company will reclassify the remaining amount of any gain or loss on the related cash flow hedge recorded in AOCI to interest expense at that time.
Foreign Currency Hedging
From time to time, the Company enters into foreign currency hedge contracts intended to protect the U.S. dollar value of certain forecasted foreign currency denominated transactions. The Company assesses the effectiveness of the contracts that are designated as hedging instruments. The changes in fair value of foreign currency cash flow hedges are recorded in AOCI, net of tax. Those amounts are subsequently reclassified to earnings from AOCI as impacted by the hedged item when the hedged item affects earnings. If the hedged forecasted transaction does not occur or if it becomes probable that it will not occur, the Company will reclassify the amount of any gain or loss on the related cash flow hedge to earnings at that time. For contracts not designated as hedging instruments, the changes in fair value of the contracts are recognized in other income, net in the consolidated statements of operation, along with the offsetting foreign currency gain or loss on the underlying assets or liabilities.
The success of the Company’s hedging anticipated currency exchange gains or losses to the extent that there are differences between forecasted and actual activities during periods of currency volatility. In addition, changes in currency exchange rates related to any unhedged transactions may affect earnings and cash flows.
Cross-Currency Rate Swaps
The objective of these cross-currency swaps is to reduce volatility of earnings and cash flows associated with changes in the foreign currency exchange rate. Under the terms of these contracts, which have been designated as cash flow hedges, the Company will make interest payments in Swiss francs (“CHFs”) and receive interest in U.S. dollars. Upon the maturity of these contracts, the Company will pay the principal amount of the loans in CHFs and receive U.S. dollars from the counterparties.
On September 22, 2023, the Company amended the Swiss franc denominated intercompany loan to partially settle CHF 20.0 million and extend the termination date to September 2024 and as a result, the Company terminated the cross-currency swap designated as cash flow hedge of an intercompany loan with aggregate notional amount of $48.5 million. Simultaneously, the Company entered into a cross-currency swap agreement to hedge a notional amount of CHF 28.5 million equivalent to $31.5 million of this amended intercompany loan into U.S. dollars. The loss recorded by the Company upon the settlement of the swap was not material for the period.
On December 21, 2020, the Company entered into cross-currency swap agreements to convert a notional amount of $471.6 million equivalent to 420.1 million of a CHF-denominated intercompany loan into U.S. dollars. The CHF-denominated intercompany loan was the result of an intra-entity transfer of certain intellectual property rights to a subsidiary in Switzerland completed during the fourth quarter of 2020. The intercompany loan requires quarterly payments of CHF 5.8 million plus accrued interest. As a result, the aggregate notional amount of the related cross-currency swaps will decrease by a corresponding amount.
The Company held the following cross-currency rate swaps as of March 31, 2024 and December 31, 2023 (dollar amounts in thousands):
March 31, 2024December 31, 2023March 31, 2024December 31, 2023
Effective DateTermination DateFixed RateAggregate Notional AmountFair Value
Asset (Liability)
Pay CHFDecember 21, 2020December 22, 20253.00%CHF333,887 351,137 (9,902)(38,324)
Receive U.S.$3.98%$374,817 394,183 
Pay CHFSeptember 22, 2023September 29, 20242.40%CHF28,500 28,500 (2,578)(2,348)
Receive U.S.$6.27%$31,457 31,457 
Total$(12,480)$(40,672)
The cross-currency swaps are carried on the consolidated balance sheet at fair value, and changes in the fair values are recorded as unrealized gains or losses in AOCI. For the three months ended March 31, 2024 the Company recorded a gain of $30.1 million in other income, net related to change in fair value related to the foreign currency rate translation to offset the losses recognized on the intercompany loans. For the three months ended March 31, 2023, the Company recorded a loss of $4.9 million in other income, net related to change in fair value related to the foreign currency rate translation to offset the losses recognized on the intercompany loans.
For the three months ended March 31, 2024, the Company recorded a gain of $29.5 million in AOCI related to change in fair value of the cross-currency swaps. For the three months ended March 31, 2023, the Company recorded a gain of $2.2 million in AOCI related to change in fair value of the cross-currency swaps.
For the three months ended March 31, 2024, the Company recorded a gain of $1.3 million in other income, net included in the consolidated statements of operations related to the interest rate differential of the cross-currency swaps. For the three months ended March 31, 2023, the Company recorded a gain of $1.5 million in other income, net included in the consolidated statements of operations related to the interest rate differential of the cross-currency swaps.
The estimated loss that is expected to be reclassified to other income (expense), net from AOCI as of March 31, 2024 within the next twelve months is $1.9 million. As of March 31, 2024, the Company does not expect any gains or losses will be reclassified into earnings because the original forecasted transactions will not occur.
Net Investment Hedges
The Company manages certain foreign exchange risks through a variety of strategies, including hedging. The Company is exposed to foreign exchange risk from its international operations through foreign currency purchases, net investments in foreign subsidiaries, and foreign currency assets and liabilities created in the normal course of business. On October 1, 2018 May 24, 2022, and November 17, 2023, the Company entered into cross-currency swap agreements designated as net investment hedges to partially offset the effects of foreign currency on foreign subsidiaries.
The Company held the following cross-currency rate swaps designated as net investment hedges as of March 31, 2024 and December 31, 2023, respectively (dollar amounts in thousands):
March 31, 2024December 31, 2023
March 31, 2024
December 31, 2023
Effective DateTermination DateFixed RateAggregate Notional AmountFair Value
Asset (Liability)
Pay EUROctober 3, 2018September 30, 2025—%EUR38,820 38,820 3,459 2,475 
Receive U.S.$2.19%$45,000 45,000 
Pay CHFMay 26, 2022December 16, 2028—%CHF288,210 288,210 (29,614)(48,047)
Receive U.S.$1.94%$300,000 300,000 
Pay CHFNovember 21, 2023December 17, 2029—%CHF66,525 66,525 (736)(4,037)
Receive U.S.$2.54%$75,000 75,000 
Total$(26,891)$(49,609)
The cross-currency swaps were carried on the consolidated balance sheet at fair value and changes in the fair values were recorded as unrealized gains or losses in AOCI. For the three months ended March 31, 2024, the Company recorded a gain of $24.9 million in AOCI related to the change in fair value of the cross-currency swaps. For the three months ended March 31, 2023, the Company recorded a gain of $1.0 million in AOCI related to change in fair value of the cross-currency swaps.
For the three months ended March 31, 2024, the Company recorded a gain of $2.2 million in interest income included in the consolidated statements of operations related to the interest rate differential of the cross-currency swaps. For the three months ended March 31, 2023, the Company recorded a gain of $2.1 million in interest income included in the consolidated statements of operations related to the interest rate differential of the cross-currency swaps.
The estimated gain that is expected to be reclassified to interest income from AOCI as of March 31, 2024 within the next twelve months is $4.1 million.
On May 2, 2024, the Company entered into a cross-currency swap agreement with a notional amount of CHF 68.5 million, equivalent to $75.0 million, where the Company agreed with third-parties to sell Swiss francs in exchange for U.S. dollars at a specified rate at the maturity of the contract. The new cross-currency swap agreement was designated as a net investment hedge to partially offset the effects of foreign currency on foreign subsidiaries.
Foreign Currency Forward Contracts
The Company has entered into a hedge for forecasted intercompany purchases denominated in foreign currencies through the use of forward contracts designated as cash flow hedges. To the extent these forward contracts meet hedge accounting criteria, changes in their fair value are not included in accumulated comprehensive loss. These changes in fair value will be recognized into earnings as a component of cost of sales when the forecasted-transaction occurs.
In the first quarter of 2024, the Company entered into foreign currency forwards to mitigate the exchange rate risk of Swiss franc denominated intercompany purchases. These contracts typically settle at various dates within twelve months of execution. As of March 31, 2024 the notional amount of foreign currency forward contracts was CHF13.3 million. For the three months ended March 31, 2024 the Company recorded a loss of $0.6 million in AOCI related to the change in fair value of the foreign currency forward contracts and a loss of $0.1 million in cost of goods sold included in the consolidated statements of operations.
Counterparty Credit Risk
The Company manages its concentration of counterparty credit risk on its derivative instruments by limiting acceptable counterparties to a group of major financial institutions with investment grade credit ratings, and by actively monitoring their credit ratings and outstanding positions on an ongoing basis. Therefore, the Company considers the credit risk of the counterparties to be low. Furthermore, none of the Company’s derivative transactions are subject to collateral or other security arrangements, and none contain provisions that depend upon the Company’s credit ratings from any credit rating agency.
Fair Value of Derivative Instruments
The Company has classified all of its derivative instruments within Level 2 of the fair value hierarchy because observable inputs are available for substantially the full term of the derivative instruments. The fair values of the interest rate swaps and cross-currency swaps were developed using a market approach based on publicly available market yield curves and the terms of the swap. The Company performs ongoing assessments of counterparty credit risk.
The following table summarizes the fair value for derivatives designated as hedging instruments in the condensed consolidated balance sheets as of March 31, 2024 and December 31, 2023:
Fair Value as of
Location on Balance Sheet (1):
March 31, 2024December 31, 2023
Dollars in thousands
Derivatives designated as hedges — Assets:
Prepaid expenses and other current assets
Cash Flow Hedges
Interest rate swap(2)
$14,188 $14,675 
Cross-currency swap680 537 
Net Investment Hedges
Cross-currency swap4,084 2,938 
Other assets
Cash Flow Hedges
Interest rate swap(2)
40,998 30,710 
Cross-currency swap— — 
Net Investment Hedges
Cross-currency swap2,454 1,470 
Total derivatives designated as hedges — Assets$62,404 $50,330 
Derivatives designated as hedges — Liabilities:
Accrued expenses and other current liabilities
Cash Flow Hedges
Interest rate swap(2)
$540 $579 
Cross-currency swap2,578 4,813 
Foreign currency forward contracts629 — 
Net Investment Hedges
Cross-currency swap— 2,903 
Other liabilities
Cash Flow Hedges
Interest rate swap(2)
1,586 1,250 
Cross-currency swap10,582 36,396 
Net Investment Hedges
Cross-currency swap33,427 51,114 
Total derivatives designated as hedges — Liabilities$49,342 $97,055 
(1) The Company classifies derivative assets and liabilities as current based on the cash flows expected to be incurred within the following 12 months.
(2) At March 31, 2024 and December 31, 2023, the total notional amounts related to the Company’s interest rate swaps were $1.5 billion.
The following presents the effect of derivative instruments designated as cash flow hedges and net investment hedges on the accompanying condensed consolidated statement of operations during the three months ended March 31, 2024 and 2023:
Dollars in thousandsBalance in AOCI
Beginning of
Quarter		Amount of
Gain (Loss)
Recognized in
AOCI		Amount of Gain (Loss)
Reclassified from
AOCI into
Earnings		Balance in AOCI
End of Quarter		Location in
Statements of
Operations
Three Months Ended March 31, 2024
Cash Flow Hedges
Interest rate swap$43,556 $14,723 $5,219 $53,060 Interest expense
Cross-currency swap(15,763)29,532 31,473 (17,704)Other income (expense), net
Foreign currency forward contract— (629)(110)(519)Cost of sales
Net Investment Hedges
Cross-currency swap(45,498)24,920 2,202 (22,780)Interest income
$(17,705)$68,546 $38,784 $12,057 
Three Months Ended March 31, 2023
Cash Flow Hedges
Interest rate swap$56,712 $(10,534)$3,500 $42,678 Interest expense
Cross-currency swap(20,271)2,191 (3,504)(14,576)Other income (expense), net
Foreign currency forward contract$(69)$(69)
Net Investment Hedges
Cross-currency swap(6,914)950 2,096 (8,060)Interest income
$29,527 $(7,462)$2,092 $19,973 
Derivative Instruments not Designated Hedges:
During the second quarter of 2021, the Company entered into a foreign currency swap, with a notional amount of $7.3 million to mitigate the risk from fluctuations in foreign currency exchange rates associated with an intercompany loan denominated in Japanese yen. In a foreign currency swap transaction, the Company agrees with another party to exchange, at specified intervals, the difference between one currency and another currency at a fixed exchange rate, generally set at inception, calculated by reference to an agreed upon notional amount. The notional amount of each currency is exchanged at the inception and termination of the currency swap by each party. The Company subsequently paid down a portion of this swap, bringing the notional amount down to $5.5 million as of March 31, 2024.
The fair value of the foreign currency swaps not designated as hedges was $1.5 million and $1.2 million as of March 31, 2024 and December 31, 2023, respectively. The following table summarizes the gains (losses) on derivative instruments not designated as hedges on the condensed consolidated statements of income, which was included in other income:
Dollars in thousandsThree Months Ended March 31,
20242023
Foreign currency swaps273 55 
Total$273 $55 
XML 26 R14.htm IDEA: XBRL DOCUMENT v3.24.1.u1
STOCK-BASED COMPENSATION
 3 Months Ended
Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]  
STOCK-BASED COMPENSATION STOCK-BASED COMPENSATION
As of March 31, 2024, the Company had stock options, restricted stock awards, performance stock awards, contract stock awards and restricted stock unit awards outstanding under the Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan (the “2003 Plan”).
Stock options issued under the 2003 Plan become exercisable over specified periods, generally within four years from the date of grant for officers and employees, within one year from date of grant for directors which generally expire eight years from the grant date for employees, and from six to ten years for directors and certain executive officers, except in certain instances that result in accelerated vesting due to death, disability, retirement age or change in-control provisions within their grant agreements. The Company values stock option grants using the binomial distribution model. Restricted stock issued under the 2003 Plan vests over specified periods, generally three years after the date of grant. The vesting of performance stock issued under the 2003 Plan is subject to service and performance conditions.
Stock Options
As of March 31, 2024, there were approximately $4.9 million of total unrecognized compensation costs related to unvested stock options. These costs are expected to be recognized over a weighted-average period of approximately three years. There were 243,964 stock options granted during the three months ended March 31, 2024. For the three months ended March 31, 2024, the weighted average grant date fair value for stock options granted was $15.68 per option.
Awards of Restricted Stock and Performance Stock
Performance stock and restricted stock awards generally have requisite service periods of three years, except in certain instances that result in accelerated vesting due to death, disability, retirement age provision or change in-control provisions in their grant agreements. Performance stock units are subject to graded vesting conditions based on revenue goals of the Company. The Company expenses the fair value of restricted stock awards on a straight-line basis over the requisite service period. As of March 31, 2024, there was approximately $48.6 million of total unrecognized compensation costs related to these unvested awards. The Company expects to recognize these costs over a weighted-average period of approximately two years. The Company granted 532,379 restricted stock awards and 263,350 performance stock awards during the three months ended March 31, 2024. For the three months ended March 31, 2024, the weighted average grant date fair value for restricted stock awards and performance stock units granted was $36.46 and $36.22 per award, respectively.
The Company also maintains an Employee Stock Purchase Plan (the “ESPP”), which provides eligible employees with the opportunity to acquire shares of common stock at periodic intervals by means of accumulated payroll deductions. The ESPP is a non-compensatory plan based on its terms.
CEO Separation
On February 27th, 2024, the Company announced that Mr. De Witte would retire from his position as President and Chief Executive Officer and director of the Company following the completion of a succession process and entered into a letter agreement with Mr. De Witte to modify his current employment agreement and put forth the form of a post-employment consulting agreement. The Company applied modification accounting to the outstanding equity-based awards granted to Mr. De Witte as of that date, which revalued and accelerated stock-based compensation associated with equity-based awards granted to him over his expected service period to the Company. Pursuant to this letter agreement, Mr. De Witte’s unvested equity-based awards will continue to vest during his continued service period to the Company and vested stock options were modified such that they will remain exercisable until the lesser of (a) the stated term of the stock options and (b) six months following his cessation of continued service to the Company. As a result of the modifications, the Company recorded incremental stock-based compensation expense of $0.2 million during the three months ended March 31, 2024. The Company will record a total of $1.9 million in accelerated stock-based compensation expenses for the twelve months ended 2024 that would not have been recognized if Mr. De Witte had not announced his retirement from Integra.
XML 27 R15.htm IDEA: XBRL DOCUMENT v3.24.1.u1
RETIREMENT PLANS
 3 Months Ended
Mar. 31, 2024
Retirement Benefits [Abstract]  
RETIREMENT PLANS RETIREMENT PLANS
The Company maintains defined benefit pension plans that cover certain employees in France, Japan, Germany and Switzerland.
Net periodic benefit costs for the Company’s defined benefit pension plans for the three months ended March 31, 2024 were $0.4 million. The components of the net periodic benefit costs other than the service cost component of $0.8 million for the three months ended March 31, 2024 are included in other income, net in the consolidated statements of operations.
Net periodic benefit costs for the Company’s defined benefit pension plans for the three months ended March 31, 2023 were $0.3 million. The components of the net periodic benefit costs other than the service cost component of $0.5 million for the three months ended March 31, 2023 are included in other income, net in the consolidated statements of operations.
The estimated fair values of plan assets were $40.4 million and $45.7 million as of March 31, 2024 and December 31, 2023, respectively. The net plan assets of the pension plans are invested in common trusts as of March 31, 2024 and December 31, 2023. Common trusts are classified as Level 2 in the fair value hierarchy. The fair value of common trusts is valued at the net asset value based on the fair values of the underlying investments of the trusts as determined by the sponsor of the trusts. The investment strategy of the Company’s defined benefit plans is both to meet the liabilities of the plans as they fall due and to maximize the return on invested assets within an appropriate risk profile.
Deferred Compensation Plan
The Company maintains a Deferred Compensation Plan in which certain employees of the Company may defer the payment and taxation of up to 75% of their base salary and up to 100% of bonus amounts and other eligible cash compensation.
This deferred compensation is invested in funds offered under this plan and is valued based on Level 1 measurements in the fair value hierarchy. Assets of the Company’s deferred compensation plan are included in other current assets and recorded at fair value based on their quoted market prices. The fair value of these assets were $5.7 million and $6.1 million as of March 31, 2024 and December 31, 2023, respectively. Offsetting liabilities relating to the deferred compensation plan are included in other liabilities.
XML 28 R16.htm IDEA: XBRL DOCUMENT v3.24.1.u1
LEASES AND RELATED PARTY LEASES
 3 Months Ended
Mar. 31, 2024
Leases [Abstract]  
LEASES AND RELATED PARTY LEASES LEASES AND RELATED PARTY LEASES
The Company leases administrative, manufacturing, research and distribution facilities, and vehicles through operating lease agreements. The Company has no finance leases as of March 31, 2024. Many of the Company’s leases include both lease (e.g., fixed payments including rent) and non-lease components (e.g., common-area or other maintenance costs). For vehicles, the Company has elected the practical expedient to group lease and non-lease components.
Most facility leases include one or more options to renew. The exercise of lease renewal options is typically at the Company’s sole discretion, therefore, the majority of renewals to extend the lease terms are not included in the Right of Use (“ROU”) assets and lease liabilities as they are not reasonably certain of exercise. The Company regularly evaluates renewal options and when they are reasonably certain of exercise, the renewal period is included in the lease term.
As most of the Company’s leases do not provide an implicit rate, the Company uses a collateralized incremental borrowing rate based on the information available at the lease commencement date in determining the present value of the lease payments.
Total operating lease expense for the three months ended March 31, 2024 and March 31, 2023 was $6.3 million and $6.0 million, respectively, which includes $0.3 million, in related party operating lease expense.
Supplemental balance sheet information related to operating leases were as follows:
Dollars in thousands, except lease term and discount rateMarch 31, 2024
December 31, 2023
ROU assets$151,834 $156,184 
Current lease liabilities16,303 15,284 
Non-current lease liabilities170,082 166,849 
Total lease liabilities$186,385 $182,133 
Weighted average remaining lease term (in years):
Leased facilities16.5 years16.3 years
Leased vehicles2.1 years1.9 years
Weighted average discount rate:
Leased facilities5.7 %5.9 %
Leased vehicles2.7 %2.7 %
Supplemental cash flow information related to leases for the three months ended March 31, 2024 and 2023 were as follows:
Dollars in thousandsMarch 31, 2024
March 31, 2023
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$5,734 $4,319 
ROU assets obtained in exchange for lease liabilities:
Operating leases$746 $1,721 
Future minimum lease payments under operating leases at March 31, 2024 were as follows:
Dollars in thousandsRelated PartiesThird PartiesTotal
Remainder of 2024
$222 $17,884 $18,106 
2025296 22,859 23,155 
2026296 20,210 20,506 
2027296 18,892 19,188 
2028296 16,603 16,899 
2029246 15,771 16,017 
Thereafter— 163,479 163,479 
Total minimum lease payments$1,652 $275,698 $277,350 
Less: Imputed interest90,965 
Total lease liabilities186,385 
Less: Current lease liabilities16,303 
Long-term lease liabilities170,082 
There were no future minimum lease payments under finance leases at March 31, 2024.
Related Party Leases
The Company leases its manufacturing facility in Plainsboro, New Jersey, from a general partnership that is 50% owned by a principal stockholder of the Company. The term of the current lease agreement is through October 31, 2029 at an annual rate of approximately $0.3 million. The current lease agreement also provides (i) a 5-year renewal option for the Company to extend the lease from November 1, 2029 through October 31, 2034 at the fair market rental rate of the premises, and (ii) another 5-year renewal option to extend the lease from November 1, 2034 through October 31, 2039 at the fair market rental rate of the premises.
XML 29 R17.htm IDEA: XBRL DOCUMENT v3.24.1.u1
TREASURY STOCK
 3 Months Ended
Mar. 31, 2024
Equity [Abstract]  
TREASURY STOCK TREASURY STOCK
As of March 31, 2024 and December 31, 2023, there were 12.7 million and 12.8 million shares of treasury stock outstanding with a cost of $646.4 million and $647.3 million, at a weighted average cost per share of $50.76 and $50.76, respectively.
On August 15, 2023, the Company entered into a $125 million accelerated share repurchase (“August 2023 ASR”) and received 2.3 million shares of common stock at inception of the August 2023 ASR, which represented approximately 80% of the expected total shares under the August 2023 ASR. On October 18, 2023 the early exercise provision was exercised by the August 2023 ASR counterparty. The Company received an additional 0.9 million shares determined using the volume-weighted average price of the Company’s common stock during the term of the August 2023 ASR.
On January 26, 2023, the Company entered into a $150 million accelerated share repurchase (“January 2023 ASR”) and received 2.1 million shares of common stock at inception of the January 2023 ASR, which represented approximately 80% of the expected total shares under the January 2023 ASR. The settlement of the January 2023 ASR agreement was completed in the second quarter of 2023, where the Company received 0.6 million shares, determined using the volume-weighted average price of the Company’s common stock during the term of the January 2023 ASR.
On August 16, 2022, the Inflation Reduction Act of 2022 (the “Inflation Act”) was signed into law. The Inflation Act implements a new excise tax of 1% on the net share repurchases made by the Company effective for share repurchases performed January 1, 2023, or after.
On July 18, 2023, the Board of Directors authorized a new $225 million share repurchase program, replacing the existing $225 million program authorized in April 2022, under which $75 million remained authorized at the time of its replacement. As of March 31, 2024, $100 million remained authorized. The program authorized in July 2023 allows the Company to repurchase its shares opportunistically from time to time. The Company may utilize various methods to effect any repurchases, including open market transactions, privately negotiated transactions, transactions structured through investment banking institutions, including accelerated share repurchases, or a combination of the foregoing, some of which may be effected through Rule 10b5-1 plans. The price and timing of any future purchases under the share repurchase program will depend on factors such as levels of cash generation from operations, the volume of stock option exercises by employees, cash requirements for acquisitions, dividends, economic and market conditions and stock price, and such repurchases may be discontinued at any time.
XML 30 R18.htm IDEA: XBRL DOCUMENT v3.24.1.u1
INCOME TAXES
 3 Months Ended
Mar. 31, 2024
Income Tax Disclosure [Abstract]  
INCOME TAXES INCOME TAXES
The following table provides a summary of the Company’s effective tax rate:
 Three Months Ended March 31,
 20242023
Reported tax rate37.3 %18.6 %
The Company’s effective income tax rates for the three months ended March 31, 2024 and 2023 were 37.3% and 18.6%, respectively. For the three months ended March 31, 2024, the higher tax rate is attributable to a $1.5 million shortfall from stock based compensation, offset by a tax benefit for the intangible asset impairment, as compared to previous year. The Company does not have tax basis in the impaired intangible asset and has treated the tax impact as a discrete event in this quarter.
XML 31 R19.htm IDEA: XBRL DOCUMENT v3.24.1.u1
NET INCOME PER SHARE
 3 Months Ended
Mar. 31, 2024
Earnings Per Share [Abstract]  
NET INCOME PER SHARE NET INCOME PER SHARE
Basic and diluted net income per share was as follows:
 Three Months Ended March 31,
 Dollars in thousands, except per share amounts20242023
Basic net (loss) income per share:
Net (loss) income$(3,281)$24,226 
Weighted average common shares outstanding77,735 81,871 
Basic net (loss) income per common share$(0.04)$0.30 
Diluted net (loss) income per share:
Net (loss) income$(3,281)$24,226 
Weighted average common shares outstanding — Basic77,735 81,871 
Effect of dilutive securities:
Stock options and restricted stock— 452 
Weighted average common shares for diluted earnings per share77,735 82,323 
Diluted net (loss) income per common share$(0.04)$0.29 
Basic earnings per share is computed by dividing net income by the weighted-average common shares outstanding during the period. Diluted earnings per share is computed based on the weighted-average common shares outstanding plus the effect of dilutive potential common shares outstanding during the period calculated using the treasury stock method. Dilutive potential common shares include employee equity share options, non-vested shares, and similar equity instruments granted by the Company. Potential common share equivalents have been excluded where their inclusion would be anti-dilutive.
Common stock of approximately 1.3 million and 0.3 million shares at March 31, 2024, and 2023, respectively, were not included in the computation of diluted net (loss) income per share because their effect would have been anti-dilutive.
XML 32 R20.htm IDEA: XBRL DOCUMENT v3.24.1.u1
ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)
 3 Months Ended
Mar. 31, 2024
Equity [Abstract]  
ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)
Comprehensive income for the three months ended March 31, 2024 and 2023:
 Three Months Ended March 31,
Dollars in thousands20242023
Net (loss) income$(3,281)$24,226 
Foreign currency translation adjustment730 3,192 
Change in unrealized loss/(gain) on derivatives, net of tax3,735 (6,493)
Pension liability adjustment, net of tax(5)103 
Comprehensive income, net$1,179 $21,028 
Changes in accumulated other comprehensive income by component between December 31, 2023 and March 31, 2024 are presented in the table below, net of tax:
Dollars in thousandsGains and Losses on DerivativesDefined Benefit Pension ItemsForeign Currency ItemsTotal
Balance at January 1, 2024
$21,489 $2,712 $(39,307)$(15,106)
Other comprehensive gain (loss)34,939 (5)2,425 37,359 
Less: Amounts reclassified from accumulated other comprehensive income, net31,204 — 1,695 32,899 
Net current-period other comprehensive gain (loss)3,735 (5)730 4,460 
Balance at March 31, 2024
$25,224 $2,707 $(38,577)$(10,646)
For the three months ended March 31, 2024, the Company reclassified a gain of $27.2 million and $5.7 million from accumulated other comprehensive income to other income, net and interest income, respectively.
XML 33 R21.htm IDEA: XBRL DOCUMENT v3.24.1.u1
SEGMENT AND GEOGRAPHIC INFORMATION
 3 Months Ended
Mar. 31, 2024
Segment Reporting [Abstract]  
SEGMENT AND GEOGRAPHIC INFORMATION SEGMENT AND GEOGRAPHIC INFORMATION
The Company internally manages two global reportable segments and reports the results of its businesses to its chief operating decision maker. The two reportable segments and their activities are described below.
•The Codman Specialty Surgical segment includes (i) the Neurosurgery business, which sells a full line of products for neurosurgery and neuro critical care such as tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment and (ii) the Instruments business, which sells more than 40,000 instrument patterns and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices.
•The Tissue Technologies segment includes such offerings as skin and wound repair, plastics & surgical reconstruction products, bone grafts, and nerve and tendon repair products.
The Corporate and other category includes (i) various executive, finance, human resource, information systems and legal functions, (ii) brand management, and (iii) share-based compensation costs.
The operating results of the various reportable segments as presented are not comparable to one another because (i) certain operating segments are more dependent than others on corporate functions for unallocated general and administrative and/or operational manufacturing functions, and (ii) the Company does not allocate certain manufacturing costs and general and administrative costs to the operating segment results. Net sales and profit by each reportable segment for the three months ended March 31, 2024 and 2023 are as follows:
Three Months Ended March 31,
Dollars in thousands20242023
Segment Net Sales
Codman Specialty Surgical$256,434 $248,136 
Tissue Technologies
112,438 132,710 
Total revenues$368,872 $380,846 
Segment Profit
Codman Specialty Surgical$103,492 $110,933 
Tissue Technologies
30,66652,281 
Segment profit134,158 163,214 
Amortization(10,107)(3,108)
Corporate and other(120,087)(123,724)
Operating income$3,964 $36,382 
The Company does not allocate any assets to the reportable segments. No asset information is reported to the chief operating decision maker and disclosed in the financial information for each segment. The Company attributes revenues to geographic areas based on the location of the customer. Total revenue by major geographic area consisted of the following:
 Three Months Ended March 31,
Dollars in thousands20242023
United States$256,229 $271,002 
Europe41,596 41,064 
Asia Pacific49,545 50,473 
Rest of World21,502 18,307 
Total Revenues$368,872 $380,846 
XML 34 R22.htm IDEA: XBRL DOCUMENT v3.24.1.u1
COMMITMENTS AND CONTINGENCIES
 3 Months Ended
Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES
In consideration for certain technology, manufacturing, distribution, and selling rights and licenses granted to the Company, the Company has agreed to pay royalties on sales of certain products that it sells. The royalty payments that the Company made under these agreements were not significant for any of the periods presented.
In the ordinary course of its business, the Company is involved in, from time to time, various legal actions, including any matters described below, involving product liability, employment, intellectual property and commercial disputes, shareholder related matters, environmental proceedings, tax disputes, and governmental proceedings and investigations, some of which have been settled by the Company. In the opinion of management, such matters are either adequately covered by insurance or otherwise indemnified, or are not expected, individually or in the aggregate, to result in a material, adverse effect on the Company’s financial condition. However, it is possible that the Company’s results of operations, financial position and cash flows in a particular period could be materially affected by these contingencies.
The Company accrues for loss contingencies when it is deemed probable that a loss has been incurred and that loss is estimable. The amounts accrued are based on the full amount of the estimated loss before considering insurance proceeds and do not include an estimate for legal fees expected to be incurred in connection with the loss contingency. The Company consistently accrues legal fees expected to be incurred in connection with loss contingencies as those fees are incurred by outside counsel as a period cost.
On December 21, 2023, Fortis Advisors, LLC (representative of the security holders of ACell, Inc. (“ACell”)) filed for arbitration against Integra Life Sciences claiming breach of contract related to the earnout consideration from the 2021 acquisition of ACell. Refer below for additional information on the ACell contingent considerations. The Company believes that it has strong defenses to the allegations in the arbitration and intends to defend the matter vigorously.
On September 12, 2023, a securities class action complaint, captioned Pembroke Pines Firefighters & Police Officers Pension Fund v. Integra LifeSciences Holdings Corporation, No. 23-cv-20321 (D.N.J.), was filed by a purported stockholder of the Company in the United States District Court for the District of New Jersey (the “Pembroke Litigation”) against the Company and certain of the Company’s current and former executive officers. The Pembroke Litigation, filed on behalf of a putative class of stockholders who purchased or acquired the Company’s common stock between March 11, 2019 and May 22, 2023, inclusive, alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder, on the basis of purportedly materially false and misleading statements and omissions relating to certain quality systems issues identified by the U.S. Food and Drug Administration at the Company’s Boston, Massachusetts manufacturing facility, the Company’s efforts to remediate those issues, and the Company’s forecasts for certain products in its Tissue Technologies segment. The complaint seeks, among other things, compensatory damages, attorneys’ fees, expert fees, and other costs. The Company believes that it has strong defenses to the allegations in the Pembroke Litigation, and intends to defend the matter vigorously.
Contingent Consideration
The Company determined the fair value of contingent consideration during the three month period ended March 31, 2024 and March 31, 2023 to reflect the change in estimate, additions, payments, transfers and the time value of money during the period.
A reconciliation of the opening balances to the closing balances of these Level 3 measurements for the three months ended March 31, 2024 and March 31, 2023 is as follows (in thousands):
Three Months Ended March 31, 2024Contingent Consideration Liability Related to Acquisition of:
ArkisLocation in Financial StatementsDerma SciencesACellSurgical Innovations Associates (SIA), Inc.Location in Financial Statements
Balance as of January 1, 2024
$15,755 $2,557 $300 68,700 
Change in fair value of contingent consideration liabilities (83)Research and development39 — 500 Selling, general and administrative
Balance as of March 31, 202415,672 2,596 300 69,200 
Short-Term $7,562 $— $— $29,300 Accrued expenses and other current liabilities
Long-Term8,110 2,596 300 39,900 Other liabilities
Total15,672 2,596 300 69,200 
Three Months Ended March 31, 2023Contingent Consideration Liability Related to Acquisition of:
Arkis Location in Financial StatementsDerma SciencesACellSurgical Innovations Associates (SIA), Inc.Location in Financial Statements
Balance as of January 1, 2023
$12,895 $230 $3,700 $57,607 
Change in fair value of contingent consideration liabilities3,299 Research and development— (2,200)3,600 Selling, general and administrative
Balance as of March 31, 2023
$16,194 $230 $1,500 $61,207 
Short-Term $4,388 $— $— $12,500 Accrued expenses and other current liabilities
Long-Term11,806 230 1,500 48,707 Other liabilities
Total16,194 230 1,500 61,207 
Arkis BioSciences Inc.
As part of the acquisition of Arkis BioSciences Inc. (“Arkis”), the Company is required to pay the former shareholders of Arkis up to $25.5 million based on the timing of certain development milestones of $10.0 million and commercial sales milestones of $15.5 million, respectively. The Company used a probability weighted income approach to calculate the fair value of the contingent consideration that considered the possible outcomes of scenarios related to each specified milestone. The Company estimated the fair value of the contingent consideration to be $13.1 million at the acquisition date.
Derma Sciences, Inc.
The Company assumed contingent consideration incurred by Derma Sciences, Inc. (“Derma Sciences”) related to its acquisitions of BioD, LLC and the intellectual property related to Medihoney® products. The Company accounted for the contingent liabilities by recording the fair value on the date of the acquisition based on a probability weighted income approach. The Company has already paid $33.3 million related to the aforementioned contingent liabilities. One contingent milestone remains which relates to net sales of Medihoney®™ products exceeding certain amounts defined in the agreement between the Company and Derma Sciences. The potential maximum undiscounted payment amounts to $3.0 million.
ACell, Inc.
As part of the acquisition of ACell, the Company is required to make payments to the former shareholders of ACell up to $100 million in total for years 2022, 2023, and 2025 based on the achievement by the Company of certain revenue-based performance milestones. The 2022 and 2023 milestones were not achieved, leaving only one contingent milestone remaining. The Company used iterations of the Monte Carlo simulation to calculate the fair value of the contingent consideration that considered the possible outcomes of scenarios related to each specific milestone. The Company estimated the fair value of the contingent consideration to be $23.9 million at the acquisition date.
Surgical Innovations Associates, Inc.
As part of the acquisition of Surgical Innovations Associates, Inc. (“SIA”), the Company is required to pay to the former shareholders of SIA up to $90.0 million for two separate payments, which are dependent on 1) achieving certain revenue-based performance milestones in 2023, 2024, and 2025 (up to $50.0 million in additional payments), as well as 2) the approval by the FDA of the PMA for DuraSorb for certain uses by certain timing targets (up to $40.0 million in additional payments). The Company used iterations of the Monte Carlo simulation to calculate the fair value of the contingent consideration for the revenue-based milestone that considered the possible outcomes of scenarios related to each specific milestone for the revenue based performance milestone. The Company used probabilities of achieving the conditions to calculate the fair value of the contingent consideration for the PMA approval milestone. The Company estimated the fair value of the contingent consideration for the revenue based milestone to be $32.6 million at the acquisition date and $25.0 million for the PMA approval milestone at the acquisition date.
XML 35 R23.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Pay vs Performance Disclosure - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Pay vs Performance Disclosure    
Net (Loss) Income $ (3,281) $ 24,226
XML 36 R24.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Insider Trading Arrangements
 3 Months Ended
Mar. 31, 2024
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 37 R25.htm IDEA: XBRL DOCUMENT v3.24.1.u1
BASIS OF PRESENTATION (Policies)
 3 Months Ended
Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis Of Presentation BASIS OF PRESENTATION
General
The terms “we,” “our,” “us,” “Company” and “Integra” refer to Integra LifeSciences Holdings Corporation, a Delaware corporation, and its subsidiaries unless the context suggests otherwise.
In the opinion of management, the March 31, 2024 unaudited condensed consolidated financial statements contain all adjustments (consisting only of normal recurring adjustments) necessary for a fair statement of the financial position, statement of changes in shareholders’ equity, results of operations and cash flows of the Company. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) have been condensed or omitted in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements for the year ended December 31, 2023 included in the Company’s Annual Report on Form 10-K. The December 31, 2023 consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by GAAP. Operating results for the three-month period ended March 31, 2024 are not necessarily indicative of the results to be expected for the entire year.
The preparation of consolidated financial statements is in conformity with GAAP, which requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, the disclosure of contingent liabilities, and the reported amounts of revenues and expenses. Significant estimates affecting amounts reported or disclosed in the condensed consolidated financial statements include allowances for doubtful accounts receivable and sales returns and allowances, net realizable value of inventories, valuation of intangible assets including amortization periods for acquired intangible assets, discount rates and estimated projected cash flows used to value and test impairments of long-lived assets and goodwill, estimates of projected cash flows and depreciation and amortization periods for long-lived assets, computation of taxes, valuation allowances recorded against deferred tax assets, the valuation of stock-based compensation, valuation of derivative instruments, valuation of contingent liabilities, the fair value of debt instruments and loss contingencies. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the current circumstances. Actual results could differ from these estimates.
Recent Accounting Pronouncements
Recent Accounting Pronouncements
In March 2020, the Financial Accounting Standards Board (“FASB”) issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting, and, in January 2021, subsequently amended the initial guidance in: ASU 2021-01, Reference Rate Reform (Topic 848): Scope (collectively, “Topic 848”). Topic 848 provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments apply only to contracts, hedging relationships, and other transactions that reference London Inter-Bank Offered Rate (“LIBOR”) or another reference rate expected to be discontinued because of reference rate reform. In December 2022, the FASB issued ASU 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848, which delayed the effective date from December 31, 2022 to December 31, 2024. The Alternative Reference Rates Committee, a group of private-market participants convened by the U.S. Federal Reserve Board and the New York Federal Reserve, has recommended the use of the Secured Overnight Financing Rate (“SOFR”) as a more robust reference rate alternative to LIBOR. On March 24, 2023, the Company entered into the seventh amendment and restatement (the “March 2023 Amendment”) of its Senior Credit Facility (the “Senior Credit Facility”) with a syndicate of lending banks with Bank of America, N.A., as Administrative Agent. In connection with the March 2023 Amendment, the Company replaced all LIBOR-based contracts with SOFR, which is calculated based on overnight transactions under repurchase agreements backed by Treasury securities. In addition, on April 17, 2023 the Company entered into an amendment (the “April 2023 Amendment”) of the Securitization Facility (as defined below) and amended the interest rate from LIBOR to SOFR indexed rate. (See Note 6, Debt). In March 2023, the Company entered into a basis swap where the Company receives Term SOFR and pays LIBOR to convert the portfolio of interest rate swaps from LIBOR to SOFR. Integra has elected to adopt the optional expedient under Topic 848, which will allow the interest rate swap hedging relationship to continue, without de-designation, due to the change in the indexed rate from LIBOR to SOFR.
In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures which enhances the transparency of income tax disclosures by expanding annual disclosure requirements related to the rate reconciliation and income taxes paid. The amendments are effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company does not plan to early adopt and is currently evaluating this ASU to determine its impact on the Company’s disclosures.
In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which updates reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. The amendments are effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company does not plan to early adopt and is currently evaluating this ASU to determine its impact on the Company’s disclosures.
There are no other recently issued accounting pronouncements that are expected to have any significant effect on the Company’s financial position, results of operations or cash flows.
Summary of Accounting Policies on Revenue Recognition and Shipping and Handling Fees
Summary of Accounting Policies on Revenue Recognition
Revenue is recognized upon the transfer of control of promised products or services to the customers in an amount that reflects the consideration the Company expects to receive in exchange for those products and services.
Performance Obligations
The Company’s performance obligations consist mainly of transferring control of goods and services identified in the contracts, purchase orders, or invoices. The Company has no significant multi-element contracts with customers.
Significant Estimates
Usage-based royalties and licenses are estimated based on the provisions of contracts with customers and recognized in the same period that the royalty-based products are sold by the Company’s strategic partners. The Company estimates and recognizes royalty revenue based upon communication with licensees, historical information, and expected sales trends. Differences between actual reported licensee sales and those that were estimated are adjusted in the period in which they become known, which is typically the following quarter. Historically, such adjustments have not been significant.
The Company estimates returns, price concessions, and discount allowances using the expected value method based on historical trends and other known factors. Rebate allowances are estimated using the most likely method based on each customer contract.
The Company’s return policy, as set forth in its product catalogs and sales invoices, requires review and authorization in advance prior to the return of product. Upon the authorization, a credit will be issued for the goods returned within a set amount of days from the shipment, which is generally 90 days.
In 2023, due to the voluntary recall of all products manufactured at the Boston facility, including PriMatrix®, SurgiMend®, Revize™, and TissueMend™ (the “Boston recall”), the Company recorded a total of $18.7 million provision for product returns. As of March 31, 2024, the Company has credited $16.7 million to customers and holds a remaining return reserve of $2.0 million.
The Company disregards the effects of a financing component if the Company expects, at contract inception, that the period between the transfer and customer payment for the goods or services will be one year or less. The Company has no significant revenues recognized on payments expected to be received more than one year after the transfer of control of products or services to customers.
Contract Asset and Liability
Revenues recognized from the Company’s private label business that are not invoiced to the customers as a result of recognizing revenue over time are recorded as a contract asset included in the other current assets account in the consolidated balance sheets.
Other operating revenues may include fees received under service agreements. Non-refundable fees received under multiple-period service agreements are recognized as revenue as the Company satisfies the performance obligations to the other party. A portion of the transaction price allocated to the performance obligations to be satisfied in the future periods is recognized as contract liability.
Shipping and Handling Fees
The Company elected to account for shipping and handling activities as a fulfillment cost rather than a separate performance obligation. Amounts billed to customers for shipping and handling are included as part of the transaction price and recognized as revenue when control of underlying products is transferred to the customer. The related shipping and freight charges incurred by the Company are included in the cost of goods sold.
Product Warranties
Product Warranties
Certain of the Company’s medical devices, including monitoring systems and neurosurgical systems, are designed to operate over long periods of time. These products are sold with warranties which may extend for up to two years from the date of purchase. The warranties are not considered a separate performance obligation. The Company estimates its product warranties using the expected value method based on historical trends and other known factors. The Company includes them in accrued expenses and other current liabilities in the consolidated balance sheet.
Taxes Collected from Customers
Taxes Collected from Customers
The Company elected to exclude from the measurement of the transaction price all taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction and collected by the entity from a customer.
XML 38 R26.htm IDEA: XBRL DOCUMENT v3.24.1.u1
REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)
 3 Months Ended
Mar. 31, 2024
Revenue from Contract with Customer [Abstract]  
Schedule of Changes in Contract Assets and Contract Liabilities
The following table summarizes the changes in the contract asset and liability balances for the three months ended March 31, 2024:
Dollars in thousandsTotal
Contract Asset
Contract asset, January 1, 2024
$9,233 
Transferred to trade receivable from contract asset included in beginning of the year contract asset(9,233)
Contract asset, net of transferred to trade receivables on contracts during the period7,478 
Contract asset, March 31, 2024
$7,478 
Contract Liability
Contract liability, January 1, 2024
$16,252 
Recognition of revenue included in beginning of year contract liability(3,523)
Contract liability, net of revenue recognized on contracts during the period2,017 
Foreign currency translation(63)
Contract liability, March 31, 2024
$14,683 
Schedule of Disaggregation of Revenue
The following table presents revenues disaggregated by the major sources of revenues for the three months ended March 31, 2024 and 2023 (dollar amounts in thousands):
Three Months Ended March 31, 2024Three Months Ended March 31, 2023
Neurosurgery$202,268 $192,870 
Instruments54,166 55,266 
Total Codman Specialty Surgical256,434 248,136 
Wound Reconstruction and Care80,877 100,940 
Private Label31,561 31,770 
Total Tissue Technologies112,438 132,710 
Total revenue$368,872 $380,846 
XML 39 R27.htm IDEA: XBRL DOCUMENT v3.24.1.u1
INVENTORIES (Tables)
 3 Months Ended
Mar. 31, 2024
Inventory Disclosure [Abstract]  
Schedule of Inventories, Net
Inventories, net consisted of the following:
Dollars in thousandsMarch 31, 2024December 31, 2023
Finished goods$192,287 $196,402 
Work in process83,334 74,035 
Raw materials127,801 119,171 
Total inventories, net$403,422 $389,608 
XML 40 R28.htm IDEA: XBRL DOCUMENT v3.24.1.u1
GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)
 3 Months Ended
Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Changes in Carrying Amount of Goodwill
Changes in the carrying amount of goodwill for the three-month period ended March 31, 2024 were as follows:
Dollars in thousandsCodman Specialty
Surgical		Tissue TechnologiesTotal
Goodwill at December 31, 2023$666,937 $388,525 $1,055,462 
Foreign currency translation(9,622)(5,605)(15,227)
Goodwill at March 31, 2024
$657,315 $382,920 $1,040,235 
Schedule of Finite-Lived Intangible Assets
The components of the Company’s identifiable intangible assets were as follows:
 March 31, 2024
Dollars in thousandsWeighted
Average
Life		CostAccumulated
Amortization		Net
Completed technology18 years$1,209,921 $(460,545)$749,376 
Customer relationships12 years$167,360 $(134,587)$32,773 
Trademarks/brand names28 years$97,668 $(39,330)$58,338 
Codman tradenameIndefinite$168,678 $— $168,678 
Supplier relationships30 years$30,211 $(18,393)$11,818 
All other11 years$6,052 $(4,426)$1,626 
$1,679,890 $(657,281)$1,022,609 
 December 31, 2023
Dollars in thousandsWeighted
Average
Life		CostAccumulated
Amortization		Net
Completed technology18 years$1,226,128 $(448,519)$777,609 
Customer relationships12 years193,895 (152,160)41,735 
Trademarks/brand names28 years98,892 (38,754)60,138 
Codman tradenameIndefinite174,531 — 174,531 
Supplier relationships30 years30,211 (18,148)12,063 
All other11 years6,180 (4,423)1,757 
$1,729,837 $(662,004)$1,067,833 
Schedule of Indefinite-Lived Intangible Assets
The components of the Company’s identifiable intangible assets were as follows:
 March 31, 2024
Dollars in thousandsWeighted
Average
Life		CostAccumulated
Amortization		Net
Completed technology18 years$1,209,921 $(460,545)$749,376 
Customer relationships12 years$167,360 $(134,587)$32,773 
Trademarks/brand names28 years$97,668 $(39,330)$58,338 
Codman tradenameIndefinite$168,678 $— $168,678 
Supplier relationships30 years$30,211 $(18,393)$11,818 
All other11 years$6,052 $(4,426)$1,626 
$1,679,890 $(657,281)$1,022,609 
 December 31, 2023
Dollars in thousandsWeighted
Average
Life		CostAccumulated
Amortization		Net
Completed technology18 years$1,226,128 $(448,519)$777,609 
Customer relationships12 years193,895 (152,160)41,735 
Trademarks/brand names28 years98,892 (38,754)60,138 
Codman tradenameIndefinite174,531 — 174,531 
Supplier relationships30 years30,211 (18,148)12,063 
All other11 years6,180 (4,423)1,757 
$1,729,837 $(662,004)$1,067,833 
XML 41 R29.htm IDEA: XBRL DOCUMENT v3.24.1.u1
DEBT (Tables)
 3 Months Ended
Mar. 31, 2024
Debt Disclosure [Abstract]  
Schedule of Long-term Debt Maximum Leverage Ratios
The Company’s maximum consolidated total leverage ratio in the financial covenants (as defined in the Senior Credit Facility) was modified to the following:
Fiscal Quarter EndingMaximum Consolidated Total Leverage Ratio
March 31, 2023 through December 31, 2024
4.50 to 1.00
March 31, 2025 through June 30, 2026
4.25 to 1.00
September 30, 2026 and the last day of each fiscal quarter thereafter
4.00 to 1.00
Schedule of Contractual Repayments of Long-Term Debt
Contractual repayments of the term loan component of the Senior Credit Facility are due as follows:
As of March 31, 2024
Principal Repayment
Dollars in thousands
Remainder of 2024
$14,531 
2025
33,906 
2026
38,750 
2027
53,281 
Thereafter634,532 
$775,000 
XML 42 R30.htm IDEA: XBRL DOCUMENT v3.24.1.u1
DERIVATIVE INSTRUMENTS (Tables)
 3 Months Ended
Mar. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Derivative Instruments
The Company held the following interest rate swaps as of March 31, 2024 and December 31, 2023 (dollar amounts in thousands):
March 31, 2024December 31, 2023March 31, 2024December 31, 2023
Hedged ItemNotional AmountDesignation DateEffective DateTermination DateFixed Interest RateEstimated Fair Value
Asset (Liability)
1-month Term SOFR Loan150,000 150,000 December 13, 2017July 1, 2019June 30, 20242.423 %1,125 2,105 
1-month Term SOFR Loan200,000 200,000 December 13, 2017January 1, 2018December 31, 20242.313 %4,341 4,978 
1-month Term SOFR Loan75,000 75,000 October 10, 2018July 1, 2020June 30, 20253.220 %1,556 1,349 
1-month Term SOFR Loan75,000 75,000 October 10, 2018July 1, 2020June 30, 20253.199 %1,548 1,312 
1-month Term SOFR Loan75,000 75,000 October 10, 2018July 1, 2020June 30, 20253.209 %1,548 1,346 
1-month Term SOFR Loan100,000 100,000 December 18, 2018December 30, 2022December 31, 20272.885 %4,512 3,015 
1-month Term SOFR Loan100,000 100,000 December 18, 2018December 30, 2022December 31, 20272.867 %4,519 3,052 
1-month Term SOFR Loan575,000 575,000 December 15, 2020July 31, 2025December 31, 20271.415 %29,267 22,965 
1-month Term SOFR Loan125,000 125,000 December 15, 2020July 1, 2025December 31, 20271.404 %6,770 5,263 
Basis Swap (1)
—— March 31, 2023March 24, 2023December 31, 2027N/A(2,127)0(1,829)
$1,475,000 $1,475,000 $53,059 $43,556 
(1) The notional of the basis swap amortizes to match the total notional of the interest rate swap portfolio over time
The Company held the following cross-currency rate swaps as of March 31, 2024 and December 31, 2023 (dollar amounts in thousands):
March 31, 2024December 31, 2023March 31, 2024December 31, 2023
Effective DateTermination DateFixed RateAggregate Notional AmountFair Value
Asset (Liability)
Pay CHFDecember 21, 2020December 22, 20253.00%CHF333,887 351,137 (9,902)(38,324)
Receive U.S.$3.98%$374,817 394,183 
Pay CHFSeptember 22, 2023September 29, 20242.40%CHF28,500 28,500 (2,578)(2,348)
Receive U.S.$6.27%$31,457 31,457 
Total$(12,480)$(40,672)
The Company held the following cross-currency rate swaps designated as net investment hedges as of March 31, 2024 and December 31, 2023, respectively (dollar amounts in thousands):
March 31, 2024December 31, 2023
March 31, 2024
December 31, 2023
Effective DateTermination DateFixed RateAggregate Notional AmountFair Value
Asset (Liability)
Pay EUROctober 3, 2018September 30, 2025—%EUR38,820 38,820 3,459 2,475 
Receive U.S.$2.19%$45,000 45,000 
Pay CHFMay 26, 2022December 16, 2028—%CHF288,210 288,210 (29,614)(48,047)
Receive U.S.$1.94%$300,000 300,000 
Pay CHFNovember 21, 2023December 17, 2029—%CHF66,525 66,525 (736)(4,037)
Receive U.S.$2.54%$75,000 75,000 
Total$(26,891)$(49,609)
Schedule of Fair Value and Presentation of Derivatives
The following table summarizes the fair value for derivatives designated as hedging instruments in the condensed consolidated balance sheets as of March 31, 2024 and December 31, 2023:
Fair Value as of
Location on Balance Sheet (1):
March 31, 2024December 31, 2023
Dollars in thousands
Derivatives designated as hedges — Assets:
Prepaid expenses and other current assets
Cash Flow Hedges
Interest rate swap(2)
$14,188 $14,675 
Cross-currency swap680 537 
Net Investment Hedges
Cross-currency swap4,084 2,938 
Other assets
Cash Flow Hedges
Interest rate swap(2)
40,998 30,710 
Cross-currency swap— — 
Net Investment Hedges
Cross-currency swap2,454 1,470 
Total derivatives designated as hedges — Assets$62,404 $50,330 
Derivatives designated as hedges — Liabilities:
Accrued expenses and other current liabilities
Cash Flow Hedges
Interest rate swap(2)
$540 $579 
Cross-currency swap2,578 4,813 
Foreign currency forward contracts629 — 
Net Investment Hedges
Cross-currency swap— 2,903 
Other liabilities
Cash Flow Hedges
Interest rate swap(2)
1,586 1,250 
Cross-currency swap10,582 36,396 
Net Investment Hedges
Cross-currency swap33,427 51,114 
Total derivatives designated as hedges — Liabilities$49,342 $97,055 
(1) The Company classifies derivative assets and liabilities as current based on the cash flows expected to be incurred within the following 12 months.
(2) At March 31, 2024 and December 31, 2023, the total notional amounts related to the Company’s interest rate swaps were $1.5 billion.
Effect of Derivative Instruments Designated as Cash Flow Hedges on Statements of Operations
The following presents the effect of derivative instruments designated as cash flow hedges and net investment hedges on the accompanying condensed consolidated statement of operations during the three months ended March 31, 2024 and 2023:
Dollars in thousandsBalance in AOCI
Beginning of
Quarter		Amount of
Gain (Loss)
Recognized in
AOCI		Amount of Gain (Loss)
Reclassified from
AOCI into
Earnings		Balance in AOCI
End of Quarter		Location in
Statements of
Operations
Three Months Ended March 31, 2024
Cash Flow Hedges
Interest rate swap$43,556 $14,723 $5,219 $53,060 Interest expense
Cross-currency swap(15,763)29,532 31,473 (17,704)Other income (expense), net
Foreign currency forward contract— (629)(110)(519)Cost of sales
Net Investment Hedges
Cross-currency swap(45,498)24,920 2,202 (22,780)Interest income
$(17,705)$68,546 $38,784 $12,057 
Three Months Ended March 31, 2023
Cash Flow Hedges
Interest rate swap$56,712 $(10,534)$3,500 $42,678 Interest expense
Cross-currency swap(20,271)2,191 (3,504)(14,576)Other income (expense), net
Foreign currency forward contract$(69)$(69)
Net Investment Hedges
Cross-currency swap(6,914)950 2,096 (8,060)Interest income
$29,527 $(7,462)$2,092 $19,973 
Derivatives Not Designated as Hedging Instruments The following table summarizes the gains (losses) on derivative instruments not designated as hedges on the condensed consolidated statements of income, which was included in other income:
Dollars in thousandsThree Months Ended March 31,
20242023
Foreign currency swaps273 55 
Total$273 $55 
XML 43 R31.htm IDEA: XBRL DOCUMENT v3.24.1.u1
LEASES AND RELATED PARTY LEASES (Tables)
 3 Months Ended
Mar. 31, 2024
Leases [Abstract]  
Supplemental Balance Sheet Information
Supplemental balance sheet information related to operating leases were as follows:
Dollars in thousands, except lease term and discount rateMarch 31, 2024
December 31, 2023
ROU assets$151,834 $156,184 
Current lease liabilities16,303 15,284 
Non-current lease liabilities170,082 166,849 
Total lease liabilities$186,385 $182,133 
Weighted average remaining lease term (in years):
Leased facilities16.5 years16.3 years
Leased vehicles2.1 years1.9 years
Weighted average discount rate:
Leased facilities5.7 %5.9 %
Leased vehicles2.7 %2.7 %
Supplemental Cash Flow Information
Supplemental cash flow information related to leases for the three months ended March 31, 2024 and 2023 were as follows:
Dollars in thousandsMarch 31, 2024
March 31, 2023
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$5,734 $4,319 
ROU assets obtained in exchange for lease liabilities:
Operating leases$746 $1,721 
Schedule of Operating Lease Maturities
Future minimum lease payments under operating leases at March 31, 2024 were as follows:
Dollars in thousandsRelated PartiesThird PartiesTotal
Remainder of 2024
$222 $17,884 $18,106 
2025296 22,859 23,155 
2026296 20,210 20,506 
2027296 18,892 19,188 
2028296 16,603 16,899 
2029246 15,771 16,017 
Thereafter— 163,479 163,479 
Total minimum lease payments$1,652 $275,698 $277,350 
Less: Imputed interest90,965 
Total lease liabilities186,385 
Less: Current lease liabilities16,303 
Long-term lease liabilities170,082 
XML 44 R32.htm IDEA: XBRL DOCUMENT v3.24.1.u1
INCOME TAXES (Tables)
 3 Months Ended
Mar. 31, 2024
Income Tax Disclosure [Abstract]  
Schedule of Effective Income Tax Rate
The following table provides a summary of the Company’s effective tax rate:
 Three Months Ended March 31,
 20242023
Reported tax rate37.3 %18.6 %
XML 45 R33.htm IDEA: XBRL DOCUMENT v3.24.1.u1
NET INCOME PER SHARE (Tables)
 3 Months Ended
Mar. 31, 2024
Earnings Per Share [Abstract]  
Basic and Diluted Net Income (Loss) Per Share
Basic and diluted net income per share was as follows:
 Three Months Ended March 31,
 Dollars in thousands, except per share amounts20242023
Basic net (loss) income per share:
Net (loss) income$(3,281)$24,226 
Weighted average common shares outstanding77,735 81,871 
Basic net (loss) income per common share$(0.04)$0.30 
Diluted net (loss) income per share:
Net (loss) income$(3,281)$24,226 
Weighted average common shares outstanding — Basic77,735 81,871 
Effect of dilutive securities:
Stock options and restricted stock— 452 
Weighted average common shares for diluted earnings per share77,735 82,323 
Diluted net (loss) income per common share$(0.04)$0.29 
XML 46 R34.htm IDEA: XBRL DOCUMENT v3.24.1.u1
ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Tables)
 3 Months Ended
Mar. 31, 2024
Equity [Abstract]  
Schedule of Comprehensive Income (Loss)
Comprehensive income for the three months ended March 31, 2024 and 2023:
 Three Months Ended March 31,
Dollars in thousands20242023
Net (loss) income$(3,281)$24,226 
Foreign currency translation adjustment730 3,192 
Change in unrealized loss/(gain) on derivatives, net of tax3,735 (6,493)
Pension liability adjustment, net of tax(5)103 
Comprehensive income, net$1,179 $21,028 
Schedule of Changes in Accumulated Other Comprehensive Loss by Component
Changes in accumulated other comprehensive income by component between December 31, 2023 and March 31, 2024 are presented in the table below, net of tax:
Dollars in thousandsGains and Losses on DerivativesDefined Benefit Pension ItemsForeign Currency ItemsTotal
Balance at January 1, 2024
$21,489 $2,712 $(39,307)$(15,106)
Other comprehensive gain (loss)34,939 (5)2,425 37,359 
Less: Amounts reclassified from accumulated other comprehensive income, net31,204 — 1,695 32,899 
Net current-period other comprehensive gain (loss)3,735 (5)730 4,460 
Balance at March 31, 2024
$25,224 $2,707 $(38,577)$(10,646)
XML 47 R35.htm IDEA: XBRL DOCUMENT v3.24.1.u1
SEGMENT AND GEOGRAPHIC INFORMATION (Tables)
 3 Months Ended
Mar. 31, 2024
Segment Reporting [Abstract]  
Schedule of Net Sales and Profit by Segments Net sales and profit by each reportable segment for the three months ended March 31, 2024 and 2023 are as follows:
Three Months Ended March 31,
Dollars in thousands20242023
Segment Net Sales
Codman Specialty Surgical$256,434 $248,136 
Tissue Technologies
112,438 132,710 
Total revenues$368,872 $380,846 
Segment Profit
Codman Specialty Surgical$103,492 $110,933 
Tissue Technologies
30,66652,281 
Segment profit134,158 163,214 
Amortization(10,107)(3,108)
Corporate and other(120,087)(123,724)
Operating income$3,964 $36,382 
Total revenue by major geographic area consisted of the following:
 Three Months Ended March 31,
Dollars in thousands20242023
United States$256,229 $271,002 
Europe41,596 41,064 
Asia Pacific49,545 50,473 
Rest of World21,502 18,307 
Total Revenues$368,872 $380,846 
Schedule of Geographic Revenue by Area Net sales and profit by each reportable segment for the three months ended March 31, 2024 and 2023 are as follows:
Three Months Ended March 31,
Dollars in thousands20242023
Segment Net Sales
Codman Specialty Surgical$256,434 $248,136 
Tissue Technologies
112,438 132,710 
Total revenues$368,872 $380,846 
Segment Profit
Codman Specialty Surgical$103,492 $110,933 
Tissue Technologies
30,66652,281 
Segment profit134,158 163,214 
Amortization(10,107)(3,108)
Corporate and other(120,087)(123,724)
Operating income$3,964 $36,382 
Total revenue by major geographic area consisted of the following:
 Three Months Ended March 31,
Dollars in thousands20242023
United States$256,229 $271,002 
Europe41,596 41,064 
Asia Pacific49,545 50,473 
Rest of World21,502 18,307 
Total Revenues$368,872 $380,846 
XML 48 R36.htm IDEA: XBRL DOCUMENT v3.24.1.u1
COMMITMENTS AND CONTINGENCIES (Tables)
 3 Months Ended
Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Contingent Consideration
A reconciliation of the opening balances to the closing balances of these Level 3 measurements for the three months ended March 31, 2024 and March 31, 2023 is as follows (in thousands):
Three Months Ended March 31, 2024Contingent Consideration Liability Related to Acquisition of:
ArkisLocation in Financial StatementsDerma SciencesACellSurgical Innovations Associates (SIA), Inc.Location in Financial Statements
Balance as of January 1, 2024
$15,755 $2,557 $300 68,700 
Change in fair value of contingent consideration liabilities (83)Research and development39 — 500 Selling, general and administrative
Balance as of March 31, 202415,672 2,596 300 69,200 
Short-Term $7,562 $— $— $29,300 Accrued expenses and other current liabilities
Long-Term8,110 2,596 300 39,900 Other liabilities
Total15,672 2,596 300 69,200 
Three Months Ended March 31, 2023Contingent Consideration Liability Related to Acquisition of:
Arkis Location in Financial StatementsDerma SciencesACellSurgical Innovations Associates (SIA), Inc.Location in Financial Statements
Balance as of January 1, 2023
$12,895 $230 $3,700 $57,607 
Change in fair value of contingent consideration liabilities3,299 Research and development— (2,200)3,600 Selling, general and administrative
Balance as of March 31, 2023
$16,194 $230 $1,500 $61,207 
Short-Term $4,388 $— $— $12,500 Accrued expenses and other current liabilities
Long-Term11,806 230 1,500 48,707 Other liabilities
Total16,194 230 1,500 61,207 
XML 49 R37.htm IDEA: XBRL DOCUMENT v3.24.1.u1
ACQUISITIONS AND DIVESTITURES - Narrative (Details) - Acclarent Inc. - USD ($)
$ in Millions
 1 Months Ended
Apr. 01, 2024
Dec. 31, 2023
Business Acquisition [Line Items]    
Purchase price of business combination   $ 275.0
Contingent consideration, cash payments due upon achievement of certain revenue-based performance milestones (up to)   $ 5.0
Subsequent Event    
Business Acquisition [Line Items]    
Purchase price of business combination $ 282.0  
Percentage of shares acquired 100.00%  
XML 50 R38.htm IDEA: XBRL DOCUMENT v3.24.1.u1
REVENUES FROM CONTRACTS WITH CUSTOMERS - Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Dec. 31, 2023
Revenue from Contract with Customer [Abstract]    
Number of days from shipment to issue a credit 90 days  
Product returns provision $ 18,700  
Product returns, payments 16,700  
Product returns, reserve 2,000  
Short-term portion of contract liability 7,841 $ 8,540
Long-term portion of contract liability $ 6,900  
Product warranty period (up to) 2 years  
XML 51 R39.htm IDEA: XBRL DOCUMENT v3.24.1.u1
REVENUES FROM CONTRACTS WITH CUSTOMERS - Schedule of Changes in Contract Assets and Liabilities (Details)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
USD ($)
Contract Asset  
Contract asset, Beginning of period $ 9,233
Transferred to trade receivable from contract asset included in beginning of the year contract asset (9,233)
Contract asset, net of transferred to trade receivables on contracts during the period 7,478
Contract asset, End of Period 7,478
Contract Liability  
Contract liability, beginning of period 16,252
Recognition of revenue included in beginning of year contract liability (3,523)
Contract liability, net of revenue recognized on contracts during the period 2,017
Foreign currency translation (63)
Contract liability, end of period $ 14,683
XML 52 R40.htm IDEA: XBRL DOCUMENT v3.24.1.u1
REVENUES FROM CONTRACTS WITH CUSTOMERS - Narrative, Revenue Remaining Performance Obligation (Details) - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-04-01
Mar. 31, 2024
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Expected performance obligation, percentage 53.00%
Performance obligations expected to be satisfied, expected timing 12 months
XML 53 R41.htm IDEA: XBRL DOCUMENT v3.24.1.u1
REVENUES FROM CONTRACTS WITH CUSTOMERS - Schedule of Revenues Disaggregated by Major Source (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Disaggregation of Revenue [Line Items]    
Total Revenues $ 368,872 $ 380,846
Codman Specialty Surgical    
Disaggregation of Revenue [Line Items]    
Total Revenues 256,434 248,136
Codman Specialty Surgical | Neurosurgery    
Disaggregation of Revenue [Line Items]    
Total Revenues 202,268 192,870
Codman Specialty Surgical | Instruments    
Disaggregation of Revenue [Line Items]    
Total Revenues 54,166 55,266
Tissue Technologies    
Disaggregation of Revenue [Line Items]    
Total Revenues 112,438 132,710
Tissue Technologies | Wound Reconstruction and Care    
Disaggregation of Revenue [Line Items]    
Total Revenues 80,877 100,940
Tissue Technologies | Private Label    
Disaggregation of Revenue [Line Items]    
Total Revenues $ 31,561 $ 31,770
XML 54 R42.htm IDEA: XBRL DOCUMENT v3.24.1.u1
INVENTORIES - Schedule of Net Inventories (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Inventory Disclosure [Abstract]    
Finished goods $ 192,287 $ 196,402
Work in process 83,334 74,035
Raw materials 127,801 119,171
Inventories, net $ 403,422 $ 389,608
XML 55 R43.htm IDEA: XBRL DOCUMENT v3.24.1.u1
GOODWILL AND OTHER INTANGIBLE ASSETS - Schedule of Changes in Carrying Amount of Goodwill (Details)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
USD ($)
Goodwill [Roll Forward]  
Beginning of period $ 1,055,462
Foreign currency translation (15,227)
End of period 1,040,235
Codman Specialty Surgical  
Goodwill [Roll Forward]  
Beginning of period 666,937
Foreign currency translation (9,622)
End of period 657,315
Tissue Technologies  
Goodwill [Roll Forward]  
Beginning of period 388,525
Foreign currency translation (5,605)
End of period $ 382,920
XML 56 R44.htm IDEA: XBRL DOCUMENT v3.24.1.u1
GOODWILL AND OTHER INTANGIBLE ASSETS - Components of Company's Identifiable Intangible Assets (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Acquired Finite-Lived Intangible Assets [Line Items]    
Cost $ 1,679,890 $ 1,729,837
Accumulated Amortization (657,281) (662,004)
Net 1,022,609 1,067,833
Codman tradename    
Acquired Finite-Lived Intangible Assets [Line Items]    
Cost 168,678 174,531
Net $ 168,678 $ 174,531
Completed technology    
Acquired Finite-Lived Intangible Assets [Line Items]    
Weighted Average Life 18 years 18 years
Cost $ 1,209,921 $ 1,226,128
Accumulated Amortization (460,545) (448,519)
Net $ 749,376 $ 777,609
Customer relationships    
Acquired Finite-Lived Intangible Assets [Line Items]    
Weighted Average Life 12 years 12 years
Cost $ 167,360 $ 193,895
Accumulated Amortization (134,587) (152,160)
Net $ 32,773 $ 41,735
Trademarks/brand names    
Acquired Finite-Lived Intangible Assets [Line Items]    
Weighted Average Life 28 years 28 years
Cost $ 97,668 $ 98,892
Accumulated Amortization (39,330) (38,754)
Net $ 58,338 $ 60,138
Supplier relationships    
Acquired Finite-Lived Intangible Assets [Line Items]    
Weighted Average Life 30 years 30 years
Cost $ 30,211 $ 30,211
Accumulated Amortization (18,393) (18,148)
Net $ 11,818 $ 12,063
All other    
Acquired Finite-Lived Intangible Assets [Line Items]    
Weighted Average Life 11 years 11 years
Cost $ 6,052 $ 6,180
Accumulated Amortization (4,426) (4,423)
Net $ 1,626 $ 1,757
XML 57 R45.htm IDEA: XBRL DOCUMENT v3.24.1.u1
GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
USD ($)
Mar. 31, 2023
USD ($)
Dec. 31, 2023
USD ($)
Goodwill [Line Items]      
Amortization $ 27,700 $ 20,600  
Expected annual amortization expense, remainder of 2024 60,100    
Expected annual amortization expense, in 2025 80,200    
Expected annual amortization expense, in 2026 80,000    
Expected annual amortization expense, in 2027 79,100    
Expected annual amortization expense, in 2028 78,700    
Expected annual amortization expense, in 2029 74,900    
Expected annual amortization expense, thereafter 403,500    
Non-cash impairment charges 7,064 0  
Intangible assets, net $ 1,022,609   $ 1,067,833
Tissue Technologies      
Goodwill [Line Items]      
Fair value in excess of carrying amount, percent 20.00%    
Measurement Input, Long-Term Revenue Growth Rate | Valuation Technique, Discounted Cash Flow      
Goodwill [Line Items]      
Reporting unit, measurement input 0.02    
Measurement Input, Discount Rate | Valuation Technique, Discounted Cash Flow      
Goodwill [Line Items]      
Reporting unit, measurement input 0.15    
Customer Relationships      
Goodwill [Line Items]      
Non-cash impairment charges $ 7,100    
Completed technology      
Goodwill [Line Items]      
Cost, amortization 17,600 $ 17,500  
Completed technology | Completed Technology, Surgimend      
Goodwill [Line Items]      
Intangible assets, net 38,300    
Completed technology | Completed Technology, PriMatrix      
Goodwill [Line Items]      
Intangible assets, net $ 27,700    
XML 58 R46.htm IDEA: XBRL DOCUMENT v3.24.1.u1
DEBT - Narrative (Details)
 3 Months Ended
Feb. 04, 2020
USD ($)
$ / shares
Mar. 31, 2024
USD ($)
Mar. 31, 2023
USD ($)
Dec. 31, 2023
USD ($)
Dec. 15, 2023
USD ($)
Mar. 24, 2023
USD ($)
Dec. 09, 2020
USD ($)
Debt Instrument [Line Items]              
Term loan component of senior credit facility   $ 19,375,000   $ 14,531,000      
Interest payments, remainder of fiscal year   39,300,000          
Interest payments, year one   50,800,000          
Interest payments, year two   48,100,000          
Interest payments, year three   45,000,000          
Interest payments, after year three   10,000,000          
Securitization program outstanding borrowings, maximum limit   150,000,000          
Transferor's interests in transferred financial assets, issuance costs         $ 300,000    
Debt instrument, securitization facility, agreement term         3 years    
Transferor's interests in transferred financial assets, unamortized issuance costs         $ 100,000    
Secured long-term debt, securitization program   $ 94,600,000   $ 89,200,000      
Weighted average interest rate, accounts receivable securitization revolving loan facility   6.50%   5.90%      
Fair Value, Inputs, Level 2              
Debt Instrument [Line Items]              
Securitization facility, outstanding borrowings, fair value   $ 92,700,000          
Revolving Credit Facility              
Debt Instrument [Line Items]              
Maximum borrowing capacity           $ 1,300,000,000  
Debt issuance costs capitalized   7,600,000          
Write off of debt issuance costs     $ 200,000        
Line of credit facility outstanding   $ 420,000,000   $ 70,000,000      
Standby Letters of Credit              
Debt Instrument [Line Items]              
Maximum borrowing capacity           60,000,000  
Swingline Loans              
Debt Instrument [Line Items]              
Maximum borrowing capacity           60,000,000  
Senior Credit Facility              
Debt Instrument [Line Items]              
Maximum borrowing capacity           2,100,000,000  
Senior Credit Facility | Overnight Federal Funds              
Debt Instrument [Line Items]              
Interest rates available   0.50%          
Senior Credit Facility | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate              
Debt Instrument [Line Items]              
Interest rate adjustment   0.10%          
Interest rates available   1.00%          
Senior Credit Facility | Minimum              
Debt Instrument [Line Items]              
Line of credit, commitment fee percentage   0.15%          
Senior Credit Facility | Minimum | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate              
Debt Instrument [Line Items]              
Interest rates available   1.00%          
Senior Credit Facility | Maximum              
Debt Instrument [Line Items]              
Line of credit, commitment fee percentage   0.30%          
Senior Credit Facility | Maximum | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate              
Debt Instrument [Line Items]              
Interest rates available   1.75%          
Senior Credit Facility | Standby Letters of Credit              
Debt Instrument [Line Items]              
Line of credit facility outstanding   $ 0          
Letters of credit outstanding   1,700,000   1,700,000      
Term Loan Facility | Secured Debt              
Debt Instrument [Line Items]              
Maximum borrowing capacity           $ 775,000,000  
Line of credit facility outstanding   $ 775,000,000   $ 775,000,000      
Weighted average interest rate on debt   6.80%   6.80%      
Term loan component of senior credit facility   $ 19,400,000   $ 14,500,000      
Term Loan Facility | Secured Debt | Fair Value, Inputs, Level 2              
Debt Instrument [Line Items]              
Line of credit facility, fair value of amount outstanding   765,500,000          
2025 Notes | Convertible Debt              
Debt Instrument [Line Items]              
Convertible notes, maximum borrowing capacity $ 575,000,000 575,000,000.0          
Convertible notes, interest rate 0.50%            
Incremental financing costs capitalized $ 13,200,000            
Initial conversion rate 0.0135739            
Initial conversion price (in dollars per share) | $ / shares $ 73.67            
Maximum selling price of the company's common stock of the conversion price 130.00%            
Maximum average conversion value of notes 98.00%            
Minimum settled in cash per principal amount             $ 1,000
Redemption price, percentage 100.00%            
Warrant strike price (in dollars per share) | $ / shares $ 113.34            
Fair value   $ 549,700,000          
2025 Notes | Convertible Debt | Call Option              
Debt Instrument [Line Items]              
Cost of call transactions $ 104,200,000            
Proceeds from warrant transactions $ 44,500,000            
Initial strike price (in dollars per share) | $ / shares $ 73.67            
XML 59 R47.htm IDEA: XBRL DOCUMENT v3.24.1.u1
DEBT - Maximum Total Leverage Ratio Table (Details) - Senior Credit Facility
Mar. 24, 2023
March 31, 2023 through December 31, 2024  
Debt Instrument [Line Items]  
Maximum Consolidated Total Leverage Ratio 4.50
March 31, 2025 through June 30, 2026  
Debt Instrument [Line Items]  
Maximum Consolidated Total Leverage Ratio 4.25
September 30, 2026 and the last day of each fiscal quarter thereafter  
Debt Instrument [Line Items]  
Maximum Consolidated Total Leverage Ratio 4.00
XML 60 R48.htm IDEA: XBRL DOCUMENT v3.24.1.u1
DEBT - Contractual Maturity Table (Details)
$ in Thousands
Mar. 31, 2024
USD ($)
Debt Disclosure [Abstract]  
Remainder of 2024 $ 14,531
2025 33,906
2026 38,750
2027 53,281
Thereafter 634,532
Total long-term debt $ 775,000
XML 61 R49.htm IDEA: XBRL DOCUMENT v3.24.1.u1
DERIVATIVE INSTRUMENTS - Schedule of Derivative Instruments (Details) - Cash Flow Hedges - Designated as Hedging Instrument - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Derivative [Line Items]    
Notional Amount $ 1,475,000 $ 1,475,000
Estimated Fair Value 53,059 43,556
Interest Rate Swap Designated March 31, 2023    
Derivative [Line Items]    
Notional Amount 0 0
Estimated Fair Value (2,127) (1,829)
Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Interest Rate Swap Designated December 13, 2017 Tranche 2    
Derivative [Line Items]    
Notional Amount $ 150,000 150,000
Fixed Interest Rate 2.423%  
Estimated Fair Value $ 1,125 2,105
Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Interest Rate Swap Designated December 13, 2017 Tranche 3    
Derivative [Line Items]    
Notional Amount $ 200,000 200,000
Fixed Interest Rate 2.313%  
Estimated Fair Value $ 4,341 4,978
Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Interest Rate Swap Designated October 10, 2018 Tranche 1    
Derivative [Line Items]    
Notional Amount $ 75,000 75,000
Fixed Interest Rate 3.22%  
Estimated Fair Value $ 1,556 1,349
Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Interest Rate Swap Designated October 10, 2018 Tranche 2    
Derivative [Line Items]    
Notional Amount $ 75,000 75,000
Fixed Interest Rate 3.199%  
Estimated Fair Value $ 1,548 1,312
Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Interest Rate Swap Designated October 10, 2018 Tranche 3    
Derivative [Line Items]    
Notional Amount $ 75,000 75,000
Fixed Interest Rate 3.209%  
Estimated Fair Value $ 1,548 1,346
Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Interest Rate Swap Designated December 18, 2018 Tranche 1    
Derivative [Line Items]    
Notional Amount $ 100,000 100,000
Fixed Interest Rate 2.885%  
Estimated Fair Value $ 4,512 3,015
Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Interest Rate Swap Designated December 18, 2018 Tranche 2    
Derivative [Line Items]    
Notional Amount $ 100,000 100,000
Fixed Interest Rate 2.867%  
Estimated Fair Value $ 4,519 3,052
Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Interest Rate Swap Designated December 15, 2020 Tranche 1    
Derivative [Line Items]    
Notional Amount $ 575,000 575,000
Fixed Interest Rate 1.415%  
Estimated Fair Value $ 29,267 22,965
Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Interest Rate Swap Designated December 15, 2020 Tranche 2    
Derivative [Line Items]    
Notional Amount $ 125,000 125,000
Fixed Interest Rate 1.404%  
Estimated Fair Value $ 6,770 $ 5,263
XML 62 R50.htm IDEA: XBRL DOCUMENT v3.24.1.u1
DERIVATIVE INSTRUMENTS - Narrative (Details)
$ in Thousands, SFr in Millions
 3 Months Ended
Mar. 31, 2024
USD ($)
Mar. 31, 2024
CHF (SFr)
Mar. 31, 2023
USD ($)
May 02, 2024
USD ($)
May 02, 2024
CHF (SFr)
Mar. 31, 2024
CHF (SFr)
Dec. 31, 2023
USD ($)
Sep. 22, 2023
USD ($)
Sep. 22, 2023
CHF (SFr)
Jun. 30, 2021
USD ($)
Dec. 21, 2020
USD ($)
Dec. 21, 2020
CHF (SFr)
Derivative [Line Items]                        
Gain expected to be reclassified to earnings in the next twelve months $ 4,100                      
Designated as Hedging Instrument                        
Derivative [Line Items]                        
Gain (loss) recorded in AOCI, change in fair value 68,546   $ (7,462)                  
Amount of Gain (Loss) Reclassified from AOCI into Earnings 38,784   2,092                  
Cash Flow Hedges | Designated as Hedging Instrument                        
Derivative [Line Items]                        
Current notional amount 1,475,000           $ 1,475,000          
Estimated Fair Value 53,059           43,556          
Cross-currency swap                        
Derivative [Line Items]                        
Gain (loss) reclassified into other income 1,300   1,500                  
Gain expected to be reclassified to earnings in the next twelve months (1,900)                      
Current notional amount                     $ 471,600 SFr 420.1
Intercompany loan quarterly payments | SFr   SFr 5.8                    
Cross-currency swap | Cash Flow Hedges | Designated as Hedging Instrument                        
Derivative [Line Items]                        
Gain (loss) reclassified into other income 30,100   4,900                  
Cross-currency swap | Cash Flow Hedges | Designated as Hedging Instrument | Other income, net                        
Derivative [Line Items]                        
Gain (loss) recorded in AOCI, change in fair value 29,532   2,191                  
Amount of Gain (Loss) Reclassified from AOCI into Earnings 31,473   (3,504)                  
Cross-currency swap | Net Investment Hedges | Designated as Hedging Instrument                        
Derivative [Line Items]                        
Gain (loss) reclassified into other income 2,200   2,100                  
Estimated Fair Value (26,891)           (49,609)          
Cross-currency swap | Codman                        
Derivative [Line Items]                        
Notional amount settled | SFr                 SFr 20.0      
Cross-currency swap | Codman | Cash Flow Hedges | Designated as Hedging Instrument                        
Derivative [Line Items]                        
Estimated Fair Value (12,480)           (40,672)          
Cross-currency swap | Short | Codman                        
Derivative [Line Items]                        
Notional amount terminated               $ 48,500        
Current notional amount               $ 31,500 SFr 28.5      
Foreign currency swaps | Not Designated as Hedging Instrument                        
Derivative [Line Items]                        
Current notional amount 5,500                 $ 7,300    
Estimated Fair Value 1,500           1,200          
Foreign currency swaps | Net Investment Hedges | Designated as Hedging Instrument | Subsequent Event                        
Derivative [Line Items]                        
Current notional amount       $ 75,000 SFr 68.5              
Foreign currency forward contracts | Cash Flow Hedges | Designated as Hedging Instrument                        
Derivative [Line Items]                        
Current notional amount | SFr           SFr 13.3            
Foreign currency forward contracts | Cash Flow Hedges | Designated as Hedging Instrument | Cost of Sales                        
Derivative [Line Items]                        
Gain (loss) recorded in AOCI, change in fair value (629)   (69)                  
Amount of Gain (Loss) Reclassified from AOCI into Earnings (110)                      
Interest Rate Swap                        
Derivative [Line Items]                        
Gain expected to be reclassified to earnings in the next twelve months 13,600                      
Interest Rate Swap | Cash Flow Hedges | Designated as Hedging Instrument                        
Derivative [Line Items]                        
Other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification and tax 14,700   (10,500)                  
Gain (loss) reclassified into other income 5,200   $ 3,500                  
Current notional amount $ 1,500,000           $ 1,500,000          
XML 63 R51.htm IDEA: XBRL DOCUMENT v3.24.1.u1
DERIVATIVE INSTRUMENTS - Schedule of Cross Currency Swap Derivatives (Details)
SFr in Thousands, $ in Thousands
Mar. 31, 2024
USD ($)
Mar. 31, 2024
CHF (SFr)
Dec. 31, 2023
USD ($)
Dec. 31, 2023
CHF (SFr)
Sep. 22, 2023
USD ($)
Sep. 22, 2023
CHF (SFr)
Dec. 21, 2020
USD ($)
Dec. 21, 2020
CHF (SFr)
Cross-currency swap                
Derivative [Line Items]                
Aggregate Notional Amount             $ 471,600 SFr 420,100
Cross-currency swap | Short | Codman                
Derivative [Line Items]                
Aggregate Notional Amount         $ 31,500 SFr 28,500    
Cash Flow Hedges | Designated as Hedging Instrument                
Derivative [Line Items]                
Aggregate Notional Amount $ 1,475,000   $ 1,475,000          
Fair Value Asset (Liability) 53,059   43,556          
Cash Flow Hedges | Designated as Hedging Instrument | Cross-currency swap | Codman                
Derivative [Line Items]                
Fair Value Asset (Liability) (12,480)   (40,672)          
Cash Flow Hedges | Designated as Hedging Instrument | Cross Currency Interest Rate Swap One | Codman                
Derivative [Line Items]                
Fair Value Asset (Liability) $ (9,902)   (38,324)          
Cash Flow Hedges | Designated as Hedging Instrument | Cross Currency Interest Rate Swap One | Long | Codman                
Derivative [Line Items]                
Fixed Rate 3.00% 3.00%            
Aggregate Notional Amount | SFr   SFr 333,887   SFr 351,137        
Cash Flow Hedges | Designated as Hedging Instrument | Cross Currency Interest Rate Swap One | Short | Codman                
Derivative [Line Items]                
Fixed Rate 3.98% 3.98%            
Aggregate Notional Amount $ 374,817   394,183          
Cash Flow Hedges | Designated as Hedging Instrument | Cross Currency Interest Rate Swap Two | Codman                
Derivative [Line Items]                
Fair Value Asset (Liability) $ (2,578)   (2,348)          
Cash Flow Hedges | Designated as Hedging Instrument | Cross Currency Interest Rate Swap Two | Long | Codman                
Derivative [Line Items]                
Fixed Rate 2.40% 2.40%            
Aggregate Notional Amount | SFr   SFr 28,500   SFr 28,500        
Cash Flow Hedges | Designated as Hedging Instrument | Cross Currency Interest Rate Swap Two | Short | Codman                
Derivative [Line Items]                
Fixed Rate 6.27% 6.27%            
Aggregate Notional Amount $ 31,457   $ 31,457          
XML 64 R52.htm IDEA: XBRL DOCUMENT v3.24.1.u1
DERIVATIVE INSTRUMENTS - Schedule of Net Investment Hedges Derivatives (Details)
€ in Thousands, SFr in Thousands, $ in Thousands
Mar. 31, 2024
USD ($)
Mar. 31, 2024
CHF (SFr)
Mar. 31, 2024
EUR (€)
Dec. 31, 2023
USD ($)
Dec. 31, 2023
CHF (SFr)
Dec. 31, 2023
EUR (€)
Dec. 21, 2020
USD ($)
Dec. 21, 2020
CHF (SFr)
Cross-currency swap                
Derivative [Line Items]                
Aggregate Notional Amount             $ 471,600 SFr 420,100
Designated as Hedging Instrument | Net Investment Hedges | Cross-currency swap                
Derivative [Line Items]                
Fair Value Asset (Liability) $ (26,891)     $ (49,609)        
Designated as Hedging Instrument | Net Investment Hedges | Cross Currency Interest Rate Swap One                
Derivative [Line Items]                
Fair Value Asset (Liability) $ 3,459     2,475        
Designated as Hedging Instrument | Net Investment Hedges | Cross Currency Interest Rate Swap One | Long                
Derivative [Line Items]                
Fixed Rate 0.00% 0.00% 0.00%          
Aggregate Notional Amount | €     € 38,820     € 38,820    
Designated as Hedging Instrument | Net Investment Hedges | Cross Currency Interest Rate Swap One | Short                
Derivative [Line Items]                
Fixed Rate 2.19% 2.19% 2.19%          
Aggregate Notional Amount $ 45,000     45,000        
Designated as Hedging Instrument | Net Investment Hedges | Cross Currency Interest Rate Swap Two                
Derivative [Line Items]                
Fair Value Asset (Liability) $ (29,614)     (48,047)        
Designated as Hedging Instrument | Net Investment Hedges | Cross Currency Interest Rate Swap Two | Long                
Derivative [Line Items]                
Fixed Rate 0.00% 0.00% 0.00%          
Aggregate Notional Amount | €     € 288,210     € 288,210    
Designated as Hedging Instrument | Net Investment Hedges | Cross Currency Interest Rate Swap Two | Short                
Derivative [Line Items]                
Fixed Rate 1.94% 1.94% 1.94%          
Aggregate Notional Amount $ 300,000     300,000        
Designated as Hedging Instrument | Net Investment Hedges | Cross Currency Interest Rate Swap Three                
Derivative [Line Items]                
Fair Value Asset (Liability) $ (736)     (4,037)        
Designated as Hedging Instrument | Net Investment Hedges | Cross Currency Interest Rate Swap Three | Long                
Derivative [Line Items]                
Fixed Rate 0.00% 0.00% 0.00%          
Aggregate Notional Amount | SFr   SFr 66,525     SFr 66,525      
Designated as Hedging Instrument | Net Investment Hedges | Cross Currency Interest Rate Swap Three | Short                
Derivative [Line Items]                
Fixed Rate 2.54% 2.54% 2.54%          
Aggregate Notional Amount $ 75,000     $ 75,000        
XML 65 R53.htm IDEA: XBRL DOCUMENT v3.24.1.u1
DERIVATIVE INSTRUMENTS - Fair Value of Derivative Instruments By Balance Sheet Location (Details)
$ in Thousands, SFr in Millions
Mar. 31, 2024
USD ($)
Mar. 31, 2024
CHF (SFr)
Dec. 31, 2023
USD ($)
Dec. 21, 2020
USD ($)
Dec. 21, 2020
CHF (SFr)
Designated as Hedging Instrument          
Derivatives, Fair Value [Line Items]          
Total derivatives designated as hedges — Assets $ 62,404   $ 50,330    
Total derivatives designated as hedges — Liabilities 49,342   97,055    
Cash Flow Hedges | Designated as Hedging Instrument          
Derivatives, Fair Value [Line Items]          
Current notional amount 1,475,000   1,475,000    
Interest rate swap | Cash Flow Hedges | Designated as Hedging Instrument          
Derivatives, Fair Value [Line Items]          
Current notional amount 1,500,000   1,500,000    
Interest rate swap | Cash Flow Hedges | Designated as Hedging Instrument | Prepaid expenses and other current assets          
Derivatives, Fair Value [Line Items]          
Total derivatives designated as hedges — Assets 14,188   14,675    
Interest rate swap | Cash Flow Hedges | Designated as Hedging Instrument | Other assets          
Derivatives, Fair Value [Line Items]          
Total derivatives designated as hedges — Assets 40,998   30,710    
Interest rate swap | Cash Flow Hedges | Designated as Hedging Instrument | Accrued expenses and other current liabilities          
Derivatives, Fair Value [Line Items]          
Total derivatives designated as hedges — Liabilities 540   579    
Interest rate swap | Cash Flow Hedges | Designated as Hedging Instrument | Other liabilities          
Derivatives, Fair Value [Line Items]          
Total derivatives designated as hedges — Liabilities 1,586   1,250    
Cross-currency swap          
Derivatives, Fair Value [Line Items]          
Current notional amount       $ 471,600 SFr 420.1
Cross-currency swap | Cash Flow Hedges | Designated as Hedging Instrument | Prepaid expenses and other current assets          
Derivatives, Fair Value [Line Items]          
Total derivatives designated as hedges — Assets 680   537    
Cross-currency swap | Cash Flow Hedges | Designated as Hedging Instrument | Other assets          
Derivatives, Fair Value [Line Items]          
Total derivatives designated as hedges — Assets 0   0    
Cross-currency swap | Cash Flow Hedges | Designated as Hedging Instrument | Accrued expenses and other current liabilities          
Derivatives, Fair Value [Line Items]          
Total derivatives designated as hedges — Liabilities 2,578   4,813    
Cross-currency swap | Cash Flow Hedges | Designated as Hedging Instrument | Other liabilities          
Derivatives, Fair Value [Line Items]          
Total derivatives designated as hedges — Liabilities 10,582   36,396    
Cross-currency swap | Net Investment Hedges | Designated as Hedging Instrument | Prepaid expenses and other current assets          
Derivatives, Fair Value [Line Items]          
Total derivatives designated as hedges — Assets 4,084   2,938    
Cross-currency swap | Net Investment Hedges | Designated as Hedging Instrument | Other assets          
Derivatives, Fair Value [Line Items]          
Total derivatives designated as hedges — Assets 2,454   1,470    
Cross-currency swap | Net Investment Hedges | Designated as Hedging Instrument | Accrued expenses and other current liabilities          
Derivatives, Fair Value [Line Items]          
Total derivatives designated as hedges — Liabilities 0   2,903    
Cross-currency swap | Net Investment Hedges | Designated as Hedging Instrument | Other liabilities          
Derivatives, Fair Value [Line Items]          
Total derivatives designated as hedges — Liabilities 33,427   51,114    
Foreign currency forward contracts | Cash Flow Hedges | Designated as Hedging Instrument          
Derivatives, Fair Value [Line Items]          
Current notional amount | SFr   SFr 13.3      
Foreign currency forward contracts | Cash Flow Hedges | Designated as Hedging Instrument | Accrued expenses and other current liabilities          
Derivatives, Fair Value [Line Items]          
Total derivatives designated as hedges — Liabilities $ 629   $ 0    
XML 66 R54.htm IDEA: XBRL DOCUMENT v3.24.1.u1
DERIVATIVE INSTRUMENTS - Effect of Derivative Instruments Designated Cash Flow Hedges on Statements of Operations (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Derivative Instruments, Gain (Loss) [Roll Forward]    
Balance, beginning of period $ 1,587,884 $ 1,804,403
Balance, end of period 1,597,952 1,674,938
Accumulated Other Comprehensive Loss    
Derivative Instruments, Gain (Loss) [Roll Forward]    
Balance, beginning of period (15,106) 10,265
Balance, end of period (10,646) 7,067
Designated as Hedging Instrument    
Derivative Instruments, Gain (Loss) [Roll Forward]    
Amount of Gain (Loss) Recognized in AOCI 68,546 (7,462)
Amount of Gain (Loss) Reclassified from AOCI into Earnings 38,784 2,092
Designated as Hedging Instrument | Accumulated Other Comprehensive Loss    
Derivative Instruments, Gain (Loss) [Roll Forward]    
Balance, beginning of period (17,705) 29,527
Balance, end of period 12,057 19,973
Designated as Hedging Instrument | Interest rate swap | Cash Flow Hedges | Interest expense    
Derivative Instruments, Gain (Loss) [Roll Forward]    
Balance, beginning of period 43,556 56,712
Amount of Gain (Loss) Recognized in AOCI 14,723 (10,534)
Amount of Gain (Loss) Reclassified from AOCI into Earnings 5,219 3,500
Balance, end of period 53,060 42,678
Designated as Hedging Instrument | Cross-currency swap | Cash Flow Hedges | Other income, net    
Derivative Instruments, Gain (Loss) [Roll Forward]    
Balance, beginning of period (15,763) (20,271)
Amount of Gain (Loss) Recognized in AOCI 29,532 2,191
Amount of Gain (Loss) Reclassified from AOCI into Earnings 31,473 (3,504)
Balance, end of period (17,704) (14,576)
Designated as Hedging Instrument | Cross-currency swap | Net Investment Hedges | Interest income    
Derivative Instruments, Gain (Loss) [Roll Forward]    
Balance, beginning of period (45,498) (6,914)
Amount of Gain (Loss) Recognized in AOCI 24,920 950
Amount of Gain (Loss) Reclassified from AOCI into Earnings 2,202 2,096
Balance, end of period (22,780) (8,060)
Designated as Hedging Instrument | Foreign currency forward contracts | Cash Flow Hedges | Cost of Sales    
Derivative Instruments, Gain (Loss) [Roll Forward]    
Balance, beginning of period 0  
Amount of Gain (Loss) Recognized in AOCI (629) (69)
Amount of Gain (Loss) Reclassified from AOCI into Earnings (110)  
Balance, end of period $ (519) $ (69)
XML 67 R55.htm IDEA: XBRL DOCUMENT v3.24.1.u1
DERIVATIVE INSTRUMENTS - Schedule of Derivatives Not Designated as Hedging Instruments (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Derivative Instruments, Gain (Loss) [Line Items]    
Derivative instruments not designated as hedging instruments, gain (loss), net $ 273 $ 55
Foreign currency swaps    
Derivative Instruments, Gain (Loss) [Line Items]    
Derivative instruments not designated as hedging instruments, gain (loss), net $ 273 $ 55
XML 68 R56.htm IDEA: XBRL DOCUMENT v3.24.1.u1
STOCK-BASED COMPENSATION - Narrative (Details) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended 12 Months Ended
Mar. 31, 2024
Dec. 31, 2024
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Grants in period, net of forfeitures (in shares) 243,964  
Options, weighted average grant date fair value (in dollars per share) $ 15.68  
Chief Executive Officer    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Plan modification, expiration period (in months) 6 months  
Plan modification, compensation expense $ 0.2  
Chief Executive Officer | Forecast    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Accelerated stock based compensation expenses   $ 1.9
Stock Options    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total unrecognized compensation costs $ 4.9  
Weighted-average period for cost recognition 3 years  
Stock Options | Directors    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Stock options exercisable, vesting period 1 year  
Stock Options | Employees    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Expiration period 8 years  
Restricted Stock    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Stock options exercisable, vesting period 3 years  
Total unrecognized compensation costs $ 48.6  
Weighted-average period for cost recognition 2 years  
Awards granted during the period (in shares) 532,379  
Other than options, weighted average grant date fair value (in dollars per share) $ 36.46  
Performance Stock and Restricted Stock Awards    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Requisite service periods of awards 3 years  
Performance Stock    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Awards granted during the period (in shares) 263,350  
Other than options, weighted average grant date fair value (in dollars per share) $ 36.22  
Minimum | Stock Options | Directors and Certain Executive Officers    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Expiration period 6 years  
Maximum | Stock Options    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Stock options exercisable, vesting period 4 years  
Maximum | Stock Options | Directors and Certain Executive Officers    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Expiration period 10 years  
XML 69 R57.htm IDEA: XBRL DOCUMENT v3.24.1.u1
RETIREMENT PLANS - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Retirement Benefits [Abstract]      
Net periodic benefit costs $ 0.4 $ 0.3  
Service cost component 0.8 $ 0.5  
Estimated fair value of plan assets $ 40.4   $ 45.7
Defer payment and taxation, base salary, percentage (up to) 75.00%    
Defer payment and taxation, bonus and other eligible cash compensation, percentage (up to) 100.00%    
Deferred compensation plan, fair value of assets $ 5.7   $ 6.1
XML 70 R58.htm IDEA: XBRL DOCUMENT v3.24.1.u1
LEASES AND RELATED PARTY LEASES - Narrative (Details)
$ in Millions
 3 Months Ended
Mar. 31, 2024
USD ($)
renewalOption
Mar. 31, 2023
USD ($)
Operating Leased Assets [Line Items]    
Number of renewal options (or more) | renewalOption 1  
Operating lease expense $ 6.3 $ 6.0
Related Party    
Operating Leased Assets [Line Items]    
Operating lease expense $ 0.3 $ 0.3
Percent of manufacturing facility owned by corporation whose shareholders are trusts whose beneficiaries include family members of company's former director 50.00%  
Annual rate of lease agreement $ 0.3  
Related Party | Five Year Option Lease From November 1, 2029 Through October 31, 2034    
Operating Leased Assets [Line Items]    
Option to extend lease, years 5 years  
Period for extended lease November 1, 2029 through October 31, 2034  
Related Party | Five Year Option Lease From November 1, 2034 Through October 31, 2039    
Operating Leased Assets [Line Items]    
Option to extend lease, years 5 years  
Period for extended lease November 1, 2034 through October 31, 2039  
XML 71 R59.htm IDEA: XBRL DOCUMENT v3.24.1.u1
LEASES AND RELATED PARTY LEASES - Supplemental Balance Sheet Information (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Lessee, Lease, Description [Line Items]    
ROU assets $ 151,834 $ 156,184
Current lease liabilities 16,303 15,284
Non-current lease liabilities 170,082 166,849
Total lease liabilities $ 186,385 $ 182,133
Leased facilities    
Lessee, Lease, Description [Line Items]    
Weighted average remaining lease term (in years) 16 years 6 months 16 years 3 months 18 days
Weighted average discount rate 5.70% 5.90%
Leased vehicles    
Lessee, Lease, Description [Line Items]    
Weighted average remaining lease term (in years) 2 years 1 month 6 days 1 year 10 months 24 days
Weighted average discount rate 2.70% 2.70%
XML 72 R60.htm IDEA: XBRL DOCUMENT v3.24.1.u1
LEASES AND RELATED PARTY LEASES - Supplemental Cash Flow Information (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Cash paid for amounts included in the measurement of lease liabilities:    
Operating cash flows from operating leases $ 5,734 $ 4,319
ROU assets obtained in exchange for lease liabilities:    
Operating leases $ 746 $ 1,721
XML 73 R61.htm IDEA: XBRL DOCUMENT v3.24.1.u1
LEASES AND RELATED PARTY LEASES - Future Minimum Lease Payment Under Operating Leases (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Operating Leased Assets [Line Items]    
Remainder of 2024 $ 18,106  
2025 23,155  
2026 20,506  
2027 19,188  
2028 16,899  
2029 16,017  
Thereafter 163,479  
Total minimum lease payments 277,350  
Less: Imputed interest 90,965  
Total lease liabilities 186,385 $ 182,133
Less: Current lease liabilities 16,303 15,284
Long-term lease liabilities 170,082 $ 166,849
Related Parties    
Operating Leased Assets [Line Items]    
Remainder of 2024 222  
2025 296  
2026 296  
2027 296  
2028 296  
2029 246  
Thereafter 0  
Total minimum lease payments 1,652  
Third Parties    
Operating Leased Assets [Line Items]    
Remainder of 2024 17,884  
2025 22,859  
2026 20,210  
2027 18,892  
2028 16,603  
2029 15,771  
Thereafter 163,479  
Total minimum lease payments $ 275,698  
XML 74 R62.htm IDEA: XBRL DOCUMENT v3.24.1.u1
TREASURY STOCK - Narrative (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 12 Months Ended
Mar. 31, 2024
Dec. 31, 2023
Oct. 18, 2023
Aug. 15, 2023
Jul. 18, 2023
Jun. 30, 2023
Jan. 26, 2023
Apr. 26, 2022
Class of Stock [Line Items]                
Treasury stock (in shares) 12,735,000 12,751,000            
Treasury stock $ 646,422 $ 647,262            
Treasury stock, average cost per share (in dollars per share) $ 50.76 $ 50.76            
Accelerated share repurchase program, receipt (payment)       $ 125,000     $ 150,000  
Accelerated share repurchases, shares received at inception (in shares)       2,300,000     2,100,000  
Accelerated share repurchases, percentage of expected total repurchased       80.00%     80.00%  
Accelerated share repurchases, additional shares received (in shares)     900,000     600,000    
2022 Share Repurchase Program                
Class of Stock [Line Items]                
Stock repurchase program, authorized amount               $ 225,000
Remaining amount under share repurchase         $ 75,000      
2023 Share Repurchase Program                
Class of Stock [Line Items]                
Stock repurchase program, authorized amount         $ 225,000      
Remaining amount under share repurchase $ 100,000              
XML 75 R63.htm IDEA: XBRL DOCUMENT v3.24.1.u1
INCOME TAXES - Summary of Effective Tax Rate (Details)
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Tax Disclosure [Abstract]    
Reported tax rate 37.30% 18.60%
XML 76 R64.htm IDEA: XBRL DOCUMENT v3.24.1.u1
INCOME TAXES - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Tax Disclosure [Abstract]    
Effective income tax rate 37.30% 18.60%
Income tax benefit, tax credit, research and development $ 1.5  
XML 77 R65.htm IDEA: XBRL DOCUMENT v3.24.1.u1
NET INCOME PER SHARE - Basic and Diluted Net Income Per Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Basic net (loss) income per share:    
Net (loss) income $ (3,281) $ 24,226
Weighted average common shares outstanding - basic (in shares) 77,735 81,871
Basic net (loss) income per common share (in dollars per share) $ (0.04) $ 0.30
Diluted net (loss) income per share:    
Net (loss) income $ (3,281) $ 24,226
Weighted average common shares outstanding - basic (in shares) 77,735 81,871
Effect of dilutive securities:    
Stock options and restricted stock (in shares) 0 452
Weighted average common shares for diluted earnings per share (in shares) 77,735 82,323
Diluted net (loss) income per common share (in dollars per share) $ (0.04) $ 0.29
XML 78 R66.htm IDEA: XBRL DOCUMENT v3.24.1.u1
NET INCOME PER SHARE - Narrative (Details) - shares
shares in Millions
Mar. 31, 2024
Mar. 31, 2023
Earnings Per Share [Abstract]    
Shares excluded from computation as their effect would be antidilutive (in shares) 1.3 0.3
XML 79 R67.htm IDEA: XBRL DOCUMENT v3.24.1.u1
ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Schedule of Comprehensive Income (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Equity [Abstract]    
Net (loss) income $ (3,281) $ 24,226
Foreign currency translation adjustment 730 3,192
Change in unrealized loss/(gain) on derivatives, net of tax 3,735 (6,493)
Pension liability adjustment, net of tax (5) 103
Comprehensive income, net $ 1,179 $ 21,028
XML 80 R68.htm IDEA: XBRL DOCUMENT v3.24.1.u1
ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Schedule of Changes in Accumulated Other Comprehensive Income by Component (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Accumulated Other Comprehensive Income (Loss) [Roll Forward]    
Balance, beginning of period $ 1,587,884 $ 1,804,403
Other comprehensive gain (loss) 37,359  
Less: Amounts reclassified from accumulated other comprehensive income, net 32,899  
Net current-period other comprehensive gain (loss) 4,460 (3,198)
Balance, end of period 1,597,952 1,674,938
Total    
Accumulated Other Comprehensive Income (Loss) [Roll Forward]    
Balance, beginning of period (15,106) 10,265
Net current-period other comprehensive gain (loss) 4,460 (3,198)
Balance, end of period (10,646) $ 7,067
Gains and Losses on Derivatives    
Accumulated Other Comprehensive Income (Loss) [Roll Forward]    
Balance, beginning of period 21,489  
Other comprehensive gain (loss) 34,939  
Less: Amounts reclassified from accumulated other comprehensive income, net 31,204  
Net current-period other comprehensive gain (loss) 3,735  
Balance, end of period 25,224  
Defined Benefit Pension Items    
Accumulated Other Comprehensive Income (Loss) [Roll Forward]    
Balance, beginning of period 2,712  
Other comprehensive gain (loss) (5)  
Less: Amounts reclassified from accumulated other comprehensive income, net 0  
Net current-period other comprehensive gain (loss) (5)  
Balance, end of period 2,707  
Foreign Currency Items    
Accumulated Other Comprehensive Income (Loss) [Roll Forward]    
Balance, beginning of period (39,307)  
Other comprehensive gain (loss) 2,425  
Less: Amounts reclassified from accumulated other comprehensive income, net 1,695  
Net current-period other comprehensive gain (loss) 730  
Balance, end of period $ (38,577)  
XML 81 R69.htm IDEA: XBRL DOCUMENT v3.24.1.u1
ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Narrative (Details)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
USD ($)
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Gain (loss) reclassified from AOCI $ 32,899
Gains and Losses on Derivatives  
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Gain (loss) reclassified from AOCI 31,204
Other Income | Gains and Losses on Derivatives  
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Gain (loss) reclassified from AOCI 27,200
Interest income | Gains and Losses on Derivatives  
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Gain (loss) reclassified from AOCI $ 5,700
XML 82 R70.htm IDEA: XBRL DOCUMENT v3.24.1.u1
SEGMENT AND GEOGRAPHIC INFORMATION - Narrative (Details)
 3 Months Ended
Mar. 31, 2024
product
Segment
Segment Reporting Information [Line Items]  
Number of reportable segments | Segment 2
Codman Specialty Surgical  
Segment Reporting Information [Line Items]  
Number of products offered (more than) | product 40,000
XML 83 R71.htm IDEA: XBRL DOCUMENT v3.24.1.u1
SEGMENT AND GEOGRAPHIC INFORMATION - Net Sales and Profit by Reportable Segment (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Segment Net Sales    
Total Revenues $ 368,872 $ 380,846
Segment Profit    
Operating income 3,964 36,382
Amortization (10,107) (3,108)
Operating Segments    
Segment Profit    
Operating income 134,158 163,214
Corporate and other    
Segment Profit    
Operating income (120,087) (123,724)
Codman Specialty Surgical    
Segment Net Sales    
Total Revenues 256,434 248,136
Codman Specialty Surgical | Operating Segments    
Segment Profit    
Operating income 103,492 110,933
Tissue Technologies    
Segment Net Sales    
Total Revenues 112,438 132,710
Tissue Technologies | Operating Segments    
Segment Profit    
Operating income $ 30,666 $ 52,281
XML 84 R72.htm IDEA: XBRL DOCUMENT v3.24.1.u1
SEGMENT AND GEOGRAPHIC INFORMATION - Total Revenue by Major Geographic Area (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Segment Reporting Information [Line Items]    
Total Revenues $ 368,872 $ 380,846
United States    
Segment Reporting Information [Line Items]    
Total Revenues 256,229 271,002
Europe    
Segment Reporting Information [Line Items]    
Total Revenues 41,596 41,064
Asia Pacific    
Segment Reporting Information [Line Items]    
Total Revenues 49,545 50,473
Rest of World    
Segment Reporting Information [Line Items]    
Total Revenues $ 21,502 $ 18,307
XML 85 R73.htm IDEA: XBRL DOCUMENT v3.24.1.u1
COMMITMENTS AND CONTINGENCIES - Fair Value Contingent Consideration, Balance Information (Details) - Contingent Consideration Liability - Fair Value, Inputs, Level 3 - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Arkis    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, Beginning of Period $ 15,755 $ 12,895
Change in fair value of contingent consideration liabilities (83) 3,299
Balance, End of Period 15,672 16,194
Arkis | Other Current Liabilities    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, End of Period 7,562 4,388
Arkis | Other Long-term Liabilities    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, End of Period 8,110 11,806
Derma Sciences    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, Beginning of Period 2,557 230
Change in fair value of contingent consideration liabilities 39 0
Balance, End of Period 2,596 230
Derma Sciences | Other Current Liabilities    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, End of Period 0 0
Derma Sciences | Other Long-term Liabilities    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, End of Period 2,596 230
ACell    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, Beginning of Period 300 3,700
Change in fair value of contingent consideration liabilities 0 (2,200)
Balance, End of Period 300 1,500
ACell | Other Current Liabilities    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, End of Period 0 0
ACell | Other Long-term Liabilities    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, End of Period 300 1,500
Surgical Innovation Associates, Inc.    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, Beginning of Period 68,700 57,607
Change in fair value of contingent consideration liabilities 500 3,600
Balance, End of Period 69,200 61,207
Surgical Innovation Associates, Inc. | Other Current Liabilities    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, End of Period 29,300 12,500
Surgical Innovation Associates, Inc. | Other Long-term Liabilities    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, End of Period $ 39,900 $ 48,707
XML 86 R74.htm IDEA: XBRL DOCUMENT v3.24.1.u1
COMMITMENTS AND CONTINGENCIES - Narrative (Details)
$ in Millions
 3 Months Ended
Dec. 06, 2022
USD ($)
payment
Mar. 31, 2024
USD ($)
liability
Jan. 20, 2021
USD ($)
Jul. 29, 2019
USD ($)
Arkis        
Loss Contingencies [Line Items]        
Contingent consideration, estimated fair value       $ 25.5
Contingent consideration       13.1
Arkis | Development Milestones        
Loss Contingencies [Line Items]        
Contingent consideration, estimated fair value       10.0
Arkis | Commercial Sales Milestones        
Loss Contingencies [Line Items]        
Contingent consideration, estimated fair value       $ 15.5
Derma Sciences        
Loss Contingencies [Line Items]        
Number of contingent liabilities remaining | liability   1    
Contingent consideration, maximum undiscounted payment amount   $ 3.0    
Derma Sciences | BioD Earnout Payments and Medihoney Earnout Payments        
Loss Contingencies [Line Items]        
Payment for contingent consideration   $ 33.3    
ACell, Inc.        
Loss Contingencies [Line Items]        
Contingent consideration     $ 23.9  
Contingent consideration, maximum undiscounted payment amount     $ 100.0  
Surgical Innovation Associates, Inc.        
Loss Contingencies [Line Items]        
Contingent consideration, maximum undiscounted payment amount $ 90.0      
Number of contingent liabilities | payment 2      
Surgical Innovation Associates, Inc. | Revenue Based Performance Milestones        
Loss Contingencies [Line Items]        
Contingent consideration, estimated fair value $ 32.6      
Contingent consideration, maximum undiscounted payment amount 50.0      
Surgical Innovation Associates, Inc. | FDA Approval Of Premarket Approval        
Loss Contingencies [Line Items]        
Contingent consideration, estimated fair value 25.0      
Contingent consideration, maximum undiscounted payment amount $ 40.0      
EXCEL 87 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( !N!IE@'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " ;@:98X^%RA^\ K @ $0 &1O8U!R;W!S+V-O&ULS9)1 M2\,P$,>_BN2]O;35(:'+BV-/"H(#Q;>0W+9@DX;DI-VW-ZU;A^@'\#%W__SN M=W"M#D+W$9]C'S"2Q70SNLXGH<.:'8F" $CZB$ZE,B=\;N[[Z!3E9SQ 4/I# M'1!JSE?@D)11I& "%F$A,MD:+71$17T\XXU>\.$S=C/,:, .'7I*4)45,#E- M#*>Q:^$*F&"$T:7O IJ%.%?_Q,X=8.?DF.R2&H:A')HYEW>HX.WI\65>M[ ^ MD?(:\Z]D!9T"KMEE\FOSL-EMF:QY?5OPNX*O=C47_%XTS?OD^L/O*NQZ8_?V M'QM?!&4+O^Y"?@%02P,$% @ &X&F6)E&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" ;@:98B'+*Y< % "9'@ & 'AL+W=O6E7A;%M'D M@N]8K+Y9MRY;R&=KFH9RP9\^L@-05_MY/$RR M_^@IO[=+6LA+$\FC@UB5( KB_),^'Q[$"X$SJ!"0@X#\(,!.A< Y")P,-"]9 MAG5#)1T-!7]"0M^MW/1!]FPRM:()8EV-2RG4MX'2R9'+'YE ;91LJ6#)T)+* M4W]C>0?]^UQ/*O0.^L1CN4W0)/:9_UIOJ;(4!2+' KTGH.$G*BZ0@]\A8I.. MH3QNG7R/;,>D?E4:IW@\3F;G@(_GW_$JD4*UN/],#RAWZ)@==#>\2G;48]B@NJ#H3KU?@]4[#FS,1<%]W M0J2& 6/EP4Y%MZOL=Z#^3,Y^P=D_L64*JF:0; *HKD?8:TW#Q%B1H.Q,P,L" M\!(LU"26@=RCVR!D:)9&*R9,8+"';=MMTB/FV@.E9\(-"KC!*7 +M@GT,*JJ M<48C8QN%?::SA\F'Q1C=36\G2WYF.ONP1.[GQ=Q$#GJ>28[M MQE+LU:=O?" U[C<3$S$L.A?Y1:+ MIR _T&PQR6,C61.1!Y>9 M!\.IY4"6]4@C&BR?_6%D:B+SX#+T8#BJ')CF/)$T1/\$N^KQ!3:R+[L=VPC8 M1.K!9>S!<%IQLPZGEJW58+!!SS:/)$V$'%RF' Q'DSONJ?J:;WD,I8 :$]+O MMNVN;:ZV)C(.+D,.AA/*0R!5ON%KA,F;U5NT9%XJJD84V,GE4:0FE*7DWK=W M:$X%^D+#E*%?+VRLPS!:ZO6L\1$TD81P&84PG&%4@/6#>(.6^VC%0R-Y30@: M+QZ,7$WD'%+F' (GD6-=HLFSMZ7QAE5FO!JCV7AY,S:N(V'AN81EK"$GQ1HW M%4*O1/+E1U:5:NI(C?-^C>-7XPL7%U:=RUG&&7)2G)G&:KFR_X<(X%-7XW%&A6OO8\Y@R4C9^;FDD;B+J MD#+J$#BK+",::MBRZ:IA=$=C,S7L5;F*AG7G,I;1A]1$GXB)C4;[H*1R"Q+" M3M6$360?4F8? D>78V#=LC $\6";:KPF,A I,Q"!X\MQF'TUP6>S>8(^IU(E MVCB;0-\$\>&E]5LC_4]*.H=GDKMU,S>],_(XZE_V!X/>H#.T'DV\928B<)(9 M1RSVLW=;MR'=&%%@@^J*;"+ID#+I$#BH%._L;H-$Q]JO3*6T6W71/%7"9I6; M 4VD'J=,/4[-^YT9_, M..;46-GJ;X#[76)48[%XV5^A]>HU=NXU)VS%7Z$\-/M:+ MS3\]^65[H@GR])O%?!^PN%KLNXZSW4:KO#W?M/U$]=R9H)"ME=2^Z*L!3^3[ MH/F)Y+ML*W'%I>11=KAEU&="WZ"^7W,NCR?Z!XK=Z-'_4$L#!!0 ( !N! MIE@MX1"T804 $<4 8 >&PO=V]R:W-H965T&ULK9AM M;Z,X$,>_BI5;G5*I;;!Y3"^-E"99;:1M6C7M[HO3O7"#DZ %G,-.VKU/?V.@ M0,#07:EO B8SPV_&#W_CT0M/?H@=8Q*]1F$LKGL[*?=7@X%8[UA$Q27?LQC^ MV? DHA*:R78@]@FC?NH4A0-B&,X@HD'<&X_29_?)>,0/,@QB=I\@<8@BFOR\ M82%_N>[AWMN#AV"[D^K!8#S:TRU;,?FTOT^@-2BB^$'$8A'P&"5L<]V;X*LI ML91#:O$M8"^BDGFF@DUY^#WPY>ZZY_60SS;T$,H'_O*%Y0G9*MZ:AR+]12^Y MK=%#ZX.0/,J=@2 *XNQ*7_-"5!P@CMZ!Y ZD[F"U.)BY@YDFFI&E:+6?SY6H^0W"WNONZF$T>H;%Z MA,OM?/FX0G>?T=W]_&'RN #-%DJR]O[A_D7<%M\FZ/%$MISU']:3IYF"W ^ M0Q?H:35#_4]G2.QHP@0*8O2XXP=!8U^Z:^[FQTX9M$G9AK/ M;(FWB-<\8F@EJ60P8R3Z>_(L9 (C_A]=L;)@ECZ86@:NQ)ZNV74/YKE@R9'U MQG_^@1WC+UVF'Q3L)&^KR-OJBCY^Y)*&L#8<67Q@YRAF4I=N%L-)8ZA%ZC@V M'<]SR6APK":B,?,,SW(*LQ-$NT"T.[MFRH44"(8M8J^PD@HFKG2,]D=VR0<% M.\G7*?)U.KM$Y8OX!FTY]P42//1UZ68Q[$JML4,,TZMUB<;,NK>\2MT!T M.Q$?(&F:K'=IK_@P>$*^5[-&!^HV"(@S=.P:I\[*50N##M,K,+U.S!4H51!O MS]&6Q2R!<:YPJ0]+>J#FMA(S';&G*:WM#NNEU9DY8*AG'A;,PT[F12QIO V> M0X:H$+"GH!%/9/ ?50JLHQTV,0QLN#78II6)#4^/BHU2R(Q?6#W6C0FJU1>C MB>!80Z->5IV=95E.RUC %=7%G;!W>Z;Z/-Z"%*K%7@N)FR\?5EZ=(VJL'-,C M+82D)"3O]3V#]41V 9+&JVW#,NJ 32NK.B9.^4J-Q)U25/+E_:P%-!NOOL"F M0QHUU-D1;!@MD*6@X6Y%NY,[EJ!^CGB6U[)5VO)H)QP.;A2T:85-;]C"6BH; M[A22&@-Z]A-,]NVVZ96*5BX6[&6L)+VPTJUM8AN M8P-S81(/UQ&;9L0BI&6;@TNUPE[G1J?!B&#%RK;S6MI.\?O='<]'13O-O50] MW"U[-U0$:]2'CQ2?AR%-1)G[F3;Y+)Q;[2KCTFBL,DTSX]+4=Q0I98]TR]XL M" ^2^;^!FP=\#U=C9ER2EF6&E,I'<.? ^IY^6 ,P/8($;ADH=A3!M,V_%/E! M"MAT^$H:^RO&T))+AK!YIMUGDTZ5_=UA]U'13BM3*B[I5MQRV&6UT'=>4TU= MUS7K6UB-F8<]%[?T7JFZI%MUJZ.MB[(IJ%K*IIE'3-(V)TK9)=VR.^41]-!. M'38="PVKC"9+#]W\9,38K6N"Q@IV"J0N98/*D4S$DFUZ4B5@L!]BF1U,%$^+ MT[!)>@94>WZ#KZ;9F589)CMBNZ7)-H@%"MD&0AJ7+M0QR4ZMLH;D^_3@YYE+ MR:/T=L>HSQ)E /]O.%0C;Z@7%&>'X_\!4$L#!!0 ( !N!IE@E16:ZO0< M "D@ 8 >&PO=V]R:W-H965T&ULM9II<]LX$H;_"DKC MFIJIDB,W=2E4E<43+[&:9@BQ6*T("0'<^OWP9U4"(.9W:R7V*2 M:C3?QM%/ \S%D])?VZ64!GU;U4U[.5H:LWX]F;3E4JY$^TJM90._W"N]$@9N M]<.D76LI%EVC53VA&*>3E:B:T?2B>W:KIQ=J8^JJD;<:M9O52NCGM[)63YK,6#G$OS97VKX6YR\+*H5K)I*]4@+>\O1U?D]2S!MD%G M\4@(=?^Z_]4%#\'(3*36O4:M<8%*RJ9OM7?-MUQ%$#D@0:T%T#^KT-V*X!ZP+=*NO"NA9&3"^T M>D+:6H,W>]'U3=<:HJD:.XQSH^'7"MJ9Z>SCA^N;#_.;:P17\X_OWUU??8:; MMU?OKS[,;M#\MYN;SW/TRY)W8%?_3F6B7"$8-E?9"_KFI'D4-P7M'<>LJ[5S9M/ XY04I M<'HQ>3R.QS6C69I@>C [49H=9X8N'.TII0G!!!P%YS'C!:.:/*#U$E$8C>@=]W1BE M*]EV,?@$ILZ;$\P2.A3HFK&\2''N%Y@=!&91@;=:KD6U0#??@&BM],Z(S)T1 M-$VS@3[7*LU8&IBV^4%>'I7WT2RE1ON43A/"4XX%(CQWF.6:I7R;!/:+P"T,-58LVSV.T MKH65"LO&IJRU307!V;ES>M)I"6=\F+:\=I@414#V$5E)5'97$MG5OFGEMGN! MG3828:KF =52!*;MSN])3W*2LV$J\]JE) \D,]*#D$39 XO?B.:A@ORUFQ;A M3J:>0:[$W/7!*2.:(=3Y>)3EE#KKQD.D#!3F 221GDDD^ZX2LJ[$ M7557!NCIK2-)E&U_MY#\4=Y.@^Y)1^*HVP>]AD+-[LP@X]TI#6X@R[5HTRQ@ M4K6RJ91&)2R$RJ![4=K>>?9VC)>W"8,LR&<7C,. VE<-HSD\:9>;6O1=?B>5N(&ENC>C0!(O MU/(?*^: MA^WF]!^D/.H"DY",'%?.NS!.QI< ML3T\:1R>[_\GN% /_3)8?DZ>\=BE:9X$]C:TQR2-8_*DJGUID;J(8R1A3N;V MF '0 ^<8K"77I:HA-;0__Y13DKWI]N+FV5OHLA]Z M8OJCO)W&?G1F&J?KK=[/^M;VPAO4*"BO-'H4]4:^082/,<9(;,Q2Z>HO:[84 MH,/:-1*IC6EA6[V E>WM*1>HP\09-3F-J< Q)'!4M:TM/H1!OPM=+K<]OS_?[PRO92E7=U*?_,3&"!RN M9?=!I_:2A;G\+HBS-CU&.)#I6$]X%B?\U0+P#>2#U6G/&\^K!I5B7<%J]0KU MH)P1S.FPFO8:0C>%*G_6LYR]L$W6@(V-?MZ.Z=@.1ZE: _.3CC/&=^/7#8=] MPLGAR?]AW%S4GZ=)ZIX1^PTS&CI_87U5P.)5 93$F]6F%D8>*F&HX;5U?ISK4O\6AY](<"^YQ"Y#5+!*]JWYRVR@CNSPF>89WEHD21]49#$BP(' MM]TT_WMA[%YQ_,'+?][D,?2?-TV.ON/:C^BP'!^JIH5"\!Y:XE<9](3>?I?> MWABU[C[MWBECU*J[7$K8YFMK +_?*V7V-_9K\>%_!TS_"U!+ P04 " ; M@:98??UKKD\# !="@ & 'AL+W=O8&9_S^GD/J9&5:+VYL6T5)9!2=2TVD.&3 ME9 IU=B5:UMM)-"X2$JY[3E.UTXIRZQP6(S-93@4N>8L@[DD*D]3*K_? A>[ MD>5:SP.?V3K19L .AQNZA@7HQ\U<8L^N56*60J:8R(B$U<@:NS<3US$)1<3? M#'9JKTV,E:403Z9S%X\LQQ !AT@;"8H_6Y@ YT8).?ZM1*WZG29QO_VL_KXP MCV:65,%$\']8K).1U;=(#"N:<_U9[#Y 92@P>I'@JO@FNRK6L4B4*RW2*AD) M4I:5O_1;58B]!-=_)<&K$KQ3$SI50J*^P_$7E->FX5\1S/+\E?7(\?0I1G=YIIMM8E;HT7ET:K]#KO**W MT%0#SEA-Q(J\9QG-(D8YF0O%BAGX9;Q46N(\_-IFM=3VV[7-XKQ1&QK!R,+5 MIT!NP0I__\WM.G^V&?]%8HTR=.HR=(ZIAP^2QH#++1)YIA4NW0C8EBXY7!'* M<1? LD!; 4K5;J%J-I-M&#B!,[2W^\8.@_Q^;U '-8#]&M@_"CS'C0"DA)C@ MZHF>KLB&2K*E/ =R@1,T%IQ3J<@&<#=+<"Y?MM'[!V OT8]%-+B#FCLXCYOF M.A&2_3 C!E05_&6S%;K4#_:0W, I/B_83PAL6.C6%KKG6<"#0VG<#5BV/M%# M]P#M)?RQB 9UKZ;N':6>B#3%]?P3LZ74[^TC73ON"^XW@AKH_1J]?P;ZV1.F M?U!*SW=:9\PID0T'@]K!X P'3*G\9/K! =/ ]?O^(7Q+H#/P7F=WG?]/3^>- MS1&HRN7WDO\MX$JLL>Z\7B!I=!XN2B:"=[_0)H ?+X20C]WS VCOE&&_P%02P,$% @ M&X&F6& /!2&6!P 51\ !@ !X;"]W;W)K/7W+YP,4ON:)4H<=U7LBKSDJIS46O)],572?R ]_0 M GZSX&*=*+@5RY[<")IDY:!UWL.>%_76"2LZP\ORV9T87O*MREE![P22V_4Z M$4\?:_@)6-K6DC&"R3HXJHS M\B_&)-8#2HL?C#[(HVND0YES_DO?3+*KCJ<5T9RF2KM(X,>.CFF>:T^@X]^] MT\[A;^J!Q]?/WC^5P4,P\T32,<]_LDRMKCIQ!V5TD6QS]8T_?*;[@$+M+^6Y M+/]'#WM;KX/2K51\O1\,"M:LJ'XFC_N).!H ?NP#\'X ;@X(6@:0_0!2!EHI M*\.Z3E0RO!3\ 0EM#=[T13DWY6B(AA5Z&6=*P&\9C%/#\>WT^F8ZN[E&<#6[ M_3*Y'MW#S>P>?GR]F=[/T.TG-![-/J-/7VY_SM#9]^GH^_4$;,Y1%WV?7:.S M=^?H'6(%NE_QK4R*3%[V%"C3_GOI7L7'2@5N44'05UZHE40W14:ST_$]B.@0 M%GX.ZR-V.OR:B ^(^.\1]G!@T3-^_7#BD$,.LTQ*?Z3%W^W=S;?1_63Z-QJ- M[R<_)O>3F]F%;9HJ-X'=C2[I"[E)4GK5@9J55.QH9_CG'W[D_66+\8V- 7.E=DE/T#Q07[D9)(<=B04EZD+*>H .&L5*R?Z[LTD2NT$7S'(#?1 M_ G!'BH2Q8IEM0DQQ:BTKF;XEJOY1LY.9BLZS%;D7,UK"DY3EE0[;Y&A9,V% M8O^5#VR15^["HS4C7AA%C96U6/E^0.PKVS]H[;LSCQ?=I,PH9<8I:M$ M+*EU8^H;&OI>%#2$FD:>761\$!F_,*$+*@2DTW.J)8]5BI5X/)O3@BZ8.K<) MC@TM71R'S:DUK?Q!V#*S@X/H@5/T#&:1=C4T,P2JX20A6Q-@8/S],!P,&B)- M(Q+AEIGUO9IHGE/FZ"@W$5\ U.=0TE)NDR*E(%Q"R>L,1L_W4IGE-8C.= K#)]4T#0 M7 :;$8[:5.):)7:JU+L_.EO"4?(JIVH=_MVRC2Y3 M:P#8HJVIW[3IXI9<]VMD^TX^#L>KI%A2?;!9P#:"=DF^I5H[@$+O_>6VPN$X MFY4PV.^+7*VHL!^ B"$R,*K69A0=EUT"FK<^TX^#D=IRK<:]L QRG;)/+?72VBF6Q3C?G.=+&:> M%_@M"U5CUG=S=E+L(*^X8'96^28PN_[ P\T3D\T.AT%K3=1H]=ULO1,4F'J\ M=3[G//0JP#.HB2K!K.I-BG9QU#=JP&;F'R'Y5'M-7-^-W-M29J&WSI>EFO@D MQ-@V+22./*^M6FO*^F[,'E)UDSSI/'T/Q\Q4;*ESVH^*V1J0B5K('.Q[S9@L M=L$@;IE\7#,9NYD\ADU3P&GY)9W8!&87@-7DJL4L("W PC56L1NK9H:\I-8" MSC@VQ)I6$%/HM50CK@&+W8"=OK8YL6JW@#7L&T2RF.'(#UNZ+US3%;L[XLGT MQ\WL-1TQ?M.6^*V\G49=@QB[N^*[K8!61%?P;QV"]EY/,R@,HK"Y6#8[TO?: MRK>F)W;3\T2WAM2^=;:*-=G8)7'H-;<:BUU;!=?\Q&Y^'BIB*\O>"OYIK:^H M!@LQ0S(P9]A&8,<,UV3%?6<]?)I,1]/Q:^K!2>C?KH I MI9E$"\'7:,X%>(#%*M,LY\6RJZA8PR+JCHQF!97VQ;/0NN]9,L[2%'O8:\NZ M&MC8#>R[Y*EZD:2['%!JU6@#<.B;&FUV.&@326H"$S>!]R);&F+KNT@3LDVU M%I-N/^S'+6)K$A,WB4_V&R6@R]V*)R053W]9E9J$-93:( PITCJQ-86)F\*G M.4P?J4B9WGU*M8!CW1O:Y]=$:V2^0K!88=+V]I,?G5LG'L.=OO^.?H M\-KFA2V?F+ D86SV(Q:[KA_A*&XYOY&:JL1-U9O%@J9E1=+'M'K; $1EYB(6\PB$@S(--L0/HMP=3H)2^CEQ6I*-](G66T MNCK7B?5[0=A>"H>AUWPE:['3G0(>M*"8U"@F[B9WW"87)0K-Z9(5AO@V/"J_B#:>?_0OQM47WMI-]<'Y M:R)@923*Z0)<>A_Z,*>B^H9;W2B^*3^#SKE2?%U>KFB24:$-X/<+SM7SC?X# MAR_IP_\!4$L#!!0 ( !N!IEC"FPZMB0@ $5" 8 >&PO=V]R:W-H M965T&ULQ5QMDFO7%R M[^S2C*55RST_)Q4JU+&B]:IU4V(8;A M3%9QFH\NSMKO/I479\6FSM*YH5S^TOE]_*MG99(>R2%121J'UN(_*7VN]HY1/^\0MZV%X\NYC/ M<46G1?;?=%$OST?>""WH0[S)ZMOB^0/M+LAN\)(BJ]J_Z+FS-48HV51UL>J< M60M6:;[]C+]V';'G@,T##J1S(,SRSMV,K]C'[\%UW=S=!.BZ8?+ZRB8HZMK M-/]P>1M\N/DX"V[GOZ#@W_=7=[^CD_OKR_O9%7,\16-T/Y^ADY]/T<\HS='= MLMA4<;ZHSB8U:VX3=))T37N_;1HYT+2[HHXSA=M4[S8M5BO&\7E=)%\4WK-7 M@K+Q7&W*;P?] [W_Y6*1-F,LSM"G.%V,KW(TC=>I^DK"5["29+/:9'%-%^BF M7M(2L6MC!6?95((GBCX6E:I;(SWJ+:U9A6*005SF:?XH0$P8@78L(CL6D1;3 M.H#Y/L[B/*%OT&?ZF.8-*BH>T)J6:;%X@TX8#ZIE7-+J%,4UFM'D+3+Q&T0, M0E2TT,9J:O.[:ATG]'S$^J*BY1,=7?SK)^P8OZK(L@6S6["F+C]=^(;E.H9A MG$V>]GD!&36 ! LAP2(@,(XFYHXFYG?3Y"AF;.&=O61BS[ LP^1S.97M?,,6 M\BW;C$V'> [A[0)%3.(ZONOR=J'"SB".$#62K3S7Q]C;F7$=:^TZUOJ!\5>_ MU+2JJ6F#AZ,V]-#A" DVLZ2Q/78\8DIC.X",&D*"14!@'&OL'6OL%MT\P)JK M/&F80=$)XT![=-I,V>W,MRRR!2TK-L7_L4GK;^A_MT66(;;Z>X[+Q?]5-+$A M:0()-H,$"R#!0DBP" B,HY*SHY*C+4#7[*;II%F/G"+&JF)%50QQI.%*+$(< MH79K PU-/218 D60H)%K_4LEU-WEU-7F]/MDC/AEIQIFUQTDC6I?H-REG8V MT=3Q5U6^7;D\F]CWA'QK&S$TWY!@ 218>%1G1$ AN7Q[NWQ[VGQ?5=6F644T M&4VV-U';!4.]+(O-XQ+1U3HKOE':?;W>E,FRF3[6;/&QOZI0<4$;>NCLX,ET MQ_*"'C)D D60H)%0& <9?P=9?R_CC(JFOA29C$VA)7V5-NFH14#$BPXIODA M9,0("(S+/C9Z\T7BYI MMF@]V7S"OGJEHNB;-K2D=&C[J3.Q0B50V"G, M#&A:!H$10:SYD]P1'_8YQ1 M\@3+,Z]E8"P4E)8C9EX5SK.%B3[4=]+@E *A\2GMU3^LE__F M33[&VU0UZT6V6(P;$529#EF0,QTY&T3J:B)F U2P4S;+\,6L@4IQ4&A\UGHQ M#NO5N,LDH1DM6WFY&U$E?9FA%^A$5WNUR(-K+R3:K$/C!B#!6%X@!J!Q0U"T M" J-YT:O)V*]H*CGAI(2"C$.VYB(O3[51QZ<;4N6<3'V'4G&5;7/Q+8I%690 M>0\*C4]C+_!AK>C3Z\(T7^Q)[8("_%M<[A1@4YE;4&VO0^.W9#PLR[8ST+@! M*%H(BA9!H?$\Z=4[K)?O#O#D*&[(VA-V7,L7!]:T,^0W93PQX[(16STQ0$\< MSHJPQ+*)+]YM*0Q=PQ&L(H65;YBF9:DE--QK:%@OHOW(SLSK?0^I4$U!T698 M(7AY/O84TS"HS@:*%D&A\>SI%3FLE^2^>U]=31=0$0[+*IQO^&R^E\LXJ!(' MBA:"HD50:#Q=>C4.Z^6X(?OK:H;X\DVP[;F>9XG%7#;TQ;NEF<)H[%@ND==F M"MW,-(@EA@T5ALTBTW#$\")ZP0MJHUW9^T36EL:8N+9\ MZS+5-W-HK3X^< :. 1%BZ#0>&[TPA;!?^-V.H$4B*:@:#-0M 4+01%BZ#0 M>$KM/5:G%]:.VE8GLE8V-HDG2FKZ4(,I /NX'.SS%1_1% Q^:SWPAK1"VM_Z2:[/O;@.4-6 MS!3/ULU @P:@:"$H6@2%QE.G%_.(7LP#WVPG"B%.?&!UJF_4X/H!JN@=XE'8J3;<01L7@J)%4&@\9WH) MDN@ER+][PYW(RA\Q,1'KBOOJ#J_"Q+.DQ,O1L.4:8A$ 506AT/B$]JH@T:N" M0[;;B:S2V8Z<#$_J:4M,!JB(IVR6N!L0@L:,H-#XK/7B'-&+<\.W5(FL8DFK M>]!GX4#1 E"T$!0M@D+C7X/J943S2!GQZ'U92_DZ%.@C<*:L OK88A57FI-! MXP:@:"$H6@2%QO.DEQ1-_;-RQ^W+JKFA>)[-]EW?%FN_PM#'TLMRLM'8L1R+ M2&_+*<*:V+")]+J< A$;CO@\7:1JGF7:[H$WYLQ>6S-_Y)W5XW=FU;VO$(TP M<4U;EO+US1Q:PH\/'( &#D'1(BBT+3^_'-S^PP-+'4EZAC#XP>..MR[JK MW/YFP?:D+M;M*_.?B[HN5NWADL8+6C8&[/\/15&_G#1OX>]^.>+B3U!+ P04 M " ;@:98!S[KGYT+ "-'P & 'AL+W=O5-5[L^FTY?[E=1F=/*.GUVYDW>V M":4VZLH)WU25= ^GJK2;X]'!J'UPK==%H ?[)^]JN58+%3[75PZ_]CLIN:Z4 M\=H:X=3J>#0_>'-Z1.MYP5^TVOC!WX(L65I[2S\N\N/1E!12IG=GRKSH/Q?'H]4CD:B6;,ES;S<\J MV?."Y&6V]/ROV*2UTY'(&A]LE39#@TJ;^+^\3W[XG@VSM&'&>L>#6,OW,LB3 M=\YNA*/5D$9_L*F\&\II0T%9!(>W&OO"R>E\<;$0E^?BZOK#XL.GF_G-Q>6G M=_L!HFG!?I;$G$8QLR?$'(I?K F%%Q],KO+M_?M0J=-KUNIU.ONFP%^DFXC# M@[&836='WY!WV-EYR/(.GY!WZ=;2Z'])@L)8G%GC;:ES&9%ACFLYR=VIT M\N,/!R^G;[]AWE%GWM&WI']_&'^'&/&3,LK!$S>%$D&YRHL??W@]FTW?;M28 M_SIXVSZQC7O\J/&/GYS9JI;FH7U*[D]O+DQ0:R?;-TA0Y42P(CT7'_5*+3*M M3*:\^-F6N39KCVBZVKH46BG>JU)NI%,BVWJ.4S1BZ)NEU[F63D-$8TKEO0@% M+<89]P'OUVOEL=#BJ=MHKR8XGI?86IL$CTH:E"Q"Q9A? :Y9T>$5 M+>!QY3R%Y^#56Z%^;71X&$,)CQKH:0>:172X9X=GTA=BA<+OVS-3["?B3#DV M5IO86=I$7%D;C U*Y-IGI?4-I"=K8;DV6=F@PI!*.WV(W*JA*2^0&1"08XU" M40V%6$<<0PS>J)KB0$L:PYZMX<9,UV6TEW3];#B$7 0A831G^;SJP30YZ*0 M=THLE3*#0,/CMM(A[%:"!&N#,M)DT4^ -_47<3#=^S-[X+HI%?V:'I#3KM6Z M*:-[%GM_FU 2>O4[ >8+VY0Y]!74OTD[[/G2F-@@._4&^8DP^^\03"BCG0]* M.J&H!2 +,U4MD;XI*0ZW8K?KF+DQ#<1>*R0MX&B(43JF]BIJBP")M\^271Y6"ZA2=V6:L9I#G.I/$5MJL::4#*PB>NJ_! M:BJF 5=,_O/ =0^H8&2$4D=P4!&CL6FT- X&>\'I8_4J>0M MSD=MJCA)"+_2@^'5"=R%#$*N5M W&4+!I<2K*.](.2Q7(>XLM5SJ$I5(^5A6 M>^\G,\C7=/+62MJZ0SC7'*?NE&F29N0XI(J?B(5>&[V"ER%KH#TKRM4T2>A$ MPM-)F1[ OR7U!IBR&\G]BZ*7VV895DW9%B(Z,5/Z3BY1 TAE+TM&7FA^AI!P6-%F/6FL5'QT?-DM$N)(Z40!NU ME%D"_E>[Q^P5#J7K - Z- <.[9<(U4$G:,AC@$[4EH.''4*C&F@7O05%2VO6 M>R7G[P A:VOSC2[+\2!J6+SS'%J?*Z0"8M&UER=M_.J\,:):U4U/"8.\WW;G M()8X!%6>]JXE57<:#)0CEV%7)Y! LQ4-T/OL=H^FBIQ/ YH27=E:QH4L%H38 M.E+5VEKT5'9PIZ?^WZ$C5\LP%!1SSWK?RP#'\FVO&>0'\C JBR,+,!(@+ /. M*:\B'D6&B8_L2IFW-5RO2*VR,4^;"L^05/)2,Z\;_=7SAK\G:7\!,6+E1E5 M>1J=UH\ @VT@ R:7#J YM?BO8P7G\\5IQPHT[(5A\\5G%KOW\C3B7&46M!QR4^, ER4%#D)\ (1ZT9'MH*M;UH3#D!&OLN$108& M2(2UY+'[3I7@A\E%W;K63P!8^X@R^$[GE,V,DP2J7'?X5/=$V1A"7)+JNGP@ M0ZE'$80(NC2: ?&%RM>Q)T?BY M=IS81\8B%2+3$OV+1CUW==192-:.?9*%& MT'H]ZF+1L)(<7'Q)R5>S: M*([4?V,!>,P59V3JXX=',7KS$EXUL;QNZTJC9<547M%@N7:VJ6.[H7(,>B?= M+=0$U0H:HX-,0QQZ;X03#Q&3Q42-E (V, MK:4:)&H*#KN)IC\\OKR# 73]U)8"X&P+&(O+\QX7D"D%VB B:I>8&1_'60[\ M :\QJ$!UNP)Y%-GW>$CBB8*JQ! LO_!$O, AN]Q@48E0&,Z/EDBP5\"^"2'(](^(VL$1>\>!17XO H'S<*E8X/)VUK^>![ MG;A0N#@64==>88"PB:(/#*$C_ YS)MVE&!4)ON6.!5WF:*'IONIQ*TUXZ.II M"RJBU)'.[G E&[FK?;4=CAK'F)%J:8Q6>^CCF*\2D\T;+B-,Y_@^J1V?AO%X MPL"M1G/X9*,YW)O^88SE*)1*W!!-;]O+JZ,IVLM%1?0BP9ZO$]N5XOU@OH^^ M4*:(G)['>$HFNE RV4.,#>\D4C^\&4 .P</Y[,$8*AY: M8VN%'PGJ_:#2GP3YF(SRKZF&&_8^(D4K'(F3Z1X .BD$S+!"*X2S=^7!B[: MQ_LV%^.MJVX>HE#R!=MO$(=F^D$Z(I5YQ!U5*@B,-V%?*=]?11%CT@0#%9SU M=4L;& MO=X%Y+B,AZ9VYQ#0;7HW=1H4"M&?=Y46^!7RYI)3W M@]N45G!_U_)_V/[OP?:&>UJ\G!3M#)'%LQ)NMZ[.MV;I;L0?SAE\4TZ&#<$2 M35BY%P\>-O_!%LS1]"0 & 'AL+W=O-_J342DVN$3_4-Y96O5;E%06J)TT M&BQFXV ZN+P^8?E:X+O$G>M\ WNR-N:1%XMT'$1,"!4FGA$$_6UQADHQ$-'X MN<<,6I.LV/T^H'^N?2=?UL+AS*@_9>KS<7 10(J9J)2_-[LON/?GE/$2HUS] M"[M&]C0*(*F<-\5>F1@44C?_XFD?AX["Q7L*\5XAKGDWAFJ6-\*+RUV"=/;&[A9?)\O5XO5P_U\ M.>I[,L&"_60/=]W Q>_ #>&KT3YW,-#ZY^@\R: N8^EXG1C7"/\%VU=C*5 M-%B8Z>\FUXY('XNBO#JL>D!##([B\],PHEY2BMV2&A+A$D7YUYL>8_V@ MJ<'TFA9DU+*R24[]#Z65"3F1_J C]H**B>M'T(A)TSI60L%1UP81]03,'E$-F2(])+,:>[ C-W/8"7=02-D^N<'<&KYA)R_2 MU:'>TK M*2O,B\@_(J6"K128RH38D03YX*!R=8)@+FP/;HTC@ZO<&HK%(?SS MVU4;^-*:!-.*:KICDD\'YU>.^#N:A([-L&W1--*.0@!KI-/26-]8ZU1)JSTS M:4$17):82*'\,RPKNZFY-IIBK1 <;NIXU17 **GP6$?OI4Y#^*9A2C%2L)\: MK\O250EY[K)*J6=*3%$J9%I-2EY5^R"*?GE=]5P^HJ0P/$FZ#Y CN*+^-_% M]$X%=4J&7*GA?'X(2%M>+]UAD>J!N9GZ:J-4$WHI/05E+930G$$:4MIE:&TC MU_$TA)6!3"12D0:%B8_V_NX=?,/G3A=V@Y9:NE[;J%O<&K5E.IR9#M@2-9?F MC,A(#Y\;VZ1=619F"9^3&Z.X7;*!]DDW^ 5!+ P04 " ;@:98D::1-F$+ #^'0 & 'AL M+W=OUL86L\-5NCMS.*IGQIB(_ MFHQ&\Z-"ZG)P\IJ??;,GKTU=Y;I4WZQP=5%(NW^KQ ?G>K.MZ,'1 MR>N=W*@+57W??;/X=M1(R72A2J=-*:Q:OQFN\UG025;& M_*0OG[(W@Q$9I'*55B1!XL^5.E-Y3H)@QI]!YJ!121N[GZ/T#WQVG&4EG3HS M^0^=5=LW@^5 9&HMZ[PZ-][X?W'MU\X6 Y'6KC)%V P+"EWZ MO_(F^*&S83FZ9\,D;)BPW5X16_E.5O+DM377PM)J2*,/?%3>#>-T24&YJ"Q^ MU=A7G9R___W]E^_O+\2'\Z^?Q=G7+Y?GIV>7%^+'I\N/XNS[Q>77S^_/+UX? M5=!%.X[2(/>MESNY1^Y4?#9EM77B?9FIK+__"#8VADZBH6\G#PK\+.U03,>) MF(PFLP?D39N#3UG>]+Z#JRM5UDJLK2G$&6RU2! XO]J*,W:[LN*?IRO'S_]U MR %>_NRP?"JFEVXG4_5F@&IQREZIP&]:0B9$QJ5CG\% M&86?9$7001C@_$(#/,F4E6P1/3DSQ4Z6>Z%N=GZ5(>L4L()DJ9MT*\L-\@1: MJZUQJK5#EEECR%!\4Y8QLDR5^+K*]895.''9ZOCUE^5DO'CEQ*ZSUG36LG6N M$H2F.;LW.L62@SM>V1B3]2T0.!;BL-9PE2[C83E]72)VM<5!8+VQ.#T>X#BZ MO#+>]HZ- JM$:833B,]:IQ)N+ !Q^CF0%&AZ8M50H4-F?!+0WC@[2OMV#LQ+P[H9G&=I H. M<+)0Y&QM,I\+]-#;L \6M=&$#<[D4+_OYD43,T*"2FUT*G;25B4?N.LWU1RX M9XN+^O#(I[_7RVF?FJ*H2SB,LY&/%'RB$*(M4L%8_)KC/+[_8EG"\GVV0HZ3 M.96!564&@][I-9)%E90/*U5=*\6-KX8(JW;&THZH(6PE:3ZQV4/7JA<+\HK, M_H"?6Z\&A^+;]5:G6WJVAS8<1HF?I;F&B?X'%'JUW]$!; "" M)F#T*!PL\*!-BH;B>T3WG@18)U*K,DT=-\\17.2*JW%F#[,JX)L7B,=4&J25 MCQ3 '6HRN7>^@W.U;_6.LJ:3?AN%0N7T>S'BU4/QJ20*,4U$A@ 'PZ],#HG4 MT5"W6$ZRZ4\##H#JFD);6ZH)CR-O$3?#$=>YKN!Q7:9YG7$GM/JSK*R^0<-? MS%XE:)AVHS\C8^(#]$* V(W6TY>^!R/, ;K#0)P+ :93/!DOAPL0QSRGP#5@RGZ.V1!*9BA.&6/!M."\2+7Z M*J@Y^,!!S9/QO",;KNS#\19@BD\03^V,W!+R(] A-F\R'$4)_8I&G5JUD3;S M?5L!U[CW(S!BK4LDG^^(!1*,NI)>'^KF"04KE@T%2.U\_C7=((!9!,L>$:%3 M-,6WDWMN?_T,[7*1F,HP2.R5M/0C2NOQ_AHZ0X\64;2\1M>B$GR\4I&>9$ . MRZA=MBKE&JCZ")TZR*(Z;;QAPZ>.RPU>^$W+%6=Y)'$]6YL*O,-SK+XB%,SE M2L$UA'GPAW<^P2$!>P">["Z5DSY['-@'61X5^DSRO=1LQC#4N%W(C55,J2#LBRF?@ZAB@5SEA[$ MN$C7.$JZ7GDXF.S6Q,-"#1RDHR$BWE/$>O; "$$T@@K>K-L\DW[&]CV7>EXJ MJS:D#\A?J<:6)C+KFG V5*:[-2Y(UP8VCUGI*ZQE%Q4[T5\T, ?C8#*1=[?) M<4@/ST=CEH=8NZ;:JRV)'UPR$-^JJ+.> MZD3\ ]V%FD\0)9Z(%\ED.A67D?P'5UJ9Q>KW64)U]T":KT!72T;>$"N&B%L; MGK*N9W>,*E75&T .V\##7LO*L]I&6A.R=)',%LL[PON^PX%O+6OQYNQ.L _Y M:SQ/)L>3WK3)B!$&SOM\TO='&_ZGT^1XTO5)1WGP2Y3=A^R'/#%)1N.%^ #, M!O0'X$GWWL&Y)U9/Y_.O\2R9+Z?BM#K8KAVH5O4#%< M-HW<#P0 ;5-N[LAX,A^^:%?:OF\CF$;9<<[S -)Y2B3344\#O.7,G!Z'V\?) MB>YWRB8R;;< >=BA =XP!P. M)P$J$C_4>7(<:5 \6=/-8P*1FQ1W<,S2(+,[6DT._(C_M:N+=_G4M.POFEPT="=PA 3@>?:/Z2%/1R",V4K M9$0\^FWN5(!ETZ"9J2L_E[7C!7)+TQR*CVZ/R;SP95:JVAI'DP;M"[\D;&*F MB&]Z#WC&$K@3%7G3:S\/ ]0'?<[:CX?XSZ70-"+C#C*'A0 M3E-+@RVI\W==C9A#-Q0@'37"8U\'-FIZ'?:R];;&Q05\@^",H.D5:[3^?\#;L@GH$L'\31CDABN,/I<\=E+F$F2NF]. M;DMZ;,54?(DHH,"0GM"S9#)?$F5X,4F6BY'X5+K*UGY@.)XEX_E<'!]CS;PA MJQF*3%Q0J M6$:AS!3@..^'N'<5S5--ETO%I#OT0N>H\TX.:S;\YI%F%\3=OYYKGC8O-T_] M.[UVN7\SB@"#LSJ1JS6VCH:+XX&P_FVC_U*9';_A0]7!(/ZX5>#IEA;@][6! M/\(74M"\\CWY-U!+ P04 " ;@:98]!^YG)4" "1!0 &0 'AL+W=O MQ!EER)87 WW=E)V[:">G%WEWM>WHK:7>TT>;%EH@.WBJI[#@H MG:N'463S$BMN3W6-BE:6VE3FU MDT+AO0&[KBINWJKTOE -!G5?(4/Z+[7]X:\J&,I1(7*"JW MX'(<7"3#:>;SFX0G@1N[9X.O9*'UBW=NBG$0>T$H,7>>@=/O%2]12D]$,GYM M.8-N2P_:,IM4&3.*'\I3PX0ZN"<&YR<_=T=??X;7YS]3"*'!'Z<)1OP=,6S#X IW"K ME2LM7*D"B[_Q$0GIU+"=FBD[2GC+S2FD20@L9MD1OK2K+FWXTH^J4Z^HG#;O M,!,VE]JN#<*/BX5UAI[#ST,5MX3984+?(D-;\QS' ?6 1?.*P>3SIZ07?SDB M-^OD9L?8_W<91\&'I>TQPNXP!-H0%/5[KJFWK,,"]!);-1=MF M?]+;844GL1+*@L0E0>/3_ED IAT K>-TW33=0CMJX<8L:6:B\0FTOM3:[1R_ M03>%)[\!4$L#!!0 ( !N!IEC]A->,! D /@7 9 >&PO=V]R:W-H M965TKA- CA)9Z9 IRV: M[/;#8C_($FT3E40-2=7U_/H]EWKX$2=9S,XNL!_:R!3O\QS>>ZG+C51?]9IS MP[Z71:6O1FMCZM>3B<[6O$SU6-:\PINE5&5J\%.M)KI6/,VM4%E,?->-)F4J MJM'UI5W[I*XO96,*4?%/BNFF+%.UO>&%W%R-O%&_\%FLUH86)M>7=;KB]]S\ MK?ZD\&LR:,E%R2LM9,447UZ-YM[KFRGMMQO^+OA&[STSBF0AY5?Z\2Z_&KGD M$"]X9DA#BC_?^"TO"E($-W[O=(X&DR2X_]QK_]G&CE@6J>:WLO@BGUI9(;IF@WM-&##=5*PSE1$2CW1N&M@)RY_N7CQ[LO M[]Z_9_,/=^SCPZ]O/[-W'Q[F'WYY=_/^+9O?W[]]N+^<&%BB_9.LTWK3:O6? MT!JPWV1EUIJ]K7*>'\I/X.'@IM^[>>,_J_"W5(U9X#G,=_WI,_J"(>S Z@N> M"EO*?".*@J55SMY5)JU68E%P-M>:&\WNA,X*J1O%V3_F"VT4R///4VEHK4Q/ M6Z$#]5K7:<:O1C@QFJMO?'3]TP]>Y+YY)H;I$,/T.>U_&KK_7"L;TG>[1N:X M9J)B9LU9EBJU%=6*I:5L*L/DDJWZK2@@=H]9*\Y?E<0/5G,E9,XXL80!XVP] M@,PV'-E/->0*5 []FMWA(56=+=EH0*?9KQ!:-YP]\&Q= MR4*N!+Q[D"8M=DZGAMWQC)<+KGIS 3MC410YLR#&4Y D3NB'>/(<-PR=:>0S MU "<\ IG4BE>95L&4E2Z2&UM.9\YD>]?L//0B=P0?[W0\?WXXL#F47PP&,9. MX(76H._,?+_^;@/'V$8L7.Z97OOB%92-E?WIN+,9OGN:"L MD1N.=:(/LTRW1 EJ-10?R%%VH8LE-#/^C4*0&3#0#'%E0F5-J0UYJUEFN0B% MR'4FFR)GM300$#9>Q?,FX];<$LE@W]("- %!4[RJI3)$VP:)(\5'67R<;;:@ M=L8$7#OB_-@"-RP.9G@*\(\L"8T&@C!1UV%CL27=X!B])S\[7"FEA4@7HD#: MN';@3%8T>;^+?Q?:JGR>'LBTI'.C^9$7>GR":D>L@6M<6%0[>&R\1!OXE%)? M!3:(M#T-D+7OD/KN)2EMS3PA(BA,ZZG6UB(RMD31E>H@WJ/\:3KU2[ 2,XI* M3;M#HQ]K*AP;3KF@>I&CCRIP#6/'5VYL?E:\@DC!>"8K64(%_K:T;#,UX,(V M:VXC;_$J40: QE<.2H%I%:ND:2EWR"Q]DEI0@#.C6\D3Y-F/M8?S$!XZ(G:D M(2<7VSJUVJ#WB<02D%J6W(*"?, KLGM$ 9N2_N0]A]WA,L,_@FS5*_9DLY2*7->.$BWR*B,H0I!UNJV9P(PP_J>17(9T3=E M;5%#9G).1$4[P#1I261U.;0(9^!;E1JT=(>EP!#5@KHZ:LP?[=EK4$24P1AK MMF-VAQCL>4%U?%6C..)L A;#4!4(G8TVCRH[GWLEOX\Z^;5?M'% *JI8BC4*$1% JA% MU8ELV28Y= MZ:(< $0R$,P2W1Z2)T:\XYGX:*8\.2)_L3=3@'F+&L+FF)Z0:DN$#VB&Y$'! M;?7H\[%E7L*VG!310.J[,PRG'I[/IY'KA%,,N&?O-$08_$<< >%,XB]64]62CB2H6:J9F_#=J#L5E 9CW/29":.?51"S,V]/LCW!1\FR-GZD=V-^X$4?LWGCG)S&: M9GX_\=KWKN_COC [<1OY[P#I1X[GVU1.I[CA>#,+9!Q;)UX"TIL%""*DNXWO MX I[P::>$]-%Y04(9PGD?,"7.'$XO6#@D/<">%X,G@3> %S_^R78.M (,F^: M7,!YQXV"4X A$XG;@@5H$4@8VQS%/J"RE\#S*(*T.^V@ HF3(.BNDCC_*!9_ M#!7M\4D]N.VRLOT:B_-\YL?CF)68]J 0-<06![2:MLZ@FIUY\3CJ-U@1 MFX&VYQ][LX<_?;#:OPSH[G) 0V8[7&3$I>Z>COXIBWS,SN*Q-QC;,T0![34H M.^%FIVASD! 8;%L6?2/,L=-6L7T?]G?OQ]*-(+C@&=Y;[$9]V!G_Y6 $'1CN M+M=/@1'^C\#H>LQA O^*W-U89["Q&^U><3OB=)=H.\DXAQK[^>=\=T?I4M)U MSZ=BN* IAJ3[(77!:210\KL=2'"3.HOV78YI.=F=MFXYH>7I>':T/+,0G4W=8 ]QJB3?LU=[>]_28.=JY$19?&)43=<1R.F&J_,[<_ MC*SMM]V%-#B%]I%&$:YH ]XOI33]#S(P?.R__A=02P,$% @ &X&F6 ^Z M^)S[$ #S4 !D !X;"]W;W)K&UL[5M;;=6&VLL)7\W!N2Z-DRI.VV?EL,KDXWTJ=G[Q_R\^^F/=OB[K*=*Z^ M&&'K[5::W:W*BJ=W)].3\.!./VPJ>G#^_FTI']2]JOY6?C'X=AZII'JK6)2&I;%5L_&1QL=>[^RF]>#ZT)5Y,#$V9^PHSY=@LQ MEQ]E)=^_-<63,#0:U.@#B\JSP9S.:5/N*X.W&O.J]Q]_N/WE[7D%2O3]//&S M;MVLV8%9<_%CD5<;*W[(4Y5VYY^#@\C&++!Q.SM*\$=IQF(^'8G99+8X0F\> MQ9HSO?DAL=2J$A^U3;+"UD:)?]ZL;&5@ O\:$M;16@S3(K=X;4N9J'?_'/TPO)F^.<+J(G"Z.43^X <_/$C=PCA3_5Z(J1+51XEX]XMO&O5"I MD'DJ[I2M9(4O]RK7A1$?C$IU)6X>C%(\]^=<0/O)1LP6K/[YB&E]*+:ES'<" M0Q2F")W[1:Q?1,;5:1GCEN'O9S3LCW^XFLTF;SQID&W8Y5?3-R]%L?9LMSG[ M)!.=Z6K7(3,\)!)ZTL20L+L\U0G8(,H95M/Y WPV_VK=B%M\I%?@Q&#<2/PT MOAF/A+3B)H5O:3(1"A+0#M@35R MFO*#$_@-V6$M,^BLE#NB9X,FH.JMR J98]RV+'*\&[%ZVR0T[XBMA*'UUJ;8 MBK]\OOWYCI:^__G3W2N-H=_EUD"/VT%6NW;UK9U^),O\2.G5Y>+L<3!#9'II'?#]TY\<^T&ST=S^.2 M1CT6V2.139Q5-%.>-AH; #&R.H6EX,NG.6L99?ZZAN_F$GUY@!KWR,^Y567F*X3WM!DF32?A! M*G>T44J"[MK)]*N7"6, 5=;T<4&D LG;PAC6@A4UO,4 Z(X1ZX >'@*_2VSVHK)>#IY MX3ZRGY9EAM!%GL:+G!F9/[!OT722[843\G+YXN5(0!RMG3%N@$\H:A3KUWC- MQ)X8LU"B\/L*(S,Y/1.?%+0"]M=0C^6E.$Z69/- &ZF DQ"),.[.)<888G\" M'OL?X+%1D&(Y>?%&S-RZ"#$0+P1HXP/V8'1^0R+,W33$PU=;PATM_3%U%MM) MV=,/G!_9GV!;*HI\<..>=\:SX&[2[8%["D[/Y,ON=-(6NV4*_*'27%E+DRBP MU#!.3A 9/4RDI> (8]%6Y$5%P>3?9 449A&DR=2@! :NGN_:*M[._!'O7-8G MXZ;, 197/4Y^N/W\R\>;3K#P.Q92R5&PL(<2VLFX_S*D8=A;B*DEMK!(2?!U M41MF324UY]:NAUKAK8 #JM?1RV[&>D+ %4B58!'_Y36'PRTB+W.V5GTO@,LL MV0LFX_F$O.!_M_^C,-/GPR;7D;2K$$E:@>1@:G)R'8@SFGC),O !A]+_<3L& MNZ"<5"$'(.?BGP 5I+6J 0Y]H?XVOA_S7)UJ:9!P1\ LE Z)*<0R4A=)X*@\ MQU;+.!]!K8#+-9F)["8GZ$";VZ0I/.9@V GWBRZVI/RD'=;)-*=@!^0@)=M" MI-9#,++4E5?1Z>7X(F9DT(*Q*T-XU3-(>U#8RJ^3Y[X8Y'48O'%Z3*3SM*-X ME 1],@4'J[4XG8QG<6%,1&GP2)K)NOSUV4@!%?'%)7>#.%^4IT[[X<*A16GB]FDA:)H_.EEZ\F(XDFIN #.@(^*6E2,= Z9;5F8YQ7R MFUD=15YM'_ 5]1 C S#XN;VAK+N7SKI(&10NQE@Y@_B_&<$3(!TK -R6#6I8>,T)P]%1:IRBG&=8+:2&3L5=P>< M"ZVE-O#AK&9UM+6_:A#144YBB!F28<_?_9Y?+!N5$".(*2U.GCA)$;V0IVI+ M+$F1(E=0S"7)*&.N@:'(9576Q/2@BZTT7U75W7/;+4Q:L8?58 E"N"-#S7TX9:I4/[P/T94"&BULI7- &2&H4!JKU?%&L0?0@\9V(6 MM-N2?Z-AKM :F J#/%NH$*GCD%?A 4,&8K;%7,BY',L)(@2N8&]*$TO0HX$- M(C0Q@ C??&E)U'@4B(>X&%-Q]'UE_'/Q"RRF->VAKQ10(0_&HR^Q.K\+RXJ/A!J,==4@4I D MR'ZGJ"6;QLRR$*=BNA@MYU-7=\WGH^O)A:NFYE>C2U1H^'PIEO/1[&KJ5.<* MIXLY39MA/F+W:(+JZ5-=45,MNEHC?_X[Y=_SYKX;8SGUC0*IJV1;K0AQ.K\> MSV,(#MY@^O*/Q.ER,KYJ@P52!!XOKL;3WN,+>MQ.5.[QY'V-4F] /Z )USVU%@RF+= M Z(;N.9_'!IJ&G&Q@J >/@H-"+!2;/2@?9OI[G:KH=3BOV'^!$2K&P'[V3P49VL^06ZT,0-E.N-&3 M+F:E;A$%FF4'QQQOG^F**^ 7AYJNV^I4KM) RR-#@DP@P(P1- MKE[Q)4/.(K1!XJB48$Y90\7.8 V^IF1ZO.4R069-&W@?/"&&RT8>J-$M'NJ(^NPO 2V.&,3>FLW>&_#EE.12F5M521?&U^6Y!"ZBN' M;,O+^758@/;L=,JQN&]O UH59ZXA&M&$/< $YVZ:?WHY'U]<\C*\XK[A>1U M(&6:$&_$V2PN'RH#).^T8>.(.@>T"6MD+V"X!%N/?;[KJ\A66*?%7D3= M/7*>81EZ)OOM74IC.;DX1)E'41H?R#(7W7.F1PG0-2,9FZ1J6[KSSV-T,>=L MP:2I6G&X%5Y;,AHF;>56)MXK$GC*<+5$\3\/,EI7EV@W2WW3C!)#X[;GB-WR M)BMH!RE9MMQQ3+$Y0K_KH=B\=U;UB4OL^[HL,TZ$T,CG('0H" JC'S3I*JI# MN/+)(;]^-NA$Z$@LGD2M5/5$QMIFBV3^ #W0253KS*DR!)SA]0^N[>JM=J^Q MW$J.[4C9[HAH0TF2VIY00N90$CD=1%1T1I'S+A[L6M.X9%,4V+)RL[,,V0$J M*JMV*N"M@T.&_#GAQXI&&I3S?/[@@?] T).[C2_8%>91Q9T#WT>@=EA8WSOF/4V>9.0.OE-<7#^-T\'TQ!5'6 MD0& 0@P-Q9@C,!9_*K+4ERB]B;Q\/,4SW+N'Q@R"DC:=/7>/0Y9FU;B\13U% M4E,7DZ(Z;?LHHNXD1EV\Z\OD^_QL[DEB:N_J=(L!ACN!Y3/L0A1 D^4S1T\E0]UAFMG"8E?7"-00$ *RQJI]'W+$J5++Q M6G_:%#'?[6EFH*\8\/F^2#YZ&I]ZJ%0I!LZ0\;S)I2D\&$OO0O\^R,5:0\CW M>;2)] = 5/>@<\@+!L,HI9=N N ^*""AI".(UHL1G^M(H[.=[^.NUP#B7+_Y M%0/F"%8X:-+M +M1*0RAE+!,LC9 ERX4IJ9JA )[G+H&W631PH6A/#P420T2 M#-0-.+EHM?%<@[=(E$)E[0[JZ/AL0 D'%]CG3N=4UU#+Q&F#@1-[8^E)A87V MM3"*B720B4C:*O#?I^MM;I]JN$?!1X6 ?I717Y7'2!R/&%5%G-\FZH0,^]N9 M>7Q[&&EVD6]>Z5>ISFH'6R(.MKW#D-"$8W$*[N4-:OX84X/:.IX2;L7B M@2^+.P37P_>4!A>-\-!U'5TY-K0&]2!]]DB++:D^Z1SCN:H5>8E!&<'M5YA= M '7Q*;=FYY8.Q+LX6Y)G4!^6. UJVX(JTLZ! M0N1DUZO<8.-V#AFI;ZI1-<624_7((<)TCPQV M:J/!=LY^A3O.<7/XI@$%PKP/^_P[^NROTCHLNC<[]NNAB4,"\'8_T.F%T3;6 M=PX3QY8,G2892GH,B,,ZRE%NSNF'R]NV21XXO'9@LJV)5DT\H!6 ]S1H)>W6 MN+Z-=^Q")H6J>"NQ'8@BD>>N7@YOK@L*1ZXY,C;Y$?JF"XZ<9,!-G_.+7I6: M.RG[%PDGK?8]^,K54P-5W:DY@DF1:(Y!49:IN,Z5&3P04 ;:@V2/8NY MV+DFICOSR1] 9U@+C4%AB\-U&8^^#^AU+#[6T>)B80'S:*Z')+*$=BL?'MWQ M!#V'^-.V^'7>,.ZDCS@PW#$0,G+8J6YZ$N\+&H2)\T=!+5PTR-2U:_C&RPW2 M-3+N97/D_9TFZ C\/OO[W7=>Z;VSN@,[Q:2'6!.I3CD_=>K"?L/$71!J7_#Z MOFL048?D]J?7B];M%3Y9NKINBI6!RP,'LHD+CA3@CB64WW1!8NDN2"S'UWL7 M)(:1YR!+S^[O,$:]GO6.;VU[1>N.J*/DG+ZNB0GG& M'S=*PD=H -ZO"X!;_X46B+^!>O]?4$L#!!0 ( !N!IE@&%5L2CA0 !Y, M 9 >&PO=V]R:W-H965TBJ&Z> MG7@G[8N/^6K=X(OSYT^W?"6N1/-Y^Z&&_\[-*EF^$:7,JY+58OGLY,)[_"+$ M\33@]US<2.LS0TH65?4%_[G,GIVXB) H1-K@"AP>U^*E* I<"-#X4Z]Y8D#B M1/MSN_H;HAUH67 I7E;%?^59LWYVDIRP3"SYKF@^5C>_"DU/A.NE52'I+[M1 M8VX!/>"A!A^8HW_/G3NKIA-8Z& MU? #D4JS ;F\1*%<-35\F\.\YOFKUQ\O?[_X=/G[:W;Y[NK3Q\^_O7[WZ>KI M>0-KXXCS5*_S0JWC'U@G8+]59;.6['69B:P__QQP,HCY+6(O_*,+_L;K*0L\ MA_FN'QY9+S"$!K1><(A04>?7'%6 79:RJ7>@68UDO,S8KR);Y>6*7:"&Y$TN M)'N5R[2HY*X6[+\O%C IK-<(&-.PC[P1AG.?UH*]K#9;7M[^_6^) M[\5/),O;D36.K'/Y!8RX@,^2-17[/+V:LJPJ"EZ#$945J#9\E;%K7N=\48C! M]$55 W, E)S:P-A.BB$D><.WL*21=FY)&P!O> G.A@E>E[@<*4#*Y9HMP3\Q M\76KI [K@5TC;I#4^C((;J( RR]W1:WC+-E_A4HZX] A\2V M54VNJ5JR9H2#@ SX+IAZ]?[-QTF-KD0I@E62?1+TA:,26+;^5+.,Y$)'"R&J'IJV^AC73JKP6 M=4,+(2'+JL@K)$413VP[.+EI ?7%N19%1@O"8@41.SQ<8W_^G0/0!("PRT9LV+L*Q0NVDA=YY#JNZYJG(< +D O9O_<@8B(&F\. M_Y2"!:ZFUI^&0.$O\*WG1\QW/#2 %J_?8[ X>4.PKX&E>RQ$L$%'H(+ MG2#TX.\\3@Z!BR."HA_OTZ8B6*Y>NZ/)=WLT12R8^O .:8JB&?P-POF/ .+- MYPI(F" 0S_\AE+@](.'LH!9HJ7A[TDGVI*&6]_?D$X-\DB0B^41 3^"XWD%U M^&X 9[$&.$> T4$V1IJ![;,#&!GF 2?UTM$(,&\:>DB=/W=\@.K[SGQVF#Y? M@6F?!\ =A>:& &WFQ#%@#2 #]H)\]!7ZZ(EWQB@.^$_,L^>*6L_DA_K??1#O MSB_8!(S6C\^8"RLZB3\_8Z> 5*B9U/\<(8/G\"$,R#80!W3.9>O5=)BR0@EX M58A@_Q(ZLC: $(YHJ@:&#^>-A&DK;D L8>#H!($<<_HW&+527MG$T9%!.*2>M:"+916;.@Z#@2T?8#>XE*+\C39K9@'8T M]7L4G09'R=C3!MG 0V5]L!P4L37%63FDM4]/ED.$KF%6?DQO=1(J3&0F031K MT+G<2ML PH+4JN!2YLML%TUG)FD$[!BIG.000E5I"I'DB-86B7!J\QJ1FDVARU'PT 41%M(E,*I6;' MUP;Y(2Y&S)V2C9ACR_?1Q6QZ8$4^1/INXT56.\#+AN#PKPZ,;_*"0*Y5,I=C M,L>)1/BO+14<]"DWZQRDLZU B@RYHDQ0K<]N%(T]<;>S(5E?VC ZO+,*$ -G MR2IP*[6#J^5+P &4!Q5$LFU=+:@F4AH&2("P[1FV*=%W!HE;^JX6V)[!;%JE MP4CY'O+:I;;F,>2KD5WK,VQ51I4O0?Z\43BB(R>O($!6[.6N!I-*;TVY^ 95 MGIP]&B$\1TH7J2J7I5XC;==0V("I4TVNBC]R-# 8&-6 S&@QN\ T:I5"P8(T MXZI (-*Y!\"N1@%&*3GUCQYJ#1:*Q!)>BX'NKC4W+$M1,"S+Z%O%'JY#BR4H M0TG9RHX *A24+H=PO-PMI/AS!_"+VX/JVW=3.3"!;&-QNVF\0,LX]OMP>;-GMI;PD=D[I2[,_2(^]ZP6[&5\:HD%X4'R.3J\4?NK]@0G)*$PQ> M*I?.B76UR':0+W=TX:P#D%&T59H3$:0IP_ ]U)0> Z;L,RJ)RA&ADK)2!J/7 MCHZM:P[H+U!8?;,9^KH1X][P+U:ZMN6W2ML!Q:N;7*(/@P)!FKS\Y:]O9)N7 M$[FZ#V:G:'8< ?9_WFJEA[P/-$6Q;(^0/<0 %=4G ^5"[2XLQX/O"Z@I"4]$ MJ8>*#5[Y8&77.T1QRVME8.^!0K%M5 $(E>M(BLTW.DRNA &Q ;T"^%K $=:?NKWTG$PP,P)NNUKH>7 1"[NV"J#L3;59^YBV\]L\ M<5^!CVN&\N8CQ)#>\M6J%BM$R]2GG2Q.PZ2K,J;L*H+'-#9Z1A48J@%F$$TALRWT#-/ \_ZCC0&[+>5YSZ9A%%?;3^1CDDK M ]>!V_316[U6,B:DM6ZJGC%7D0S+G1IKHZ6N^)2C) TT'0A?]ZN.,.PHNZ3= M7A[EV&D8>UW1,^!7",KIV?SBR.%'QQ7] -/NGHB<47D":G*G>S5_A&4D> CR M\1")[ 04UREP9Q+##V0QP$886>,6(E'/*2O+LQP[ILI_-?^"*$M.&< 7 K'1 MP4KYWUT-VOWG#JQ5@4()3+MN2@_I&CD&&+?CP;B-M]0*&4T3P\-ML9/8]*AW MUC[&E%T,+?BH;?62J;&@1)XR$RD4;^!.%[AS LJ*E7Y59EWQ.P6#QGW3? MX'Y; 13?+PQ;AQL,UH[ !P@Q*+<]*[3>^*9S[+J_T.@@")PDB5D0>8X7Q&PR M=^:N?\8F0>($?GC&/EIQZ!0FSI-?&#SCT$D\F#8/'2\)#/#](&2_FG?;"AJ\ MGS@1;AJHQ\1WHC@YPV<0)D/8LZD?$VS/":.X?7RB5N,IFWB^$R8N]CO, M8E\U+TVSNQJ!@>WZ1BL#*Q,=;?,-VF-[>1V9 M$[FT0FEK4^F*06#U%>0G([3? M1R=SOF =V7D#/+AK+W7U5#T,Z5U-$7V>N" MHH_K2O5\W8$<($.4K?:V)*O&F1YNTF?"&&/VWD*Z687? M6=TJAOEGTUE#B6?_"JRX:TG>:;&3.?9YJ>8Q^_5Z5_LW2(3TEJROP+ZKKO7. M<#QFL0^IBOI5;Y_XM@'<*]BM^"1T W:LBUR-L^TO)-KWP?3^R7A_N^__9VK^ M^O-'HRR!5I8N-39G.O1>_R\T'G+P!/+W]@'Y[ISYN&$_R(S]J3?'S#A4._GZ MT>;DI)*SX1D+3[U).H@J'T\GS1$'^>MPY_X_)4/T^S7C M3T5F/S_\/SUG$79LHMA/CG5,E1[4&E9-Z4-MX5EBGWH9](7CJ+,=9^18+P') MVHV]O,X>Z0T#G"T%I(^];9'<2M*PO=O;>L =;(9!6/&7I*AVVX9;(68C1 FO M%#=W<8 /$P8^FC)\W]QF[W "O+CA=0;<:S=:>^D/ET.Y*J204U:*WBOW3:HZ MV&49HDDBT?DN[:C*=KN?,.JV?H_OB '#!_NAN"^UO\H&HYC>CTAI*TEE[FIJ[/:=@'X?K'X3#P-:>D!_?W;:JHFY#N[>W3H=\\ 1YJ3$1_81 JJ.U%%Y&I77,+O?)C]FOGL*I=FI3CQ"Q4#)GV*Z MM>&IJAQ8_EY;;49/#*^ZLR.WVSRU=]_ Z+ L@WR7-M>D<5P]?X4;N5]%NFL. M%K"ZN-GS.H<(MG!"@P7GY 5="^4[]#!-*\^U=G:^(6.Y!P&#$Y*#GFFK7ZL* M3P! J,N^+01.@4JS30OY,.A4WK"/J!AC53E6P[!N*A#+]EI(:J^0JA64:I4T MX<"!N\4ME+2HG;AKDJ909] IF?ZVL=IG6H';V2*H#?\#71GH)S@D4 E<+V]V M;;,!8HCED%H0%#]"32^VC7 0+7!LZUD MKN#1KC+\757XGDXX:5F@GM:8U=2Z0R7!#"D\0H&!6JL/_"#M M!!'5$M.:;5U=YU+W/C@>&MKBCKK9F1VB-. EI3?$#OL]A%FT@:E=C@*)!R[# M#0.>E5"!"\*)1W1.^Z&W D3/?&.-G7VN();T^>J%GC93%_WVN[TV29^ MS?."7F)LQ:C=\%)'?5IR![C0!:)C!T5U[FC78H?/\ZHJ[F!MF"%-8-@@#4E, M!6.IOV IN 6I<7!N>#&4:L?M;E'D*5[[,E3HL;;QHQ:VS$@8QA-AO MNH OP7NWTEB".G9HG,TA]Z!I-YT:9?[JXJTZKM\7#3*ZX^(PSQ@YL&8YP@S[ MKMF1@ODAK9['MJ*J:6^K5+O#DKW0ZUY1(8X7%.[1[WFE4UB[3V19P!BU\+*] M=4$WK>1C]J$66YYG[5%7[;S(PI7*-&U#\26F96\P+=,]V,L]A6,3GVYBX.YI MHC[,XD@?[NKGR;/$95$0'VCOCLT('3<)H3*9!PE[3P@^$+'0=>;S!)M2L>>. M@AA>3;D_&/%=8+ O;\LWW9MWL?L0I]G M.")0NRU\?ZE&(=VFB><'&!#%"P!^0>"$?LSPT($7/E0/+"EBTW/N!*$/'^:Q MXT:1N;5DLH,VAO4"UX'>/\8\+7OCT<@!UT'R QQ0F;W#SJ_Z_DZ$YX2 M.R^:>_:[*33T+U&UW>Y!)GS\UK45PV@?<&'?$NG0I%O?=.[*5-/H>0\$^N-% MJ$IL1CO^FIE8F!NH^_0,S ML\E;T."SO?$F,,&+3X2,_1,(0V3N8W+FZAU%A!ABURE>#?3F^G;>S.UFM5Y7Y_=W!)(R<<)Z#3MZIIB1";SM+G"A$ MC@4)C,:HX/G@".([11+<4R31#,*@3T#!VP4A @WHO!*(RX>XG=Q3*+[K^#%X M)]_QYAZ;X!JXLP*2CN+97Q4*H#>CVYWT> #K9\X<-WCF$;+=!2\^25#1QKB. MV@1>&V#$3CBC6(=3D#?>W)G'P:&Z AM&KSJOH= !J^R,&8HD< 2#OHQWM*VZ M5^/1[T__[)X2ML M]-R*4ETF&"?'+C8'Q[FQ?2I;B"IM464 -L\TAG1CK6O:$EJ0\.L3ZMW]"',] M@NI1LS^.79+2SHCP96-^T*+'!X=!H8F%K^I4X3C0&['5-R1XD>H&X0*;/BU< MN@[1]JFITAW(;=J_@=P)4V#59;"BW0"%3=:VI0UX56Q9F[AM6Z#':<"+UB0F M]JNPW@4I*@*RZF;O]SOTG6B'+5"K6\4>HDXSL7D?6<=RQNJC8?EZL+VE8OSX M-2.AFG6],T!TF=:S;]=^XT;\O8I,M<A\=]3?#'V6S_GUF\V;42] MHE^FDJJB5S_?9-Z:'[^Z4+_YU U7OYP%&*Z0RX58PE1W&DD7 MH!95TU0;^K@6' 2! ^#[954U[3\(P/PDV//_!5!+ P04 " ;@:98]X_P M>*T' @% &0 'AL+W=O;DQ]IO+E/+BL#X]27?F]OK2U/[7)=J;H6KBT+:[8W* MS>:J=]IK;GS1Z\S3C>'U9277:J'\7ZNYQ=6PM9+J0I5.FU)8M;KJS4[?WTQ) MG@7^IM7&=7X+BF1IS#>Z^)1>]4;DD,I5XLF"Q+\'=:ORG S!C3^CS5Y[)"EV M?S?6?^'8$8AX["Q>B(PC@JC-GO7UIS498DH8U^L&A MLC:$MGFKH^>O%U_O;WTYN9HN[C^+V_O/\[O?%[.NG^]\OAQ[626:8 M1$LWP=+XB*6)^&Q*GSEQ5Z8JW=4?PJO6M7'CVLWX18.?I1V(R6E?C$?CZ0OV M)FVH$[8W.19J)JTZN4$)4S&76R#+BYFULEPK_OWWV=)Y"YC\X[G@@^WI\[:I M==Z[2B;JJH?><,H^J-[USS^=GH\^O.#YM/5\^I+U'RK2?V=)S)PP*X&4)UF; M\[[PF1*WIJADN1693 7@F'P3IJ*&.>VD&5Z:*PNM6\$0"?.0TJ7:]Q/E677/I5>K:T4?]$KM4BTPG%._&IR M$G-PW%;&2F[^7_3*9V*&.@.;?-P7'"?I,-#71-S]66N_A<$$2 !-B'DN2_&: M#OGYIXOQ>/2!Q>@N7Y]^>#,0BVXVA':NAKDG[UH-L52)*910C\HFVLEEKH1Y M@)2K5*)7&EI(F#:4G[4JE95YO@4/^$R78F5J*[9*6B=6UA1L.87C5"[$#MPB MT[A8Z439D$E55+G9*@5ST8@I%=L()@[54VW!D@;ZFTP# 4]>J,<*SP23V[X; M09^MD9'.L>0%BSG]&--T']-T%&@X94-_9%59\ZA!N KGOYH.WH'W\IRJ"$5O MO,R19/AKUJ7^%W*'W&)$N5#HQ#CO@*6<:^L-1!]0:;6'W8'XFJ%-H[BD"!]1 MC*BS5*)CGTLEX1SE0*4G$M>85[%FY-2NRSZS*J0['-,$-IY.^N_.I[N.A"3B ME+2V!&[*:S!0!#8-B-W-UT!@(OUGHJ&'&]]%XWNW=%);\2#S.E3Q>>\VTHE7 MIV>#\PL*.SX>B%GLSA6W4^S>4&^"P+Q# ^'N_) 8GFO]V/5/,,S@.,30I4[# M9R)8X+UI&P;&4];[*&:B*B^ ?#2%QVJ"G\0?Q \^DYY.Q-@F 9DD6!$LPX60 M0D5(D0O (%729WTT!UI6Y^ '8CR/=N!QP1"PYD'S?H+,)1F-$M@\89+#*&\? M.SH)A4"F0^;E&MZ2&4#D,"?$? &5KE[^$[ D;Z"8=GS$&:D.15KR2.,EZ4&5 M\'UM9!Z3TO(W0[$ED!K?V>OQB<_T]-[[FYV]8/$1QF(($6I%NS42^8^^&VWYA.T[?G-!UT-AGW M)V_?'4TO]<'X?-*?G(V.CL__&Y)X*8A#YP.<=ZADJD1%KKA<'S?+>;S9G+WXY3C]DS1!"K7 M:TU3N1UA/#@Y*Z;"$N$IA"UA12; .#4F+9.,:B 1J6WRX",^=(*6]V@#ZL3E M5A1*EBP.OJF+.B"UDEO01 ZB2>OD:2X),HK M#BF@=WMW+Q:JDG'ANFSM-(=V&49W"H,DZ'ERDGYH@?V2,R0QEO,ZU6XNY1)37O3_=A(>%GS7:Q MQTA 4HYWP@;0%&:N?&QY4$T-9G9,KB@4_0S+#645+B.[J(: AJ=C&CX-A=L) M!7(%"K+:<@A);2W)A5)')F^4&;\U[T2Q_ 3EX ]B]R<=+1 PS1!ROS6P!]>J MRFFYX]-U(N-K:(*DLUH@JIW=5O$>>A(*W$S!V#@0WXE+1HJ7H4<;5&,(4)^& M+;<[W1BAT?0.?4KG3*)9AK/W'2QM<,'G>EJHA-^ ,7] MPO5W@J-6/7W[P3UQ^'-.;3 B^(U"EV%BDVQ#DESL^.P[[G&JGEL3P^(6ZD?/ MZB0+"8?R-AR/;8#VB^YN3^7-V7X.U"K&_6OYAN_$EPYJVJ8==D\D5UXOW_#F M'"G[J4\X)MB439LPM;=_SSO'$8E\V*G_8^P@P['RU*91=\[%2Z\J?@;T-)X M;PK^F2GLDY8$\'QEC&\NZ(#VH^#UOP%02P,$% @ &X&F6)@PXP_G! MT T !D !X;"]W;W)K&ULQ5?;+(T]M[E1%X\%KITI[W<^^IX,'!)3H5T?5-1B97,V$)Z#.UBX"I+ M,@U.A1Z,A\.#02%5V9N=A+EK.SLQM=>JI&LK7%T4TJ[.29OE:6_46T_6(P.ZGD@F[)_UY=6XP&+4JJ"BJ=,J6PE)WVSD;'YU.V#P9_*%JZSK/@3.;& MW//@8WK:&S(ATI1X1I#X>:!WI#4#@<;G!K/7AF3'[O,:_4/(';G,I:-W1O^I M4I^?]HYZ(J5,UMK?F.4OU.2SSWB)T2[\%\MH.T'$I';>%(TSQH4JXZ]\;.K0 M<3@:/N$P;AS&@7<,%%B^EU[.3JQ9"LO60..'D&KP!CE5\J;<>HM5!3\_N[FX M^WAS<7EQ=2>N/YU=W9X,/%!Y;9 T".<18?P$PD1:B*KIM$I+K/I<>I&8![(B(@HI*FQ61 M$QA\L+),:$_\*@&[)WXF= C@99F*VZ7R7\@")NV+*V)DJTRJDC948ASV "<* MPK34WKPZ&H\.WWZ+V-K+YY9(%%%ZQ-(3$$Z2M\H12[(D7@_[4_2-UD#HATHD M"&=*J,$)DP6H\FF.!NL<3Y;!DC=;)106-T",@SA'ZS@OX"A!496)KGD-98WQ M,&,*%)>)J1@Y,:4S6J72P]!Y_!3K%'! 6\E'G/L?RSUIRSWYC\J]_^)R3WYX MN3E!KK?/]S,!+>O%0*S]Y10 M,0?3=2)[>!^ZBL(;3:\BCU#63LBFVMO;&0OP ,ZQ $@<]1+>UES^[R?09QEU M/8&;:$16F0(R@#X1J(GQNJ";VHAU5+ &[;1H9;Y $OT0\+59K MLV\V5]@%I#6'](0WHN"+%WMJ)>=**Z\VY)LMX\.85LA.:Y$B9]X0]I2/JE!? M*)A:\K4MN1#M[JZ5IWRN6&U"5I4UE54@+*QR]P+#3&GJ8WLSLA8^3!]Z"?(6 MURRFW>\.^9P+HBUS!0G]^\6Q724 KKA"%-NWDJM0TY"??(R(\*@K3O=P_Z?& M7<5[F'!2XQH9S*/):#@,-G-3UN!8F)KWFM=CGY-6"S774*IT>3A/UL1Y7Y6+ M7#BI[AKO5K=E,FB*,X$I)H+ P I&L?D0;:/:5IZQ&T;8;NEJVQPFS[;&V587 M[]#5#J:1P"TD@D8O$$@6.UX.X$GE.A"#&_QN:O8XE(6ZO6^H_.MVARX(; M<:7R7V5JL_/>K,=2L>1U;N_4^C^BT6=,]!*5&_=D:P\[C'LLJ8U518,,"0I9 M^C=_;.RPA3 +CR#$#4+LY/:,G)37W/*+,ZW63!,TJ-'"J>JP(9PLR2GW5N-4 M L]>O+^YO+^Y9YO4!OV&D\=/2&QS06 M<*)A_[M<&*L1%+\=TM&3&!TF08ER8BJ>B/,>,L$(_2!Z%S]\%TW"TQ<$''4" MCEZB_D]<\J\(LL^98%>JJ'BY8;FW#D\1:Y(,1$D3(.+*>@ECU5J6JX"1TEPG M&>-ERE*"DXO:91F 9"ZM%"9PAP\BDTD.BC;3JEYE#.6$B)8KSXKQE18"68[2 MLB-(Q@TK%5O*DI>)Z.0R3"W9!\>[C8D^OH& ??N$_\-WLSB:GIH6499)7J>" M+93-&LZO17_5#\#A4:2LXALG1 -(\FE\OW%*E*I\ZW$24%>E VS0L5/@F*,B M,J49R O-J!I:X25/E+'F39^AB'36"+9%=:JZ,@4Y:+^BL)0)SYEXK$0JP8Y9 MQ58P8-5:[8A4L 78M5[8[&L/(!*R4!KOBAQFB#(T%6MO?O$H=")!$^;TQ-TA M9&GA)5 V%8F7;QBW!XUN5"XH+A(M",FIBVH+ME[S@O^N-,D'+@U])XAXA-6\ M$3QS*W0!KT/<4ME6C10+!^-:"-'X0NXD[G%X>O?IBUM%IW">,0*N(FMY>KGD MBR8^*99 9--1AP>-*OD":B5"6[B02+<&V8U.+59USC5 Q0//:VY!;]]0Q'6= MB?*)R\LM()0X:BPE"E L%:00:@ZH^AQ B<$Y65>TZGG\-E7A$66=O7L6@ ^ MHI0EQV&G81#.8N!,@MEHWKC].1SXSD!V-G:K.(B&0_:K&\M@*?X ,ZTHOZ@X M/UG>:?X:IMF@HYDW)\S-!^E6(P/?_M@?TW+8+!NXKL'%_:@%ZL^;U3/N.^8] MQ&O1O@\^)9@VL?>RZ4K$J_B M,G4"\((,\+RL%9"Q]C7FJ?ELN?>$?>HBO5,8@FE5/,^!5VP<3%THCH)A--^. M4[6@PNOY(@ 73.&(_UAB(!(WELJB+O?+$:AA6/Q<- MM7#/7-]FX[O&G;!M%X3-L3OQT&<132:^RAIVX;V+,Y,G&.])[1]LQO3X() M93/RCH/)?.96TV X#I$J!G;[J:AJZSP+)@)M<1X&\\GX:,%HRX7'_LMB]5Z5 MJ[>N7ARO44Y)[U&:7K\A0/8GW/WPZ.]X?L.:^\N!H5V"YLZ@_C0'(I)N]6 ?N(V_+/0AN!QN42B+,5Y@Y-

&PO=V]R:W-H965T&UL4$L! A0#% @ &X&F6*%2M2[<" -' !D M ("!K%D! 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ &X&F6+[P*U+E @ !PD !D ("!&',! M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M&X&F6 &UL4$L! A0#% @ &X&F6)$G_5 -!0 ME1T !D ("!JXP! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ &X&F6.?P*%V? @ GP8 !D M ("!IYH! 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ &X&F6$9KJ!9# P IP@ !D ("!\Z,! 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ &X&F M6/>\8,:G @ TP8 !D ("!I+ ! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ &X&F6#F< =5O!@ +BX M !D ("!%[P! 'AL+W=O&PO=V]R:W-H965T7!E&UL4$L%!@ !2 %( =18 -#8 0 ! $! end XML 88 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 89 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 91 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 355 332 1 false 117 0 false 11 false false R1.htm 0000001 - Document - Cover Sheet http://integralife.com/role/Cover Cover Cover 1 false false R2.htm 0000002 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (UNAUDITED) Sheet http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (UNAUDITED) Statements 2 false false R3.htm 0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) Sheet http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) Statements 3 false false R4.htm 0000004 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) Sheet http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) Statements 4 false false R5.htm 0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Sheet http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Statements 5 false false R6.htm 0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (UNAUDITED) Sheet http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (UNAUDITED) Statements 6 false false R7.htm 0000007 - Disclosure - BASIS OF PRESENTATION Sheet http://integralife.com/role/BASISOFPRESENTATION BASIS OF PRESENTATION Notes 7 false false R8.htm 0000008 - Disclosure - ACQUISITIONS AND DIVESTITURES Sheet http://integralife.com/role/ACQUISITIONSANDDIVESTITURES ACQUISITIONS AND DIVESTITURES Notes 8 false false R9.htm 0000009 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS Sheet http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERS REVENUES FROM CONTRACTS WITH CUSTOMERS Notes 9 false false R10.htm 0000010 - Disclosure - INVENTORIES Sheet http://integralife.com/role/INVENTORIES INVENTORIES Notes 10 false false R11.htm 0000011 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS Sheet http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETS GOODWILL AND OTHER INTANGIBLE ASSETS Notes 11 false false R12.htm 0000012 - Disclosure - DEBT Sheet http://integralife.com/role/DEBT DEBT Notes 12 false false R13.htm 0000013 - Disclosure - DERIVATIVE INSTRUMENTS Sheet http://integralife.com/role/DERIVATIVEINSTRUMENTS DERIVATIVE INSTRUMENTS Notes 13 false false R14.htm 0000014 - Disclosure - STOCK-BASED COMPENSATION Sheet http://integralife.com/role/STOCKBASEDCOMPENSATION STOCK-BASED COMPENSATION Notes 14 false false R15.htm 0000015 - Disclosure - RETIREMENT PLANS Sheet http://integralife.com/role/RETIREMENTPLANS RETIREMENT PLANS Notes 15 false false R16.htm 0000016 - Disclosure - LEASES AND RELATED PARTY LEASES Sheet http://integralife.com/role/LEASESANDRELATEDPARTYLEASES LEASES AND RELATED PARTY LEASES Notes 16 false false R17.htm 0000017 - Disclosure - TREASURY STOCK Sheet http://integralife.com/role/TREASURYSTOCK TREASURY STOCK Notes 17 false false R18.htm 0000018 - Disclosure - INCOME TAXES Sheet http://integralife.com/role/INCOMETAXES INCOME TAXES Notes 18 false false R19.htm 0000019 - Disclosure - NET INCOME PER SHARE Sheet http://integralife.com/role/NETINCOMEPERSHARE NET INCOME PER SHARE Notes 19 false false R20.htm 0000020 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) Sheet http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSS ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) Notes 20 false false R21.htm 0000021 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION Sheet http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATION SEGMENT AND GEOGRAPHIC INFORMATION Notes 21 false false R22.htm 0000022 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://integralife.com/role/COMMITMENTSANDCONTINGENCIES COMMITMENTS AND CONTINGENCIES Notes 22 false false R23.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 23 false false R24.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 24 false false R25.htm 9954471 - Disclosure - BASIS OF PRESENTATION (Policies) Sheet http://integralife.com/role/BASISOFPRESENTATIONPolicies BASIS OF PRESENTATION (Policies) Policies 25 false false R26.htm 9954472 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables) Sheet http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSTables REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables) Tables http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERS 26 false false R27.htm 9954473 - Disclosure - INVENTORIES (Tables) Sheet http://integralife.com/role/INVENTORIESTables INVENTORIES (Tables) Tables http://integralife.com/role/INVENTORIES 27 false false R28.htm 9954474 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Tables) Sheet http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables GOODWILL AND OTHER INTANGIBLE ASSETS (Tables) Tables http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETS 28 false false R29.htm 9954475 - Disclosure - DEBT (Tables) Sheet http://integralife.com/role/DEBTTables DEBT (Tables) Tables http://integralife.com/role/DEBT 29 false false R30.htm 9954476 - Disclosure - DERIVATIVE INSTRUMENTS (Tables) Sheet http://integralife.com/role/DERIVATIVEINSTRUMENTSTables DERIVATIVE INSTRUMENTS (Tables) Tables http://integralife.com/role/DERIVATIVEINSTRUMENTS 30 false false R31.htm 9954477 - Disclosure - LEASES AND RELATED PARTY LEASES (Tables) Sheet http://integralife.com/role/LEASESANDRELATEDPARTYLEASESTables LEASES AND RELATED PARTY LEASES (Tables) Tables http://integralife.com/role/LEASESANDRELATEDPARTYLEASES 31 false false R32.htm 9954478 - Disclosure - INCOME TAXES (Tables) Sheet http://integralife.com/role/INCOMETAXESTables INCOME TAXES (Tables) Tables http://integralife.com/role/INCOMETAXES 32 false false R33.htm 9954479 - Disclosure - NET INCOME PER SHARE (Tables) Sheet http://integralife.com/role/NETINCOMEPERSHARETables NET INCOME PER SHARE (Tables) Tables http://integralife.com/role/NETINCOMEPERSHARE 33 false false R34.htm 9954480 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Tables) Sheet http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSTables ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Tables) Tables http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSS 34 false false R35.htm 9954481 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION (Tables) Sheet http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTables SEGMENT AND GEOGRAPHIC INFORMATION (Tables) Tables http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATION 35 false false R36.htm 9954482 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) Sheet http://integralife.com/role/COMMITMENTSANDCONTINGENCIESTables COMMITMENTS AND CONTINGENCIES (Tables) Tables http://integralife.com/role/COMMITMENTSANDCONTINGENCIES 36 false false R37.htm 9954483 - Disclosure - ACQUISITIONS AND DIVESTITURES - Narrative (Details) Sheet http://integralife.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails ACQUISITIONS AND DIVESTITURES - Narrative (Details) Details 37 false false R38.htm 9954484 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS - Narrative (Details) Sheet http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSNarrativeDetails REVENUES FROM CONTRACTS WITH CUSTOMERS - Narrative (Details) Details 38 false false R39.htm 9954485 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS - Schedule of Changes in Contract Assets and Liabilities (Details) Sheet http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofChangesinContractAssetsandLiabilitiesDetails REVENUES FROM CONTRACTS WITH CUSTOMERS - Schedule of Changes in Contract Assets and Liabilities (Details) Details 39 false false R40.htm 9954486 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS - Narrative, Revenue Remaining Performance Obligation (Details) Sheet http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSNarrativeRevenueRemainingPerformanceObligationDetails REVENUES FROM CONTRACTS WITH CUSTOMERS - Narrative, Revenue Remaining Performance Obligation (Details) Details 40 false false R41.htm 9954487 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS - Schedule of Revenues Disaggregated by Major Source (Details) Sheet http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofRevenuesDisaggregatedbyMajorSourceDetails REVENUES FROM CONTRACTS WITH CUSTOMERS - Schedule of Revenues Disaggregated by Major Source (Details) Details 41 false false R42.htm 9954488 - Disclosure - INVENTORIES - Schedule of Net Inventories (Details) Sheet http://integralife.com/role/INVENTORIESScheduleofNetInventoriesDetails INVENTORIES - Schedule of Net Inventories (Details) Details 42 false false R43.htm 9954489 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Schedule of Changes in Carrying Amount of Goodwill (Details) Sheet http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails GOODWILL AND OTHER INTANGIBLE ASSETS - Schedule of Changes in Carrying Amount of Goodwill (Details) Details 43 false false R44.htm 9954490 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Components of Company's Identifiable Intangible Assets (Details) Sheet http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSComponentsofCompanysIdentifiableIntangibleAssetsDetails GOODWILL AND OTHER INTANGIBLE ASSETS - Components of Company's Identifiable Intangible Assets (Details) Details 44 false false R45.htm 9954491 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details) Sheet http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details) Details 45 false false R46.htm 9954492 - Disclosure - DEBT - Narrative (Details) Sheet http://integralife.com/role/DEBTNarrativeDetails DEBT - Narrative (Details) Details 46 false false R47.htm 9954493 - Disclosure - DEBT - Maximum Total Leverage Ratio Table (Details) Sheet http://integralife.com/role/DEBTMaximumTotalLeverageRatioTableDetails DEBT - Maximum Total Leverage Ratio Table (Details) Details 47 false false R48.htm 9954494 - Disclosure - DEBT - Contractual Maturity Table (Details) Sheet http://integralife.com/role/DEBTContractualMaturityTableDetails DEBT - Contractual Maturity Table (Details) Details 48 false false R49.htm 9954495 - Disclosure - DERIVATIVE INSTRUMENTS - Schedule of Derivative Instruments (Details) Sheet http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDetails DERIVATIVE INSTRUMENTS - Schedule of Derivative Instruments (Details) Details 49 false false R50.htm 9954496 - Disclosure - DERIVATIVE INSTRUMENTS - Narrative (Details) Sheet http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails DERIVATIVE INSTRUMENTS - Narrative (Details) Details 50 false false R51.htm 9954497 - Disclosure - DERIVATIVE INSTRUMENTS - Schedule of Cross Currency Swap Derivatives (Details) Sheet http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails DERIVATIVE INSTRUMENTS - Schedule of Cross Currency Swap Derivatives (Details) Details 51 false false R52.htm 9954498 - Disclosure - DERIVATIVE INSTRUMENTS - Schedule of Net Investment Hedges Derivatives (Details) Sheet http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails DERIVATIVE INSTRUMENTS - Schedule of Net Investment Hedges Derivatives (Details) Details 52 false false R53.htm 9954499 - Disclosure - DERIVATIVE INSTRUMENTS - Fair Value of Derivative Instruments By Balance Sheet Location (Details) Sheet http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails DERIVATIVE INSTRUMENTS - Fair Value of Derivative Instruments By Balance Sheet Location (Details) Details 53 false false R54.htm 9954500 - Disclosure - DERIVATIVE INSTRUMENTS - Effect of Derivative Instruments Designated Cash Flow Hedges on Statements of Operations (Details) Sheet http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails DERIVATIVE INSTRUMENTS - Effect of Derivative Instruments Designated Cash Flow Hedges on Statements of Operations (Details) Details 54 false false R55.htm 9954501 - Disclosure - DERIVATIVE INSTRUMENTS - Schedule of Derivatives Not Designated as Hedging Instruments (Details) Sheet http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativesNotDesignatedasHedgingInstrumentsDetails DERIVATIVE INSTRUMENTS - Schedule of Derivatives Not Designated as Hedging Instruments (Details) Details 55 false false R56.htm 9954502 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details) Sheet http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails STOCK-BASED COMPENSATION - Narrative (Details) Details 56 false false R57.htm 9954503 - Disclosure - RETIREMENT PLANS - Narrative (Details) Sheet http://integralife.com/role/RETIREMENTPLANSNarrativeDetails RETIREMENT PLANS - Narrative (Details) Details 57 false false R58.htm 9954504 - Disclosure - LEASES AND RELATED PARTY LEASES - Narrative (Details) Sheet http://integralife.com/role/LEASESANDRELATEDPARTYLEASESNarrativeDetails LEASES AND RELATED PARTY LEASES - Narrative (Details) Details 58 false false R59.htm 9954505 - Disclosure - LEASES AND RELATED PARTY LEASES - Supplemental Balance Sheet Information (Details) Sheet http://integralife.com/role/LEASESANDRELATEDPARTYLEASESSupplementalBalanceSheetInformationDetails LEASES AND RELATED PARTY LEASES - Supplemental Balance Sheet Information (Details) Details 59 false false R60.htm 9954506 - Disclosure - LEASES AND RELATED PARTY LEASES - Supplemental Cash Flow Information (Details) Sheet http://integralife.com/role/LEASESANDRELATEDPARTYLEASESSupplementalCashFlowInformationDetails LEASES AND RELATED PARTY LEASES - Supplemental Cash Flow Information (Details) Details 60 false false R61.htm 9954507 - Disclosure - LEASES AND RELATED PARTY LEASES - Future Minimum Lease Payment Under Operating Leases (Details) Sheet http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails LEASES AND RELATED PARTY LEASES - Future Minimum Lease Payment Under Operating Leases (Details) Details 61 false false R62.htm 9954508 - Disclosure - TREASURY STOCK - Narrative (Details) Sheet http://integralife.com/role/TREASURYSTOCKNarrativeDetails TREASURY STOCK - Narrative (Details) Details 62 false false R63.htm 9954509 - Disclosure - INCOME TAXES - Summary of Effective Tax Rate (Details) Sheet http://integralife.com/role/INCOMETAXESSummaryofEffectiveTaxRateDetails INCOME TAXES - Summary of Effective Tax Rate (Details) Details 63 false false R64.htm 9954510 - Disclosure - INCOME TAXES - Narrative (Details) Sheet http://integralife.com/role/INCOMETAXESNarrativeDetails INCOME TAXES - Narrative (Details) Details 64 false false R65.htm 9954511 - Disclosure - NET INCOME PER SHARE - Basic and Diluted Net Income Per Share (Details) Sheet http://integralife.com/role/NETINCOMEPERSHAREBasicandDilutedNetIncomePerShareDetails NET INCOME PER SHARE - Basic and Diluted Net Income Per Share (Details) Details 65 false false R66.htm 9954512 - Disclosure - NET INCOME PER SHARE - Narrative (Details) Sheet http://integralife.com/role/NETINCOMEPERSHARENarrativeDetails NET INCOME PER SHARE - Narrative (Details) Details 66 false false R67.htm 9954513 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Schedule of Comprehensive Income (Details) Sheet http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofComprehensiveIncomeDetails ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Schedule of Comprehensive Income (Details) Details http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSTables 67 false false R68.htm 9954514 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Schedule of Changes in Accumulated Other Comprehensive Income by Component (Details) Sheet http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofChangesinAccumulatedOtherComprehensiveIncomebyComponentDetails ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Schedule of Changes in Accumulated Other Comprehensive Income by Component (Details) Details http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSTables 68 false false R69.htm 9954515 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Narrative (Details) Sheet http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSNarrativeDetails ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Narrative (Details) Details http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSTables 69 false false R70.htm 9954516 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Narrative (Details) Sheet http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNarrativeDetails SEGMENT AND GEOGRAPHIC INFORMATION - Narrative (Details) Details 70 false false R71.htm 9954517 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Net Sales and Profit by Reportable Segment (Details) Sheet http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNetSalesandProfitbyReportableSegmentDetails SEGMENT AND GEOGRAPHIC INFORMATION - Net Sales and Profit by Reportable Segment (Details) Details 71 false false R72.htm 9954518 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Total Revenue by Major Geographic Area (Details) Sheet http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTotalRevenuebyMajorGeographicAreaDetails SEGMENT AND GEOGRAPHIC INFORMATION - Total Revenue by Major Geographic Area (Details) Details 72 false false R73.htm 9954519 - Disclosure - COMMITMENTS AND CONTINGENCIES - Fair Value Contingent Consideration, Balance Information (Details) Sheet http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails COMMITMENTS AND CONTINGENCIES - Fair Value Contingent Consideration, Balance Information (Details) Details 73 false false R74.htm 9954520 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details) Sheet http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails COMMITMENTS AND CONTINGENCIES - Narrative (Details) Details 74 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:DebtInstrumentConvertibleConversionRatio1, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod - iart-20240331.htm 4 iart-20240331.htm iart-20240331.xsd iart-20240331_cal.xml iart-20240331_def.xml iart-20240331_lab.xml iart-20240331_pre.xml http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 94 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "iart-20240331.htm": { "nsprefix": "iart", "nsuri": "http://integralife.com/20240331", "dts": { "inline": { "local": [ "iart-20240331.htm" ] }, "schema": { "local": [ "iart-20240331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" ] }, "calculationLink": { "local": [ "iart-20240331_cal.xml" ] }, "definitionLink": { "local": [ "iart-20240331_def.xml" ] }, "labelLink": { "local": [ "iart-20240331_lab.xml" ] }, "presentationLink": { "local": [ "iart-20240331_pre.xml" ] } }, "keyStandard": 282, "keyCustom": 50, "axisStandard": 37, "axisCustom": 1, "memberStandard": 60, "memberCustom": 56, "hidden": { "total": 7, "http://fasb.org/us-gaap/2023": 2, "http://xbrl.sec.gov/dei/2023": 5 }, "contextCount": 355, "entityCount": 1, "segmentCount": 117, "elementCount": 688, "unitCount": 11, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 856, "http://xbrl.sec.gov/dei/2023": 29, "http://xbrl.sec.gov/ecd/2023": 4 }, "report": { "R1": { "role": "http://integralife.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true } }, "R2": { "role": "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED", "longName": "0000002 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (UNAUDITED)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (UNAUDITED)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "unique": true } }, "R3": { "role": "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "longName": "0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true } }, "R4": { "role": "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical", "longName": "0000004 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true } }, "R5": { "role": "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "longName": "0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherDepreciationAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "unique": true } }, "R6": { "role": "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUNAUDITED", "longName": "0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (UNAUDITED)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (UNAUDITED)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-23", "name": "us-gaap:SharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-23", "name": "us-gaap:SharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true } }, "R7": { "role": "http://integralife.com/role/BASISOFPRESENTATION", "longName": "0000007 - Disclosure - BASIS OF PRESENTATION", "shortName": "BASIS OF PRESENTATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true } }, "R8": { "role": "http://integralife.com/role/ACQUISITIONSANDDIVESTITURES", "longName": "0000008 - Disclosure - ACQUISITIONS AND DIVESTITURES", "shortName": "ACQUISITIONS AND DIVESTITURES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true } }, "R9": { "role": "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERS", "longName": "0000009 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS", "shortName": "REVENUES FROM CONTRACTS WITH CUSTOMERS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true } }, "R10": { "role": "http://integralife.com/role/INVENTORIES", "longName": "0000010 - Disclosure - INVENTORIES", "shortName": "INVENTORIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true } }, "R11": { "role": "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETS", "longName": "0000011 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true } }, "R12": { "role": "http://integralife.com/role/DEBT", "longName": "0000012 - Disclosure - DEBT", "shortName": "DEBT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true } }, "R13": { "role": "http://integralife.com/role/DERIVATIVEINSTRUMENTS", "longName": "0000013 - Disclosure - DERIVATIVE INSTRUMENTS", "shortName": "DERIVATIVE INSTRUMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true } }, "R14": { "role": "http://integralife.com/role/STOCKBASEDCOMPENSATION", "longName": "0000014 - Disclosure - STOCK-BASED COMPENSATION", "shortName": "STOCK-BASED COMPENSATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true } }, "R15": { "role": "http://integralife.com/role/RETIREMENTPLANS", "longName": "0000015 - Disclosure - RETIREMENT PLANS", "shortName": "RETIREMENT PLANS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true } }, "R16": { "role": "http://integralife.com/role/LEASESANDRELATEDPARTYLEASES", "longName": "0000016 - Disclosure - LEASES AND RELATED PARTY LEASES", "shortName": "LEASES AND RELATED PARTY LEASES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true } }, "R17": { "role": "http://integralife.com/role/TREASURYSTOCK", "longName": "0000017 - Disclosure - TREASURY STOCK", "shortName": "TREASURY STOCK", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:TreasuryStockTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:TreasuryStockTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true } }, "R18": { "role": "http://integralife.com/role/INCOMETAXES", "longName": "0000018 - Disclosure - INCOME TAXES", "shortName": "INCOME TAXES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true } }, "R19": { "role": "http://integralife.com/role/NETINCOMEPERSHARE", "longName": "0000019 - Disclosure - NET INCOME PER SHARE", "shortName": "NET INCOME PER SHARE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true } }, "R20": { "role": "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSS", "longName": "0000020 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)", "shortName": "ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true } }, "R21": { "role": "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATION", "longName": "0000021 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION", "shortName": "SEGMENT AND GEOGRAPHIC INFORMATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true } }, "R22": { "role": "http://integralife.com/role/COMMITMENTSANDCONTINGENCIES", "longName": "0000022 - Disclosure - COMMITMENTS AND CONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true } }, "R23": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true }, "uniqueAnchor": null }, "R24": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true } }, "R25": { "role": "http://integralife.com/role/BASISOFPRESENTATIONPolicies", "longName": "9954471 - Disclosure - BASIS OF PRESENTATION (Policies)", "shortName": "BASIS OF PRESENTATION (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true } }, "R26": { "role": "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSTables", "longName": "9954472 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)", "shortName": "REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true } }, "R27": { "role": "http://integralife.com/role/INVENTORIESTables", "longName": "9954473 - Disclosure - INVENTORIES (Tables)", "shortName": "INVENTORIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true } }, "R28": { "role": "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables", "longName": "9954474 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true } }, "R29": { "role": "http://integralife.com/role/DEBTTables", "longName": "9954475 - Disclosure - DEBT (Tables)", "shortName": "DEBT (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true } }, "R30": { "role": "http://integralife.com/role/DERIVATIVEINSTRUMENTSTables", "longName": "9954476 - Disclosure - DERIVATIVE INSTRUMENTS (Tables)", "shortName": "DERIVATIVE INSTRUMENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true } }, "R31": { "role": "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESTables", "longName": "9954477 - Disclosure - LEASES AND RELATED PARTY LEASES (Tables)", "shortName": "LEASES AND RELATED PARTY LEASES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "iart:AssetsAndLiabilitiesLesseeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "iart:AssetsAndLiabilitiesLesseeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true } }, "R32": { "role": "http://integralife.com/role/INCOMETAXESTables", "longName": "9954478 - Disclosure - INCOME TAXES (Tables)", "shortName": "INCOME TAXES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true } }, "R33": { "role": "http://integralife.com/role/NETINCOMEPERSHARETables", "longName": "9954479 - Disclosure - NET INCOME PER SHARE (Tables)", "shortName": "NET INCOME PER SHARE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true } }, "R34": { "role": "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSTables", "longName": "9954480 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Tables)", "shortName": "ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true } }, "R35": { "role": "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTables", "longName": "9954481 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION (Tables)", "shortName": "SEGMENT AND GEOGRAPHIC INFORMATION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true }, "uniqueAnchor": null }, "R36": { "role": "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESTables", "longName": "9954482 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)", "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true } }, "R37": { "role": "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails", "longName": "9954483 - Disclosure - ACQUISITIONS AND DIVESTITURES - Narrative (Details)", "shortName": "ACQUISITIONS AND DIVESTITURES - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-38", "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-38", "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true } }, "R38": { "role": "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSNarrativeDetails", "longName": "9954484 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS - Narrative (Details)", "shortName": "REVENUES FROM CONTRACTS WITH CUSTOMERS - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-1", "name": "iart:ReturnPolicyIssueOfCreditNumberOfDaysFromShipment", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "iart:ReturnPolicyIssueOfCreditNumberOfDaysFromShipment", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true } }, "R39": { "role": "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofChangesinContractAssetsandLiabilitiesDetails", "longName": "9954485 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS - Schedule of Changes in Contract Assets and Liabilities (Details)", "shortName": "REVENUES FROM CONTRACTS WITH CUSTOMERS - Schedule of Changes in Contract Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:ContractWithCustomerAssetNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:ContractWithCustomerAssetNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true } }, "R40": { "role": "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSNarrativeRevenueRemainingPerformanceObligationDetails", "longName": "9954486 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS - Narrative, Revenue Remaining Performance Obligation (Details)", "shortName": "REVENUES FROM CONTRACTS WITH CUSTOMERS - Narrative, Revenue Remaining Performance Obligation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-42", "name": "us-gaap:RevenueRemainingPerformanceObligationPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-42", "name": "us-gaap:RevenueRemainingPerformanceObligationPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true } }, "R41": { "role": "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofRevenuesDisaggregatedbyMajorSourceDetails", "longName": "9954487 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS - Schedule of Revenues Disaggregated by Major Source (Details)", "shortName": "REVENUES FROM CONTRACTS WITH CUSTOMERS - Schedule of Revenues Disaggregated by Major Source (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-43", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "unique": true } }, "R42": { "role": "http://integralife.com/role/INVENTORIESScheduleofNetInventoriesDetails", "longName": "9954488 - Disclosure - INVENTORIES - Schedule of Net Inventories (Details)", "shortName": "INVENTORIES - Schedule of Net Inventories (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:InventoryFinishedGoodsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:InventoryFinishedGoodsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true } }, "R43": { "role": "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails", "longName": "9954489 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Schedule of Changes in Carrying Amount of Goodwill (Details)", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS - Schedule of Changes in Carrying Amount of Goodwill (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillForeignCurrencyTranslationGainLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "unique": true } }, "R44": { "role": "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSComponentsofCompanysIdentifiableIntangibleAssetsDetails", "longName": "9954490 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Components of Company's Identifiable Intangible Assets (Details)", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS - Components of Company's Identifiable Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-4", "name": "iart:CostOfDefiniteAndIndefiniteLivedIntangibleAssetsGrossExcludingGoodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "iart:CostOfDefiniteAndIndefiniteLivedIntangibleAssetsGrossExcludingGoodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true } }, "R45": { "role": "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails", "longName": "9954491 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details)", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AdjustmentForAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AdjustmentForAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true } }, "R46": { "role": "http://integralife.com/role/DEBTNarrativeDetails", "longName": "9954492 - Disclosure - DEBT - Narrative (Details)", "shortName": "DEBT - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:SecuredDebtCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "iart:InterestPaymentsReminderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "unique": true } }, "R47": { "role": "http://integralife.com/role/DEBTMaximumTotalLeverageRatioTableDetails", "longName": "9954493 - Disclosure - DEBT - Maximum Total Leverage Ratio Table (Details)", "shortName": "DEBT - Maximum Total Leverage Ratio Table (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-84", "name": "iart:DebtInstrumentCovenantMaximumLeverageRatio", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-84", "name": "iart:DebtInstrumentCovenantMaximumLeverageRatio", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true } }, "R48": { "role": "http://integralife.com/role/DEBTContractualMaturityTableDetails", "longName": "9954494 - Disclosure - DEBT - Contractual Maturity Table (Details)", "shortName": "DEBT - Contractual Maturity Table (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true } }, "R49": { "role": "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDetails", "longName": "9954495 - Disclosure - DERIVATIVE INSTRUMENTS - Schedule of Derivative Instruments (Details)", "shortName": "DERIVATIVE INSTRUMENTS - Schedule of Derivative Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-128", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-126", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "unique": true } }, "R50": { "role": "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "longName": "9954496 - Disclosure - DERIVATIVE INSTRUMENTS - Narrative (Details)", "shortName": "DERIVATIVE INSTRUMENTS - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true } }, "R51": { "role": "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails", "longName": "9954497 - Disclosure - DERIVATIVE INSTRUMENTS - Schedule of Cross Currency Swap Derivatives (Details)", "shortName": "DERIVATIVE INSTRUMENTS - Schedule of Cross Currency Swap Derivatives (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-135", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-139", "name": "us-gaap:DerivativeFairValueOfDerivativeNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "unique": true } }, "R52": { "role": "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails", "longName": "9954498 - Disclosure - DERIVATIVE INSTRUMENTS - Schedule of Net Investment Hedges Derivatives (Details)", "shortName": "DERIVATIVE INSTRUMENTS - Schedule of Net Investment Hedges Derivatives (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-135", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-159", "name": "us-gaap:DerivativeFairValueOfDerivativeNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "unique": true } }, "R53": { "role": "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails", "longName": "9954499 - Disclosure - DERIVATIVE INSTRUMENTS - Fair Value of Derivative Instruments By Balance Sheet Location (Details)", "shortName": "DERIVATIVE INSTRUMENTS - Fair Value of Derivative Instruments By Balance Sheet Location (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-196", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-196", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true } }, "R54": { "role": "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails", "longName": "9954500 - Disclosure - DERIVATIVE INSTRUMENTS - Effect of Derivative Instruments Designated Cash Flow Hedges on Statements of Operations (Details)", "shortName": "DERIVATIVE INSTRUMENTS - Effect of Derivative Instruments Designated Cash Flow Hedges on Statements of Operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-223", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "unique": true } }, "R55": { "role": "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativesNotDesignatedasHedgingInstrumentsDetails", "longName": "9954501 - Disclosure - DERIVATIVE INSTRUMENTS - Schedule of Derivatives Not Designated as Hedging Instruments (Details)", "shortName": "DERIVATIVE INSTRUMENTS - Schedule of Derivatives Not Designated as Hedging Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true } }, "R56": { "role": "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "longName": "9954502 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)", "shortName": "STOCK-BASED COMPENSATION - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true } }, "R57": { "role": "http://integralife.com/role/RETIREMENTPLANSNarrativeDetails", "longName": "9954503 - Disclosure - RETIREMENT PLANS - Narrative (Details)", "shortName": "RETIREMENT PLANS - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true } }, "R58": { "role": "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESNarrativeDetails", "longName": "9954504 - Disclosure - LEASES AND RELATED PARTY LEASES - Narrative (Details)", "shortName": "LEASES AND RELATED PARTY LEASES - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-1", "name": "iart:LesseeOperatingLeaseNumberOfRenewalOptions", "unitRef": "renewaloption", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "iart:LesseeOperatingLeaseNumberOfRenewalOptions", "unitRef": "renewaloption", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true } }, "R59": { "role": "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESSupplementalBalanceSheetInformationDetails", "longName": "9954505 - Disclosure - LEASES AND RELATED PARTY LEASES - Supplemental Balance Sheet Information (Details)", "shortName": "LEASES AND RELATED PARTY LEASES - Supplemental Balance Sheet Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-258", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "iart:AssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "unique": true } }, "R60": { "role": "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESSupplementalCashFlowInformationDetails", "longName": "9954506 - Disclosure - LEASES AND RELATED PARTY LEASES - Supplemental Cash Flow Information (Details)", "shortName": "LEASES AND RELATED PARTY LEASES - Supplemental Cash Flow Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeasePayments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "iart:CashFlowLesseeTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeasePayments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "iart:CashFlowLesseeTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true } }, "R61": { "role": "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails", "longName": "9954507 - Disclosure - LEASES AND RELATED PARTY LEASES - Future Minimum Lease Payment Under Operating Leases (Details)", "shortName": "LEASES AND RELATED PARTY LEASES - Future Minimum Lease Payment Under Operating Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true } }, "R62": { "role": "http://integralife.com/role/TREASURYSTOCKNarrativeDetails", "longName": "9954508 - Disclosure - TREASURY STOCK - Narrative (Details)", "shortName": "TREASURY STOCK - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:TreasuryStockCommonShares", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:TreasuryStockAcquiredAverageCostPerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "unique": true } }, "R63": { "role": "http://integralife.com/role/INCOMETAXESSummaryofEffectiveTaxRateDetails", "longName": "9954509 - Disclosure - INCOME TAXES - Summary of Effective Tax Rate (Details)", "shortName": "INCOME TAXES - Summary of Effective Tax Rate (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true }, "uniqueAnchor": null }, "R64": { "role": "http://integralife.com/role/INCOMETAXESNarrativeDetails", "longName": "9954510 - Disclosure - INCOME TAXES - Narrative (Details)", "shortName": "INCOME TAXES - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxReconciliationTaxCreditsResearch", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "unique": true } }, "R65": { "role": "http://integralife.com/role/NETINCOMEPERSHAREBasicandDilutedNetIncomePerShareDetails", "longName": "9954511 - Disclosure - NET INCOME PER SHARE - Basic and Diluted Net Income Per Share (Details)", "shortName": "NET INCOME PER SHARE - Basic and Diluted Net Income Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "unique": true } }, "R66": { "role": "http://integralife.com/role/NETINCOMEPERSHARENarrativeDetails", "longName": "9954512 - Disclosure - NET INCOME PER SHARE - Narrative (Details)", "shortName": "NET INCOME PER SHARE - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-277", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-277", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true } }, "R67": { "role": "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofComprehensiveIncomeDetails", "longName": "9954513 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Schedule of Comprehensive Income (Details)", "shortName": "ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Schedule of Comprehensive Income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "unique": true } }, "R68": { "role": "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofChangesinAccumulatedOtherComprehensiveIncomebyComponentDetails", "longName": "9954514 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Schedule of Changes in Accumulated Other Comprehensive Income by Component (Details)", "shortName": "ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Schedule of Changes in Accumulated Other Comprehensive Income by Component (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "unique": true } }, "R69": { "role": "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSNarrativeDetails", "longName": "9954515 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Narrative (Details)", "shortName": "ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-288", "name": "us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "unique": true } }, "R70": { "role": "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNarrativeDetails", "longName": "9954516 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Narrative (Details)", "shortName": "SEGMENT AND GEOGRAPHIC INFORMATION - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true } }, "R71": { "role": "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNetSalesandProfitbyReportableSegmentDetails", "longName": "9954517 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Net Sales and Profit by Reportable Segment (Details)", "shortName": "SEGMENT AND GEOGRAPHIC INFORMATION - Net Sales and Profit by Reportable Segment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-294", "name": "us-gaap:OperatingIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "unique": true } }, "R72": { "role": "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTotalRevenuebyMajorGeographicAreaDetails", "longName": "9954518 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Total Revenue by Major Geographic Area (Details)", "shortName": "SEGMENT AND GEOGRAPHIC INFORMATION - Total Revenue by Major Geographic Area (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-298", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "unique": true } }, "R73": { "role": "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails", "longName": "9954519 - Disclosure - COMMITMENTS AND CONTINGENCIES - Fair Value Contingent Consideration, Balance Information (Details)", "shortName": "COMMITMENTS AND CONTINGENCIES - Fair Value Contingent Consideration, Balance Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "c-306", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-306", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true } }, "R74": { "role": "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails", "longName": "9954520 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)", "shortName": "COMMITMENTS AND CONTINGENCIES - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "c-346", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-346", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "iart-20240331.htm", "first": true, "unique": true } } }, "tag": { "iart_A2022ShareRepurchaseProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240331", "localname": "A2022ShareRepurchaseProgramMember", "presentation": [ "http://integralife.com/role/TREASURYSTOCKNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2022 Share Repurchase Program", "label": "2022 Share Repurchase Program [Member]", "documentation": "2022 Share Repurchase Program" } } }, "auth_ref": [] }, "iart_A2023ShareRepurchaseProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240331", "localname": "A2023ShareRepurchaseProgramMember", "presentation": [ "http://integralife.com/role/TREASURYSTOCKNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2023 Share Repurchase Program", "label": "2023 Share Repurchase Program [Member]", "documentation": "2023 Share Repurchase Program" } } }, "auth_ref": [] }, "iart_ACellIncMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240331", "localname": "ACellIncMember", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ACell, Inc.", "label": "ACell, Inc. [Member]", "documentation": "ACell, Inc." } } }, "auth_ref": [] }, "iart_ACellMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240331", "localname": "ACellMember", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ACell", "label": "ACell [Member]", "documentation": "ACell" } } }, "auth_ref": [] }, "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AOCIAttributableToParentNetOfTaxRollForward", "presentation": [ "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofChangesinAccumulatedOtherComprehensiveIncomebyComponentDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) [Roll Forward]", "verboseLabel": "Accumulated Other Comprehensive Income (Loss) [Roll Forward]", "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "iart_AcceleratedShareRepurchasesAdditionalSharesReceived": { "xbrltype": "sharesItemType", "nsuri": "http://integralife.com/20240331", "localname": "AcceleratedShareRepurchasesAdditionalSharesReceived", "presentation": [ "http://integralife.com/role/TREASURYSTOCKNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accelerated share repurchases, additional shares received (in shares)", "label": "Accelerated Share Repurchases, Additional Shares Received", "documentation": "Accelerated Share Repurchases, Additional Shares Received" } } }, "auth_ref": [] }, "iart_AcceleratedShareRepurchasesPercentageOfExpectedTotalRepurchased": { "xbrltype": "percentItemType", "nsuri": "http://integralife.com/20240331", "localname": "AcceleratedShareRepurchasesPercentageOfExpectedTotalRepurchased", "presentation": [ "http://integralife.com/role/TREASURYSTOCKNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accelerated share repurchases, percentage of expected total repurchased", "label": "Accelerated Share Repurchases, Percentage Of Expected Total Repurchased", "documentation": "Accelerated Share Repurchases, Percentage Of Expected Total Repurchased" } } }, "auth_ref": [] }, "us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AcceleratedShareRepurchasesSettlementPaymentOrReceipt", "crdr": "debit", "presentation": [ "http://integralife.com/role/TREASURYSTOCKNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accelerated share repurchase program, receipt (payment)", "label": "Accelerated Share Repurchases, Settlement (Payment) or Receipt", "documentation": "Amount of cash receipt from (payment to) bank; or stock received from (issuance to) bank in the settlement of the accelerated share repurchase agreement." } } }, "auth_ref": [ "r168" ] }, "iart_AcceleratedShareRepurchasesSharesReceivedAtInception": { "xbrltype": "sharesItemType", "nsuri": "http://integralife.com/20240331", "localname": "AcceleratedShareRepurchasesSharesReceivedAtInception", "presentation": [ "http://integralife.com/role/TREASURYSTOCKNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accelerated share repurchases, shares received at inception (in shares)", "label": "Accelerated Share Repurchases, Shares Received at Inception", "documentation": "Accelerated Share Repurchases, Shares Received at Inception" } } }, "auth_ref": [] }, "iart_AcclarentInc.Member": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240331", "localname": "AcclarentInc.Member", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acclarent Inc.", "label": "Acclarent Inc. [Member]", "documentation": "Acclarent Inc." } } }, "auth_ref": [] }, "us-gaap_AccountsPayableTradeCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableTradeCurrent", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable, trade", "label": "Accounts Payable, Trade, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r34", "r36" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Trade accounts receivable, net of allowances of $5,050 and $4,879", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r303", "r304" ] }, "iart_AccruedExpensesAndOtherCurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240331", "localname": "AccruedExpensesAndOtherCurrentLiabilitiesMember", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other current liabilities", "label": "Accrued Expenses And Other Current Liabilities [Member]", "documentation": "Accrued expenses and other current liabilities." } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other current liabilities", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r39" ] }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "presentation": [ "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofChangesinAccumulatedOtherComprehensiveIncomebyComponentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Pension Items", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent." } } }, "auth_ref": [ "r8", "r19", "r48", "r865", "r866", "r867" ] }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "presentation": [ "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSNarrativeDetails", "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofChangesinAccumulatedOtherComprehensiveIncomebyComponentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gains and Losses on Derivatives", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": [ "r213", "r221", "r222", "r509", "r733", "r865" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": [ "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSNarrativeDetails", "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofChangesinAccumulatedOtherComprehensiveIncomebyComponentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r220", "r221", "r533", "r534", "r535", "r536", "r537", "r538" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r47", "r48", "r137", "r204", "r590", "r622", "r623" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": [ "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSNarrativeDetails", "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofChangesinAccumulatedOtherComprehensiveIncomebyComponentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r220", "r221", "r533", "r534", "r535", "r536", "r537", "r538" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofChangesinAccumulatedOtherComprehensiveIncomebyComponentDetails", "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUNAUDITED", "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Accumulated Other Comprehensive Loss", "terseLabel": "Total", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r6", "r19", "r48", "r518", "r521", "r553", "r618", "r619", "r865", "r866", "r867", "r876", "r877", "r878" ] }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedTranslationAdjustmentMember", "presentation": [ "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofChangesinAccumulatedOtherComprehensiveIncomebyComponentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency Items", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent." } } }, "auth_ref": [ "r7", "r19", "r48", "r221", "r222", "r534", "r535", "r536", "r537", "r538", "r865" ] }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSComponentsofCompanysIdentifiableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]", "label": "Acquired Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r816" ] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r126" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-In Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r484", "r485", "r486", "r633", "r876", "r877", "r878", "r921", "r946" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r822" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r822" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r822" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r822" ] }, "us-gaap_AdjustmentForAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentForAmortization", "crdr": "debit", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization", "label": "Amortization", "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives." } } }, "auth_ref": [ "r14", "r66" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r80", "r81", "r449" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r787", "r798", "r808", "r833" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r790", "r801", "r811", "r836" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r822" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r829" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r794", "r802", "r812", "r829", "r837", "r841", "r849" ] }, "iart_AllOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240331", "localname": "AllOtherMember", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSComponentsofCompanysIdentifiableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "All other", "label": "All Other [Member]", "documentation": "All Other [Member]" } } }, "auth_ref": [] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r847" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Trade accounts receivable, allowance", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r205", "r305", "r309" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://integralife.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "iart_AmortizationOfDebtIssuanceCostsAndDebtRefinancedFees": { "xbrltype": "monetaryItemType", "nsuri": "http://integralife.com/20240331", "localname": "AmortizationOfDebtIssuanceCostsAndDebtRefinancedFees", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of debt issuance costs and expenses associated with debt refinancing", "label": "Amortization Of Debt Issuance Costs And Debt Refinanced Fees", "documentation": "Amortization Of Debt Issuance Costs And Debt Refinanced Fees" } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED", "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNetSalesandProfitbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible asset amortization", "negatedTerseLabel": "Amortization", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r14", "r61", "r66" ] }, "iart_AnnualRateOfLeaseAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://integralife.com/20240331", "localname": "AnnualRateOfLeaseAgreement", "crdr": "debit", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Annual rate of lease agreement", "label": "Annual Rate Of Lease Agreement", "documentation": "Annual rate of lease agreement." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://integralife.com/role/NETINCOMEPERSHARENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares excluded from computation as their effect would be antidilutive (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r263" ] }, "iart_ArkisBioSciencesInc.Member": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240331", "localname": "ArkisBioSciencesInc.Member", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails", "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Arkis", "label": "Arkis BioSciences Inc. [Member]", "documentation": "Arkis BioSciences Inc. [Member]" } } }, "auth_ref": [] }, "srt_AsiaPacificMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "AsiaPacificMember", "presentation": [ "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTotalRevenuebyMajorGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asia Pacific", "label": "Asia Pacific [Member]" } } }, "auth_ref": [ "r948", "r949", "r950", "r951" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r177", "r200", "r231", "r273", "r288", "r294", "r306", "r344", "r345", "r347", "r348", "r349", "r351", "r353", "r355", "r356", "r507", "r510", "r531", "r586", "r660", "r763", "r778", "r907", "r908", "r931" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "iart_AssetsAndLiabilitiesLesseeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://integralife.com/20240331", "localname": "AssetsAndLiabilitiesLesseeTableTextBlock", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental Balance Sheet Information", "label": "Assets And Liabilities, Lessee [Table Text Block]", "documentation": "Assets And Liabilities, Lessee [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r194", "r209", "r231", "r306", "r344", "r345", "r347", "r348", "r349", "r351", "r353", "r355", "r356", "r507", "r510", "r531", "r763", "r907", "r908", "r931" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r844" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r845" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r840" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r840" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r840" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r840" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r840" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r840" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r843" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r842" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r841" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r841" ] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Axis]", "label": "Balance Sheet Location [Axis]", "documentation": "Information by location on balance sheet (statement of financial position)." } } }, "auth_ref": [] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Domain]", "label": "Balance Sheet Location [Domain]", "documentation": "Location in the balance sheet (statement of financial position)." } } }, "auth_ref": [ "r97", "r102" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://integralife.com/role/BASISOFPRESENTATIONPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis Of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "iart_BioDEarnoutPaymentsandMedihoneyEarnoutPaymentsMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240331", "localname": "BioDEarnoutPaymentsandMedihoneyEarnoutPaymentsMember", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BioD Earnout Payments and Medihoney Earnout Payments", "label": "BioD Earnout Payments and Medihoney Earnout Payments [Member]", "documentation": "BioD Earnout Payments and Medihoney Earnout Payments [Member]" } } }, "auth_ref": [] }, "us-gaap_BuildingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BuildingMember", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leased facilities", "label": "Building [Member]", "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities." } } }, "auth_ref": [ "r158" ] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails", "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails", "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r504", "r757", "r758" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails", "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails", "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r82", "r84", "r504", "r757", "r758" ] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionLineItems", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Line Items]", "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r504" ] }, "iart_BusinessAcquisitionNumberOfContingentLiabilities": { "xbrltype": "integerItemType", "nsuri": "http://integralife.com/20240331", "localname": "BusinessAcquisitionNumberOfContingentLiabilities", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of contingent liabilities", "label": "Business Acquisition, Number Of Contingent Liabilities", "documentation": "Business Acquisition, Number Of Contingent Liabilities" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of shares acquired", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination." } } }, "auth_ref": [ "r83" ] }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationConsiderationTransferred1", "crdr": "credit", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase price of business combination", "label": "Business Combination, Consideration Transferred", "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer." } } }, "auth_ref": [ "r2", "r3", "r17" ] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "verboseLabel": "Change in fair value of contingent consideration and others", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement." } } }, "auth_ref": [ "r506", "r869" ] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "crdr": "credit", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration, maximum undiscounted payment amount", "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High", "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid." } } }, "auth_ref": [ "r90" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails", "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration, cash payments due upon achievement of certain revenue-based performance milestones (up to)", "verboseLabel": "Contingent consideration, estimated fair value", "label": "Business Combination, Contingent Consideration, Liability", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination." } } }, "auth_ref": [ "r4", "r89", "r505" ] }, "iart_BusinessCombinationContingentConsiderationNumberOfLiabilities": { "xbrltype": "integerItemType", "nsuri": "http://integralife.com/20240331", "localname": "BusinessCombinationContingentConsiderationNumberOfLiabilities", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of contingent liabilities remaining", "label": "Business Combination, Contingent Consideration, Number Of Liabilities", "documentation": "Business Combination, Contingent Consideration, Number Of Liabilities" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability", "crdr": "credit", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability", "documentation": "The amount of liability arising from an inherited contingency (as defined) which has been recognized as of the acquisition date." } } }, "auth_ref": [ "r85", "r86" ] }, "us-gaap_CallOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CallOptionMember", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Call Option", "label": "Call Option [Member]", "documentation": "Financial contract between two parties, the buyer and the seller of the option, where the buyer has the right but not the obligation to buy an agreed quantity of a particular commodity or financial instrument (the underlying instrument) from the seller of the option for a certain price (the strike price). Seller is obligated to sell the asset to the buyer, if the buyer exercises the option." } } }, "auth_ref": [ "r698", "r699" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r54", "r196", "r725" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents at beginning of period", "periodEndLabel": "Cash and cash equivalents at end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r54", "r150", "r229" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase (decrease) in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r5", "r150" ] }, "us-gaap_CashFlowHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowHedgingMember", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Flow Hedges", "label": "Cash Flow Hedging [Member]", "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk." } } }, "auth_ref": [ "r94" ] }, "iart_CashFlowLesseeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://integralife.com/20240331", "localname": "CashFlowLesseeAbstract", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESSupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:", "label": "Cash Flow, Lessee [Abstract]", "documentation": "Cash Flow, Lessee [Abstract]" } } }, "auth_ref": [] }, "iart_CashFlowLesseeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://integralife.com/20240331", "localname": "CashFlowLesseeTableTextBlock", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental Cash Flow Information", "label": "Cash Flow, Lessee [Table Text Block]", "documentation": "Cash Flow, Lessee [Table Text Block]" } } }, "auth_ref": [] }, "iart_ChangeInContractWithCustomerAssetRollForward": { "xbrltype": "stringItemType", "nsuri": "http://integralife.com/20240331", "localname": "ChangeInContractWithCustomerAssetRollForward", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofChangesinContractAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract Asset", "label": "Change In Contract With Customer, Asset [Roll Forward]", "documentation": "Change In Contract With Customer, Asset [Roll Forward]" } } }, "auth_ref": [] }, "iart_ChangeInContractWithCustomerLiabilityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://integralife.com/20240331", "localname": "ChangeInContractWithCustomerLiabilityRollForward", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofChangesinContractAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract Liability", "label": "Change In Contract With Customer, Liability [Roll Forward]", "documentation": "Change In Contract With Customer, Liability [Roll Forward]" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r820" ] }, "srt_ChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ChiefExecutiveOfficerMember", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Chief Executive Officer", "label": "Chief Executive Officer [Member]" } } }, "auth_ref": [ "r883" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://integralife.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockLineItems", "presentation": [ "http://integralife.com/role/TREASURYSTOCKNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Line Items]", "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r201", "r202", "r203", "r268", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r627", "r628", "r629", "r630", "r744", "r855", "r871" ] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant strike price (in dollars per share)", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r392" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r821" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r821" ] }, "iart_CodmanMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240331", "localname": "CodmanMember", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Codman", "label": "Codman [Member]", "documentation": "Codman [Member]" } } }, "auth_ref": [] }, "iart_CodmanSpecialtySurgicalMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240331", "localname": "CodmanSpecialtySurgicalMember", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails", "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofRevenuesDisaggregatedbyMajorSourceDetails", "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNarrativeDetails", "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNetSalesandProfitbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Codman Specialty Surgical", "verboseLabel": "Codman Specialty Surgical", "label": "Codman Specialty Surgical [Member]", "documentation": "Codman Specialty Surgical [Member]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIES" ], "lang": { "en-us": { "role": { "terseLabel": "COMMITMENTS AND CONTINGENCIES", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r159", "r336", "r337", "r709", "r900" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r766", "r767", "r768", "r770", "r771", "r772", "r775", "r876", "r877", "r921", "r943", "r946" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r125" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, authorized shares (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r125", "r648" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, issued shares (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r125" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock; $0.01 par value; 240,000 authorized shares; 91,484 and 90,920 issued at March\u00a031, 2024 and December\u00a031, 2023, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r125", "r589", "r763" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r826" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r825" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r827" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r824" ] }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CompensationAndRetirementDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Retirement Benefits [Abstract]", "label": "Retirement Benefits [Abstract]" } } }, "auth_ref": [] }, "iart_CompletedTechnologyMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240331", "localname": "CompletedTechnologyMember", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSComponentsofCompanysIdentifiableIntangibleAssetsDetails", "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Completed technology", "label": "Completed Technology [Member]", "documentation": "Completed technology." } } }, "auth_ref": [] }, "iart_CompletedTechnologyPriMatrixMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240331", "localname": "CompletedTechnologyPriMatrixMember", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Completed Technology, PriMatrix", "label": "Completed Technology, PriMatrix [Member]", "documentation": "Completed Technology, PriMatrix" } } }, "auth_ref": [] }, "iart_CompletedTechnologySurgiMendMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240331", "localname": "CompletedTechnologySurgiMendMember", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Completed Technology, Surgimend", "label": "Completed Technology, SurgiMend [Member]", "documentation": "Completed Technology, SurgiMend" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofComprehensiveIncomeDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofComprehensiveIncomeDetails", "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Comprehensive income (See Note 14)", "totalLabel": "Comprehensive income, net", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r49", "r217", "r219", "r225", "r582", "r597" ] }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNoteTextBlock", "presentation": [ "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)", "label": "Comprehensive Income (Loss) Note [Text Block]", "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income." } } }, "auth_ref": [ "r135", "r224", "r581", "r596" ] }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidationItemsAxis", "presentation": [ "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNetSalesandProfitbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Axis]", "label": "Consolidation Items [Axis]" } } }, "auth_ref": [ "r237", "r275", "r286", "r287", "r288", "r289", "r290", "r292", "r296", "r344", "r345", "r346", "r347", "r349", "r350", "r352", "r354", "r355", "r907", "r908" ] }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidationItemsDomain", "presentation": [ "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNetSalesandProfitbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Activities [Domain]", "label": "Consolidation Items [Domain]" } } }, "auth_ref": [ "r237", "r275", "r286", "r287", "r288", "r289", "r290", "r292", "r296", "r344", "r345", "r346", "r347", "r349", "r350", "r352", "r354", "r355", "r907", "r908" ] }, "us-gaap_ContingentConsiderationByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContingentConsiderationByTypeAxis", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent Consideration by Type [Axis]", "label": "Contingent Consideration by Type [Axis]", "documentation": "Information by type of contingent consideration." } } }, "auth_ref": [] }, "iart_ContingentConsiderationLiabilityMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240331", "localname": "ContingentConsiderationLiabilityMember", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent Consideration Liability", "label": "Contingent Consideration Liability [Member]", "documentation": "Contingent Consideration Liability [Member]" } } }, "auth_ref": [] }, "us-gaap_ContingentConsiderationTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContingentConsiderationTypeDomain", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent Consideration Type [Domain]", "label": "Contingent Consideration Type [Domain]", "documentation": "Description of contingent payment arrangement." } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Changes in Contract Assets and Contract Liabilities", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability." } } }, "auth_ref": [ "r911" ] }, "us-gaap_ContractWithCustomerAssetNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerAssetNet", "crdr": "debit", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofChangesinContractAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Contract asset, Beginning of period", "periodEndLabel": "Contract asset, End of Period", "label": "Contract with Customer, Asset, after Allowance for Credit Loss", "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time." } } }, "auth_ref": [ "r395", "r397", "r416" ] }, "iart_ContractWithCustomerAssetNetOfReclassifiedToReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://integralife.com/20240331", "localname": "ContractWithCustomerAssetNetOfReclassifiedToReceivable", "crdr": "debit", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofChangesinContractAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract asset, net of transferred to trade receivables on contracts during the period", "label": "Contract With Customer, Asset, Net Of Reclassified To Receivable", "documentation": "Contract With Customer, Asset, Net Of Reclassified To Receivable" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerAssetReclassifiedToReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerAssetReclassifiedToReceivable", "crdr": "credit", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofChangesinContractAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Transferred to trade receivable from contract asset included in beginning of the year contract asset", "label": "Contract with Customer, Asset, Reclassified to Receivable", "documentation": "Amount of decrease in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time from transfer to receivable due to right to consideration becoming unconditional." } } }, "auth_ref": [ "r745" ] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofChangesinContractAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Contract liability, beginning of period", "periodEndLabel": "Contract liability, end of period", "label": "Contract with Customer, Liability", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r395", "r396", "r416" ] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract liabilities", "verboseLabel": "Short-term portion of contract liability", "label": "Contract with Customer, Liability, Current", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r395", "r396", "r416" ] }, "iart_ContractWithCustomerLiabilityIncreaseDecreaseFromForeignCurrencyTranslation": { "xbrltype": "monetaryItemType", "nsuri": "http://integralife.com/20240331", "localname": "ContractWithCustomerLiabilityIncreaseDecreaseFromForeignCurrencyTranslation", "crdr": "credit", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofChangesinContractAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation", "label": "Contract With Customer, Liability, Increase (Decrease) From Foreign Currency Translation", "documentation": "Contract With Customer, Liability, Increase (Decrease) From Foreign Currency Translation" } } }, "auth_ref": [] }, "iart_ContractWithCustomerLiabilityNetOfRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://integralife.com/20240331", "localname": "ContractWithCustomerLiabilityNetOfRevenueRecognized", "crdr": "credit", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofChangesinContractAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Recognition of revenue included in beginning of year contract liability", "label": "Contract With Customer, Liability, Net Of Revenue Recognized", "documentation": "Contract With Customer, Liability, Net Of Revenue Recognized" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityNoncurrent", "crdr": "credit", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term portion of contract liability", "label": "Contract with Customer, Liability, Noncurrent", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": [ "r395", "r396", "r416" ] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofChangesinContractAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Contract liability, net of revenue recognized on contracts during the period", "label": "Contract with Customer, Liability, Revenue Recognized", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": [ "r417" ] }, "us-gaap_ConvertibleDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtMember", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible Debt", "label": "Convertible Debt [Member]", "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock." } } }, "auth_ref": [ "r161", "r358", "r359", "r369", "r370", "r371", "r375", "r376", "r377", "r378", "r379", "r739", "r740", "r741", "r742", "r743" ] }, "us-gaap_ConvertibleDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtNoncurrent", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term convertible securities", "label": "Convertible Debt, Noncurrent", "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock." } } }, "auth_ref": [ "r43" ] }, "us-gaap_CorporateNonSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CorporateNonSegmentMember", "presentation": [ "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNetSalesandProfitbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate and other", "label": "Corporate, Non-Segment [Member]", "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment." } } }, "auth_ref": [ "r28", "r287", "r288", "r289", "r290", "r296", "r882" ] }, "iart_CostOfDefiniteAndIndefiniteLivedIntangibleAssetsGrossExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://integralife.com/20240331", "localname": "CostOfDefiniteAndIndefiniteLivedIntangibleAssetsGrossExcludingGoodwill", "crdr": "debit", "calculation": { "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSComponentsofCompanysIdentifiableIntangibleAssetsDetails": { "parentTag": "iart_DefiniteAndIndefiniteLivedIntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSComponentsofCompanysIdentifiableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost", "label": "Cost Of Definite And Indefinite Lived Intangible Assets Gross Excluding Goodwill", "documentation": "Cost Of Definite And Indefinite Lived Intangible Assets Gross Excluding Goodwill." } } }, "auth_ref": [] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of goods sold", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r141", "r565" ] }, "us-gaap_CostOfGoodsAndServicesSoldAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSoldAmortization", "crdr": "debit", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost, amortization", "label": "Cost, Amortization", "documentation": "Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service." } } }, "auth_ref": [ "r868" ] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfSalesMember", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of Sales", "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsAndExpenses", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "Total costs and expenses", "label": "Costs and Expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": [ "r140" ] }, "us-gaap_CostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsAndExpensesAbstract", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Costs and expenses:", "label": "Costs and Expenses [Abstract]" } } }, "auth_ref": [] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r235", "r236", "r361", "r387", "r557", "r730", "r732" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityAxis", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityDomain", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_CrossCurrencyInterestRateContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CrossCurrencyInterestRateContractMember", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cross-currency swap", "label": "Cross Currency Interest Rate Contract [Member]", "documentation": "Derivative instrument whose primary underlying risk is tied to interest rates and foreign exchange rates." } } }, "auth_ref": [ "r913", "r919" ] }, "iart_CrossCurrencyInterestRateContractOneMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240331", "localname": "CrossCurrencyInterestRateContractOneMember", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cross Currency Interest Rate Swap One", "label": "Cross Currency Interest Rate Contract One [Member]", "documentation": "Cross Currency Interest Rate Contract One [Member]" } } }, "auth_ref": [] }, "iart_CrossCurrencyInterestRateContractThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240331", "localname": "CrossCurrencyInterestRateContractThreeMember", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cross Currency Interest Rate Swap Three", "label": "Cross Currency Interest Rate Contract Three [Member]", "documentation": "Cross Currency Interest Rate Contract Three [Member]" } } }, "auth_ref": [] }, "iart_CrossCurrencyInterestRateContractTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240331", "localname": "CrossCurrencyInterestRateContractTwoMember", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cross Currency Interest Rate Swap Two", "label": "Cross Currency Interest Rate Contract Two [Member]", "documentation": "Cross Currency Interest Rate Contract Two [Member]" } } }, "auth_ref": [] }, "us-gaap_CurrencySwapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrencySwapMember", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativesNotDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency swaps", "label": "Currency Swap [Member]", "documentation": "Swap involving the exchange of principal and interest in one currency for another currency." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://integralife.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerRelationshipsMember", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSComponentsofCompanysIdentifiableIntangibleAssetsDetails", "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Customer relationships", "terseLabel": "Customer Relationships", "label": "Customer Relationships [Member]", "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships." } } }, "auth_ref": [ "r88" ] }, "iart_DebtCovenantPeriod1Member": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240331", "localname": "DebtCovenantPeriod1Member", "presentation": [ "http://integralife.com/role/DEBTMaximumTotalLeverageRatioTableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "March 31, 2023 through December 31, 2024", "label": "Debt Covenant Period 1 [Member]", "documentation": "Debt Covenant Period 1" } } }, "auth_ref": [] }, "iart_DebtCovenantPeriod2Member": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240331", "localname": "DebtCovenantPeriod2Member", "presentation": [ "http://integralife.com/role/DEBTMaximumTotalLeverageRatioTableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "March 31, 2025 through June 30, 2026", "label": "Debt Covenant Period 2 [Member]", "documentation": "Debt Covenant Period 2" } } }, "auth_ref": [] }, "iart_DebtCovenantPeriod3Member": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240331", "localname": "DebtCovenantPeriod3Member", "presentation": [ "http://integralife.com/role/DEBTMaximumTotalLeverageRatioTableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "September 30, 2026 and the last day of each fiscal quarter thereafter", "label": "Debt Covenant Period 3 [Member]", "documentation": "Debt Covenant Period 3 [Member]" } } }, "auth_ref": [] }, "iart_DebtCovenantPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "http://integralife.com/20240331", "localname": "DebtCovenantPeriodAxis", "presentation": [ "http://integralife.com/role/DEBTMaximumTotalLeverageRatioTableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Covenant Period [Axis]", "label": "Debt Covenant Period [Axis]", "documentation": "Debt Covenant Period [Axis]" } } }, "auth_ref": [] }, "iart_DebtCovenantPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240331", "localname": "DebtCovenantPeriodDomain", "presentation": [ "http://integralife.com/role/DEBTMaximumTotalLeverageRatioTableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Covenant Period [Domain]", "label": "Debt Covenant Period [Domain]", "documentation": "[Domain] for Debt Covenant Period [Axis]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://integralife.com/role/DEBT" ], "lang": { "en-us": { "role": { "terseLabel": "DEBT", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r160", "r230", "r357", "r363", "r364", "r365", "r366", "r367", "r368", "r373", "r380", "r381", "r383" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://integralife.com/role/DEBTMaximumTotalLeverageRatioTableDetails", "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r33", "r122", "r123", "r178", "r179", "r237", "r358", "r359", "r360", "r361", "r362", "r364", "r369", "r370", "r371", "r372", "r374", "r375", "r376", "r377", "r378", "r379", "r541", "r739", "r740", "r741", "r742", "r743", "r872" ] }, "iart_DebtInstrumentBasisSpreadAdjustmentOnVariableRate": { "xbrltype": "percentItemType", "nsuri": "http://integralife.com/20240331", "localname": "DebtInstrumentBasisSpreadAdjustmentOnVariableRate", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate adjustment", "label": "Debt Instrument, Basis Spread Adjustment On Variable Rate", "documentation": "Debt Instrument, Basis Spread Adjustment On Variable Rate" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rates available", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "iart_DebtInstrumentCombinationSettlementForDebtConversionMinimumSettledInCashPerPrincipalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://integralife.com/20240331", "localname": "DebtInstrumentCombinationSettlementForDebtConversionMinimumSettledInCashPerPrincipalAmount", "crdr": "credit", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum settled in cash per principal amount", "label": "Debt Instrument, Combination Settlement For Debt Conversion, Minimum Settled In Cash Per Principal Amount", "documentation": "Debt Instrument, Combination Settlement For Debt Conversion, Minimum Settled In Cash Per Principal Amount" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleConversionPrice1", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Initial conversion price (in dollars per share)", "label": "Debt Instrument, Convertible, Conversion Price", "documentation": "The price per share of the conversion feature embedded in the debt instrument." } } }, "auth_ref": [ "r162", "r360" ] }, "us-gaap_DebtInstrumentConvertibleConversionRatio1": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleConversionRatio1", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Initial conversion rate", "label": "Debt Instrument, Convertible, Conversion Ratio", "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount." } } }, "auth_ref": [ "r42", "r73", "r164", "r165", "r360" ] }, "iart_DebtInstrumentCovenantMaximumLeverageRatio": { "xbrltype": "pureItemType", "nsuri": "http://integralife.com/20240331", "localname": "DebtInstrumentCovenantMaximumLeverageRatio", "presentation": [ "http://integralife.com/role/DEBTMaximumTotalLeverageRatioTableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum Consolidated Total Leverage Ratio", "label": "Debt Instrument, Covenant, Maximum Leverage Ratio", "documentation": "Debt Instrument, Covenant, Maximum Leverage Ratio" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible notes, maximum borrowing capacity", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r116", "r118", "r358", "r541", "r740", "r741" ] }, "us-gaap_DebtInstrumentFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFairValue", "crdr": "credit", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value", "label": "Debt Instrument, Fair Value Disclosure", "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable." } } }, "auth_ref": [ "r371", "r530", "r740", "r741" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible notes, interest rate", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r41", "r359" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://integralife.com/role/DEBTMaximumTotalLeverageRatioTableDetails", "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r237", "r358", "r359", "r360", "r361", "r362", "r364", "r369", "r370", "r371", "r372", "r374", "r375", "r376", "r377", "r378", "r379", "r382", "r541", "r739", "r740", "r741", "r742", "r743", "r872" ] }, "iart_DebtInstrumentMaximumAverageConversionValueOfNotes": { "xbrltype": "percentItemType", "nsuri": "http://integralife.com/20240331", "localname": "DebtInstrumentMaximumAverageConversionValueOfNotes", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum average conversion value of notes", "label": "Debt Instrument, Maximum Average Conversion Value Of Notes", "documentation": "Debt Instrument, Maximum Average Conversion Value Of Notes" } } }, "auth_ref": [] }, "iart_DebtInstrumentMaximumSellingPriceOfCommonStockOfTheConversionPriceDuringPeriod": { "xbrltype": "percentItemType", "nsuri": "http://integralife.com/20240331", "localname": "DebtInstrumentMaximumSellingPriceOfCommonStockOfTheConversionPriceDuringPeriod", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum selling price of the company's common stock of the conversion price", "label": "Debt Instrument, Maximum Selling Price Of Common Stock Of The Conversion Price During Period", "documentation": "Debt Instrument, Maximum Selling Price Of Common Stock Of The Conversion Price During Period" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://integralife.com/role/DEBTMaximumTotalLeverageRatioTableDetails", "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r43", "r237", "r358", "r359", "r360", "r361", "r362", "r364", "r369", "r370", "r371", "r372", "r374", "r375", "r376", "r377", "r378", "r379", "r541", "r739", "r740", "r741", "r742", "r743", "r872" ] }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentRedemptionPricePercentage", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Redemption price, percentage", "label": "Debt Instrument, Redemption Price, Percentage", "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer." } } }, "auth_ref": [ "r27" ] }, "iart_DebtInstrumentSecuritizationFacilityAgreementTerm": { "xbrltype": "durationItemType", "nsuri": "http://integralife.com/20240331", "localname": "DebtInstrumentSecuritizationFacilityAgreementTerm", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, securitization facility, agreement term", "label": "Debt Instrument, Securitization Facility, Agreement Term", "documentation": "Debt Instrument, Securitization Facility, Agreement Term" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://integralife.com/role/DEBTMaximumTotalLeverageRatioTableDetails", "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r43", "r73", "r76", "r115", "r116", "r118", "r119", "r163", "r165", "r237", "r358", "r359", "r360", "r361", "r362", "r364", "r369", "r370", "r371", "r372", "r374", "r375", "r376", "r377", "r378", "r379", "r382", "r541", "r739", "r740", "r741", "r742", "r743", "r872" ] }, "us-gaap_DebtWeightedAverageInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtWeightedAverageInterestRate", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average interest rate on debt", "label": "Debt, Weighted Average Interest Rate", "documentation": "Weighted average interest rate of debt outstanding." } } }, "auth_ref": [] }, "iart_DebtWeightedAverageInterestRateFromSecuritization": { "xbrltype": "percentItemType", "nsuri": "http://integralife.com/20240331", "localname": "DebtWeightedAverageInterestRateFromSecuritization", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average interest rate, accounts receivable securitization revolving loan facility", "label": "Debt, Weighted Average Interest Rate, From Securitization", "documentation": "Debt, Weighted Average Interest Rate, From Securitization" } } }, "auth_ref": [] }, "us-gaap_DeferredCompensationPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCompensationPlanAssets", "crdr": "debit", "presentation": [ "http://integralife.com/role/RETIREMENTPLANSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred compensation plan, fair value of assets", "label": "Deferred Compensation Plan Assets", "documentation": "Carrying amount as of the balance sheet date of assets held under deferred compensation agreements." } } }, "auth_ref": [ "r862" ] }, "us-gaap_DeferredFinanceCostsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFinanceCostsGross", "crdr": "debit", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Incremental financing costs capitalized", "label": "Debt Issuance Costs, Gross", "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r117" ] }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFinanceCostsNet", "crdr": "debit", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt issuance costs capitalized", "label": "Debt Issuance Costs, Net", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r117", "r910" ] }, "us-gaap_DeferredIncomeTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxAssetsNet", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets, net", "label": "Deferred Income Tax Assets, Net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting." } } }, "auth_ref": [ "r488", "r489" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income tax provision (benefit)", "label": "Deferred Income Tax Expense (Benefit)", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r14", "r170", "r188", "r499", "r500", "r874" ] }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax liabilities", "label": "Deferred Income Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": [ "r488", "r489", "r587" ] }, "iart_DefinedBenefitPlanDeferPaymentAndTaxationBaseSalaryPercentage": { "xbrltype": "percentItemType", "nsuri": "http://integralife.com/20240331", "localname": "DefinedBenefitPlanDeferPaymentAndTaxationBaseSalaryPercentage", "presentation": [ "http://integralife.com/role/RETIREMENTPLANSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defer payment and taxation, base salary, percentage (up to)", "label": "Defined Benefit Plan, Defer Payment And Taxation, Base Salary, Percentage", "documentation": "Defined Benefit Plan, Defer Payment And Taxation, Base Salary, Percentage" } } }, "auth_ref": [] }, "iart_DefinedBenefitPlanDeferPaymentAndTaxationBonusAndOtherCompensationPercentage": { "xbrltype": "percentItemType", "nsuri": "http://integralife.com/20240331", "localname": "DefinedBenefitPlanDeferPaymentAndTaxationBonusAndOtherCompensationPercentage", "presentation": [ "http://integralife.com/role/RETIREMENTPLANSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defer payment and taxation, bonus and other eligible cash compensation, percentage (up to)", "label": "Defined Benefit Plan, Defer Payment And Taxation, Bonus And Other Compensation, Percentage", "documentation": "Defined Benefit Plan, Defer Payment And Taxation, Bonus And Other Compensation, Percentage" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanFairValueOfPlanAssets", "crdr": "debit", "presentation": [ "http://integralife.com/role/RETIREMENTPLANSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated fair value of plan assets", "label": "Defined Benefit Plan, Plan Assets, Amount", "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee." } } }, "auth_ref": [ "r421", "r423", "r425", "r426", "r753", "r754", "r755" ] }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanNetPeriodicBenefitCost", "crdr": "debit", "presentation": [ "http://integralife.com/role/RETIREMENTPLANSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net periodic benefit costs", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)", "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan." } } }, "auth_ref": [ "r431", "r440", "r755", "r756" ] }, "us-gaap_DefinedBenefitPlanServiceCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanServiceCost", "crdr": "debit", "presentation": [ "http://integralife.com/role/RETIREMENTPLANSNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Service cost component", "label": "Defined Benefit Plan, Service Cost", "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan." } } }, "auth_ref": [ "r420", "r432", "r441", "r755", "r756" ] }, "iart_DefiniteAndIndefiniteLivedIntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://integralife.com/20240331", "localname": "DefiniteAndIndefiniteLivedIntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSComponentsofCompanysIdentifiableIntangibleAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSComponentsofCompanysIdentifiableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net", "label": "Definite And Indefinite Lived Intangible Assets Net Excluding Goodwill", "documentation": "Definite And Indefinite Lived Intangible Assets Net Excluding Goodwill." } } }, "auth_ref": [] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativesNotDesignatedasHedgingInstrumentsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Contract [Domain]", "verboseLabel": "Derivative, Name [Domain]", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r638", "r640", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r661", "r662", "r663", "r664", "r675", "r676", "r677", "r678", "r681", "r682", "r683", "r684", "r699", "r700", "r703", "r704", "r766", "r768" ] }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeFairValueOfDerivativeAsset", "crdr": "debit", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total derivatives designated as hedges \u2014 Assets", "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset", "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement." } } }, "auth_ref": [ "r30", "r100", "r134", "r210", "r732" ] }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeFairValueOfDerivativeLiability", "crdr": "credit", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total derivatives designated as hedges \u2014 Liabilities", "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset", "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement." } } }, "auth_ref": [ "r30", "r100", "r134", "r210", "r732" ] }, "us-gaap_DerivativeFairValueOfDerivativeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeFairValueOfDerivativeNet", "crdr": "debit", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Estimated Fair Value", "terseLabel": "Fair Value Asset (Liability)", "label": "Derivative, Fair Value, Net", "documentation": "Fair value of the assets less the liabilities of a derivative or group of derivatives." } } }, "auth_ref": [ "r530" ] }, "us-gaap_DerivativeFixedInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeFixedInterestRate", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fixed Interest Rate", "verboseLabel": "Fixed Rate", "label": "Derivative, Fixed Interest Rate", "documentation": "Fixed interest rate related to the interest rate derivative." } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativesNotDesignatedasHedgingInstrumentsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instrument [Axis]", "verboseLabel": "Derivative, by Nature [Axis]", "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r98", "r101", "r103", "r105", "r638", "r640", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r661", "r662", "r663", "r664", "r675", "r676", "r677", "r678", "r681", "r682", "r683", "r684", "r699", "r700", "r703", "r704", "r732", "r766", "r768" ] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTS" ], "lang": { "en-us": { "role": { "terseLabel": "DERIVATIVE INSTRUMENTS", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts." } } }, "auth_ref": [ "r174", "r515", "r523" ] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Axis]", "label": "Hedging Relationship [Axis]", "documentation": "Information by type of hedging relationship." } } }, "auth_ref": [ "r21", "r98", "r103" ] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativesNotDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) by Hedging Relationship, by Income Statement Location, by Derivative Instrument Risk [Table]", "label": "Derivative Instruments, Gain (Loss) [Table]", "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": [ "r21", "r98", "r103", "r105", "r109", "r110", "r514" ] }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsGainLossLineItems", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativesNotDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r514" ] }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "crdr": "credit", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativesNotDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative instruments not designated as hedging instruments, gain (loss), net", "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net", "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments." } } }, "auth_ref": [ "r104", "r860" ] }, "us-gaap_DerivativeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLineItems", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Line Items]", "label": "Derivative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r523" ] }, "us-gaap_DerivativeNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeNotionalAmount", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Notional Amount", "terseLabel": "Current notional amount", "netLabel": "Aggregate Notional Amount", "label": "Derivative, Notional Amount", "documentation": "Nominal or face amount used to calculate payment on derivative." } } }, "auth_ref": [ "r917", "r918" ] }, "iart_DerivativeNotionalAmountSettled": { "xbrltype": "monetaryItemType", "nsuri": "http://integralife.com/20240331", "localname": "DerivativeNotionalAmountSettled", "crdr": "debit", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notional amount settled", "label": "Derivative, Notional Amount, Settled", "documentation": "Derivative, Notional Amount, Settled" } } }, "auth_ref": [] }, "iart_DerivativeNotionalAmountTerminated": { "xbrltype": "monetaryItemType", "nsuri": "http://integralife.com/20240331", "localname": "DerivativeNotionalAmountTerminated", "crdr": "credit", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notional amount terminated", "label": "Derivative, Notional Amount, Terminated", "documentation": "Derivative, Notional Amount, Terminated" } } }, "auth_ref": [] }, "us-gaap_DerivativeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeTable", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Table]", "label": "Derivative [Table]", "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item." } } }, "auth_ref": [ "r21", "r91", "r92", "r93", "r96", "r99", "r103", "r107", "r108", "r110", "r523" ] }, "us-gaap_DerivativesFairValueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativesFairValueLineItems", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivatives, Fair Value [Line Items]", "label": "Derivatives, Fair Value [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "iart_DermaSciencesMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240331", "localname": "DermaSciencesMember", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails", "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derma Sciences", "label": "Derma Sciences [Member]", "documentation": "Derma Sciences [Member]" } } }, "auth_ref": [] }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DesignatedAsHedgingInstrumentMember", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Designated as Hedging Instrument", "label": "Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r21" ] }, "us-gaap_DilutiveSecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DilutiveSecuritiesAbstract", "presentation": [ "http://integralife.com/role/NETINCOMEPERSHAREBasicandDilutedNetIncomePerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of dilutive securities:", "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "srt_DirectorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "DirectorMember", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Directors", "label": "Director [Member]" } } }, "auth_ref": [ "r883", "r944" ] }, "iart_DirectorsandCertainExecutiveOfficersMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240331", "localname": "DirectorsandCertainExecutiveOfficersMember", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Directors and Certain Executive Officers", "label": "Directors and Certain Executive Officers [Member]", "documentation": "Directors and Certain Executive Officers [Member]" } } }, "auth_ref": [] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofRevenuesDisaggregatedbyMajorSourceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Line Items]", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r415", "r746", "r747", "r748", "r749", "r750", "r751", "r752" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofRevenuesDisaggregatedbyMajorSourceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r415", "r746", "r747", "r748", "r749", "r750", "r751", "r752" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Disaggregation of Revenue", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r912" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATION" ], "lang": { "en-us": { "role": { "terseLabel": "STOCK-BASED COMPENSATION", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r447", "r452", "r479", "r480", "r483", "r760" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://integralife.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://integralife.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://integralife.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://integralife.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r782" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://integralife.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r815" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://integralife.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "verboseLabel": "Net (loss) income per share", "terseLabel": "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED", "http://integralife.com/role/NETINCOMEPERSHAREBasicandDilutedNetIncomePerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in dollars per share)", "verboseLabel": "Basic net (loss) income per common share (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r226", "r243", "r244", "r245", "r246", "r247", "r253", "r255", "r260", "r261", "r262", "r266", "r525", "r526", "r583", "r598", "r734" ] }, "us-gaap_EarningsPerShareBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasicAbstract", "presentation": [ "http://integralife.com/role/NETINCOMEPERSHAREBasicandDilutedNetIncomePerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic net (loss) income per share:", "label": "Earnings Per Share, Basic [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED", "http://integralife.com/role/NETINCOMEPERSHAREBasicandDilutedNetIncomePerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in dollars per share)", "verboseLabel": "Diluted net (loss) income per common share (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r226", "r243", "r244", "r245", "r246", "r247", "r255", "r260", "r261", "r262", "r266", "r525", "r526", "r583", "r598", "r734" ] }, "us-gaap_EarningsPerShareDilutedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDilutedAbstract", "presentation": [ "http://integralife.com/role/NETINCOMEPERSHAREBasicandDilutedNetIncomePerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted net (loss) income per share:", "label": "Earnings Per Share, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://integralife.com/role/NETINCOMEPERSHARE" ], "lang": { "en-us": { "role": { "terseLabel": "NET INCOME PER SHARE", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r252", "r263", "r264", "r265" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of exchange rate changes on cash and cash equivalents", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r532" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [ "http://integralife.com/role/INCOMETAXESNarrativeDetails", "http://integralife.com/role/INCOMETAXESSummaryofEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Reported tax rate", "terseLabel": "Effective income tax rate", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r491" ] }, "iart_EmployeeMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240331", "localname": "EmployeeMember", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employees", "label": "Employee [Member]", "documentation": "Employee [Member]" } } }, "auth_ref": [] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued compensation", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r39" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total unrecognized compensation costs", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r482" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average period for cost recognition", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r482" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Options", "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://integralife.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://integralife.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity City", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://integralife.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://integralife.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity State", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://integralife.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r780" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://integralife.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://integralife.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://integralife.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r780" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://integralife.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://integralife.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r780" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://integralife.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://integralife.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r854" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://integralife.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r780" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://integralife.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r780" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://integralife.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Smaller Reporting Company", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r780" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://integralife.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r780" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Equity [Abstract]", "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSNarrativeDetails", "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofChangesinAccumulatedOtherComprehensiveIncomebyComponentDetails", "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUNAUDITED", "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r20", "r191", "r220", "r221", "r222", "r238", "r239", "r240", "r242", "r248", "r250", "r267", "r307", "r308", "r393", "r484", "r485", "r486", "r495", "r496", "r517", "r518", "r519", "r520", "r521", "r522", "r524", "r533", "r534", "r535", "r536", "r537", "r538", "r553", "r618", "r619", "r620", "r633", "r687" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r823" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r787", "r798", "r808", "r833" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r784", "r795", "r805", "r830" ] }, "srt_EuropeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "EuropeMember", "presentation": [ "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTotalRevenuebyMajorGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Europe", "label": "Europe [Member]" } } }, "auth_ref": [ "r948", "r949", "r950", "r951" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r829" ] }, "us-gaap_ExtendedProductWarrantyPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ExtendedProductWarrantyPolicy", "presentation": [ "http://integralife.com/role/BASISOFPRESENTATIONPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Product Warranties", "label": "Extended Product Warranty, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for extended product warranties and other guarantee contracts including the methodology for measuring the liability." } } }, "auth_ref": [ "r906" ] }, "iart_FDAApprovalOfPremarketApprovalMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240331", "localname": "FDAApprovalOfPremarketApprovalMember", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "FDA Approval Of Premarket Approval", "label": "FDA Approval Of Premarket Approval [Member]", "documentation": "FDA Approval Of Premarket Approval" } } }, "auth_ref": [] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails", "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r371", "r425", "r426", "r427", "r428", "r429", "r430", "r527", "r559", "r560", "r561", "r740", "r741", "r753", "r754", "r755" ] }, "us-gaap_FairValueByLiabilityClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByLiabilityClassAxis", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liability Class [Axis]", "label": "Liability Class [Axis]", "documentation": "Information by class of liability." } } }, "auth_ref": [ "r114", "r176" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Inputs, Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r371", "r425", "r430", "r527", "r560", "r740", "r741", "r753", "r754", "r755" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Inputs, Level 3", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r371", "r425", "r426", "r427", "r428", "r429", "r430", "r527", "r561", "r740", "r741", "r753", "r754", "r755" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value by Liability Class [Domain]", "label": "Fair Value by Liability Class [Domain]", "documentation": "Represents classes of liabilities measured and disclosed at fair value." } } }, "auth_ref": [ "r23" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3." } } }, "auth_ref": [ "r23", "r114" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Contingent Consideration", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability." } } }, "auth_ref": [ "r23", "r114" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "crdr": "credit", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Change in fair value of contingent consideration liabilities", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)." } } }, "auth_ref": [ "r529" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "crdr": "credit", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance, Beginning of Period", "periodEndLabel": "Balance, End of Period", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r23" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails", "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r371", "r425", "r426", "r427", "r428", "r429", "r430", "r559", "r560", "r561", "r740", "r741", "r753", "r754", "r755" ] }, "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]", "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]", "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position." } } }, "auth_ref": [ "r97", "r99", "r109" ] }, "us-gaap_FederalFundsEffectiveSwapRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FederalFundsEffectiveSwapRateMember", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Overnight Federal Funds", "label": "Fed Funds Effective Rate Overnight Index Swap Rate [Member]", "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap having its variable-rate leg referenced to Federal Funds effective rate with no additional spread over Federal Funds effective rate on that variable-rate leg." } } }, "auth_ref": [ "r920" ] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSComponentsofCompanysIdentifiableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Life", "label": "Finite-Lived Intangible Asset, Useful Life", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSComponentsofCompanysIdentifiableIntangibleAssetsDetails": { "parentTag": "iart_DefiniteAndIndefiniteLivedIntangibleAssetsNetExcludingGoodwill", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSComponentsofCompanysIdentifiableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Accumulated Amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r198", "r328" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "crdr": "debit", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected annual amortization expense, thereafter", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five", "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected annual amortization expense, in 2025", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r156" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "crdr": "debit", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected annual amortization expense, remainder of 2024", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "crdr": "debit", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected annual amortization expense, in 2029", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r156" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected annual amortization expense, in 2028", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r156" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected annual amortization expense, in 2027", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r156" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected annual amortization expense, in 2026", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r156" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSComponentsofCompanysIdentifiableIntangibleAssetsDetails", "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r325", "r327", "r328", "r330", "r566", "r567" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSComponentsofCompanysIdentifiableIntangibleAssetsDetails", "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r62", "r65" ] }, "iart_FiveYearOptionLeasePeriodOneMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240331", "localname": "FiveYearOptionLeasePeriodOneMember", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Five Year Option Lease From November 1, 2029 Through October 31, 2034", "label": "Five Year Option Lease Period One [Member]", "documentation": "Five-Year Option Lease Period One" } } }, "auth_ref": [] }, "iart_FiveYearOptionLeasePeriodTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240331", "localname": "FiveYearOptionLeasePeriodTwoMember", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Five Year Option Lease From November 1, 2034 Through October 31, 2039", "label": "Five Year Option Lease Period Two [Member]", "documentation": "Five-Year Option Lease Period Two" } } }, "auth_ref": [] }, "us-gaap_ForeignExchangeForwardMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignExchangeForwardMember", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency forward contracts", "label": "Foreign Exchange Forward [Member]", "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate." } } }, "auth_ref": [ "r654", "r658", "r663", "r677", "r683", "r701", "r702", "r703", "r768" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r791", "r802", "r812", "r837" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r791", "r802", "r812", "r837" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r791", "r802", "r812", "r837" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r791", "r802", "r812", "r837" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r791", "r802", "r812", "r837" ] }, "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnDerivativeInstrumentsNetPretax", "crdr": "credit", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain (loss) reclassified into other income", "label": "Gain (Loss) on Derivative Instruments, Net, Pretax", "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects." } } }, "auth_ref": [ "r98" ] }, "us-gaap_GainLossOnDispositionOfAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnDispositionOfAssets", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedLabel": "Loss (gain) on disposal of property and equipment", "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property", "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property." } } }, "auth_ref": [ "r870", "r897", "r898" ] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "periodStartLabel": "Beginning of period", "periodEndLabel": "End of period", "label": "Goodwill", "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r197", "r313", "r580", "r738", "r763", "r886", "r893" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]", "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETS" ], "lang": { "en-us": { "role": { "terseLabel": "GOODWILL AND OTHER INTANGIBLE ASSETS", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": [ "r155" ] }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r320" ] }, "us-gaap_GoodwillLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillLineItems", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails", "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Line Items]", "label": "Goodwill [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r738" ] }, "us-gaap_GoodwillRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillRollForward", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Roll Forward]", "label": "Goodwill [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_HedgingDesignationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingDesignationAxis", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Axis]", "label": "Hedging Designation [Axis]", "documentation": "Information by designation of purpose of derivative instrument." } } }, "auth_ref": [ "r21", "r514" ] }, "us-gaap_HedgingDesignationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingDesignationDomain", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Domain]", "label": "Hedging Designation [Domain]", "documentation": "Designation of purpose of derivative instrument." } } }, "auth_ref": [ "r21" ] }, "us-gaap_HedgingRelationshipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingRelationshipDomain", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Domain]", "label": "Hedging Relationship [Domain]", "documentation": "Nature or intent of a hedge." } } }, "auth_ref": [ "r21" ] }, "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOfIntangibleAssetsFinitelived", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash impairment charges", "label": "Impairment of Intangible Assets, Finite-Lived", "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value." } } }, "auth_ref": [ "r870", "r896" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "(Loss) income before income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r1", "r138", "r183", "r273", "r287", "r293", "r296", "r584", "r594", "r736" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r331", "r333", "r671" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r333", "r671" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://integralife.com/role/INCOMETAXES" ], "lang": { "en-us": { "role": { "terseLabel": "INCOME TAXES", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r232", "r487", "r492", "r493", "r494", "r497", "r501", "r502", "r503", "r632" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "(Benefit) provision for income taxes", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r186", "r189", "r249", "r250", "r281", "r490", "r498", "r599" ] }, "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationTaxCreditsResearch", "crdr": "credit", "presentation": [ "http://integralife.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax benefit, tax credit, research and development", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit." } } }, "auth_ref": [ "r916" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable, accrued expenses and other current liabilities", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r13" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r13" ] }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Contract liabilities", "label": "Increase (Decrease) in Contract with Customer, Liability", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r564", "r869" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 13.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedLabel": "Inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r13" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-current liabilities", "label": "Increase (Decrease) in Other Noncurrent Liabilities", "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingAssets", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedLabel": "Other non-current assets", "label": "Increase (Decrease) in Other Operating Assets", "documentation": "Amount of increase (decrease) in operating assets classified as other." } } }, "auth_ref": [ "r13" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other current assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r13" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "calculation": { "http://integralife.com/role/NETINCOMEPERSHAREBasicandDilutedNetIncomePerShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://integralife.com/role/NETINCOMEPERSHAREBasicandDilutedNetIncomePerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options and restricted stock (in shares)", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": [ "r256", "r257", "r258", "r262", "r451" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSComponentsofCompanysIdentifiableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets [Axis]", "label": "Indefinite-Lived Intangible Assets [Axis]", "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r326", "r329" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSComponentsofCompanysIdentifiableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company." } } }, "auth_ref": [ "r63", "r157" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r794", "r802", "r812", "r829", "r837", "r841", "r849" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r847" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r783", "r853" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r783", "r853" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r783", "r853" ] }, "iart_InstrumentsMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240331", "localname": "InstrumentsMember", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofRevenuesDisaggregatedbyMajorSourceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Instruments", "label": "Instruments [Member]", "documentation": "Instruments [Member]" } } }, "auth_ref": [] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets, net", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r60", "r64" ] }, "iart_IntercompanyLoanQuarterlyPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://integralife.com/20240331", "localname": "IntercompanyLoanQuarterlyPayment", "crdr": "debit", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intercompany loan quarterly payments", "label": "Intercompany Loan, Quarterly Payment", "documentation": "Intercompany Loan, Quarterly Payment" } } }, "auth_ref": [] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest expense", "label": "Interest Expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r117", "r185", "r223", "r277", "r540", "r672", "r776", "r945" ] }, "us-gaap_InterestExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseMember", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense", "label": "Interest Expense [Member]", "documentation": "Primary financial statement caption encompassing interest expense." } } }, "auth_ref": [ "r29" ] }, "us-gaap_InterestIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestIncomeMember", "presentation": [ "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Interest Income [Member]", "documentation": "Primary financial statement caption in which reported facts about interest income have been included." } } }, "auth_ref": [] }, "iart_InterestPaymentsAfterYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://integralife.com/20240331", "localname": "InterestPaymentsAfterYearThree", "crdr": "credit", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest payments, after year three", "label": "Interest Payments, After Year Three", "documentation": "Interest Payments, After Year Three" } } }, "auth_ref": [] }, "iart_InterestPaymentsReminderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://integralife.com/20240331", "localname": "InterestPaymentsReminderOfFiscalYear", "crdr": "credit", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest payments, remainder of fiscal year", "label": "Interest Payments, Reminder Of Fiscal Year", "documentation": "Interest Payments, Reminder Of Fiscal Year" } } }, "auth_ref": [] }, "iart_InterestPaymentsYearOne": { "xbrltype": "monetaryItemType", "nsuri": "http://integralife.com/20240331", "localname": "InterestPaymentsYearOne", "crdr": "credit", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest payments, year one", "label": "Interest Payments, Year One", "documentation": "Interest Payments, Year One" } } }, "auth_ref": [] }, "iart_InterestPaymentsYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://integralife.com/20240331", "localname": "InterestPaymentsYearThree", "crdr": "credit", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest payments, year three", "label": "Interest Payments, Year Three", "documentation": "Interest Payments, Year Three" } } }, "auth_ref": [] }, "iart_InterestPaymentsYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://integralife.com/20240331", "localname": "InterestPaymentsYearTwo", "crdr": "credit", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest payments, year two", "label": "Interest Payments, Year Two", "documentation": "Interest Payments, Year Two" } } }, "auth_ref": [] }, "us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet", "crdr": "credit", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain expected to be reclassified to earnings in the next twelve months", "label": "Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net", "documentation": "The estimated net amount of unrealized gains or losses on interest rate cash flow hedges as of the balance sheet date expected to be reclassified to earnings within the next twelve months." } } }, "auth_ref": [ "r111" ] }, "iart_InterestRateSwapDesignatedDecember132017Tranche2Member": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240331", "localname": "InterestRateSwapDesignatedDecember132017Tranche2Member", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap Designated December 13, 2017 Tranche 2", "label": "Interest Rate Swap Designated December 13, 2017 Tranche 2 [Member]", "documentation": "Interest Rate Swap Designated December 13, 2017 Tranche 2" } } }, "auth_ref": [] }, "iart_InterestRateSwapDesignatedDecember132017Tranche3Member": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240331", "localname": "InterestRateSwapDesignatedDecember132017Tranche3Member", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap Designated December 13, 2017 Tranche 3", "label": "Interest Rate Swap Designated December 13, 2017 Tranche 3 [Member]", "documentation": "Interest Rate Swap Designated December 13, 2017 Tranche 3 [Member]" } } }, "auth_ref": [] }, "iart_InterestRateSwapDesignatedDecember152020Tranche1Member": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240331", "localname": "InterestRateSwapDesignatedDecember152020Tranche1Member", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap Designated December 15, 2020 Tranche 1", "label": "Interest Rate Swap Designated December 15, 2020 Tranche 1 [Member]", "documentation": "Interest Rate Swap Designated December 15, 2020 Tranche 1" } } }, "auth_ref": [] }, "iart_InterestRateSwapDesignatedDecember152020Tranche2Member": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240331", "localname": "InterestRateSwapDesignatedDecember152020Tranche2Member", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap Designated December 15, 2020 Tranche 2", "label": "Interest Rate Swap Designated December 15, 2020 Tranche 2 [Member]", "documentation": "Interest Rate Swap Designated December 15, 2020 Tranche 2" } } }, "auth_ref": [] }, "iart_InterestRateSwapDesignatedDecember182018Tranche1Member": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240331", "localname": "InterestRateSwapDesignatedDecember182018Tranche1Member", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap Designated December 18, 2018 Tranche 1", "label": "Interest Rate Swap Designated December 18, 2018 Tranche 1 [Member]", "documentation": "Interest Rate Swap Designated December 18, 2018 Tranche 1 [Member]" } } }, "auth_ref": [] }, "iart_InterestRateSwapDesignatedDecember182018Tranche2Member": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240331", "localname": "InterestRateSwapDesignatedDecember182018Tranche2Member", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap Designated December 18, 2018 Tranche 2", "label": "Interest Rate Swap Designated December 18, 2018 Tranche 2 [Member]", "documentation": "Interest Rate Swap Designated December 18, 2018 Tranche 2 [Member]" } } }, "auth_ref": [] }, "iart_InterestRateSwapDesignatedMarch312023Member": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240331", "localname": "InterestRateSwapDesignatedMarch312023Member", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap Designated March 31, 2023", "label": "Interest Rate Swap Designated March 31, 2023 [Member]", "documentation": "Interest Rate Swap Designated March 31, 2023" } } }, "auth_ref": [] }, "iart_InterestRateSwapDesignatedOctober102018Tranche1Member": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240331", "localname": "InterestRateSwapDesignatedOctober102018Tranche1Member", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap Designated October 10, 2018 Tranche 1", "label": "Interest Rate Swap Designated October 10, 2018 Tranche 1 [Member]", "documentation": "Interest Rate Swap Designated October 10, 2018 Tranche 1 [Member]" } } }, "auth_ref": [] }, "iart_InterestRateSwapDesignatedOctober102018Tranche2Member": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240331", "localname": "InterestRateSwapDesignatedOctober102018Tranche2Member", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap Designated October 10, 2018 Tranche 2", "label": "Interest Rate Swap Designated October 10, 2018 Tranche 2 [Member]", "documentation": "Interest Rate Swap Designated October 10, 2018 Tranche 2 [Member]" } } }, "auth_ref": [] }, "iart_InterestRateSwapDesignatedOctober102018Tranche3Member": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240331", "localname": "InterestRateSwapDesignatedOctober102018Tranche3Member", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap Designated October 10, 2018 Tranche 3", "label": "Interest Rate Swap Designated October 10, 2018 Tranche 3 [Member]", "documentation": "Interest Rate Swap Designated October 10, 2018 Tranche 3 [Member]" } } }, "auth_ref": [] }, "us-gaap_InterestRateSwapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestRateSwapMember", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap", "verboseLabel": "Interest rate swap", "label": "Interest Rate Swap [Member]", "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period." } } }, "auth_ref": [ "r722", "r773", "r774" ] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureTextBlock", "presentation": [ "http://integralife.com/role/INVENTORIES" ], "lang": { "en-us": { "role": { "terseLabel": "INVENTORIES", "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r310" ] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://integralife.com/role/INVENTORIESScheduleofNetInventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://integralife.com/role/INVENTORIESScheduleofNetInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Inventory, Finished Goods, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": [ "r154", "r728" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 6.0 }, "http://integralife.com/role/INVENTORIESScheduleofNetInventoriesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "http://integralife.com/role/INVENTORIESScheduleofNetInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories, net", "totalLabel": "Inventories, net", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r206", "r726", "r763" ] }, "us-gaap_InventoryRawMaterialsAndPurchasedPartsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryRawMaterialsAndPurchasedPartsNetOfReserves", "crdr": "debit", "calculation": { "http://integralife.com/role/INVENTORIESScheduleofNetInventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://integralife.com/role/INVENTORIESScheduleofNetInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Raw materials", "label": "Inventory, Raw Materials and Purchased Parts, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of items purchased for use as components of a finished product or pieces of machinery and equipment plus any items in their natural and unrefined state. This element may be used when the reporting entity combines raw materials and purchased parts into an aggregate amount." } } }, "auth_ref": [ "r154", "r863" ] }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "calculation": { "http://integralife.com/role/INVENTORIESScheduleofNetInventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://integralife.com/role/INVENTORIESScheduleofNetInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Work in process", "label": "Inventory, Work in Process, Net of Reserves", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": [ "r154", "r729" ] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Investment Income, Interest", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r144", "r276" ] }, "us-gaap_LeaseContractualTermAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseContractualTermAxis", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease Contractual Term [Axis]", "label": "Lease Contractual Term [Axis]", "documentation": "Information by contractual term of lease arrangement." } } }, "auth_ref": [ "r859" ] }, "us-gaap_LeaseContractualTermDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseContractualTermDomain", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease Contractual Term [Domain]", "label": "Lease Contractual Term [Domain]", "documentation": "Contractual term of lease arrangement." } } }, "auth_ref": [ "r859" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Leases [Abstract]", "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionLineItems", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Line Items]", "label": "Lessee, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r546" ] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionTable", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Table]", "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": [ "r546" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Operating Lease Maturities", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r928" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total minimum lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r552" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "calculation": { "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r552" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r552" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "calculation": { "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2029", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r552" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r552" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r552" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r552" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remainder of 2024", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r928" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Less: Imputed interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r552" ] }, "iart_LesseeOperatingLeaseNumberOfRenewalOptions": { "xbrltype": "integerItemType", "nsuri": "http://integralife.com/20240331", "localname": "LesseeOperatingLeaseNumberOfRenewalOptions", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of renewal options (or more)", "label": "Lessee, Operating Lease, Number Of Renewal Options", "documentation": "Lessee, Operating Lease, Number Of Renewal Options" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseOptionToExtend": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseOptionToExtend", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Period for extended lease", "label": "Lessee, Operating Lease, Option to Extend", "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability." } } }, "auth_ref": [ "r547" ] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Option to extend lease, years", "label": "Lessee, Operating Lease, Renewal Term", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r927" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASES" ], "lang": { "en-us": { "role": { "terseLabel": "LEASES AND RELATED PARTY LEASES", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r542" ] }, "us-gaap_LettersOfCreditOutstandingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LettersOfCreditOutstandingAmount", "crdr": "credit", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Letters of credit outstanding", "label": "Letters of Credit Outstanding, Amount", "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r38", "r231", "r306", "r344", "r345", "r347", "r348", "r349", "r351", "r353", "r355", "r356", "r508", "r510", "r511", "r531", "r647", "r735", "r778", "r907", "r931", "r932" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r130", "r180", "r592", "r763", "r873", "r884", "r923" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r40", "r195", "r231", "r306", "r344", "r345", "r347", "r348", "r349", "r351", "r353", "r355", "r356", "r508", "r510", "r511", "r531", "r763", "r907", "r931", "r932" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCredit", "crdr": "credit", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit facility outstanding", "label": "Long-Term Line of Credit", "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": [ "r33", "r179", "r939" ] }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityCommitmentFeePercentage", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit, commitment fee percentage", "label": "Line of Credit Facility, Commitment Fee Percentage", "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityFairValueOfAmountOutstanding", "crdr": "credit", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit facility, fair value of amount outstanding", "label": "Line of Credit Facility, Fair Value of Amount Outstanding", "documentation": "Fair value of the amount outstanding under the credit facility." } } }, "auth_ref": [ "r530" ] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum borrowing capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r37" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://integralife.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongMember", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long", "label": "Long [Member]", "documentation": "Indicates an ownership position in, or purchase of, a security." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://integralife.com/role/DEBTContractualMaturityTableDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://integralife.com/role/DEBTContractualMaturityTableDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total long-term debt", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r33", "r179", "r370", "r384", "r740", "r741", "r939" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "calculation": { "http://integralife.com/role/DEBTContractualMaturityTableDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://integralife.com/role/DEBTContractualMaturityTableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Long-Term Debt, Maturity, Year One", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r16", "r237", "r375" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "calculation": { "http://integralife.com/role/DEBTContractualMaturityTableDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://integralife.com/role/DEBTContractualMaturityTableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Long-Term Debt, Maturity, Year Three", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r16", "r237", "r375" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "calculation": { "http://integralife.com/role/DEBTContractualMaturityTableDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://integralife.com/role/DEBTContractualMaturityTableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Long-Term Debt, Maturity, Year Two", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r16", "r237", "r375" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://integralife.com/role/DEBTContractualMaturityTableDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://integralife.com/role/DEBTContractualMaturityTableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remainder of 2024", "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year." } } }, "auth_ref": [ "r875" ] }, "iart_LongTermDebtMaturityAfterYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://integralife.com/20240331", "localname": "LongTermDebtMaturityAfterYearThree", "crdr": "credit", "calculation": { "http://integralife.com/role/DEBTContractualMaturityTableDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://integralife.com/role/DEBTContractualMaturityTableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Long-Term Debt, Maturity, after Year Three", "documentation": "Long-Term Debt, Maturity, after Year Three" } } }, "auth_ref": [] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r43" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r43", "r68" ] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesLineItems", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Line Items]", "label": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r338", "r339", "r340", "r343", "r901", "r902" ] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesTable", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Table]", "label": "Loss Contingencies [Table]", "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations." } } }, "auth_ref": [ "r338", "r339", "r340", "r343", "r901", "r902" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails", "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r339", "r340", "r341", "r342", "r445", "r563", "r617", "r639", "r640", "r691", "r693", "r695", "r696", "r705", "r719", "r720", "r737", "r744", "r759", "r765", "r909", "r933", "r934", "r935", "r936", "r937", "r938" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r821" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r821" ] }, "us-gaap_MeasurementInputDiscountRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputDiscountRateMember", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input, Discount Rate", "label": "Measurement Input, Discount Rate [Member]", "documentation": "Measurement input using interest rate to determine present value of future cash flows." } } }, "auth_ref": [ "r922" ] }, "us-gaap_MeasurementInputLongTermRevenueGrowthRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputLongTermRevenueGrowthRateMember", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input, Long-Term Revenue Growth Rate", "label": "Measurement Input, Long-Term Revenue Growth Rate [Member]", "documentation": "Measurement input using compounded annualized rate of long-term growth in revenue." } } }, "auth_ref": [ "r922" ] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeAxis", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type [Axis]", "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r528" ] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeDomain", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type [Domain]", "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": [] }, "iart_MergersAcquisitionsAndDispositionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://integralife.com/20240331", "localname": "MergersAcquisitionsAndDispositionsAbstract", "lang": { "en-us": { "role": { "label": "Mergers, Acquisitions and Dispositions [Abstract]", "documentation": "Mergers, Acquisitions and Dispositions" } } }, "auth_ref": [] }, "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURES" ], "lang": { "en-us": { "role": { "terseLabel": "ACQUISITIONS AND DIVESTITURES", "label": "Mergers, Acquisitions and Dispositions Disclosures [Text Block]", "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings." } } }, "auth_ref": [ "r121", "r171" ] }, "iart_MilestonePaymentOneMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240331", "localname": "MilestonePaymentOneMember", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Development Milestones", "label": "Milestone Payment One [Member]", "documentation": "Milestone Payment One [Member]" } } }, "auth_ref": [] }, "iart_MilestonePaymentTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240331", "localname": "MilestonePaymentTwoMember", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial Sales Milestones", "label": "Milestone Payment Two [Member]", "documentation": "Milestone Payment Two [Member]" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails", "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r339", "r340", "r341", "r342", "r445", "r563", "r617", "r639", "r640", "r691", "r693", "r695", "r696", "r705", "r719", "r720", "r737", "r744", "r759", "r765", "r909", "r933", "r934", "r935", "r936", "r937", "r938" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r840" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r848" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r822" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r228" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "FINANCING ACTIVITIES:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r228" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "INVESTING ACTIVITIES:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r150", "r151", "r152" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "OPERATING ACTIVITIES:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofComprehensiveIncomeDetails": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 }, "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofComprehensiveIncomeDetails", "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUNAUDITED", "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED", "http://integralife.com/role/NETINCOMEPERSHAREBasicandDilutedNetIncomePerShareDetails", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net (loss) income", "terseLabel": "Net (Loss) Income", "verboseLabel": "Net (loss) income", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r139", "r152", "r184", "r193", "r215", "r218", "r222", "r231", "r241", "r243", "r244", "r245", "r246", "r249", "r250", "r259", "r273", "r287", "r293", "r296", "r306", "r344", "r345", "r347", "r348", "r349", "r351", "r353", "r355", "r356", "r526", "r531", "r595", "r668", "r685", "r686", "r736", "r776", "r907" ] }, "us-gaap_NetInvestmentHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetInvestmentHedgingMember", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net Investment Hedges", "label": "Net Investment Hedging [Member]", "documentation": "Hedges of a net investment in a foreign operation." } } }, "auth_ref": [ "r95" ] }, "iart_NeurosurgeryMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240331", "localname": "NeurosurgeryMember", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofRevenuesDisaggregatedbyMajorSourceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Neurosurgery", "label": "Neurosurgery [Member]", "documentation": "Neurosurgery [Member]" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://integralife.com/role/BASISOFPRESENTATIONPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recent Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r821" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r791", "r802", "r812", "r829", "r837" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r819" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r818" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r829" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r848" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r848" ] }, "iart_NoncashLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://integralife.com/20240331", "localname": "NoncashLeaseExpense", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash lease expense", "label": "Noncash Lease Expense", "documentation": "Noncash Lease Expense" } } }, "auth_ref": [] }, "us-gaap_NondesignatedMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NondesignatedMember", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Not Designated as Hedging Instrument", "label": "Not Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r21" ] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfReportableSegments", "presentation": [ "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of reportable segments", "label": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r881" ] }, "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OciBeforeReclassificationsNetOfTaxAttributableToParent", "crdr": "credit", "calculation": { "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofChangesinAccumulatedOtherComprehensiveIncomebyComponentDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofChangesinAccumulatedOtherComprehensiveIncomebyComponentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive gain (loss)", "label": "OCI, before Reclassifications, Net of Tax, Attributable to Parent", "documentation": "Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent." } } }, "auth_ref": [ "r32", "r48" ] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED", "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNetSalesandProfitbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Operating income", "verboseLabel": "Operating income", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r273", "r287", "r293", "r296", "r736" ] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease expense", "label": "Operating Lease, Expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": [ "r926" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails", "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total lease liabilities", "totalLabel": "Total lease liabilities", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r544" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 1.0 }, "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails", "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Current portion of lease liability - operating leases", "terseLabel": "Current lease liabilities", "netLabel": "Less: Current lease liabilities", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r544" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 2.0 }, "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails", "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Lease liability - operating leases", "terseLabel": "Non-current lease liabilities", "netLabel": "Long-term lease liabilities", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r544" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESSupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating cash flows from operating leases", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r545", "r548" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Right of use asset - operating leases", "terseLabel": "ROU assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r543" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average discount rate", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r551", "r762" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining lease term (in years)", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r550", "r762" ] }, "us-gaap_OperatingLeasedAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasedAssetsLineItems", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails", "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Leased Assets [Line Items]", "label": "Operating Leased Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingSegmentsMember", "presentation": [ "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNetSalesandProfitbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Segments", "label": "Operating Segments [Member]", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r286", "r287", "r288", "r289", "r290", "r296" ] }, "us-gaap_OptionIndexedToIssuersEquityEquityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OptionIndexedToIssuersEquityEquityAxis", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Option Indexed to Issuer's Equity [Axis]", "label": "Option Indexed to Issuer's Equity [Axis]", "documentation": "Information by type of options indexed to an issuer's equity." } } }, "auth_ref": [ "r69", "r112", "r113", "r175" ] }, "us-gaap_OptionIndexedToIssuersEquityStrikePrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OptionIndexedToIssuersEquityStrikePrice1", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Initial strike price (in dollars per share)", "label": "Option Indexed to Issuer's Equity, Strike Price", "documentation": "Exercise or strike price stated in the contract for options indexed to the issuer's equity shares." } } }, "auth_ref": [ "r24", "r31" ] }, "us-gaap_OptionIndexedToIssuersEquityTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OptionIndexedToIssuersEquityTypeDomain", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Option Indexed to Issuer's Equity, Type [Domain]", "label": "Option Indexed to Issuer's Equity, Type [Domain]", "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding." } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://integralife.com/role/BASISOFPRESENTATION" ], "lang": { "en-us": { "role": { "terseLabel": "BASIS OF PRESENTATION", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r120", "r172", "r624", "r625" ] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Other Current Assets", "label": "Other Assets, Current", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r208", "r763" ] }, "us-gaap_OtherAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsMember", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets [Member]", "documentation": "Primary financial statement caption encompassing other assets." } } }, "auth_ref": [ "r97", "r109" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r199" ] }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "debit", "calculation": { "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofComprehensiveIncomeDetails": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Pension liability adjustment, net of tax", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent", "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent." } } }, "auth_ref": [ "r9", "r18", "r137", "r173" ] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofComprehensiveIncomeDetails": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation adjustment", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity." } } }, "auth_ref": [ "r12", "r18", "r173" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "crdr": "credit", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification and tax", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax", "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r211", "r212" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent", "crdr": "credit", "calculation": { "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofComprehensiveIncomeDetails": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in unrealized loss/(gain) on derivatives, net of tax", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent", "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": [ "r212" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "crdr": "credit", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain (loss) recorded in AOCI, change in fair value", "verboseLabel": "Amount\u00a0of Gain (Loss) Recognized\u00a0in AOCI", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r211", "r212", "r512", "r513", "r516" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax", "crdr": "debit", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount\u00a0of\u00a0Gain (Loss) Reclassified from AOCI into Earnings", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax", "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r212", "r214" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofChangesinAccumulatedOtherComprehensiveIncomebyComponentDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofChangesinAccumulatedOtherComprehensiveIncomebyComponentDetails", "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss), net of tax", "totalLabel": "Net current-period other comprehensive gain (loss)", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": [ "r12", "r18", "r173", "r216", "r219" ] }, "us-gaap_OtherCurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCurrentLiabilitiesMember", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Current Liabilities", "label": "Other Current Liabilities [Member]", "documentation": "Primary financial statement caption encompassing other current liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherDepreciationAndAmortization", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Other Depreciation and Amortization", "documentation": "Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other." } } }, "auth_ref": [ "r14", "r67", "r142" ] }, "us-gaap_OtherIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherIncomeMember", "presentation": [ "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Income", "label": "Other Income [Member]", "documentation": "Primary financial statement caption encompassing other revenue." } } }, "auth_ref": [ "r106" ] }, "us-gaap_OtherLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesMember", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other liabilities", "label": "Other Liabilities [Member]", "documentation": "Primary financial statement caption encompassing other liabilities." } } }, "auth_ref": [ "r97", "r109" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Other liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r44" ] }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncurrentLiabilitiesMember", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Long-term Liabilities", "label": "Other Noncurrent Liabilities [Member]", "documentation": "Primary financial statement caption encompassing other noncurrent liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Other (expense) income, net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r146" ] }, "us-gaap_OtherNonoperatingIncomeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpenseMember", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other income, net", "label": "Other Nonoperating Income (Expense) [Member]", "documentation": "Primary financial statement caption encompassing other nonoperating income (expense)." } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r821" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r789", "r800", "r810", "r835" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r792", "r803", "r813", "r838" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r792", "r803", "r813", "r838" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r817" ] }, "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities", "crdr": "credit", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payment for contingent consideration", "label": "Payment for Contingent Consideration Liability, Financing Activities", "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date." } } }, "auth_ref": [ "r11" ] }, "iart_PaymentsForOptionIndexToIssuersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://integralife.com/20240331", "localname": "PaymentsForOptionIndexToIssuersEquity", "crdr": "credit", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of call transactions", "label": "Payments For Option Index To Issuers Equity", "documentation": "Payments For Options Indexed to Issuer's Equity" } } }, "auth_ref": [] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of treasury stock", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": [ "r51" ] }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payment of debt issuance costs", "label": "Payments of Debt Issuance Costs", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt." } } }, "auth_ref": [ "r53" ] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash taxes paid in net equity settlement", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [ "r227" ] }, "us-gaap_PaymentsToAcquireInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireInvestments", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchases of Investments", "label": "Payments to Acquire Investments", "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period." } } }, "auth_ref": [ "r148" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r149" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r820" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r820" ] }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "presentation": [ "http://integralife.com/role/RETIREMENTPLANS" ], "lang": { "en-us": { "role": { "terseLabel": "RETIREMENT PLANS", "label": "Retirement Benefits [Text Block]", "documentation": "The entire disclosure for retirement benefits." } } }, "auth_ref": [ "r419", "r422", "r424", "r430", "r433", "r435", "r436", "r437", "r438", "r439", "r442", "r443", "r444", "r755" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r819" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r829" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r822" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r818" ] }, "iart_PercentOfManufacturingFacilityOwnedByCorporationWhoseShareholdersAreTrustsWhoseBeneficiariesIncludeFamilyMembersOfCompanysFormerDirector": { "xbrltype": "percentItemType", "nsuri": "http://integralife.com/20240331", "localname": "PercentOfManufacturingFacilityOwnedByCorporationWhoseShareholdersAreTrustsWhoseBeneficiariesIncludeFamilyMembersOfCompanysFormerDirector", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percent of manufacturing facility owned by corporation whose shareholders are trusts whose beneficiaries include family members of company's former director", "label": "Percent Of Manufacturing Facility Owned By Corporation Whose Shareholders Are Trusts, Whose Beneficiaries Include Family Members Of Company's Former Director", "documentation": "Percent Of Manufacturing Facility Owned By Corporation Whose Shareholders Are Trusts, Whose Beneficiaries Include Family Members Of Company's Former Director" } } }, "auth_ref": [] }, "us-gaap_PerformanceSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PerformanceSharesMember", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Performance Stock", "label": "Performance Shares [Member]", "documentation": "Share-based payment arrangement awarded for meeting performance target." } } }, "auth_ref": [] }, "iart_PerformanceStockAndRestrictedStockAwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240331", "localname": "PerformanceStockAndRestrictedStockAwardsMember", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Performance Stock and Restricted Stock Awards", "label": "Performance Stock And Restricted Stock Awards [Member]", "documentation": "Performance Stock And Restricted Stock Awards [Member]" } } }, "auth_ref": [] }, "us-gaap_PositionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PositionAxis", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Position [Axis]", "label": "Position [Axis]", "documentation": "Information by position taken for a security." } } }, "auth_ref": [] }, "us-gaap_PositionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PositionDomain", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Position [Domain]", "label": "Position [Domain]", "documentation": "Indicates position taken for a security." } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (in dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r124", "r385" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, authorized shares (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r124", "r648" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, outstanding shares (in shares)", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r124", "r648", "r666", "r946", "r947" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock; no par value; 15,000 authorized shares; none outstanding", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r124", "r588", "r763" ] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid Expenses", "label": "Prepaid Expense, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r207", "r311", "r312", "r727" ] }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expenses and Other Current Assets [Member]", "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets." } } }, "auth_ref": [] }, "iart_PrivateLabelMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240331", "localname": "PrivateLabelMember", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofRevenuesDisaggregatedbyMajorSourceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Private Label", "label": "Private Label [Member]", "documentation": "Private Label [Member]" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfSecuredDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfSecuredDebt", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from borrowings of long-term indebtedness", "label": "Proceeds from Issuance of Secured Debt", "documentation": "The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt." } } }, "auth_ref": [ "r50" ] }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfWarrants", "crdr": "debit", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Proceeds from warrant transactions", "label": "Proceeds from Issuance of Warrants", "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)." } } }, "auth_ref": [ "r10" ] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from exercised stock options", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r10", "r25" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofRevenuesDisaggregatedbyMajorSourceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r298", "r565", "r611", "r612", "r613", "r614", "r615", "r616", "r723", "r746", "r764", "r861", "r903", "r904", "r912", "r940" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofRevenuesDisaggregatedbyMajorSourceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r298", "r565", "r611", "r612", "r613", "r614", "r615", "r616", "r723", "r746", "r764", "r861", "r903", "r904", "r912", "r940" ] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r15" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r15", "r585", "r593", "r763" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r158" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r817" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r817" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails", "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r339", "r340", "r341", "r342", "r422", "r445", "r475", "r476", "r477", "r562", "r563", "r617", "r639", "r640", "r691", "r693", "r695", "r696", "r705", "r719", "r720", "r737", "r744", "r759", "r765", "r768", "r899", "r909", "r934", "r935", "r936", "r937", "r938" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails", "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r339", "r340", "r341", "r342", "r422", "r445", "r475", "r476", "r477", "r562", "r563", "r617", "r639", "r640", "r691", "r693", "r695", "r696", "r705", "r719", "r720", "r737", "r744", "r759", "r765", "r768", "r899", "r909", "r934", "r935", "r936", "r937", "r938" ] }, "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "crdr": "debit", "calculation": { "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofChangesinAccumulatedOtherComprehensiveIncomebyComponentDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSNarrativeDetails", "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofChangesinAccumulatedOtherComprehensiveIncomebyComponentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Less: Amounts reclassified from accumulated other comprehensive income, net", "verboseLabel": "Gain (loss) reclassified from AOCI", "label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent", "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent." } } }, "auth_ref": [ "r32", "r48" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r784", "r795", "r805", "r830" ] }, "iart_RegenerativeSkinAndWoundMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240331", "localname": "RegenerativeSkinAndWoundMember", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofRevenuesDisaggregatedbyMajorSourceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Wound Reconstruction and Care", "label": "Regenerative Skin And Wound [Member]", "documentation": "Regenerative Skin And Wound [Member]" } } }, "auth_ref": [] }, "iart_RelatedPartiesMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240331", "localname": "RelatedPartiesMember", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Parties", "label": "Related Parties [Member]", "documentation": "Related Parties [Member]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyDomain", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party [Domain]", "label": "Related Party, Type [Domain]", "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r434", "r554", "r555", "r642", "r643", "r644", "r645", "r646", "r665", "r667", "r690" ] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyMember", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party", "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r233", "r234", "r554", "r555", "r556", "r557", "r642", "r643", "r644", "r645", "r646", "r665", "r667", "r690" ] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party [Axis]", "label": "Related Party, Type [Axis]", "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r434", "r554", "r555", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r642", "r643", "r644", "r645", "r646", "r665", "r667", "r690", "r930" ] }, "us-gaap_RepaymentsOfSecuredDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfSecuredDebt", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments on debt", "label": "Repayments of Secured Debt", "documentation": "The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt." } } }, "auth_ref": [ "r52" ] }, "us-gaap_ReportingUnitAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReportingUnitAxis", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reporting Unit [Axis]", "label": "Reporting Unit [Axis]", "documentation": "Information by reporting unit." } } }, "auth_ref": [ "r323", "r324", "r738" ] }, "us-gaap_ReportingUnitDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReportingUnitDomain", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reporting Unit [Domain]", "label": "Reporting Unit [Domain]", "documentation": "Level of reporting at which goodwill is tested for impairment." } } }, "auth_ref": [ "r323", "r324", "r738" ] }, "iart_ReportingUnitMeasurementInput": { "xbrltype": "pureItemType", "nsuri": "http://integralife.com/20240331", "localname": "ReportingUnitMeasurementInput", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reporting unit, measurement input", "label": "Reporting Unit, Measurement Input", "documentation": "Reporting Unit, Measurement Input" } } }, "auth_ref": [] }, "us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value in excess of carrying amount, percent", "label": "Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount", "documentation": "Percentage of fair value of reporting unit in excess of carrying amount." } } }, "auth_ref": [] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r235", "r236", "r361", "r387", "r557", "r731", "r732" ] }, "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense (Excluding Acquired in Process Cost)", "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept." } } }, "auth_ref": [ "r915" ] }, "iart_RestOfWorldMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240331", "localname": "RestOfWorldMember", "presentation": [ "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTotalRevenuebyMajorGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rest of World", "label": "Rest Of World [Member]", "documentation": "Revenues from rest of the world." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r785", "r796", "r806", "r831" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r786", "r797", "r807", "r832" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r793", "r804", "r814", "r839" ] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockMember", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock", "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r55" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Retained earnings", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r127", "r166", "r591", "r621", "r623", "r631", "r649", "r763" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Retained Earnings", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r191", "r238", "r239", "r240", "r242", "r248", "r250", "r307", "r308", "r484", "r485", "r486", "r495", "r496", "r517", "r519", "r520", "r522", "r524", "r618", "r620", "r633", "r946" ] }, "iart_ReturnPolicyIssueOfCreditNumberOfDaysFromShipment": { "xbrltype": "durationItemType", "nsuri": "http://integralife.com/20240331", "localname": "ReturnPolicyIssueOfCreditNumberOfDaysFromShipment", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of days from shipment to issue a credit", "label": "Return Policy, Issue Of Credit, Number Of Days From Shipment", "documentation": "Return Policy, Issue of Credit, Number of Days from Shipment" } } }, "auth_ref": [] }, "iart_RevenueBasedPerformanceMilestonesMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240331", "localname": "RevenueBasedPerformanceMilestonesMember", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Based Performance Milestones", "label": "Revenue Based Performance Milestones [Member]", "documentation": "Revenue Based Performance Milestones" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "terseLabel": "Revenue from Contract with Customer [Abstract]", "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED", "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofRevenuesDisaggregatedbyMajorSourceDetails", "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNetSalesandProfitbyReportableSegmentDetails", "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTotalRevenuebyMajorGeographicAreaDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Total revenue, net", "terseLabel": "Total Revenues", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r274", "r275", "r286", "r291", "r292", "r298", "r300", "r302", "r414", "r415", "r565" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://integralife.com/role/BASISOFPRESENTATIONPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Accounting Policies on Revenue Recognition and Shipping and Handling Fees", "label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r190", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r721" ] }, "iart_RevenueFromContractWithCustomerProductReturnsPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://integralife.com/20240331", "localname": "RevenueFromContractWithCustomerProductReturnsPayments", "crdr": "credit", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product returns, payments", "label": "Revenue From Contract With Customer, Product Returns, Payments", "documentation": "Revenue From Contract With Customer, Product Returns, Payments" } } }, "auth_ref": [] }, "iart_RevenueFromContractWithCustomerProductReturnsProvision": { "xbrltype": "monetaryItemType", "nsuri": "http://integralife.com/20240331", "localname": "RevenueFromContractWithCustomerProductReturnsProvision", "crdr": "credit", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product returns provision", "label": "Revenue From Contract With Customer, Product Returns, Provision", "documentation": "Revenue From Contract With Customer, Product Returns, Provision" } } }, "auth_ref": [] }, "iart_RevenueFromContractWithCustomerProductReturnsReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://integralife.com/20240331", "localname": "RevenueFromContractWithCustomerProductReturnsReserve", "crdr": "credit", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product returns, reserve", "label": "Revenue From Contract With Customer, Product Returns, Reserve", "documentation": "Revenue From Contract With Customer, Product Returns, Reserve" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERS" ], "lang": { "en-us": { "role": { "terseLabel": "REVENUES FROM CONTRACTS WITH CUSTOMERS", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r190", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r418" ] }, "iart_RevenueProductWarrantyPeriod": { "xbrltype": "durationItemType", "nsuri": "http://integralife.com/20240331", "localname": "RevenueProductWarrantyPeriod", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product warranty period (up to)", "label": "Revenue, Product Warranty Period", "documentation": "Revenue, Product Warranty Period" } } }, "auth_ref": [] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSNarrativeRevenueRemainingPerformanceObligationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSNarrativeRevenueRemainingPerformanceObligationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance obligations expected to be satisfied, expected timing", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period", "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r187" ] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSNarrativeRevenueRemainingPerformanceObligationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format." } } }, "auth_ref": [ "r187" ] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSNarrativeRevenueRemainingPerformanceObligationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]", "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation." } } }, "auth_ref": [] }, "us-gaap_RevenueRemainingPerformanceObligationPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligationPercentage", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSNarrativeRevenueRemainingPerformanceObligationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected performance obligation, percentage", "label": "Revenue, Remaining Performance Obligation, Percentage", "documentation": "Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue." } } }, "auth_ref": [ "r858" ] }, "us-gaap_RevenueTransactionPriceMeasurementTaxExclusionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueTransactionPriceMeasurementTaxExclusionPolicyTextBlock", "presentation": [ "http://integralife.com/role/BASISOFPRESENTATIONPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Taxes Collected from Customers", "label": "Revenue, Transaction Price Measurement, Tax Exclusion [Policy Text Block]", "documentation": "Disclosure of accounting policy for election to exclude from measurement of transaction price tax assessed by governmental authority that are both imposed on and concurrent with specific revenue-producing transaction, and collected from customer. Includes, but is not limited to, sales, use, value-added and excise tax." } } }, "auth_ref": [ "r394" ] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevolvingCreditFacilityMember", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving Credit Facility", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "iart_RightOfUseAssetObtainedInExchangeForLeaseLiabilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://integralife.com/20240331", "localname": "RightOfUseAssetObtainedInExchangeForLeaseLiabilityAbstract", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESSupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ROU assets obtained in exchange for lease liabilities:", "label": "Right Of Use Asset Obtained In Exchange For Lease Liability [Abstract]", "documentation": "Right Of Use Asset Obtained In Exchange For Lease Liability [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESSupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating leases", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r549", "r762" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r848" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r848" ] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioForecastMember", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forecast", "label": "Forecast [Member]" } } }, "auth_ref": [ "r446", "r879" ] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Scenario [Domain]", "label": "Scenario [Domain]" } } }, "auth_ref": [ "r251", "r446", "r856", "r879" ] }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Changes in Accumulated Other Comprehensive Loss by Component", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r48", "r924", "r925" ] }, "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSComponentsofCompanysIdentifiableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]", "label": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]", "documentation": "Tabular disclosure of the major classes of acquired finite-lived intangible assets showing the amount, any significant residual value, weighted average amortization period, and other characteristics. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company." } } }, "auth_ref": [ "r62" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities." } } }, "auth_ref": [ "r82", "r84", "r504" ] }, "us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Comprehensive Income (Loss)", "label": "Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of components of comprehensive income (loss). Includes, but is not limited to, foreign currency translation adjustments, foreign currency transactions designated as economic hedges of a net investment in foreign entity, gain (loss) and prior service cost (credit) for pension plans and other postretirement benefit plans." } } }, "auth_ref": [ "r136" ] }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": [ "http://integralife.com/role/DEBTTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Maximum Leverage Ratios", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref": [ "r43", "r73", "r76", "r115", "r116", "r118", "r119", "r163", "r165", "r740", "r742", "r875" ] }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of Derivative Instruments Designated as Cash Flow Hedges on Statements of Operations", "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": [ "r98", "r103", "r514" ] }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value and Presentation of Derivatives", "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position." } } }, "auth_ref": [ "r99" ] }, "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDerivativeInstrumentsTextBlock", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Derivative Instruments", "label": "Schedule of Derivative Instruments [Table Text Block]", "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item." } } }, "auth_ref": [ "r21", "r91", "r92", "r93", "r96", "r99", "r103", "r107", "r108" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://integralife.com/role/NETINCOMEPERSHARETables" ], "lang": { "en-us": { "role": { "terseLabel": "Basic and Diluted Net Income (Loss) Per Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r880" ] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://integralife.com/role/INCOMETAXESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Effective Income Tax Rate", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r169" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": [ "r62", "r65" ] }, "us-gaap_ScheduleOfGoodwillTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfGoodwillTable", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails", "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Goodwill [Table]", "label": "Schedule of Goodwill [Table]", "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons." } } }, "auth_ref": [ "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r738" ] }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfGoodwillTextBlock", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Changes in Carrying Amount of Goodwill", "label": "Schedule of Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": [ "r738", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895" ] }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Indefinite-Lived Intangible Assets", "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment." } } }, "auth_ref": [ "r26", "r157" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://integralife.com/role/INVENTORIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Inventories, Net", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r35", "r131", "r132", "r133" ] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": [ "http://integralife.com/role/DEBTTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Contractual Repayments of Long-Term Debt", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": [ "r16" ] }, "us-gaap_ScheduleOfOperatingLeasedAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfOperatingLeasedAssetsTable", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails", "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Operating Leased Assets [Table]", "label": "Schedule of Operating Leased Assets [Table]", "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Derivatives Not Designated as Hedging Instruments", "label": "Derivatives Not Designated as Hedging Instruments [Table Text Block]", "documentation": "Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument." } } }, "auth_ref": [ "r104", "r860" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [ "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNarrativeDetails", "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNetSalesandProfitbyReportableSegmentDetails", "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTotalRevenuebyMajorGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r56", "r57", "r58", "r59" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": [ "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Net Sales and Profit by Segments", "terseLabel": "Schedule of Geographic Revenue by Area", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r56", "r57", "r58", "r59" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r448", "r450", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478" ] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://integralife.com/role/TREASURYSTOCKNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock by Class [Table]", "label": "Schedule of Stock by Class [Table]", "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity." } } }, "auth_ref": [ "r70", "r71", "r72", "r73", "r74", "r75", "r76", "r163", "r165", "r166", "r201", "r202", "r203", "r268", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r627", "r628", "r629", "r630", "r744", "r855", "r871" ] }, "us-gaap_SecuredDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecuredDebtCurrent", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current portion of borrowings under senior credit facility", "verboseLabel": "Term loan component of senior credit facility", "label": "Secured Debt, Current", "documentation": "Carrying value as of the balance sheet date of the portion of long-term, collateralized debt obligations due within one year or the operating cycle, if longer. Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower." } } }, "auth_ref": [ "r122", "r178" ] }, "us-gaap_SecuredDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecuredDebtMember", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Secured Debt", "label": "Secured Debt [Member]", "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets." } } }, "auth_ref": [] }, "us-gaap_SecuredLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecuredLongTermDebt", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term borrowings under senior credit facility", "label": "Secured Long-Term Debt, Noncurrent", "documentation": "Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets." } } }, "auth_ref": [ "r43" ] }, "iart_SecuredLongTermDebtSecuritizationProgram": { "xbrltype": "monetaryItemType", "nsuri": "http://integralife.com/20240331", "localname": "SecuredLongTermDebtSecuritizationProgram", "crdr": "credit", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Secured long-term debt, securitization program", "label": "Secured Long-Term Debt, Securitization Program", "documentation": "Secured Long-Term Debt, Securitization Program" } } }, "auth_ref": [] }, "iart_SecuredLongTermDebtSecuritizationProgramNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://integralife.com/20240331", "localname": "SecuredLongTermDebtSecuritizationProgramNoncurrent", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term borrowings under securitization facility", "label": "Secured Long-Term Debt, Securitization Program, Noncurrent", "documentation": "Secured Long-Term Debt, Securitization Program, Noncurrent" } } }, "auth_ref": [] }, "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate", "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]", "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg." } } }, "auth_ref": [ "r920" ] }, "iart_SecuritizationFacilityFairValueOfAmountOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://integralife.com/20240331", "localname": "SecuritizationFacilityFairValueOfAmountOutstanding", "crdr": "credit", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Securitization facility, outstanding borrowings, fair value", "label": "Securitization Facility, Fair Value Of Amount Outstanding", "documentation": "Securitization Facility, Fair Value Of Amount Outstanding" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://integralife.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r779" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://integralife.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r781" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentDomain", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails", "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofRevenuesDisaggregatedbyMajorSourceDetails", "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNarrativeDetails", "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNetSalesandProfitbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Domain]", "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r270", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r296", "r302", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r334", "r335", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r738", "r861", "r940" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTotalRevenuebyMajorGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]" } } }, "auth_ref": [ "r300", "r301", "r635", "r636", "r637", "r692", "r694", "r697", "r706", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r724", "r747", "r768", "r912", "r940" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting [Abstract]", "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATION" ], "lang": { "en-us": { "role": { "terseLabel": "SEGMENT AND GEOGRAPHIC INFORMATION", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r269", "r270", "r271", "r272", "r273", "r285", "r290", "r294", "r295", "r296", "r297", "r298", "r299", "r302" ] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingInformationLineItems", "presentation": [ "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNarrativeDetails", "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNetSalesandProfitbyReportableSegmentDetails", "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTotalRevenuebyMajorGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting Information [Line Items]", "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "iart_SegmentReportingInformationNumberOfProductsOffered": { "xbrltype": "integerItemType", "nsuri": "http://integralife.com/20240331", "localname": "SegmentReportingInformationNumberOfProductsOffered", "presentation": [ "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of products offered (more than)", "label": "Segment Reporting Information, Number Of Products Offered", "documentation": "Number of products sold by a segment" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingInformationOperatingIncomeLossAbstract", "presentation": [ "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNetSalesandProfitbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Net Sales", "label": "Segment Reporting Information, Operating Income (Loss) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingInformationProfitLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingInformationProfitLossAbstract", "presentation": [ "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNetSalesandProfitbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Profit", "label": "Segment Reporting Information, Profit (Loss) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r143" ] }, "iart_SeniorCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240331", "localname": "SeniorCreditFacilityMember", "presentation": [ "http://integralife.com/role/DEBTMaximumTotalLeverageRatioTableDetails", "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Credit Facility", "label": "Senior Credit Facility [Member]", "documentation": "Senior Credit Facility." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r13" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost", "crdr": "debit", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accelerated stock based compensation expenses", "label": "Share-Based Payment Arrangement, Accelerated Cost", "documentation": "Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Requisite service periods of awards", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period", "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r760" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options exercisable, vesting period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r760" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Awards granted during the period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r467" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other than options, weighted average grant date fair value (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r467" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r448", "r450", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Grants in period, net of forfeitures (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures", "documentation": "Net number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r914" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options, weighted average grant date fair value (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r470" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost", "crdr": "debit", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan modification, compensation expense", "label": "Share-Based Payment Arrangement, Plan Modification, Incremental Cost", "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification." } } }, "auth_ref": [ "r481" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478" ] }, "iart_ShareBasedPaymentArrangementPlanModificationExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://integralife.com/20240331", "localname": "ShareBasedPaymentArrangementPlanModificationExpirationPeriod", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan modification, expiration period (in months)", "label": "Share-Based Payment Arrangement, Plan Modification, Expiration Period", "documentation": "Share-Based Payment Arrangement, Plan Modification, Expiration Period" } } }, "auth_ref": [] }, "us-gaap_ShareRepurchaseProgramAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareRepurchaseProgramAxis", "presentation": [ "http://integralife.com/role/TREASURYSTOCKNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Repurchase Program [Axis]", "label": "Share Repurchase Program [Axis]", "documentation": "Information by share repurchase program." } } }, "auth_ref": [] }, "us-gaap_ShareRepurchaseProgramDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareRepurchaseProgramDomain", "presentation": [ "http://integralife.com/role/TREASURYSTOCKNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Repurchase Program [Domain]", "label": "Share Repurchase Program [Domain]", "documentation": "Name of the share repurchase program." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expiration period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r761" ] }, "us-gaap_SharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesIssued", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance, beginning of period, (in shares)", "periodEndLabel": "Balance, end of period (in shares)", "label": "Shares, Issued", "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury." } } }, "auth_ref": [ "r20" ] }, "us-gaap_ShortMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortMember", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short", "label": "Short [Member]", "documentation": "Indicates the sale of a borrowed security or written option." } } }, "auth_ref": [] }, "us-gaap_ShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermInvestments", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term investments", "label": "Short-Term Investments", "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current." } } }, "auth_ref": [ "r181", "r182", "r864" ] }, "us-gaap_StandbyLettersOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StandbyLettersOfCreditMember", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Standby Letters of Credit", "label": "Standby Letters of Credit [Member]", "documentation": "An irrevocable undertaking (typically by a financial institution) to guarantee payment of a specified financial obligation." } } }, "auth_ref": [ "r0", "r905", "r941", "r942" ] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails", "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofRevenuesDisaggregatedbyMajorSourceDetails", "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNarrativeDetails", "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNetSalesandProfitbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Axis]", "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r192", "r270", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r296", "r302", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r332", "r334", "r335", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r738", "r861", "r940" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSNarrativeDetails", "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofChangesinAccumulatedOtherComprehensiveIncomebyComponentDetails", "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUNAUDITED", "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r20", "r45", "r191", "r220", "r221", "r222", "r238", "r239", "r240", "r242", "r248", "r250", "r267", "r307", "r308", "r393", "r484", "r485", "r486", "r495", "r496", "r517", "r518", "r519", "r520", "r521", "r522", "r524", "r533", "r534", "r535", "r536", "r537", "r538", "r553", "r618", "r619", "r620", "r633", "r687" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTotalRevenuebyMajorGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]" } } }, "auth_ref": [ "r300", "r301", "r635", "r636", "r637", "r692", "r694", "r697", "r706", "r708", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r724", "r747", "r768", "r912", "r940" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r238", "r239", "r240", "r267", "r565", "r626", "r634", "r641", "r642", "r643", "r644", "r645", "r646", "r648", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r661", "r662", "r663", "r664", "r665", "r667", "r669", "r670", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r687", "r769" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementScenarioAxis", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Scenario [Axis]", "label": "Scenario [Axis]" } } }, "auth_ref": [ "r251", "r446", "r856", "r857", "r879" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r238", "r239", "r240", "r267", "r565", "r626", "r634", "r641", "r642", "r643", "r644", "r645", "r646", "r648", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r661", "r662", "r663", "r664", "r665", "r667", "r669", "r670", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r687", "r769" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r788", "r799", "r809", "r834" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock through employee stock purchase plan (in shares)", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": [ "r20", "r124", "r125", "r166" ] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock for vesting of share based awards, net of shares withheld for taxes (in shares)", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r20", "r124", "r125", "r166" ] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "crdr": "credit", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock through employee stock purchase plan", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan." } } }, "auth_ref": [ "r20", "r124", "r125", "r166" ] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock for vesting of share based awards, net of shares withheld for taxes", "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r79", "r124", "r125", "r166" ] }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchaseProgramAuthorizedAmount1", "crdr": "credit", "presentation": [ "http://integralife.com/role/TREASURYSTOCKNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock repurchase program, authorized amount", "label": "Stock Repurchase Program, Authorized Amount", "documentation": "Amount of stock repurchase plan authorized." } } }, "auth_ref": [] }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "crdr": "credit", "presentation": [ "http://integralife.com/role/TREASURYSTOCKNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining amount under share repurchase", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "documentation": "Amount remaining of a stock repurchase plan authorized." } } }, "auth_ref": [] }, "us-gaap_StockRepurchasedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchasedDuringPeriodShares", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "negatedLabel": "Accelerated shares repurchased (shares)", "label": "Stock Repurchased During Period, Shares", "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r20", "r124", "r125", "r166", "r630", "r687", "r707" ] }, "us-gaap_StockRepurchasedDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchasedDuringPeriodValue", "crdr": "debit", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accelerated shares repurchased", "label": "Stock Repurchased During Period, Value", "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r20", "r124", "r125", "r166", "r633", "r687", "r707", "r777" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofChangesinAccumulatedOtherComprehensiveIncomebyComponentDetails", "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUNAUDITED", "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Balance, beginning of period", "periodEndLabel": "Balance, end of period", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r125", "r128", "r129", "r153", "r650", "r666", "r688", "r689", "r763", "r778", "r873", "r884", "r923", "r946" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders\u2019 equity:", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r539", "r558" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r539", "r558" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r539", "r558" ] }, "iart_SupplierRelationShipsMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240331", "localname": "SupplierRelationShipsMember", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSComponentsofCompanysIdentifiableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplier relationships", "label": "Supplier Relation Ships [Member]", "documentation": "Supplier Relation Ships [Member]" } } }, "auth_ref": [] }, "iart_SurgicalInnovationAssociatesIncMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240331", "localname": "SurgicalInnovationAssociatesIncMember", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails", "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Surgical Innovation Associates, Inc.", "label": "Surgical Innovation Associates Inc [Member]", "documentation": "Surgical Innovation Associates Inc" } } }, "auth_ref": [] }, "iart_SwinglineLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240331", "localname": "SwinglineLoanMember", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Swingline Loans", "label": "Swingline Loan [Member]", "documentation": "Swingline Loan [Member]" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r828" ] }, "iart_TermLoanFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240331", "localname": "TermLoanFacilityMember", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loan Facility", "label": "Term Loan Facility [Member]", "documentation": "Term Loan Facility [Member]" } } }, "auth_ref": [] }, "iart_ThirdPartiesMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240331", "localname": "ThirdPartiesMember", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Third Parties", "label": "Third Parties [Member]", "documentation": "Third Parties [Member]" } } }, "auth_ref": [] }, "iart_TissueTechnologiesMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240331", "localname": "TissueTechnologiesMember", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails", "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails", "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofRevenuesDisaggregatedbyMajorSourceDetails", "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNetSalesandProfitbyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tissue Technologies", "label": "Tissue Technologies [Member]", "documentation": "Orthopedics and Tissue Technologies [Member]" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualAxis", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Title of Individual [Axis]", "label": "Title of Individual [Axis]" } } }, "auth_ref": [ "r883", "r929" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Title of Individual [Domain]", "label": "Title of Individual [Domain]" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r820" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r827" ] }, "us-gaap_TradeNamesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TradeNamesMember", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSComponentsofCompanysIdentifiableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Codman tradename", "label": "Trade Names [Member]", "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof." } } }, "auth_ref": [ "r87" ] }, "iart_TrademarksBrandNamesMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240331", "localname": "TrademarksBrandNamesMember", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSComponentsofCompanysIdentifiableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trademarks/brand names", "label": "Trademarks Brand Names [Member]", "documentation": "Trademarks Brand Names." } } }, "auth_ref": [] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r847" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r849" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://integralife.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "iart_TransferorsInterestsInTransferredFinancialAssetsIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://integralife.com/20240331", "localname": "TransferorsInterestsInTransferredFinancialAssetsIssuanceCosts", "crdr": "debit", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transferor's interests in transferred financial assets, issuance costs", "label": "Transferor's Interests In Transferred Financial Assets, Issuance Costs", "documentation": "Transferor's Interests In Transferred Financial Assets, Issuance Costs" } } }, "auth_ref": [] }, "iart_TransferorsInterestsInTransferredFinancialAssetsMaximumInvestmentLimit": { "xbrltype": "monetaryItemType", "nsuri": "http://integralife.com/20240331", "localname": "TransferorsInterestsInTransferredFinancialAssetsMaximumInvestmentLimit", "crdr": "debit", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Securitization program outstanding borrowings, maximum limit", "label": "Transferor's Interests In Transferred Financial Assets, Maximum Investment Limit", "documentation": "Transferor's Interests In Transferred Financial Assets, Maximum Investment Limit" } } }, "auth_ref": [] }, "iart_TransferorsInterestsInTransferredFinancialAssetsUnamortizedIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://integralife.com/20240331", "localname": "TransferorsInterestsInTransferredFinancialAssetsUnamortizedIssuanceCosts", "crdr": "debit", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transferor's interests in transferred financial assets, unamortized issuance costs", "label": "Transferor's Interests In Transferred Financial Assets, Unamortized Issuance Costs", "documentation": "Transferor's Interests In Transferred Financial Assets, Unamortized Issuance Costs" } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r850" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r851" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r849" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r849" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r852" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r850" ] }, "us-gaap_TreasuryStockAcquiredAverageCostPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockAcquiredAverageCostPerShare", "presentation": [ "http://integralife.com/role/TREASURYSTOCKNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock, average cost per share (in dollars per share)", "label": "Shares Acquired, Average Cost Per Share", "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased." } } }, "auth_ref": [ "r77" ] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonMember", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r77" ] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonShares", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical", "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUNAUDITED", "http://integralife.com/role/TREASURYSTOCKNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock (in shares)", "negatedPeriodStartLabel": "Balance, beginning of period, treasury stock (in shares)", "negatedPeriodEndLabel": "Balance, beginning of period, treasury stock (in shares)", "label": "Treasury Stock, Common, Shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r77" ] }, "us-gaap_TreasuryStockCommonValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonValue", "crdr": "debit", "calculation": { "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "http://integralife.com/role/TREASURYSTOCKNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Treasury stock, at cost; 12,735 shares and 12,751 shares at March\u00a031, 2024 and December\u00a031, 2023, respectively", "terseLabel": "Treasury stock", "label": "Treasury Stock, Common, Value", "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r46", "r77", "r78" ] }, "us-gaap_TreasuryStockTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockTextBlock", "presentation": [ "http://integralife.com/role/TREASURYSTOCK" ], "lang": { "en-us": { "role": { "terseLabel": "TREASURY STOCK", "label": "Treasury Stock [Text Block]", "documentation": "The entire disclosure for treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock." } } }, "auth_ref": [ "r167" ] }, "iart_TwoThousandTwentyFiveSeniorConvertibleNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://integralife.com/20240331", "localname": "TwoThousandTwentyFiveSeniorConvertibleNotesMember", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025 Notes", "label": "Two Thousand Twenty Five Senior Convertible Notes [Member]", "documentation": "Two Thousand Twenty Five Senior Convertible Notes [Member]" } } }, "auth_ref": [] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "US", "presentation": [ "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTotalRevenuebyMajorGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "United States", "label": "UNITED STATES" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r846" ] }, "us-gaap_UnusualOrInfrequentItemAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnusualOrInfrequentItemAxis", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unusual or Infrequent Item, or Both [Axis]", "label": "Unusual or Infrequent Item, or Both [Axis]", "documentation": "Information by an event or transaction that is unusual in nature or infrequent in occurrence, or both." } } }, "auth_ref": [ "r147" ] }, "us-gaap_UnusualOrInfrequentItemDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnusualOrInfrequentItemDomain", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unusual or Infrequent Item, or Both [Domain]", "label": "Unusual or Infrequent Item, or Both [Domain]", "documentation": "Event or transaction that is unusual in nature or infrequent in occurrence, or both." } } }, "auth_ref": [ "r147" ] }, "us-gaap_ValuationTechniqueAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationTechniqueAxis", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation Approach and Technique [Axis]", "label": "Valuation Approach and Technique [Axis]", "documentation": "Information by valuation approach and technique." } } }, "auth_ref": [ "r22" ] }, "us-gaap_ValuationTechniqueDiscountedCashFlowMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationTechniqueDiscountedCashFlowMember", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation Technique, Discounted Cash Flow", "label": "Valuation Technique, Discounted Cash Flow [Member]", "documentation": "Valuation technique calculating present value of future cash flows." } } }, "auth_ref": [ "r922" ] }, "us-gaap_ValuationTechniqueDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationTechniqueDomain", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation Approach and Technique [Domain]", "label": "Valuation Approach and Technique [Domain]", "documentation": "Valuation approach and technique." } } }, "auth_ref": [ "r22" ] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateAxis", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Axis]", "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateDomain", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Domain]", "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "us-gaap_VehiclesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VehiclesMember", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leased vehicles", "label": "Vehicles [Member]", "documentation": "Equipment used primarily for road transportation." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://integralife.com/role/NETINCOMEPERSHAREBasicandDilutedNetIncomePerShareDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED", "http://integralife.com/role/NETINCOMEPERSHAREBasicandDilutedNetIncomePerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in shares)", "totalLabel": "Weighted average common shares for diluted earnings per share (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r254", "r262" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average common shares outstanding (See Note 13):", "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://integralife.com/role/NETINCOMEPERSHAREBasicandDilutedNetIncomePerShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://integralife.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED", "http://integralife.com/role/NETINCOMEPERSHAREBasicandDilutedNetIncomePerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in shares)", "verboseLabel": "Weighted average common shares outstanding - basic (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r253", "r262" ] }, "us-gaap_WriteOffOfDeferredDebtIssuanceCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WriteOffOfDeferredDebtIssuanceCost", "crdr": "debit", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Write off of debt issuance costs", "label": "Deferred Debt Issuance Cost, Writeoff", "documentation": "Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt." } } }, "auth_ref": [ "r145" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "12", "Subparagraph": "(f)(2)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481410/810-10-15-12" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "7", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "8", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a),(b),(c)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(i),(j),(k)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(i-k)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(f)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481648/480-10-50-2" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b),(d)", "SubTopic": "30", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "e", "SubTopic": "470", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "SubTopic": "10", "Topic": "280", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-4" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(c)(2)", "SubTopic": "20", "Topic": "860", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4D" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)(2)", "SubTopic": "40", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "45", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.30)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "((a)(1),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "55", "Paragraph": "63", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481620/480-10-55-63" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(CFRR 211.02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "55", "Paragraph": "37", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-20" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-6" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a),(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4F" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-8" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "55", "Paragraph": "182", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480401/815-10-55-182" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "25", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480238/815-25-50-1" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480870/815-30-50-1" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "40", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-4" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "40", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205-20/tableOfContent" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-7" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//220/tableOfContent" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "45", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483613/220-20-50-1" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350/tableOfContent" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-10" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505-30/tableOfContent" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481138/505-30-25-5" }, "r169": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "12", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r170": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r171": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//805/tableOfContent" }, "r172": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r173": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r174": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//815/tableOfContent" }, "r175": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-3" }, "r176": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r177": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r178": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r179": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r180": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r181": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r182": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r183": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r184": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r185": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(1)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-15" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//280/tableOfContent" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//330/tableOfContent" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "32", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479866/606-10-32-2A" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-3" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//715/tableOfContent" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(o)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(p)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480126/715-20-S99-2" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-3" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-4" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4E" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5C" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480627/815-20-45-3" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-20/tableOfContent" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r721": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r722": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(1)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r723": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r724": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r725": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r726": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r727": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r728": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r729": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r730": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16" }, "r731": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21" }, "r732": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r733": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15" }, "r734": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r735": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r736": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r737": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r738": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r739": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r740": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r741": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r742": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r743": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r744": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r745": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r746": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r747": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r748": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r749": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r750": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r751": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r752": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r753": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r754": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r755": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r756": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-18" }, "r757": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r758": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r759": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r760": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r761": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r762": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r763": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r764": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r765": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r766": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r767": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r768": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r769": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r770": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r771": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r772": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r773": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r774": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column B)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r775": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r776": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r777": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r778": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r779": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r780": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r781": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r782": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r783": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r784": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r785": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r786": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r787": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r788": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r789": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r790": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r791": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r792": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r793": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r794": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r795": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r796": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r797": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r798": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r799": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r800": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r801": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r802": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r803": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r804": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r805": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r806": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r807": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r808": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r809": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r810": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r811": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r812": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r813": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r814": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r815": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r816": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r817": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r818": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r819": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r820": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r821": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r822": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r823": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r824": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r825": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r826": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r827": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r828": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r829": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r830": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r831": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r832": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r833": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r834": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r835": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r836": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r837": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r838": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r839": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r840": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r841": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r842": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r843": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r844": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r845": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r846": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r847": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r848": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r849": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r850": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r851": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r852": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r853": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r854": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r855": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r856": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10" }, "r857": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(1)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CC", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4CC" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-5" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B" }, "r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480682/815-20-25-6A" }, "r921": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r933": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r938": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-15" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-16" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" } } } ZIP 95 0000917520-24-000061-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000917520-24-000061-xbrl.zip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�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end XML 97 iart-20240331_htm.xml IDEA: XBRL DOCUMENT 0000917520 2024-01-01 2024-03-31 0000917520 2024-05-03 0000917520 2023-01-01 2023-03-31 0000917520 2024-03-31 0000917520 2023-12-31 0000917520 2022-12-31 0000917520 2023-03-31 0000917520 us-gaap:CommonStockMember 2023-12-31 0000917520 us-gaap:TreasuryStockCommonMember 2023-12-31 0000917520 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000917520 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000917520 us-gaap:RetainedEarningsMember 2023-12-31 0000917520 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0000917520 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0000917520 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0000917520 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0000917520 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-03-31 0000917520 us-gaap:CommonStockMember 2024-03-31 0000917520 us-gaap:TreasuryStockCommonMember 2024-03-31 0000917520 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0000917520 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0000917520 us-gaap:RetainedEarningsMember 2024-03-31 0000917520 us-gaap:CommonStockMember 2022-12-31 0000917520 us-gaap:TreasuryStockCommonMember 2022-12-31 0000917520 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000917520 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000917520 us-gaap:RetainedEarningsMember 2022-12-31 0000917520 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000917520 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0000917520 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000917520 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0000917520 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-03-31 0000917520 us-gaap:CommonStockMember 2023-03-31 0000917520 us-gaap:TreasuryStockCommonMember 2023-03-31 0000917520 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000917520 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0000917520 us-gaap:RetainedEarningsMember 2023-03-31 0000917520 iart:AcclarentInc.Member 2023-12-01 2023-12-31 0000917520 iart:AcclarentInc.Member 2023-12-31 0000917520 iart:AcclarentInc.Member us-gaap:SubsequentEventMember 2024-04-01 0000917520 iart:AcclarentInc.Member us-gaap:SubsequentEventMember 2024-04-01 2024-04-01 0000917520 2024-04-01 2024-03-31 0000917520 iart:NeurosurgeryMember iart:CodmanSpecialtySurgicalMember 2024-01-01 2024-03-31 0000917520 iart:NeurosurgeryMember iart:CodmanSpecialtySurgicalMember 2023-01-01 2023-03-31 0000917520 iart:InstrumentsMember iart:CodmanSpecialtySurgicalMember 2024-01-01 2024-03-31 0000917520 iart:InstrumentsMember iart:CodmanSpecialtySurgicalMember 2023-01-01 2023-03-31 0000917520 iart:CodmanSpecialtySurgicalMember 2024-01-01 2024-03-31 0000917520 iart:CodmanSpecialtySurgicalMember 2023-01-01 2023-03-31 0000917520 iart:RegenerativeSkinAndWoundMember iart:TissueTechnologiesMember 2024-01-01 2024-03-31 0000917520 iart:RegenerativeSkinAndWoundMember iart:TissueTechnologiesMember 2023-01-01 2023-03-31 0000917520 iart:PrivateLabelMember iart:TissueTechnologiesMember 2024-01-01 2024-03-31 0000917520 iart:PrivateLabelMember iart:TissueTechnologiesMember 2023-01-01 2023-03-31 0000917520 iart:TissueTechnologiesMember 2024-01-01 2024-03-31 0000917520 iart:TissueTechnologiesMember 2023-01-01 2023-03-31 0000917520 iart:CodmanSpecialtySurgicalMember 2023-12-31 0000917520 iart:TissueTechnologiesMember 2023-12-31 0000917520 iart:CodmanSpecialtySurgicalMember 2024-03-31 0000917520 iart:TissueTechnologiesMember 2024-03-31 0000917520 us-gaap:MeasurementInputLongTermRevenueGrowthRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2024-01-01 2024-03-31 0000917520 us-gaap:MeasurementInputDiscountRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2024-01-01 2024-03-31 0000917520 iart:TissueTechnologiesMember 2024-03-31 0000917520 iart:CompletedTechnologyMember 2024-03-31 0000917520 us-gaap:CustomerRelationshipsMember 2024-03-31 0000917520 iart:TrademarksBrandNamesMember 2024-03-31 0000917520 us-gaap:TradeNamesMember 2024-03-31 0000917520 iart:SupplierRelationShipsMember 2024-03-31 0000917520 iart:AllOtherMember 2024-03-31 0000917520 iart:CompletedTechnologyMember 2023-12-31 0000917520 us-gaap:CustomerRelationshipsMember 2023-12-31 0000917520 iart:TrademarksBrandNamesMember 2023-12-31 0000917520 us-gaap:TradeNamesMember 2023-12-31 0000917520 iart:SupplierRelationShipsMember 2023-12-31 0000917520 iart:AllOtherMember 2023-12-31 0000917520 iart:CompletedTechnologyMember 2024-01-01 2024-03-31 0000917520 us-gaap:CustomerRelationshipsMember 2024-01-01 2024-03-31 0000917520 iart:CompletedTechnologyMember 2023-01-01 2023-03-31 0000917520 iart:CompletedTechnologyMember iart:CompletedTechnologySurgiMendMember 2024-03-31 0000917520 iart:CompletedTechnologyMember iart:CompletedTechnologyPriMatrixMember 2024-03-31 0000917520 iart:SeniorCreditFacilityMember 2023-03-24 0000917520 us-gaap:SecuredDebtMember iart:TermLoanFacilityMember 2023-03-24 0000917520 us-gaap:RevolvingCreditFacilityMember 2023-03-24 0000917520 us-gaap:StandbyLettersOfCreditMember 2023-03-24 0000917520 iart:SwinglineLoanMember 2023-03-24 0000917520 iart:SeniorCreditFacilityMember iart:DebtCovenantPeriod1Member 2023-03-24 0000917520 iart:SeniorCreditFacilityMember iart:DebtCovenantPeriod2Member 2023-03-24 0000917520 iart:SeniorCreditFacilityMember iart:DebtCovenantPeriod3Member 2023-03-24 0000917520 iart:SeniorCreditFacilityMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2024-01-01 2024-03-31 0000917520 srt:MinimumMember iart:SeniorCreditFacilityMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2024-01-01 2024-03-31 0000917520 srt:MaximumMember iart:SeniorCreditFacilityMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2024-01-01 2024-03-31 0000917520 iart:SeniorCreditFacilityMember us-gaap:FederalFundsEffectiveSwapRateMember 2024-01-01 2024-03-31 0000917520 srt:MinimumMember iart:SeniorCreditFacilityMember 2024-01-01 2024-03-31 0000917520 srt:MaximumMember iart:SeniorCreditFacilityMember 2024-01-01 2024-03-31 0000917520 us-gaap:RevolvingCreditFacilityMember 2024-03-31 0000917520 us-gaap:RevolvingCreditFacilityMember 2023-01-01 2023-03-31 0000917520 us-gaap:RevolvingCreditFacilityMember 2023-12-31 0000917520 us-gaap:SecuredDebtMember iart:TermLoanFacilityMember 2024-03-31 0000917520 us-gaap:SecuredDebtMember iart:TermLoanFacilityMember 2023-12-31 0000917520 us-gaap:SecuredDebtMember iart:TermLoanFacilityMember us-gaap:FairValueInputsLevel2Member 2024-03-31 0000917520 us-gaap:StandbyLettersOfCreditMember iart:SeniorCreditFacilityMember 2024-03-31 0000917520 us-gaap:StandbyLettersOfCreditMember iart:SeniorCreditFacilityMember 2023-12-31 0000917520 iart:TwoThousandTwentyFiveSeniorConvertibleNotesMember us-gaap:ConvertibleDebtMember 2020-02-04 0000917520 iart:TwoThousandTwentyFiveSeniorConvertibleNotesMember us-gaap:ConvertibleDebtMember 2020-02-04 2020-02-04 0000917520 iart:TwoThousandTwentyFiveSeniorConvertibleNotesMember us-gaap:ConvertibleDebtMember 2020-12-09 0000917520 iart:TwoThousandTwentyFiveSeniorConvertibleNotesMember us-gaap:ConvertibleDebtMember us-gaap:CallOptionMember 2020-02-04 2020-02-04 0000917520 iart:TwoThousandTwentyFiveSeniorConvertibleNotesMember us-gaap:ConvertibleDebtMember 2024-03-31 0000917520 2023-12-15 0000917520 us-gaap:FairValueInputsLevel2Member 2024-03-31 0000917520 iart:InterestRateSwapDesignatedDecember132017Tranche2Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2024-03-31 0000917520 iart:InterestRateSwapDesignatedDecember132017Tranche2Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2023-12-31 0000917520 iart:InterestRateSwapDesignatedDecember132017Tranche3Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2024-03-31 0000917520 iart:InterestRateSwapDesignatedDecember132017Tranche3Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2023-12-31 0000917520 iart:InterestRateSwapDesignatedOctober102018Tranche1Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2024-03-31 0000917520 iart:InterestRateSwapDesignatedOctober102018Tranche1Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2023-12-31 0000917520 iart:InterestRateSwapDesignatedOctober102018Tranche2Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2024-03-31 0000917520 iart:InterestRateSwapDesignatedOctober102018Tranche2Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2023-12-31 0000917520 iart:InterestRateSwapDesignatedOctober102018Tranche3Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2024-03-31 0000917520 iart:InterestRateSwapDesignatedOctober102018Tranche3Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2023-12-31 0000917520 iart:InterestRateSwapDesignatedDecember182018Tranche1Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2024-03-31 0000917520 iart:InterestRateSwapDesignatedDecember182018Tranche1Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2023-12-31 0000917520 iart:InterestRateSwapDesignatedDecember182018Tranche2Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2024-03-31 0000917520 iart:InterestRateSwapDesignatedDecember182018Tranche2Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2023-12-31 0000917520 iart:InterestRateSwapDesignatedDecember152020Tranche1Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2024-03-31 0000917520 iart:InterestRateSwapDesignatedDecember152020Tranche1Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2023-12-31 0000917520 iart:InterestRateSwapDesignatedDecember152020Tranche2Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2024-03-31 0000917520 iart:InterestRateSwapDesignatedDecember152020Tranche2Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2023-12-31 0000917520 iart:InterestRateSwapDesignatedMarch312023Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0000917520 iart:InterestRateSwapDesignatedMarch312023Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000917520 us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0000917520 us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000917520 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-01-01 2024-03-31 0000917520 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-01-01 2023-03-31 0000917520 us-gaap:InterestRateSwapMember 2024-03-31 0000917520 iart:CodmanMember us-gaap:CrossCurrencyInterestRateContractMember 2023-09-22 0000917520 iart:CodmanMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:ShortMember 2023-09-22 0000917520 us-gaap:CrossCurrencyInterestRateContractMember 2020-12-21 0000917520 us-gaap:CrossCurrencyInterestRateContractMember 2024-01-01 2024-03-31 0000917520 iart:CodmanMember iart:CrossCurrencyInterestRateContractOneMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2024-03-31 0000917520 iart:CodmanMember iart:CrossCurrencyInterestRateContractOneMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2023-12-31 0000917520 iart:CodmanMember iart:CrossCurrencyInterestRateContractOneMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0000917520 iart:CodmanMember iart:CrossCurrencyInterestRateContractOneMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000917520 iart:CodmanMember iart:CrossCurrencyInterestRateContractOneMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2024-03-31 0000917520 iart:CodmanMember iart:CrossCurrencyInterestRateContractOneMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2023-12-31 0000917520 iart:CodmanMember iart:CrossCurrencyInterestRateContractTwoMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2024-03-31 0000917520 iart:CodmanMember iart:CrossCurrencyInterestRateContractTwoMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2023-12-31 0000917520 iart:CodmanMember iart:CrossCurrencyInterestRateContractTwoMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0000917520 iart:CodmanMember iart:CrossCurrencyInterestRateContractTwoMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000917520 iart:CodmanMember iart:CrossCurrencyInterestRateContractTwoMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2024-03-31 0000917520 iart:CodmanMember iart:CrossCurrencyInterestRateContractTwoMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2023-12-31 0000917520 iart:CodmanMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0000917520 iart:CodmanMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-01-01 2024-03-31 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-01-01 2023-03-31 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherNonoperatingIncomeExpenseMember 2024-01-01 2024-03-31 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherNonoperatingIncomeExpenseMember 2023-01-01 2023-03-31 0000917520 us-gaap:CrossCurrencyInterestRateContractMember 2023-01-01 2023-03-31 0000917520 us-gaap:CrossCurrencyInterestRateContractMember 2024-03-31 0000917520 iart:CrossCurrencyInterestRateContractOneMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2024-03-31 0000917520 iart:CrossCurrencyInterestRateContractOneMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2023-12-31 0000917520 iart:CrossCurrencyInterestRateContractOneMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0000917520 iart:CrossCurrencyInterestRateContractOneMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000917520 iart:CrossCurrencyInterestRateContractOneMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2024-03-31 0000917520 iart:CrossCurrencyInterestRateContractOneMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2023-12-31 0000917520 iart:CrossCurrencyInterestRateContractTwoMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2024-03-31 0000917520 iart:CrossCurrencyInterestRateContractTwoMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2023-12-31 0000917520 iart:CrossCurrencyInterestRateContractTwoMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0000917520 iart:CrossCurrencyInterestRateContractTwoMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000917520 iart:CrossCurrencyInterestRateContractTwoMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2024-03-31 0000917520 iart:CrossCurrencyInterestRateContractTwoMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2023-12-31 0000917520 iart:CrossCurrencyInterestRateContractThreeMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2024-03-31 0000917520 iart:CrossCurrencyInterestRateContractThreeMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2023-12-31 0000917520 iart:CrossCurrencyInterestRateContractThreeMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0000917520 iart:CrossCurrencyInterestRateContractThreeMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000917520 iart:CrossCurrencyInterestRateContractThreeMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2024-03-31 0000917520 iart:CrossCurrencyInterestRateContractThreeMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2023-12-31 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestIncomeMember 2024-01-01 2024-03-31 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestIncomeMember 2023-01-01 2023-03-31 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-01-01 2024-03-31 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-01-01 2023-03-31 0000917520 us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:SubsequentEventMember 2024-05-02 0000917520 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0000917520 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2024-01-01 2024-03-31 0000917520 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0000917520 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000917520 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0000917520 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000917520 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0000917520 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000917520 us-gaap:OtherAssetsMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0000917520 us-gaap:OtherAssetsMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000917520 us-gaap:OtherAssetsMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0000917520 us-gaap:OtherAssetsMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000917520 us-gaap:OtherAssetsMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0000917520 us-gaap:OtherAssetsMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000917520 us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0000917520 us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000917520 iart:AccruedExpensesAndOtherCurrentLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0000917520 iart:AccruedExpensesAndOtherCurrentLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000917520 iart:AccruedExpensesAndOtherCurrentLiabilitiesMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0000917520 iart:AccruedExpensesAndOtherCurrentLiabilitiesMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000917520 iart:AccruedExpensesAndOtherCurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0000917520 iart:AccruedExpensesAndOtherCurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000917520 iart:AccruedExpensesAndOtherCurrentLiabilitiesMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0000917520 iart:AccruedExpensesAndOtherCurrentLiabilitiesMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000917520 us-gaap:OtherLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0000917520 us-gaap:OtherLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000917520 us-gaap:OtherLiabilitiesMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0000917520 us-gaap:OtherLiabilitiesMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000917520 us-gaap:OtherLiabilitiesMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0000917520 us-gaap:OtherLiabilitiesMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000917520 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000917520 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0000917520 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2023-12-31 0000917520 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2024-01-01 2024-03-31 0000917520 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2024-03-31 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherNonoperatingIncomeExpenseMember 2023-12-31 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherNonoperatingIncomeExpenseMember 2024-03-31 0000917520 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2023-12-31 0000917520 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2024-03-31 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestIncomeMember 2023-12-31 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestIncomeMember 2024-03-31 0000917520 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000917520 us-gaap:DesignatedAsHedgingInstrumentMember 2024-01-01 2024-03-31 0000917520 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0000917520 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2022-12-31 0000917520 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2023-01-01 2023-03-31 0000917520 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2023-03-31 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherNonoperatingIncomeExpenseMember 2022-12-31 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherNonoperatingIncomeExpenseMember 2023-03-31 0000917520 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2023-01-01 2023-03-31 0000917520 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2023-03-31 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestIncomeMember 2022-12-31 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestIncomeMember 2023-03-31 0000917520 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000917520 us-gaap:DesignatedAsHedgingInstrumentMember 2023-01-01 2023-03-31 0000917520 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0000917520 us-gaap:CurrencySwapMember us-gaap:NondesignatedMember 2021-06-30 0000917520 us-gaap:CurrencySwapMember us-gaap:NondesignatedMember 2024-03-31 0000917520 us-gaap:CurrencySwapMember us-gaap:NondesignatedMember 2023-12-31 0000917520 us-gaap:CurrencySwapMember 2024-01-01 2024-03-31 0000917520 us-gaap:CurrencySwapMember 2023-01-01 2023-03-31 0000917520 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2024-01-01 2024-03-31 0000917520 srt:DirectorMember us-gaap:EmployeeStockOptionMember 2024-01-01 2024-03-31 0000917520 iart:EmployeeMember us-gaap:EmployeeStockOptionMember 2024-01-01 2024-03-31 0000917520 srt:MinimumMember iart:DirectorsandCertainExecutiveOfficersMember us-gaap:EmployeeStockOptionMember 2024-01-01 2024-03-31 0000917520 srt:MaximumMember iart:DirectorsandCertainExecutiveOfficersMember us-gaap:EmployeeStockOptionMember 2024-01-01 2024-03-31 0000917520 us-gaap:RestrictedStockMember 2024-01-01 2024-03-31 0000917520 us-gaap:EmployeeStockOptionMember 2024-03-31 0000917520 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-03-31 0000917520 iart:PerformanceStockAndRestrictedStockAwardsMember 2024-01-01 2024-03-31 0000917520 us-gaap:RestrictedStockMember 2024-03-31 0000917520 us-gaap:PerformanceSharesMember 2024-01-01 2024-03-31 0000917520 srt:ChiefExecutiveOfficerMember 2024-01-01 2024-03-31 0000917520 srt:ScenarioForecastMember srt:ChiefExecutiveOfficerMember 2024-01-01 2024-12-31 0000917520 us-gaap:RelatedPartyMember 2023-01-01 2023-03-31 0000917520 us-gaap:RelatedPartyMember 2024-01-01 2024-03-31 0000917520 us-gaap:BuildingMember 2024-03-31 0000917520 us-gaap:BuildingMember 2023-12-31 0000917520 us-gaap:VehiclesMember 2024-03-31 0000917520 us-gaap:VehiclesMember 2023-12-31 0000917520 iart:RelatedPartiesMember 2024-03-31 0000917520 iart:ThirdPartiesMember 2024-03-31 0000917520 iart:FiveYearOptionLeasePeriodOneMember us-gaap:RelatedPartyMember 2024-03-31 0000917520 iart:FiveYearOptionLeasePeriodOneMember us-gaap:RelatedPartyMember 2024-01-01 2024-03-31 0000917520 iart:FiveYearOptionLeasePeriodTwoMember us-gaap:RelatedPartyMember 2024-03-31 0000917520 iart:FiveYearOptionLeasePeriodTwoMember us-gaap:RelatedPartyMember 2024-01-01 2024-03-31 0000917520 2023-01-01 2023-12-31 0000917520 2023-08-15 0000917520 2023-10-18 0000917520 2023-01-26 0000917520 2023-06-30 0000917520 iart:A2023ShareRepurchaseProgramMember 2023-07-18 0000917520 iart:A2022ShareRepurchaseProgramMember 2022-04-26 0000917520 iart:A2022ShareRepurchaseProgramMember 2023-07-18 0000917520 iart:A2023ShareRepurchaseProgramMember 2024-03-31 0000917520 2024-03-31 2024-03-31 0000917520 2023-03-31 2023-03-31 0000917520 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-12-31 0000917520 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-12-31 0000917520 us-gaap:AccumulatedTranslationAdjustmentMember 2023-12-31 0000917520 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-01-01 2024-03-31 0000917520 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-01-01 2024-03-31 0000917520 us-gaap:AccumulatedTranslationAdjustmentMember 2024-01-01 2024-03-31 0000917520 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-03-31 0000917520 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-03-31 0000917520 us-gaap:AccumulatedTranslationAdjustmentMember 2024-03-31 0000917520 us-gaap:OtherIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-01-01 2024-03-31 0000917520 us-gaap:InterestIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-01-01 2024-03-31 0000917520 us-gaap:OperatingSegmentsMember iart:CodmanSpecialtySurgicalMember 2024-01-01 2024-03-31 0000917520 us-gaap:OperatingSegmentsMember iart:CodmanSpecialtySurgicalMember 2023-01-01 2023-03-31 0000917520 us-gaap:OperatingSegmentsMember iart:TissueTechnologiesMember 2024-01-01 2024-03-31 0000917520 us-gaap:OperatingSegmentsMember iart:TissueTechnologiesMember 2023-01-01 2023-03-31 0000917520 us-gaap:OperatingSegmentsMember 2024-01-01 2024-03-31 0000917520 us-gaap:OperatingSegmentsMember 2023-01-01 2023-03-31 0000917520 us-gaap:CorporateNonSegmentMember 2024-01-01 2024-03-31 0000917520 us-gaap:CorporateNonSegmentMember 2023-01-01 2023-03-31 0000917520 country:US 2024-01-01 2024-03-31 0000917520 country:US 2023-01-01 2023-03-31 0000917520 srt:EuropeMember 2024-01-01 2024-03-31 0000917520 srt:EuropeMember 2023-01-01 2023-03-31 0000917520 srt:AsiaPacificMember 2024-01-01 2024-03-31 0000917520 srt:AsiaPacificMember 2023-01-01 2023-03-31 0000917520 iart:RestOfWorldMember 2024-01-01 2024-03-31 0000917520 iart:RestOfWorldMember 2023-01-01 2023-03-31 0000917520 iart:ArkisBioSciencesInc.Member us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2023-12-31 0000917520 iart:DermaSciencesMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2023-12-31 0000917520 iart:ACellMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2023-12-31 0000917520 iart:SurgicalInnovationAssociatesIncMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2023-12-31 0000917520 iart:ArkisBioSciencesInc.Member us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2024-01-01 2024-03-31 0000917520 iart:DermaSciencesMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2024-01-01 2024-03-31 0000917520 iart:ACellMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2024-01-01 2024-03-31 0000917520 iart:SurgicalInnovationAssociatesIncMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2024-01-01 2024-03-31 0000917520 iart:ArkisBioSciencesInc.Member us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2024-03-31 0000917520 iart:DermaSciencesMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2024-03-31 0000917520 iart:ACellMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2024-03-31 0000917520 iart:SurgicalInnovationAssociatesIncMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2024-03-31 0000917520 us-gaap:OtherCurrentLiabilitiesMember iart:ArkisBioSciencesInc.Member us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2024-03-31 0000917520 us-gaap:OtherCurrentLiabilitiesMember iart:DermaSciencesMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2024-03-31 0000917520 us-gaap:OtherCurrentLiabilitiesMember iart:ACellMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2024-03-31 0000917520 us-gaap:OtherCurrentLiabilitiesMember iart:SurgicalInnovationAssociatesIncMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2024-03-31 0000917520 us-gaap:OtherNoncurrentLiabilitiesMember iart:ArkisBioSciencesInc.Member us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2024-03-31 0000917520 us-gaap:OtherNoncurrentLiabilitiesMember iart:DermaSciencesMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2024-03-31 0000917520 us-gaap:OtherNoncurrentLiabilitiesMember iart:ACellMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2024-03-31 0000917520 us-gaap:OtherNoncurrentLiabilitiesMember iart:SurgicalInnovationAssociatesIncMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2024-03-31 0000917520 iart:ArkisBioSciencesInc.Member us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2022-12-31 0000917520 iart:DermaSciencesMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2022-12-31 0000917520 iart:ACellMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2022-12-31 0000917520 iart:SurgicalInnovationAssociatesIncMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2022-12-31 0000917520 iart:ArkisBioSciencesInc.Member us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2023-01-01 2023-03-31 0000917520 iart:DermaSciencesMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2023-01-01 2023-03-31 0000917520 iart:ACellMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2023-01-01 2023-03-31 0000917520 iart:SurgicalInnovationAssociatesIncMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2023-01-01 2023-03-31 0000917520 iart:ArkisBioSciencesInc.Member us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2023-03-31 0000917520 iart:DermaSciencesMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2023-03-31 0000917520 iart:ACellMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2023-03-31 0000917520 iart:SurgicalInnovationAssociatesIncMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2023-03-31 0000917520 us-gaap:OtherCurrentLiabilitiesMember iart:ArkisBioSciencesInc.Member us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2023-03-31 0000917520 us-gaap:OtherCurrentLiabilitiesMember iart:DermaSciencesMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2023-03-31 0000917520 us-gaap:OtherCurrentLiabilitiesMember iart:ACellMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2023-03-31 0000917520 us-gaap:OtherCurrentLiabilitiesMember iart:SurgicalInnovationAssociatesIncMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2023-03-31 0000917520 us-gaap:OtherNoncurrentLiabilitiesMember iart:ArkisBioSciencesInc.Member us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2023-03-31 0000917520 us-gaap:OtherNoncurrentLiabilitiesMember iart:DermaSciencesMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2023-03-31 0000917520 us-gaap:OtherNoncurrentLiabilitiesMember iart:ACellMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2023-03-31 0000917520 us-gaap:OtherNoncurrentLiabilitiesMember iart:SurgicalInnovationAssociatesIncMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2023-03-31 0000917520 iart:ArkisBioSciencesInc.Member 2019-07-29 0000917520 iart:ArkisBioSciencesInc.Member iart:MilestonePaymentOneMember 2019-07-29 0000917520 iart:ArkisBioSciencesInc.Member iart:MilestonePaymentTwoMember 2019-07-29 0000917520 iart:DermaSciencesMember iart:BioDEarnoutPaymentsandMedihoneyEarnoutPaymentsMember 2024-01-01 2024-03-31 0000917520 iart:DermaSciencesMember 2024-03-31 0000917520 iart:ACellIncMember 2021-01-20 0000917520 iart:SurgicalInnovationAssociatesIncMember 2022-12-06 0000917520 iart:SurgicalInnovationAssociatesIncMember 2022-12-06 2022-12-06 0000917520 iart:SurgicalInnovationAssociatesIncMember iart:RevenueBasedPerformanceMilestonesMember 2022-12-06 0000917520 iart:SurgicalInnovationAssociatesIncMember iart:FDAApprovalOfPremarketApprovalMember 2022-12-06 shares iso4217:USD iso4217:USD shares pure iso4217:CHF iso4217:EUR iart:renewalOption iart:Segment iart:product iart:liability iart:payment false 2024 Q1 0000917520 --12-31 0.0135739 P6Y 10-Q true 2024-03-31 false 000-26224 INTEGRA LIFESCIENCES HOLDINGS CORP DE 51-0317849 1100 Campus Road 08540 Princeton NJ 609 275-0500 Common Stock, Par Value $.01 Per Share IART NASDAQ Yes Yes Large Accelerated Filer false false false 78799694 368872000 380846000 162038000 147975000 26965000 26724000 165798000 166657000 10107000 3108000 364908000 344464000 3964000 36382000 5040000 4107000 13624000 12100000 -610000 1389000 -5230000 29778000 -1949000 5552000 -3281000 24226000 -0.04 0.30 -0.04 0.29 77735000 81871000 77735000 82323000 1179000 21028000 591906000 276402000 71194000 32694000 5050000 4879000 241092000 259327000 403422000 389608000 72667000 67362000 35369000 32643000 1415650000 1058036000 345356000 340199000 151834000 156184000 1022609000 1067833000 1040235000 1055462000 34175000 46080000 68365000 58194000 4078224000 3781988000 19375000 14531000 16303000 15284000 94397000 92326000 7841000 8540000 52582000 75455000 111896000 100844000 302394000 306980000 1171036000 825563000 94600000 89200000 570984000 570255000 170082000 166849000 31431000 35317000 139745000 199940000 2480272000 2194104000 0 0 15000000 15000000 0 0 0 0 0.01 0.01 240000000 240000000 91484000 90920000 915000 909000 1310527000 1302484000 12735000 12751000 646422000 647262000 -10646000 -15106000 943578000 946859000 1597952000 1587884000 4078224000 3781988000 -3281000 24226000 30566000 31143000 7064000 0 -2856000 1953000 5599000 3620000 1398000 1890000 149000 1260000 -12000 23000 456000 4699000 -16827000 -10041000 19021000 25423000 2676000 2164000 -339000 6009000 -19210000 -4984000 -1498000 430000 1888000 -14503000 15756000 26156000 15465000 13704000 38500000 0 -53965000 -13704000 370500000 10200000 15100000 12400000 0 7578000 0 150000000 6398000 2326000 3122000 5231000 358676000 -162683000 -4963000 937000 315504000 -149294000 276402000 456661000 591906000 307367000 90920000 909000 12751000 -647262000 1302484000 -15106000 946859000 1587884000 -3281000 -3281000 4460000 4460000 23000 965000 965000 541000 2000 16000 840000 1470000 2312000 4000 5608000 5612000 0 91484000 915000 12735000 -646422000 1310527000 -10646000 943578000 1597952000 90476000 905000 6823000 -362862000 1276977000 10265000 879118000 1804403000 24226000 24226000 -3198000 -3198000 21000 1107000 1107000 316000 1000 16000 846000 -4858000 -4011000 2000 3609000 3611000 2111000 119662000 31538000 151200000 90813000 908000 8918000 -481678000 1245297000 7067000 903344000 1674938000 BASIS OF PRESENTATION<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms “we,” “our,” “us,” “Company” and “Integra” refer to Integra LifeSciences Holdings Corporation, a Delaware corporation, and its subsidiaries unless the context suggests otherwise.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the March 31, 2024 unaudited condensed consolidated financial statements contain all adjustments (consisting only of normal recurring adjustments) necessary for a fair statement of the financial position, statement of changes in shareholders’ equity, results of operations and cash flows of the Company. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) have been condensed or omitted in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements for the year ended December 31, 2023 included in the Company’s Annual Report on Form 10-K. The December 31, 2023 consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by GAAP. Operating results for the three-month period ended March 31, 2024 are not necessarily indicative of the results to be expected for the entire year.</span></div>The preparation of consolidated financial statements is in conformity with GAAP, which requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, the disclosure of contingent liabilities, and the reported amounts of revenues and expenses. Significant estimates affecting amounts reported or disclosed in the condensed consolidated financial statements include allowances for doubtful accounts receivable and sales returns and allowances, net realizable value of inventories, valuation of intangible assets including amortization periods for acquired intangible assets, discount rates and estimated projected cash flows used to value and test impairments of long-lived assets and goodwill, estimates of projected cash flows and depreciation and amortization periods for long-lived assets, computation of taxes, valuation allowances recorded against deferred tax assets, the valuation of stock-based compensation, valuation of derivative instruments, valuation of contingent liabilities, the fair value of debt instruments and loss contingencies. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the current circumstances. Actual results could differ from these estimates. BASIS OF PRESENTATION<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms “we,” “our,” “us,” “Company” and “Integra” refer to Integra LifeSciences Holdings Corporation, a Delaware corporation, and its subsidiaries unless the context suggests otherwise.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the March 31, 2024 unaudited condensed consolidated financial statements contain all adjustments (consisting only of normal recurring adjustments) necessary for a fair statement of the financial position, statement of changes in shareholders’ equity, results of operations and cash flows of the Company. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) have been condensed or omitted in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements for the year ended December 31, 2023 included in the Company’s Annual Report on Form 10-K. The December 31, 2023 consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by GAAP. Operating results for the three-month period ended March 31, 2024 are not necessarily indicative of the results to be expected for the entire year.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements is in conformity with GAAP, which requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, the disclosure of contingent liabilities, and the reported amounts of revenues and expenses. Significant estimates affecting amounts reported or disclosed in the condensed consolidated financial statements include allowances for doubtful accounts receivable and sales returns and allowances, net realizable value of inventories, valuation of intangible assets including amortization periods for acquired intangible assets, discount rates and estimated projected cash flows used to value and test impairments of long-lived assets and goodwill, estimates of projected cash flows and depreciation and amortization periods for long-lived assets, computation of taxes, valuation allowances recorded against deferred tax assets, the valuation of stock-based compensation, valuation of derivative instruments, valuation of contingent liabilities, the fair value of debt instruments and loss contingencies. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the current circumstances. Actual results could differ from these estimates. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the Financial Accounting Standards Board (“FASB”) issued ASU 2020-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and, in January 2021, subsequently amended the initial guidance in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:line-through">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ASU 2021-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Scope</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (collectively, “Topic 848”). Topic 848 provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments apply only to contracts, hedging relationships, and other transactions that reference London Inter-Bank Offered Rate (“LIBOR”) or another reference rate expected to be discontinued because of reference rate reform. In December 2022, the FASB issued ASU 2022-06</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which delayed the effective date from December 31, 2022 to December 31, 2024.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:line-through"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Alternative Reference Rates Committee, a group of private-market participants convened by the U.S. Federal Reserve Board and the New York Federal Reserve, has recommended the use of the Secured Overnight Financing Rate (“SOFR”) as a more robust reference rate alternative to LIBOR. On March 24, 2023, the Company entered into the seventh amendment and restatement (the “March 2023 Amendment”) of its Senior Credit Facility (the “Senior Credit Facility”) with a syndicate of lending banks with Bank of America, N.A., as Administrative Agent. In connection with the March 2023 Amendment, the Company replaced all LIBOR-based contracts with SOFR, which is calculated based on overnight transactions under repurchase agreements backed by Treasury securities. In addition, on April 17, 2023 the Company entered into an amendment (the “April 2023 Amendment”) of the Securitization Facility (as defined below) and amended the interest rate from LIBOR to SOFR indexed rate. (See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 6, Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). In March 2023, the Company entered into a basis swap where the Company receives Term SOFR and pays LIBOR to convert the portfolio of interest rate swaps from LIBOR to SOFR. Integra has elected to adopt the optional expedient under Topic 848, which will allow the interest rate swap hedging relationship to continue, without de-designation, due to the change in the indexed rate from LIBOR to SOFR. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which enhances the transparency of income tax disclosures by expanding annual disclosure requirements related to the rate reconciliation and income taxes paid. The amendments are effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company does not plan to early adopt and is currently evaluating this ASU to determine its impact on the Company’s disclosures. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which updates reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. The amendments are effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company does not plan to early adopt and is currently evaluating this ASU to determine its impact on the Company’s disclosures.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no other recently issued accounting pronouncements that are expected to have any significant effect on the Company’s financial position, results of operations or cash flows.</span></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the Financial Accounting Standards Board (“FASB”) issued ASU 2020-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and, in January 2021, subsequently amended the initial guidance in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:line-through">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ASU 2021-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Scope</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (collectively, “Topic 848”). Topic 848 provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments apply only to contracts, hedging relationships, and other transactions that reference London Inter-Bank Offered Rate (“LIBOR”) or another reference rate expected to be discontinued because of reference rate reform. In December 2022, the FASB issued ASU 2022-06</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which delayed the effective date from December 31, 2022 to December 31, 2024.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:line-through"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Alternative Reference Rates Committee, a group of private-market participants convened by the U.S. Federal Reserve Board and the New York Federal Reserve, has recommended the use of the Secured Overnight Financing Rate (“SOFR”) as a more robust reference rate alternative to LIBOR. On March 24, 2023, the Company entered into the seventh amendment and restatement (the “March 2023 Amendment”) of its Senior Credit Facility (the “Senior Credit Facility”) with a syndicate of lending banks with Bank of America, N.A., as Administrative Agent. In connection with the March 2023 Amendment, the Company replaced all LIBOR-based contracts with SOFR, which is calculated based on overnight transactions under repurchase agreements backed by Treasury securities. In addition, on April 17, 2023 the Company entered into an amendment (the “April 2023 Amendment”) of the Securitization Facility (as defined below) and amended the interest rate from LIBOR to SOFR indexed rate. (See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 6, Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). In March 2023, the Company entered into a basis swap where the Company receives Term SOFR and pays LIBOR to convert the portfolio of interest rate swaps from LIBOR to SOFR. Integra has elected to adopt the optional expedient under Topic 848, which will allow the interest rate swap hedging relationship to continue, without de-designation, due to the change in the indexed rate from LIBOR to SOFR. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which enhances the transparency of income tax disclosures by expanding annual disclosure requirements related to the rate reconciliation and income taxes paid. The amendments are effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company does not plan to early adopt and is currently evaluating this ASU to determine its impact on the Company’s disclosures. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which updates reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. The amendments are effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company does not plan to early adopt and is currently evaluating this ASU to determine its impact on the Company’s disclosures.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no other recently issued accounting pronouncements that are expected to have any significant effect on the Company’s financial position, results of operations or cash flows.</span></div> ACQUISITIONS AND DIVESTITURES<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Acquisition of Acclarent Inc.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the Company entered into a definitive agreement to acquire Acclarent, Inc. (“Acclarent”) from Ethicon, Inc., a subsidiary of Johnson &amp; Johnson, for $275.0 million in cash at closing, subject to customary purchase price adjustments, and an additional $5.0 million contingent upon the achievement of a regulatory milestone, which was achieved prior to closing. Acclarent is a developer and marketer of medical devices used in Ear, Nose, Throat (“ENT”) procedures. Acclarent’s results of operations will be reported in the Company’s Codman Specialty Surgical reportable segment from the date of acquisition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2024, the Company successfully completed the acquisition of 100% of Acclarent for approximately $282.0 million in cash, subject to customary adjustments set forth in the purchase agreement related to working capital balances transferred to the Company. To facilitate the completion of the acquisition of Acclarent, the Company drew from the revolving portion of the Senior Credit Facility during the three months ended March 31, 2024. For further detail on the Company’s additional borrowings, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 6. Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div> 275000000 5000000 1 282000000 REVENUES FROM CONTRACTS WITH CUSTOMERS <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Accounting Policies on Revenue Recognition</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized upon the transfer of control of promised products or services to the customers in an amount that reflects the consideration the Company expects to receive in exchange for those products and services.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance Obligations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s performance obligations consist mainly of transferring control of goods and services identified in the contracts, purchase orders, or invoices. The Company has no significant multi-element contracts with customers.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Usage-based royalties and licenses are estimated based on the provisions of contracts with customers and recognized in the same period that the royalty-based products are sold by the Company’s strategic partners. The Company estimates and recognizes royalty revenue based upon communication with licensees, historical information, and expected sales trends. Differences between actual reported licensee sales and those that were estimated are adjusted in the period in which they become known, which is typically the following quarter. Historically, such adjustments have not been significant.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates returns, price concessions, and discount allowances using the expected value method based on historical trends and other known factors. Rebate allowances are estimated using the most likely method based on each customer contract.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s return policy, as set forth in its product catalogs and sales invoices, requires review and authorization in advance prior to the return of product. Upon the authorization, a credit will be issued for the goods returned within a set amount of days from the shipment, which is generally 90 days.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, due to the voluntary recall of all products manufactured at the Boston facility, including PriMatrix®, SurgiMend®, Revize™, and TissueMend™ (the “Boston recall”), the Company recorded a total of $18.7 million provision for product returns. As of March 31, 2024, the Company has credited $16.7 million to customers and holds a remaining return reserve of $2.0 million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disregards the effects of a financing component if the Company expects, at contract inception, that the period between the transfer and customer payment for the goods or services will be one year or less. The Company has no significant revenues recognized on payments expected to be received more than one year after the transfer of control of products or services to customers.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Asset and Liability</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized from the Company’s private label business that are not invoiced to the customers as a result of recognizing revenue over time are recorded as a contract asset included in the other current assets account in the consolidated balance sheets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating revenues may include fees received under service agreements. Non-refundable fees received under multiple-period service agreements are recognized as revenue as the Company satisfies the performance obligations to the other party. A portion of the transaction price allocated to the performance obligations to be satisfied in the future periods is recognized as contract liability.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the contract asset and liability balances for the three months ended March 31, 2024:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.074%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.998%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Contract Asset</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract asset, January 1, 2024</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,233 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 34.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transferred to trade receivable from contract asset included in beginning of the year contract asset</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,233)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 34.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract asset, net of transferred to trade receivables on contracts during the period</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,478 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract asset, March 31, 2024</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,478 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Contract Liability</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract liability, January 1, 2024</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,252 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 34.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognition of revenue included in beginning of year contract liability</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,523)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 34.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract liability, net of revenue recognized on contracts during the period</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,017 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 34.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract liability, March 31, 2024</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,683 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2024, the short-term portion of the contract liability of $7.8 million and the long-term portion of $6.9 million are included in current liabilities and other liabilities, respectively, in the consolidated balance sheets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024, the Company is expected to recognize revenue of approximately 53% of unsatisfied (or partially unsatisfied) performance obligations as revenue within 12 months, with the remaining balance to be recognized thereafter.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shipping and Handling Fees</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company elected to account for shipping and handling activities as a fulfillment cost rather than a separate performance obligation. Amounts billed to customers for shipping and handling are included as part of the transaction price and recognized as revenue when control of underlying products is transferred to the customer. The related shipping and freight charges incurred by the Company are included in the cost of goods sold.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Warranties</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company’s medical devices, including monitoring systems and neurosurgical systems, are designed to operate over long periods of time. These products are sold with warranties which may extend for up to two years from the date of purchase. The warranties are not considered a separate performance obligation. The Company estimates its product warranties using the expected value method based on historical trends and other known factors. The Company includes them in accrued expenses and other current liabilities in the consolidated balance sheet.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Taxes Collected from Customers</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company elected to exclude from the measurement of the transaction price all taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction and collected by the entity from a customer.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disaggregated Revenue</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenues disaggregated by the major sources of revenues for the three months ended March 31, 2024 and 2023 (dollar amounts in thousands):</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.672%"><tr><td style="width:1.0%"></td><td style="width:61.698%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:17.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.482%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.161%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Neurosurgery</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202,268 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">192,870 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Instruments</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,166 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,266 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Codman Specialty Surgical</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">256,434 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">248,136 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Wound Reconstruction and Care</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80,877 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100,940 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Private Label</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,561 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,770 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Tissue Technologies</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112,438 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">132,710 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">368,872 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">380,846 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Note 15</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment and Geographical Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for details of revenues based on the location of the customer.</span></div> <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Accounting Policies on Revenue Recognition</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized upon the transfer of control of promised products or services to the customers in an amount that reflects the consideration the Company expects to receive in exchange for those products and services.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance Obligations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s performance obligations consist mainly of transferring control of goods and services identified in the contracts, purchase orders, or invoices. The Company has no significant multi-element contracts with customers.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Usage-based royalties and licenses are estimated based on the provisions of contracts with customers and recognized in the same period that the royalty-based products are sold by the Company’s strategic partners. The Company estimates and recognizes royalty revenue based upon communication with licensees, historical information, and expected sales trends. Differences between actual reported licensee sales and those that were estimated are adjusted in the period in which they become known, which is typically the following quarter. Historically, such adjustments have not been significant.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates returns, price concessions, and discount allowances using the expected value method based on historical trends and other known factors. Rebate allowances are estimated using the most likely method based on each customer contract.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s return policy, as set forth in its product catalogs and sales invoices, requires review and authorization in advance prior to the return of product. Upon the authorization, a credit will be issued for the goods returned within a set amount of days from the shipment, which is generally 90 days.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, due to the voluntary recall of all products manufactured at the Boston facility, including PriMatrix®, SurgiMend®, Revize™, and TissueMend™ (the “Boston recall”), the Company recorded a total of $18.7 million provision for product returns. As of March 31, 2024, the Company has credited $16.7 million to customers and holds a remaining return reserve of $2.0 million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disregards the effects of a financing component if the Company expects, at contract inception, that the period between the transfer and customer payment for the goods or services will be one year or less. The Company has no significant revenues recognized on payments expected to be received more than one year after the transfer of control of products or services to customers.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Asset and Liability</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized from the Company’s private label business that are not invoiced to the customers as a result of recognizing revenue over time are recorded as a contract asset included in the other current assets account in the consolidated balance sheets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating revenues may include fees received under service agreements. Non-refundable fees received under multiple-period service agreements are recognized as revenue as the Company satisfies the performance obligations to the other party. A portion of the transaction price allocated to the performance obligations to be satisfied in the future periods is recognized as contract liability.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shipping and Handling Fees</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company elected to account for shipping and handling activities as a fulfillment cost rather than a separate performance obligation. Amounts billed to customers for shipping and handling are included as part of the transaction price and recognized as revenue when control of underlying products is transferred to the customer. The related shipping and freight charges incurred by the Company are included in the cost of goods sold.</span></div> P90D 18700000 16700000 2000000 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the contract asset and liability balances for the three months ended March 31, 2024:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.074%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.998%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Contract Asset</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract asset, January 1, 2024</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,233 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 34.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transferred to trade receivable from contract asset included in beginning of the year contract asset</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,233)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 34.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract asset, net of transferred to trade receivables on contracts during the period</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,478 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract asset, March 31, 2024</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,478 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Contract Liability</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract liability, January 1, 2024</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,252 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 34.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognition of revenue included in beginning of year contract liability</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,523)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 34.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract liability, net of revenue recognized on contracts during the period</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,017 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 34.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract liability, March 31, 2024</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,683 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 9233000 9233000 7478000 7478000 16252000 -3523000 -2017000 -63000 14683000 7800000 6900000 0.53 P12M <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Warranties</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company’s medical devices, including monitoring systems and neurosurgical systems, are designed to operate over long periods of time. These products are sold with warranties which may extend for up to two years from the date of purchase. The warranties are not considered a separate performance obligation. The Company estimates its product warranties using the expected value method based on historical trends and other known factors. The Company includes them in accrued expenses and other current liabilities in the consolidated balance sheet.</span></div> P2Y <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Taxes Collected from Customers</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company elected to exclude from the measurement of the transaction price all taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction and collected by the entity from a customer.</span></div> <div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenues disaggregated by the major sources of revenues for the three months ended March 31, 2024 and 2023 (dollar amounts in thousands):</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.672%"><tr><td style="width:1.0%"></td><td style="width:61.698%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:17.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.482%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.161%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Neurosurgery</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202,268 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">192,870 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Instruments</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,166 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,266 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Codman Specialty Surgical</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">256,434 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">248,136 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Wound Reconstruction and Care</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80,877 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100,940 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Private Label</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,561 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,770 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Tissue Technologies</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112,438 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">132,710 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">368,872 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">380,846 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 202268000 192870000 54166000 55266000 256434000 248136000 80877000 100940000 31561000 31770000 112438000 132710000 368872000 380846000 INVENTORIES<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net consisted of the following:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">192,287 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196,402 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83,334 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74,035 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127,801 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119,171 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total inventories, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">403,422 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">389,608 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net consisted of the following:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">192,287 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196,402 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83,334 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74,035 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127,801 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119,171 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total inventories, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">403,422 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">389,608 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div> 192287000 196402000 83334000 74035000 127801000 119171000 403422000 389608000 GOODWILL AND OTHER INTANGIBLE ASSETS<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the carrying amount of goodwill for the three-month period ended March 31, 2024 were as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:55.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.915%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Codman Specialty <br/>Surgical</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Tissue Technologies</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill at December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">666,937 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">388,525 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,055,462 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,622)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,605)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,227)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill at March 31, 2024</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">657,315 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">382,920 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,040,235 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company tests goodwill and intangible assets with indefinite lives for impairment annually in the third quarter in accordance with FASB ASC Topic 350, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles—Goodwill and Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASC 350”). Additionally, the Company may perform interim tests if an event occurs or circumstances change that could potentially reduce the fair value of a reporting unit or indefinite lived intangible asset below its carrying amount. The carrying value of each reporting unit is determined by assigning the assets and liabilities, including the existing goodwill and intangible assets, to those reporting units. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company tests for impairment by either performing a qualitative evaluation or a quantitative test. The qualitative evaluation is an assessment of factors, including reporting unit specific operating results as well as industry, market and general economic conditions, to determine whether it is more likely than not that the fair values of a reporting unit is less than its carrying amount, including goodwill. The Company may elect to bypass this qualitative evaluation for some or all of its reporting units and perform a quantitative test. The quantitative test estimates the fair value of the reporting unit using a </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">discounted cash flow model, which incorporates significant estimates and assumptions made by management which, by their nature, are characterized by uncertainty.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to third-party audit findings and an update to the estimated timeframe to resume the commercial distribution of products manufactured in the Boston facility, the Company elected to perform a quantitative analysis of its Tissue Technologies reporting unit in the first quarter of 2024 in accordance with ASC 350. The quantitative test estimates the fair value of the reporting unit using a discounted cash flow model, which incorporates significant estimates and assumptions made by management with respect to future revenue and expense growth rates and discount rates which, by their nature, are characterized by uncertainty. An impairment loss is recognized when the reporting unit’s carrying amount exceeds its estimated fair value. The quantitative test utilized a terminal growth rate of 2%, a discount rate of 15%, and a range and application of the company guideline multiples. The Company determined, after performing the quantitative analysis, that the fair value of the Tissue Technologies reporting unit was not less than its carrying amount, with 20% headroom. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Intangible Assets</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the Company’s identifiable intangible assets were as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Completed technology</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,209,921 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(460,545)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">749,376 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167,360 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(134,587)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,773 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trademarks/brand names</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97,668 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(39,330)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58,338 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Codman tradename</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168,678 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168,678 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplier relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,211 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,393)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,818 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,052 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,426)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,626 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,679,890 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(657,281)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,022,609 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Completed technology</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,226,128 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(448,519)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">777,609 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">193,895 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(152,160)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,735 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trademarks/brand names</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98,892 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38,754)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,138 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Codman tradename</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174,531 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174,531 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplier relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,211 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,148)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,063 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,180 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,423)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,757 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,729,837 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(662,004)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,067,833 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total amortization of intangible assets for the three months ended March 31, 2024 was $27.7 million. Of these amounts, $17.6 million was related to amortization of technology based intangibles and included in cost of goods sold. $7.1 million related to the impairment of a customer relationship intangible and the remainder were included in intangible amortization in the statement of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total amortization of intangible assets for the three months ended March 31, 2023 was $20.6 million. Of these amounts, $17.5 million was related to amortization of technology based intangibles and included in cost of goods sold, with the remainder included in intangible amortization in the statement of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on quarter-end exchange rates, amortization expense (including amounts reported in cost of goods sold) is expected to be approximately $60.1 million for the remainder of 2024, $80.2 million in 2025, $80.0 million in 2026, $79.1 million in 2027, $78.7 million in 2028, $74.9 million in 2029 and $403.5 million thereafter.</span></div>The Company periodically performs testing for impairment on certain long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the carrying amount of goodwill for the three-month period ended March 31, 2024 were as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:55.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.915%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Codman Specialty <br/>Surgical</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Tissue Technologies</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill at December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">666,937 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">388,525 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,055,462 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,622)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,605)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,227)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill at March 31, 2024</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">657,315 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">382,920 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,040,235 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 666937000 388525000 1055462000 -9622000 -5605000 -15227000 657315000 382920000 1040235000 0.02 0.15 0.20 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the Company’s identifiable intangible assets were as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Completed technology</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,209,921 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(460,545)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">749,376 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167,360 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(134,587)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,773 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trademarks/brand names</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97,668 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(39,330)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58,338 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Codman tradename</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168,678 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168,678 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplier relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,211 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,393)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,818 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,052 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,426)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,626 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,679,890 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(657,281)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,022,609 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Completed technology</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,226,128 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(448,519)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">777,609 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">193,895 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(152,160)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,735 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trademarks/brand names</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98,892 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38,754)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,138 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Codman tradename</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174,531 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174,531 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplier relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,211 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,148)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,063 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,180 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,423)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,757 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,729,837 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(662,004)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,067,833 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the Company’s identifiable intangible assets were as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Completed technology</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,209,921 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(460,545)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">749,376 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167,360 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(134,587)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,773 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trademarks/brand names</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97,668 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(39,330)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58,338 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Codman tradename</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168,678 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168,678 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplier relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,211 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,393)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,818 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,052 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,426)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,626 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,679,890 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(657,281)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,022,609 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Completed technology</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,226,128 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(448,519)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">777,609 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">193,895 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(152,160)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,735 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trademarks/brand names</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98,892 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38,754)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,138 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Codman tradename</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174,531 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174,531 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplier relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,211 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,148)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,063 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,180 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,423)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,757 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,729,837 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(662,004)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,067,833 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div> P18Y 1209921000 460545000 749376000 P12Y 167360000 134587000 32773000 P28Y 97668000 39330000 58338000 168678000 168678000 P30Y 30211000 18393000 11818000 P11Y 6052000 4426000 1626000 1679890000 657281000 1022609000 P18Y 1226128000 448519000 777609000 P12Y 193895000 152160000 41735000 P28Y 98892000 38754000 60138000 174531000 174531000 P30Y 30211000 18148000 12063000 P11Y 6180000 4423000 1757000 1729837000 662004000 1067833000 27700000 17600000 7100000 20600000 17500000 60100000 80200000 80000000 79100000 78700000 74900000 403500000 7100000 38300000 27700000 DEBT <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amendment to the Seventh Amended and Restated Senior Credit Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 24, 2023, the Company entered into the seventh amendment and restatement (the “March 2023 Amendment”) of the Senior Credit Facility (the “Senior Credit Facility”) with a syndicate of lending banks with Bank of America, N.A., as Administrative Agent. The March 2023 Amendment extended the maturity date to March 24, 2028, amended the contractual repayments of the term loan component, and amended the interest rate from LIBOR to SOFR-indexed interest. The Company continues to have the aggregate principal amount of up to approximately $2.1 billion available to it through the following facilities: (i) a $775.0 million term loan facility, and (ii) a $1.3 billion revolving credit facility, which includes a $60 million sublimit for the issuance of standby letters of credit and a $60 million sublimit for swingline loans. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s maximum consolidated total leverage ratio in the financial covenants (as defined in the Senior Credit Facility) was modified to the following:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:394.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:111.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Quarter Ending</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maximum Consolidated Total Leverage Ratio</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 31, 2023 through December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.50 to 1.00</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 31, 2025 through June 30, 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.25 to 1.00</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 30, 2026 and the last day of each fiscal quarter thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.00 to 1.00</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Senior Credit Facility bear interest, at the Company’s option, at a rate equal to the following:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt">Term SOFR in effect from time to time plus 0.10% plus the applicable rate (ranging from 1.00% to 1.75%), or </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">The highest of: </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">the weighted average overnight Federal funds rate, as published by the Federal Reserve Bank of New York, plus 0.50%; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">the prime lending rate of Bank of America, N.A.; or</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">the one-month Term SOFR plus 1.00%. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The applicable rates are based on the Company’s consolidated total leverage ratio (defined as the ratio of (a) consolidated funded indebtedness as of such date less cash that is not subject to any restriction on the use or investment thereof to (b) consolidated EBITDA (as defined by the amended Seventh Amended and Restated Credit Agreement (the “Credit Agreement”)), for the period of four consecutive fiscal quarters ending on such date).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will pay an annual commitment fee (ranging from 0.15% to 0.30%), based on the Company’s consolidated total leverage ratio, on the amount available for borrowing under the revolving credit facility.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Credit Facility is collateralized by substantially all of the assets of the Company’s U.S. subsidiaries, excluding intangible assets. The Senior Credit Facility is subject to various financial and negative covenants and, at March 31, 2024, the Company was in compliance with all such covenants. The Company capitalized $7.6 million in deferred financing costs in connection with the modification of the Senior Credit Facility and wrote off $0.2 million of previously capitalized financing costs during the first quarter of 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2024 and December 31, 2023 there wa</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s $420.0 million and $70.0 million, respectively, ou</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tstanding under the revolving portion of the Senior Credit Facility. At March 31, 2024 and December 31, 2023, there was $775.0 million outstanding under the term loan component of the Senior Credit Facility at a weighted average interest rate of 6.8% and 6.8%, respectively. As of March 31, 2024 and December 31, 2023 there was $19.4 million and $14.5 million, respectively, of the term loan component of the Senior Credit Facility classified as current on the condensed consolidated balance sheet.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of outstanding borrowings of the Senior Credit Facility’s term loan component at March 31, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $765.5 million. This fair value was determined by using a discounted cash flow model based on current market interest rates available to the Company. These inputs are corroborated by observable market data for similar liabilities and therefore classified within Level 2 of the fair value hierarchy. Level 2 inputs represent inputs that are observable for the asset or liability, either directly or indirectly, and are other than active market observable i</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nputs that reflect unadjusted quoted prices for identical assets or liabilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Letters of credit outstanding as of March 31, 2024 and December 31, 2023 to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">taled $1.7 million. There were no amounts drawn under the letters of credit outstanding as of March 31, 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual repayments of the term loan component of the Senior Credit Facility are due as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2024</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal Repayment</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remainder of 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,531 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,906 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,281 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">634,532 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">775,000 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future interest payments on the term loan component of the Senior Credit Facility based on current interest rates are expected to approximate $39.3 million for the remainder of 2024, $50.8 million in 2025, $48.1 million in 2026, $45.0 million in 2027, and $10.0 million thereafter. Interest is calculated on the term loan portion of the Senior Credit Facility based on SOFR plus the certain amounts set forth in the Credit Agreement. As the revolving credit facility and Securitization Facility (defined below) can be repaid at any time, no interest has been included in the calculation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any outstanding borrowings on the revolving credit component of the Senior Credit Facility are due on March 24, 2028.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Senior Notes</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 4, 2020, the Company issued $575.0 million aggregate principal amount of its 0.5% Convertible Senior Notes due 2025 (the “2025 Notes”). The 2025 Notes will mature on August 15, 2025 and bear interest at a rate of 0.5% per annum payable semi-annually in arrears, unless earlier converted, repurchased or redeemed in accordance with the terms of the 2025 Notes. In connection with this offering, the Company capitalized $13.2 million of financing fees.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2025 Notes are senior, unsecured obligations of the Company, and are convertible into cash and shares of its common stock based on an initial conversion rate, subject to adjustment of 13.5739 shares per $1,000 principal amounts of the 2025 Notes (which represents an initial conversion price of $73.67 per share). The 2025 Notes convert only in the following circumstances: (1) if the closing price of the Company’s common stock has been at least 130% of the conversion price during the period; (2) if the average trading price per $1,000 principal amount of the 2025 Notes is less than or equal to 98% of the average conversion value of the 2025 Notes during a period as defined in the indenture; (3) if the Company calls the notes for optional redemption as defined in the indenture; or (4) if specified corporate transactions occur. As of March 31, 2024, none of these conditions existed and the 2025 Notes are classified as long term obligations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 9, 2020, the Company entered into the First Supplemental Indenture to the original indenture dated as of February 4, 2020 (the “Indenture”) between the Company and Citibank, N.A., as trustee, governing the Company’s outstanding 2025 Notes. The Company irrevocably elected (1) to eliminate the Company’s option to choose physical settlement on any conversion of the 2025 Notes that occurs on or after the date of the First Supplemental Indenture and (2) with respect to any Combination Settlement (as defined in the indenture) for a conversion of the 2025 Notes, the Specified Dollar Amount (as defined in the indenture) that will be settled in cash per $1,000 principal amount of the 2025 Notes shall be no lower than $1,000.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2025 Notes will have the right to require the Company to repurchase for cash all or a portion of their 2025 Notes at 100% of their principal amount, plus any accrued and unpaid interest, upon the occurrence of a fundamental change (as defined in the indenture relating to the 2025 Notes). The Company will also be required to increase the conversion rate for holders who convert their 2025 Notes in connection with certain fundamental changes occurring prior to the maturity date or following delivery by the Company of a notice of redemption.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the issuance of the 2025 Notes, the Company entered into call transactions and warrant transactions, primarily with affiliates of the initial purchasers of the 2025 Notes (the “hedge participants”). The cost of the call transactions was $104.2 million for the 2025 Notes. The Company received $44.5 million of proceeds from the warrant transactions for the 2025 Notes. The call transactions involved purchasing call options from the hedge participants, and the warrant transactions involved selling call options to the hedge participants with a higher strike price than the purchased call options. The initial strike price of the call transactions was $73.67, subject to anti-dilution adjustments substantially similar to those in the 2025 Notes. The initial strike price of the warrant transactions was $113.34 for the 2025 Notes, subject to customary anti-dilution adjustments.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the carrying amount of the liability w</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as $575.0 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million. The fair value of the 2025 Notes at March 31, 2024 was </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$549.7</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> million. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors that the Company considered when estimating the fair value of the 2025 Notes included recent quoted market prices or dealer quotes. The 2025 Notes are valued based on Level 1 measurements in the fair value hierarchy.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securitization Facility</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company entered into an accounts receivable securitization facility (the “Securitization Facility”) under which accounts receivable of certain domestic subsidiaries are sold on a non-recourse basis to a special purpose entity (“SPE”), which is a bankruptcy-remote, consolidated subsidiary of the Company. Accordingly, the assets of the SPE are not available to satisfy the obligations of the Company or any of its subsidiaries. From time to time, the SPE may finance such accounts receivable with a revolving loan facility secured by a pledge of such accounts receivable. The amount of outstanding borrowings on the Securitization Facility at any one time is limited to $150.0 million. The Securitization Facility Agreement (“Securitization Agreement”) governing the Securitization Facility contains certain covenants and termination events. An occurrence of an event of default or a termination event under this Securitization Agreement may give rise to the right of its counterparty to terminate this facility. As of March 31, 2024, the Company was in compliance with the covenants and none of the termination events had occurred.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 15, 2023, the Company entered into an amendment (the “December 2023 Amendment”) of the Securitization Facility which extended the maturity date from May 28, 2024 to December 15, 2026. The Company incurred approximately $0.3 million of new issuance costs associated with the December Amendment which will be amortized over 3 years, the length of the Securitization Agreement as amended by the December 2023 Amendment. Due to the increase in borrowing capacity, the remaining $0.1 million of unamortized costs from the previous agreement will also be amortized over the length of the amended agreement, 3 years. In addition, on April 17, 2023 the Company entered into an amendment (the “April 2023 Amendment”) of the Securitization Facility and amended the interest rate from LIBOR to SOFR-indexed rate. The December 2023 Amendment and April 2023 Amendment did not increase the Company’s total indebtedness.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2024 and December 31, 2023, the Company had $94.6 million and $89.2 million, respectively, of outstanding borrowings under its Securitization Facility at a weighted average interest rate of 6.5% and 5.9%, respectively. The fair value of the outstanding borrowing of the Securitization Facility at March 31, 2024 was $92.7 million. These fair values were determined by using a discounted cash flow model based on current market interest rates available to the Company. These inputs are corroborated by observable market data for similar liabilities and therefore classified within Level 2 of the fair value hierarchy. Level 2 inputs represent inputs that are observable for the asset or liability, either directly or indirectly, and are other than active market observable i</span>nputs that reflect unadjusted quoted prices for identical assets or liabilities. 2100000000 775000000 1300000000 60000000 60000000 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s maximum consolidated total leverage ratio in the financial covenants (as defined in the Senior Credit Facility) was modified to the following:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:394.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:111.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Quarter Ending</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maximum Consolidated Total Leverage Ratio</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 31, 2023 through December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.50 to 1.00</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 31, 2025 through June 30, 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.25 to 1.00</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 30, 2026 and the last day of each fiscal quarter thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.00 to 1.00</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 4.50 4.25 4.00 0.0010 0.0100 0.0175 0.0050 0.0100 0.0015 0.0030 7600000 200000 420000000 70000000 775000000 775000000 0.068 0.068 19400000 14500000 765500000 1700000 1700000 0 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual repayments of the term loan component of the Senior Credit Facility are due as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2024</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal Repayment</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remainder of 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,531 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,906 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,281 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">634,532 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">775,000 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 14531000 33906000 38750000 53281000 634532000 775000000 39300000 50800000 48100000 45000000 10000000 575000000 0.005 0.005 13200000 73.67 1.30 0.98 1000 1 104200000 44500000 73.67 113.34 575000000.0 549700000 150000000 300000 P3Y 100000 P3Y 94600000 89200000 0.065 0.059 92700000 DERIVATIVE INSTRUMENTS <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Hedging</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s interest rate risk relates to U.S. dollar denominated variable interest rate borrowings. The Company uses interest rate swap derivative instruments to manage earnings and cash flow exposure resulting from changes in interest rates. These interest rate swaps apply a fixed interest rate on a portion of the Company’s expected SOFR-indexed borrowings. In March 2023, the Company entered into a basis swap where the Company receives Term SOFR and pays daily compounded SOFR to convert the portfolio of swaps from daily compounded SOFR to term SOFR. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company held the following interest rate swaps as of March 31, 2024 and December 31, 2023 (dollar amounts in thousands):</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:7.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.279%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hedged Item</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Designation Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Termination Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fixed Interest Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset (Liability)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1-month Term SOFR Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 13, 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 1, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.423 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,125 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,105 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1-month Term SOFR Loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 13, 2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 1, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.313 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,341 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,978 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1-month Term SOFR Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 10, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 1, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.220 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,556 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,349 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1-month Term SOFR Loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 10, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 1, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.199 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,548 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,312 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1-month Term SOFR Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 10, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 1, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.209 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,548 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,346 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1-month Term SOFR Loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 18, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.885 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,512 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,015 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1-month Term SOFR Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 18, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.867 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,519 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,052 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1-month Term SOFR Loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">575,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">575,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 15, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.415 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,267 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,965 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1-month Term SOFR Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 15, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 1, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.404 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,770 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,263 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basis Swap </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 24, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,127)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,829)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,475,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,475,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53,059 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43,556 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="45" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> The notional of the basis swap amortizes to match the total notional of the interest rate swap portfolio over time</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate swaps were carried on the consolidated balance sheet at fair value and changes in the fair values were recorded as unrealized gains or losses in accumulated other comprehensive income (“AOCI”). For the three months ended March 31, 2024 and 2023, the Company recorded a gain of $14.7 million and a loss of $10.5 million, respectively, in AOCI related to the change in fair value of the interest rate swaps. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2024 and 2023, the Company recorded gains of $5.2 million and $3.5 million, respectively, in the consolidated statements of operations related to the interest rate differential of the interest rate swaps. The estimated gain that is expected to be reclassified to interest income from AOCI as of March 31, 2024 within the next twelve months is $13.6 million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has designated these derivative instruments as cash flow hedges. The Company assesses the effectiveness of these derivative instruments and has recorded the changes in the fair value of the derivative instrument designated as a cash flow hedge as unrealized gains or losses in AOCI, net of tax, until the hedged item affected earnings, at which point any gain or loss was reclassified to earnings. If the hedged cash flow does not occur, or if it becomes probable that it will not occur, the Company will reclassify the remaining amount of any gain or loss on the related cash flow hedge recorded in AOCI to interest expense at that time.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Hedging</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company enters into foreign currency hedge contracts intended to protect the U.S. dollar value of certain forecasted foreign currency denominated transactions. The Company assesses the effectiveness of the contracts that are designated as hedging instruments. The changes in fair value of foreign currency cash flow hedges are recorded in AOCI, net of tax. Those amounts are subsequently reclassified to earnings from AOCI as impacted by the hedged item when the hedged item affects earnings. If the hedged forecasted transaction does not occur or if it becomes probable that it will not occur, the Company will reclassify the amount of any gain or loss on the related cash flow hedge to earnings at that time. For contracts not designated as hedging instruments, the changes in fair value of the contracts are recognized in other income, net in the consolidated statements of operation, along with the offsetting foreign currency gain or loss on the underlying assets or liabilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of the Company’s hedging anticipated currency exchange gains or losses to the extent that there are differences between forecasted and actual activities during periods of currency volatility. In addition, changes in currency exchange rates related to any unhedged transactions may affect earnings and cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cross-Currency Rate Swaps</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The objective of these cross-currency swaps is to reduce volatility of earnings and cash flows associated with changes in the foreign currency exchange rate. Under the terms of these contracts, which have been designated as cash flow hedges, the Company will make interest payments in Swiss francs (“CHFs”) and receive interest in U.S. dollars. Upon the maturity of these contracts, the Company will pay the principal amount of the loans in CHFs and receive U.S. dollars from the counterparties.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 22, 2023, the Company amended the Swiss franc denominated intercompany loan to partially settle CHF 20.0 million and extend the termination date to September 2024 and as a result, the Company terminated the cross-currency swap designated as cash flow hedge of an intercompany loan with aggregate notional amount of $48.5 million. Simultaneously, the Company entered into a cross-currency swap agreement to hedge a notional amount of CHF 28.5 million equivalent to $31.5 million of this amended intercompany loan into U.S. dollars. The loss recorded by the Company upon the settlement of the swap was not material for the period. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 21, 2020, the Company entered into cross-currency swap agreements to convert a notional amount of $471.6 million equivalent to 420.1 million of a CHF-denominated intercompany loan into U.S. dollars. The CHF-denominated intercompany loan was the result of an intra-entity transfer of certain intellectual property rights to a subsidiary in Switzerland completed during the fourth quarter of 2020. The intercompany loan requires quarterly payments of CHF 5.8 million plus accrued interest. As a result, the aggregate notional amount of the related cross-currency swaps will decrease by a corresponding amount. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company held the following cross-currency rate swaps as of March 31, 2024 and December 31, 2023 (dollar amounts in thousands):</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.747%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.020%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Termination Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fixed Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Notional Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value<br/>Asset (Liability)</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pay CHF</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 21, 2020</span></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 22, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.00%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CHF</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333,887 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">351,137 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,902)</span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38,324)</span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receive U.S.$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.98%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374,817 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">394,183 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pay CHF</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 22, 2023</span></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 29, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.40%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CHF</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,578)</span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,348)</span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receive U.S.$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.27%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,457 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,457 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,480)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(40,672)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cross-currency swaps are carried on the consolidated balance sheet at fair value, and changes in the fair values are recorded as unrealized gains or losses in AOCI. For the three months ended March 31, 2024 the Company recorded a gain of $30.1 million in other income, net related to change in fair value related to the foreign currency rate translation to offset the losses recognized on the intercompany loans. For the three months ended March 31, 2023, the Company recorded a loss of $4.9 million in other income, net related to change in fair value related to the foreign currency rate translation to offset the losses recognized on the intercompany loans.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2024, the Company recorded a gain of $29.5 million in AOCI related to change in fair value of the cross-currency swaps. For the three months ended March 31, 2023, the Company recorded a gain of $2.2 million in AOCI related to change in fair value of the cross-currency swaps.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2024, the Company recorded a gain of $1.3 million in other income, net included in the consolidated statements of operations related to the interest rate differential of the cross-currency swaps. For the three months ended March 31, 2023, the Company recorded a gain of $1.5 million in other income, net included in the consolidated statements of operations related to the interest rate differential of the cross-currency swaps.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated loss that is expected to be reclassified to other income (expense), net from AOCI as of March 31, 2024 within the next twelve months is $1.9 million. As of March 31, 2024, the Company does not expect any gains or losses will be reclassified into earnings because the original forecasted transactions will not occur.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Investment Hedges</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages certain foreign exchange risks through a variety of strategies, including hedging. The Company is exposed to foreign exchange risk from its international operations through foreign currency purchases, net investments in foreign subsidiaries, and foreign currency assets and liabilities created in the normal course of business. On October 1, 2018 May 24, 2022, and November 17, 2023, the Company entered into cross-currency swap agreements designated as net investment hedges to partially offset the effects of foreign currency on foreign subsidiaries.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company held the following cross-currency rate swaps designated as net investment hedges as of March 31, 2024 and December 31, 2023, respectively (dollar amounts in thousands):</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:14.705%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.319%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.660%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.387%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.284%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Termination Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fixed Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Notional Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value<br/>Asset (Liability)</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pay EUR</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 3, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 30, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EUR</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,820 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,820 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,459 </span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,475 </span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receive U.S.$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.19%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pay CHF</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 26, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 16, 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CHF</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">288,210 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">288,210 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29,614)</span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(48,047)</span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receive U.S.$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.94%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pay CHF</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 21, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 17, 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CHF</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,525 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,525 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(736)</span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,037)</span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receive U.S.$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.54%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26,891)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(49,609)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cross-currency swaps were carried on the consolidated balance sheet at fair value and changes in the fair values were recorded as unrealized gains or losses in AOCI. For the three months ended March 31, 2024, the Company recorded a gain of $24.9 million in AOCI related to the change in fair value of the cross-currency swaps. For the three months ended March 31, 2023, the Company recorded a gain of $1.0 million in AOCI related to change in fair value of the cross-currency swaps.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2024, the Company recorded a gain of $2.2 million in interest income included in the consolidated statements of operations related to the interest rate differential of the cross-currency swaps. For the three months ended March 31, 2023, the Company recorded a gain of $2.1 million in interest income included in the consolidated statements of operations related to the interest rate differential of the cross-currency swaps.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated gain that is expected to be reclassified to interest income from AOCI as of March 31, 2024 within the next twelve months is $4.1 million.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On May 2, 2024, the Company entered into a cross-currency swap agreement with a notional amount of CHF 68.5 million, equivalent to $75.0 million, where the Company agreed with third-parties to sell Swiss francs in exchange for U.S. dollars at a specified rate at the maturity of the contract. The new cross-currency swap agreement was designated as a net investment hedge to partially offset the effects of foreign currency on foreign subsidiaries. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Forward Contracts</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into a hedge for forecasted intercompany purchases denominated in foreign currencies through the use of forward contracts designated as cash flow hedges. To the extent these forward contracts meet hedge accounting criteria, changes in their fair value are not included in accumulated comprehensive loss. These changes in fair value will be recognized into earnings as a component of cost of sales when the forecasted-transaction occurs. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2024, the Company entered into foreign currency forwards to mitigate the exchange rate risk of Swiss franc denominated intercompany purchases. These contracts typically settle at various dates within twelve months of execution. As of March 31, 2024 the notional amount of foreign currency forward contracts was CHF13.3 million. For the three months ended March 31, 2024 the Company recorded a loss of $0.6 million in AOCI related to the change in fair value of the foreign currency forward contracts and a loss of $0.1 million in cost of goods sold included in the consolidated statements of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Counterparty Credit Risk</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages its concentration of counterparty credit risk on its derivative instruments by limiting acceptable counterparties to a group of major financial institutions with investment grade credit ratings, and by actively monitoring their credit ratings and outstanding positions on an ongoing basis. Therefore, the Company considers the credit risk of the counterparties to be low. Furthermore, none of the Company’s derivative transactions are subject to collateral or other security arrangements, and none contain provisions that depend upon the Company’s credit ratings from any credit rating agency.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Derivative Instruments</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has classified all of its derivative instruments within Level 2 of the fair value hierarchy because observable inputs are available for substantially the full term of the derivative instruments. The fair values of the interest rate swaps and cross-currency swaps were developed using a market approach based on publicly available market yield curves and the terms of the swap. The Company performs ongoing assessments of counterparty credit risk.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value for derivatives designated as hedging instruments in the condensed consolidated balance sheets as of March 31, 2024 and December 31, 2023:</span></div><div style="margin-bottom:3pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:67.181%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.024%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.174%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value as of</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location on Balance Sheet </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives designated as hedges — Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Cash Flow Hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swap</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,188 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,675 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">680 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">537 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Net Investment Hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,084 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,938 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Cash Flow Hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swap</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,998 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,710 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Net Investment Hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,454 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,470 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total derivatives designated as hedges — Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62,404 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,330 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives designated as hedges — Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Cash Flow Hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swap</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">540 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">579 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,578 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,813 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">629 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Net Investment Hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,903 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Cash Flow Hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swap</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,586 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,582 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,396 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Net Investment Hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,427 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,114 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total derivatives designated as hedges — Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,342 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97,055 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company classifies derivative assets and liabilities as current based on the cash flows expected to be incurred within the following 12 months.</span></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> At March 31, 2024 and December 31, 2023, the total notional amounts related to the Company’s interest rate swaps were $1.5 billion.</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents the effect of derivative instruments designated as cash flow hedges and net investment hedges on the accompanying condensed consolidated statement of operations during the three months ended March 31, 2024 and 2023:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.597%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance in AOCI<br/>Beginning of<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount of<br/>Gain (Loss)<br/>Recognized in<br/>AOCI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount of Gain (Loss)<br/>Reclassified from<br/>AOCI into<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance in AOCI<br/>End of Quarter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location in<br/>Statements of<br/>Operations</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Cash Flow Hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swap</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,556 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,723 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,219 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,060 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,763)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,532 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,473 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17,704)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income (expense), net </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency forward contract</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(629)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(110)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(519)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Net Investment Hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(45,498)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,920 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,202 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22,780)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17,705)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68,546 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,784 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,057 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Cash Flow Hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swap</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,712 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,534)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,678 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,271)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,191 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,504)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14,576)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income (expense), net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency forward contract</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Net Investment Hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,914)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">950 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,096 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,060)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,527 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,462)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,092 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,973 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Derivative Instruments not Designated Hedges:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2021, the Company entered into a foreign currency swap, with a notional amount of $7.3 million to mitigate the risk from fluctuations in foreign currency exchange rates associated with an intercompany loan denominated in Japanese yen. In a foreign currency swap transaction, the Company agrees with another party to exchange, at specified intervals, the difference between one currency and another currency at a fixed exchange rate, generally set at inception, calculated by reference to an agreed upon notional amount. The notional amount of each currency is exchanged at the inception and termination of the currency swap by each party. The Company subsequently paid down a portion of this swap, bringing the notional amount down to $5.5 million as of March 31, 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the foreign currency swaps not designated as hedges was $1.5 million and $1.2 million as of March 31, 2024 and December 31, 2023, respectively. The following table summarizes the gains (losses) on derivative instruments not designated as hedges on the condensed consolidated statements of income, which was included in other income:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:63.726%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency swaps</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">273 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">273 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company held the following interest rate swaps as of March 31, 2024 and December 31, 2023 (dollar amounts in thousands):</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:7.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.279%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hedged Item</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Designation Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Termination Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fixed Interest Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset (Liability)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1-month Term SOFR Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 13, 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 1, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.423 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,125 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,105 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1-month Term SOFR Loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 13, 2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 1, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.313 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,341 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,978 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1-month Term SOFR Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 10, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 1, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.220 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,556 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,349 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1-month Term SOFR Loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 10, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 1, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.199 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,548 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,312 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1-month Term SOFR Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 10, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 1, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.209 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,548 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,346 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1-month Term SOFR Loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 18, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.885 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,512 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,015 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1-month Term SOFR Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 18, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.867 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,519 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,052 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1-month Term SOFR Loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">575,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">575,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 15, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.415 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,267 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,965 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1-month Term SOFR Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 15, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 1, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.404 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,770 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,263 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basis Swap </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 24, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,127)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,829)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,475,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,475,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53,059 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43,556 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="45" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> The notional of the basis swap amortizes to match the total notional of the interest rate swap portfolio over time</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company held the following cross-currency rate swaps as of March 31, 2024 and December 31, 2023 (dollar amounts in thousands):</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.747%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.020%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Termination Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fixed Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Notional Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value<br/>Asset (Liability)</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pay CHF</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 21, 2020</span></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 22, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.00%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CHF</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333,887 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">351,137 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,902)</span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38,324)</span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receive U.S.$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.98%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374,817 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">394,183 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pay CHF</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 22, 2023</span></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 29, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.40%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CHF</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,578)</span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,348)</span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receive U.S.$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.27%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,457 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,457 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,480)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(40,672)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company held the following cross-currency rate swaps designated as net investment hedges as of March 31, 2024 and December 31, 2023, respectively (dollar amounts in thousands):</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:14.705%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.319%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.660%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.387%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.284%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Termination Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fixed Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Notional Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value<br/>Asset (Liability)</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pay EUR</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 3, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 30, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EUR</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,820 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,820 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,459 </span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,475 </span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receive U.S.$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.19%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pay CHF</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 26, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 16, 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CHF</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">288,210 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">288,210 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29,614)</span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(48,047)</span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receive U.S.$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.94%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pay CHF</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 21, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 17, 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CHF</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,525 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,525 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(736)</span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,037)</span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receive U.S.$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.54%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26,891)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(49,609)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 150000000 150000000 0.02423 1125000 2105000 200000000 200000000 0.02313 4341000 4978000 75000000 75000000 0.03220 1556000 1349000 75000000 75000000 0.03199 1548000 1312000 75000000 75000000 0.03209 1548000 1346000 100000000 100000000 0.02885 4512000 3015000 100000000 100000000 0.02867 4519000 3052000 575000000 575000000 0.01415 29267000 22965000 125000000 125000000 0.01404 6770000 5263000 0 0 -2127000 -1829000 1475000000 1475000000 53059000 43556000 14700000 -10500000 5200000 3500000 13600000 20000000 48500000 28500000 31500000 471600000 420100000 5800000 0.0300 333887000 351137000 -9902000 -38324000 0.0398 374817000 394183000 0.0240 28500000 28500000 -2578000 -2348000 0.0627 31457000 31457000 -12480000 -40672000 30100000 4900000 29500000 2200000 1300000 1500000 -1900000 0 38820000 38820000 3459000 2475000 0.0219 45000000 45000000 0 288210000 288210000 -29614000 -48047000 0.0194 300000000 300000000 0 66525000 66525000 -736000 -4037000 0.0254 75000000 75000000 -26891000 -49609000 24900000 1000000 2200000 2100000 4100000 68500000 75000000 13300000 -600000 -100000 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value for derivatives designated as hedging instruments in the condensed consolidated balance sheets as of March 31, 2024 and December 31, 2023:</span></div><div style="margin-bottom:3pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:67.181%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.024%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.174%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value as of</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location on Balance Sheet </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives designated as hedges — Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Cash Flow Hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swap</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,188 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,675 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">680 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">537 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Net Investment Hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,084 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,938 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Cash Flow Hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swap</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,998 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,710 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Net Investment Hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,454 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,470 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total derivatives designated as hedges — Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62,404 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,330 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives designated as hedges — Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Cash Flow Hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swap</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">540 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">579 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,578 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,813 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">629 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Net Investment Hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,903 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Cash Flow Hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swap</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,586 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,582 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,396 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Net Investment Hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,427 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,114 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total derivatives designated as hedges — Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,342 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97,055 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company classifies derivative assets and liabilities as current based on the cash flows expected to be incurred within the following 12 months.</span></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> At March 31, 2024 and December 31, 2023, the total notional amounts related to the Company’s interest rate swaps were $1.5 billion.</span></div> 14188000 14675000 680000 537000 4084000 2938000 40998000 30710000 0 0 2454000 1470000 62404000 50330000 540000 579000 2578000 4813000 629000 0 0 2903000 1586000 1250000 10582000 36396000 33427000 51114000 49342000 97055000 1500000000 1500000000 <div style="margin-bottom:10pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents the effect of derivative instruments designated as cash flow hedges and net investment hedges on the accompanying condensed consolidated statement of operations during the three months ended March 31, 2024 and 2023:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.597%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance in AOCI<br/>Beginning of<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount of<br/>Gain (Loss)<br/>Recognized in<br/>AOCI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount of Gain (Loss)<br/>Reclassified from<br/>AOCI into<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance in AOCI<br/>End of Quarter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location in<br/>Statements of<br/>Operations</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Cash Flow Hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swap</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,556 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,723 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,219 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,060 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,763)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,532 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,473 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17,704)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income (expense), net </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency forward contract</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(629)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(110)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(519)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Net Investment Hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(45,498)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,920 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,202 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22,780)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17,705)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68,546 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,784 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,057 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Cash Flow Hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swap</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,712 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,534)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,678 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,271)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,191 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,504)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14,576)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income (expense), net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency forward contract</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Net Investment Hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,914)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">950 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,096 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,060)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,527 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,462)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,092 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,973 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div> 43556000 14723000 5219000 53060000 -15763000 29532000 31473000 -17704000 0 -629000 -110000 -519000 -45498000 24920000 2202000 -22780000 -17705000 68546000 38784000 12057000 56712000 -10534000 3500000 42678000 -20271000 2191000 -3504000 -14576000 -69000 -69000 -6914000 950000 2096000 -8060000 29527000 -7462000 2092000 19973000 7300000 5500000 1500000 1200000 The following table summarizes the gains (losses) on derivative instruments not designated as hedges on the condensed consolidated statements of income, which was included in other income:<div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:63.726%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency swaps</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">273 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">273 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 273000 55000 273000 55000 STOCK-BASED COMPENSATION <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024, the Company had stock options, restricted stock awards, performance stock awards, contract stock awards and restricted stock unit awards outstanding under the Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan (the “2003 Plan”).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options issued under the 2003 Plan become exercisable over specified periods, generally within four years from the date of grant for officers and employees, within one year from date of grant for directors which generally expire eight years from the grant date for employees, and from <span style="-sec-ix-hidden:f-704">six</span> to ten years for directors and certain executive officers, except in certain instances that result in accelerated vesting due to death, disability, retirement age or change in-control provisions within their grant agreements. The Company values stock option grants using the binomial distribution model. Restricted stock issued under the 2003 Plan vests over specified periods, generally three years after the date of grant. The vesting of performance stock issued under the 2003 Plan is subject to service and performance conditions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024, there were approximately $4.9 million of total unrecognized compensation costs related to unvested stock options. These costs are expected to be recognized over a weighted-average period of approximately three years. There were 243,964 stock options granted during the three months ended March 31, 2024. For the three months ended March 31, 2024, the weighted average grant date fair value for stock options granted was $15.68 per option.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Awards of Restricted Stock and Performance Stock</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance stock and restricted stock awards generally have requisite service periods of three years, except in certain instances that result in accelerated vesting due to death, disability, retirement age provision or change in-control provisions in their grant agreements. Performance stock units are subject to graded vesting conditions based on revenue goals of the Company. The Company expenses the fair value of restricted stock awards on a straight-line basis over the requisite service period. As of March 31, 2024, there was approximately $48.6 million of total unrecognized compensation costs related to these unvested awards. The Company expects to recognize these costs over a weighted-average period of approximately two years. The Company granted 532,379 restricted stock awards and 263,350 performance stock awards during the three months ended March 31, 2024. For the three months ended March 31, 2024, the weighted average grant date fair value for restricted stock awards and performance stock units granted was $36.46 and $36.22 per award, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also maintains an Employee Stock Purchase Plan (the “ESPP”), which provides eligible employees with the opportunity to acquire shares of common stock at periodic intervals by means of accumulated payroll deductions. The ESPP is a non-compensatory plan based on its terms.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CEO Separation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 27th, 2024, the Company announced that Mr. De Witte would retire from his position as President and Chief Executive Officer and director of the Company following the completion of a succession process and entered into a letter agreement with Mr. De Witte to modify his current employment agreement and put forth the form of a post-employment consulting agreement. The Company applied modification accounting to the outstanding equity-based awards granted to Mr. De Witte as of that date, which revalued and accelerated stock-based compensation associated with equity-based awards granted to him over his expected service period to the Company. Pursuant to this letter agreement, Mr. De Witte’s unvested equity-based awards will continue to vest during his continued service period to the Company and vested stock options were modified such that they will remain exercisable until the lesser of (a) the stated term of the stock options and (b) six months following his cessation of continued service to the Company. As a result of the modifications, the Company recorded incremental stock-based compensation expense of $0.2 million during the three months ended March 31, 2024. The Company will record a total of $1.9 million in accelerated stock-based compensation expenses for the twelve months ended 2024 that would not have been recognized if Mr. De Witte had not announced his retirement from Integra.</span></div> P4Y P1Y P8Y P10Y P3Y 4900000 P3Y 243964 15.68 P3Y 48600000 P2Y 532379 263350 36.46 36.22 P6M 200000 1900000 RETIREMENT PLANS<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains defined benefit pension plans that cover certain employees in France, Japan, Germany and Switzerland.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net periodic benefit costs for the Company’s defined benefit pension plans for the three months ended March 31, 2024 were $0.4 million. The components of the net periodic benefit costs other than the service cost component of $0.8 million for the three months ended March 31, 2024 are included in other income, net in the consolidated statements of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net periodic benefit costs for the Company’s defined benefit pension plans for the three months ended March 31, 2023 were $0.3 million. The components of the net periodic benefit costs other than the service cost component of $0.5 million for the three months ended March 31, 2023 are included in other income, net in the consolidated statements of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair values of plan assets were $40.4 million and $45.7 million as of March 31, 2024 and December 31, 2023, respectively. The net plan assets of the pension plans are invested in common trusts as of March 31, 2024 and December 31, 2023. Common trusts are classified as Level 2 in the fair value hierarchy. The fair value of common trusts is valued at the net asset value based on the fair values of the underlying investments of the trusts as determined by the sponsor of the trusts. The investment strategy of the Company’s defined benefit plans is both to meet the liabilities of the plans as they fall due and to maximize the return on invested assets within an appropriate risk profile.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Compensation Plan</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a Deferred Compensation Plan in which certain employees of the Company may defer the payment and taxation of up to 75% of their base salary and up to 100% of bonus amounts and other eligible cash compensation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This deferred compensation is invested in funds offered under this plan and is valued based on Level 1 measurements in the fair value hierarchy. Assets of the Company’s deferred compensation plan are included in other current assets and recorded at fair value based on their quoted market prices. The fair value of these assets were $5.7 million and $6.1 million as of March 31, 2024 and December 31, 2023, respectively. Offsetting liabilities relating to the deferred compensation plan are included in other liabilities.</span></div> 400000 800000 300000 500000 40400000 45700000 0.75 1 5700000 6100000 LEASES AND RELATED PARTY LEASES<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases administrative, manufacturing, research and distribution facilities, and vehicles through operating lease agreements. The Company has no finance leases as of March 31, 2024. Many of the Company’s leases include both lease (e.g., fixed payments including rent) and non-lease components (e.g., common-area or other maintenance costs). For vehicles, the Company has elected the practical expedient to group lease and non-lease components.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most facility leases include one or more options to renew. The exercise of lease renewal options is typically at the Company’s sole discretion, therefore, the majority of renewals to extend the lease terms are not included in the Right of Use (“ROU”) assets and lease liabilities as they are not reasonably certain of exercise. The Company regularly evaluates renewal options and when they are reasonably certain of exercise, the renewal period is included in the lease term.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As most of the Company’s leases do not provide an implicit rate, the Company uses a collateralized incremental borrowing rate based on the information available at the lease commencement date in determining the present value of the lease payments.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating lease expense for the three months ended March 31, 2024 and March 31, 2023 was $6.3 million and $6.0 million, respectively, which includes $0.3 million, in related party operating lease expense.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to operating leases were as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.718%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:18.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands, except lease term and discount rate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ROU assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">151,834 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">156,184 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current lease liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,303 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,284 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current lease liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170,082 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166,849 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186,385 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">182,133 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average remaining lease term (in years):</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leased facilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.5 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leased vehicles</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.1 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.9 years</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average discount rate:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leased facilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leased vehicles</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases for the three months ended March 31, 2024 and 2023 were as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,734 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,319 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">746 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,721 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under operating leases at March 31, 2024 were as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Related Parties</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Third Parties</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remainder of 2024</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,884 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,106 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">296 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,859 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,155 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">296 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,210 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,506 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">296 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,892 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,188 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">296 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,603 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,899 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">246 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,771 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,017 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163,479 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163,479 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,652 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">275,698 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">277,350 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90,965 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186,385 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Current lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,303 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170,082 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no future minimum lease payments under finance leases at March 31, 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Related Party Leases</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases its manufacturing facility in Plainsboro, New Jersey, from a general partnership that is 50% owned by a principal stockholder of the Company. The term of the current lease agreement is through October 31, 2029 at an annual rate of approximately $0.3 million. The current lease agreement also provides (i) a 5-year renewal option for the Company to extend the lease from November 1, 2029 through October 31, 2034 at the fair market rental rate of the premises, and (ii) another 5-year renewal option to extend the lease from November 1, 2034 through October 31, 2039 at the fair market rental rate of the premises.</span></div> 1 6300000 6000000 300000 300000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to operating leases were as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.718%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:18.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands, except lease term and discount rate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ROU assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">151,834 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">156,184 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current lease liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,303 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,284 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current lease liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170,082 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166,849 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186,385 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">182,133 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average remaining lease term (in years):</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leased facilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.5 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leased vehicles</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.1 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.9 years</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average discount rate:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leased facilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leased vehicles</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 151834000 156184000 16303000 15284000 170082000 166849000 186385000 182133000 P16Y6M P16Y3M18D P2Y1M6D P1Y10M24D 0.057 0.059 0.027 0.027 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases for the three months ended March 31, 2024 and 2023 were as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,734 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,319 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">746 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,721 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 5734000 4319000 746000 1721000 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under operating leases at March 31, 2024 were as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Related Parties</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Third Parties</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remainder of 2024</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,884 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,106 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">296 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,859 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,155 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">296 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,210 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,506 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">296 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,892 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,188 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">296 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,603 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,899 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">246 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,771 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,017 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163,479 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163,479 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,652 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">275,698 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">277,350 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90,965 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186,385 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Current lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,303 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170,082 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 222000 17884000 18106000 296000 22859000 23155000 296000 20210000 20506000 296000 18892000 19188000 296000 16603000 16899000 246000 15771000 16017000 0 163479000 163479000 1652000 275698000 277350000 90965000 186385000 16303000 170082000 0.50 300000 P5Y November 1, 2029 through October 31, 2034 P5Y November 1, 2034 through October 31, 2039 TREASURY STOCK<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024 and December 31, 2023, there were 12.7 million and 12.8 million shares of treasury stock outstanding with a cost of $646.4 million and $647.3 million, at a weighted average cost per share of $50.76 and $50.76, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 15, 2023, the Company entered into a $125 million accelerated share repurchase (“August 2023 ASR”) and received 2.3 million shares of common stock at inception of the August 2023 ASR, which represented approximately 80% of the expected total shares under the August 2023 ASR. On October 18, 2023 the early exercise provision was exercised by the August 2023 ASR counterparty. The Company received an additional 0.9 million shares determined using the volume-weighted average price of the Company’s common stock during the term of the August 2023 ASR.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 26, 2023, the Company entered into a $150 million accelerated share repurchase (“January 2023 ASR”) and received 2.1 million shares of common stock at inception of the January 2023 ASR, which represented approximately 80% of the expected total shares under the January 2023 ASR. The settlement of the January 2023 ASR agreement was completed in the second quarter of 2023, where the Company received 0.6 million shares, determined using the volume-weighted average price of the Company’s common stock during the term of the January 2023 ASR. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 16, 2022, the Inflation Reduction Act of 2022 (the “Inflation Act”) was signed into law. The Inflation Act implements a new excise tax of 1% on the net share repurchases made by the Company effective for share repurchases performed January 1, 2023, or after.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 18, 2023, the Board of Directors authorized a new $225 million share repurchase program, replacing the existing $225 million program authorized in April 2022, under</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$75 million remained</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> authorized at the time of its replacement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. A</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2024,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$100 million remained</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> authorized</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The program authorized in July 2023 allows the Company to repurchase its shares opportunistically from time to time. The Company may utilize various methods to effect any repurchases, including open market transactions, privately negotiated transactions, transactions structured through investment banking institutions, including accelerated share repurchases, or a combination of the foregoing, some of which may be effected through Rule 10b5-1 plans. The price and timing of any future purchases under the share repurchase program will depend on factors such as levels of cash generation from operations, the volume of stock option exercises by employees, cash requirements for acquisitions, dividends, economic and market conditions and stock price, and such repurchases may be discontinued at any time.</span></div> 12700000 12800000 646400000 647300000 50.76 50.76 125000000 2300000 0.80 900000 150000000 2100000 0.80 600000 225000000 225000000 75000000 100000000 INCOME TAXES<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of the Company’s effective tax rate:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.590%"><tr><td style="width:1.0%"></td><td style="width:56.042%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:19.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.640%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reported tax rate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s effective income tax rates for the three months ended March 31, 2024 and 2023 were 37.3% and 18.6%, respectively. For the three months ended March 31, 2024, the higher tax rate is attributable to a $1.5 million shortfall from stock based compensation, offset by a tax benefit for the intangible asset impairment, as compared to previous year. The Company does not have tax basis in the impaired intangible asset and has treated the tax impact as a discrete event in this quarter.</span></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of the Company’s effective tax rate:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.590%"><tr><td style="width:1.0%"></td><td style="width:56.042%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:19.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.640%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reported tax rate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 0.373 0.186 0.373 0.186 1500000 NET INCOME PER SHARE<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net income per share was as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.169%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.474%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> Dollars in thousands, except per share amounts</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Basic net (loss) income per share:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,281)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,226 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,735 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,871 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic net (loss) income per common share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.04)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Diluted net (loss) income per share:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,281)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,226 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding — Basic</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77,735 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81,871 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options and restricted stock</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">452 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares for diluted earnings per share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77,735 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82,323 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted net (loss) income per common share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.04)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is computed by dividing net income by the weighted-average common shares outstanding during the period. Diluted earnings per share is computed based on the weighted-average common shares outstanding plus the effect of dilutive potential common shares outstanding during the period calculated using the treasury stock method. Dilutive potential common shares include employee equity share options, non-vested shares, and similar equity instruments granted by the Company. Potential common share equivalents have been excluded where their inclusion would be anti-dilutive. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock of approximately 1.3 million and 0.3 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares at March 31, 2024, and 2023, res</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pectively, were not included in the computation of diluted net (loss) income per share because their effect would have been anti-dilutive.</span></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net income per share was as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.169%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.474%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> Dollars in thousands, except per share amounts</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Basic net (loss) income per share:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,281)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,226 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,735 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,871 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic net (loss) income per common share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.04)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Diluted net (loss) income per share:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,281)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,226 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding — Basic</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77,735 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81,871 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options and restricted stock</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">452 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares for diluted earnings per share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77,735 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82,323 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted net (loss) income per common share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.04)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> -3281000 24226000 77735000 81871000 -0.04 0.30 -3281000 24226000 77735000 81871000 0 452000 77735000 82323000 -0.04 0.29 1300000 300000 ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income for the three months ended March 31, 2024 and 2023:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,281)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,226 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">730 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,192 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in unrealized loss/(gain) on derivatives, net of tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,735 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,493)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pension liability adjustment, net of tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive income, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,179 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,028 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in accumulated other comprehensive income by component between December 31, 2023 and March 31, 2024 are presented in the table below, net of tax:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.747%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.287%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains and Losses on Derivatives</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit Pension Items</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Items</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at January 1, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,489 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,712 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(39,307)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,106)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive gain (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,939 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,425 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,359 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Amounts reclassified from accumulated other comprehensive income, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,204 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,695 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,899 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net current-period other comprehensive gain (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,735 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">730 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,460 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at March 31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,224 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,707 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38,577)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,646)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2024, the Company reclassified a gain of $27.2 million and $5.7 million from accumulated other comprehensive income to other income, net and interest income, respectively.</span></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income for the three months ended March 31, 2024 and 2023:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,281)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,226 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">730 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,192 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in unrealized loss/(gain) on derivatives, net of tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,735 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,493)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pension liability adjustment, net of tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive income, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,179 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,028 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> -3281000 24226000 730000 3192000 3735000 -6493000 5000 -103000 1179000 21028000 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in accumulated other comprehensive income by component between December 31, 2023 and March 31, 2024 are presented in the table below, net of tax:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.747%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.287%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains and Losses on Derivatives</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit Pension Items</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Items</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at January 1, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,489 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,712 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(39,307)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,106)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive gain (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,939 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,425 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,359 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Amounts reclassified from accumulated other comprehensive income, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,204 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,695 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,899 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net current-period other comprehensive gain (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,735 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">730 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,460 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at March 31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,224 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,707 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38,577)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,646)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 21489000 2712000 -39307000 -15106000 34939000 -5000 2425000 37359000 31204000 0 1695000 32899000 3735000 -5000 730000 4460000 25224000 2707000 -38577000 -10646000 27200000 5700000 SEGMENT AND GEOGRAPHIC INFORMATION<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company internally manages two global reportable segments and reports the results of its businesses to its chief operating decision maker. The two reportable segments and their activities are described below.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Codman Specialty Surgical segment includes (i) the Neurosurgery business, which sells a full line of products for neurosurgery and neuro critical care such as tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment and (ii) the Instruments business, which sells more than 40,000 instrument patterns and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">The Tissue Technologies segment includes such offerings as skin and wound repair, plastics &amp; surgical reconstruction products, bone grafts, and nerve and tendon repair products.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Corporate and other category includes (i) various executive, finance, human resource, information systems and legal functions, (ii) brand management, and (iii) share-based compensation costs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operating results of the various reportable segments as presented are not comparable to one another because (i) certain operating segments are more dependent than others on corporate functions for unallocated general and administrative and/or operational manufacturing functions, and (ii) the Company does not allocate certain manufacturing costs and general and administrative costs to the operating segment results. Net sales and profit by each reportable segment for the three months ended March 31, 2024 and 2023 are as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.274%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.130%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Segment Net Sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Codman Specialty Surgical</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">256,434 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">248,136 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tissue Technologies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112,438 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">132,710 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">368,872 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">380,846 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Segment Profit </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Codman Specialty Surgical</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103,492 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110,933 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tissue Technologies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,666</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,281 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Segment profit</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">134,158 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163,214 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,107)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,108)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate and other</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(120,087)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(123,724)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,964 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,382 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not allocate any assets to the reportable segments. No asset information is reported to the chief operating decision maker and disclosed in the financial information for each segment. The Company attributes revenues to geographic areas based on the location of the customer. Total revenue by major geographic area consisted of the following:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:64.026%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.742%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">256,229 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">271,002 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,596 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,064 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asia Pacific</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,545 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,473 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rest of World</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,502 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,307 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">368,872 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">380,846 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2 2 40000 Net sales and profit by each reportable segment for the three months ended March 31, 2024 and 2023 are as follows:<div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.274%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.130%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Segment Net Sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Codman Specialty Surgical</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">256,434 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">248,136 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tissue Technologies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112,438 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">132,710 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">368,872 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">380,846 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Segment Profit </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Codman Specialty Surgical</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103,492 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110,933 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tissue Technologies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,666</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,281 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Segment profit</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">134,158 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163,214 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,107)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,108)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate and other</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(120,087)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(123,724)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,964 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,382 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>Total revenue by major geographic area consisted of the following:<div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:64.026%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.742%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">256,229 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">271,002 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,596 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,064 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asia Pacific</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,545 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,473 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rest of World</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,502 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,307 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">368,872 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">380,846 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 256434000 248136000 112438000 132710000 368872000 380846000 103492000 110933000 30666000 52281000 134158000 163214000 10107000 3108000 -120087000 -123724000 3964000 36382000 256229000 271002000 41596000 41064000 49545000 50473000 21502000 18307000 368872000 380846000 COMMITMENTS AND CONTINGENCIES<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration for certain technology, manufacturing, distribution, and selling rights and licenses granted to the Company, the Company has agreed to pay royalties on sales of certain products that it sells. The royalty payments that the Company made under these agreements were not significant for any of the periods presented.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of its business, the Company is involved in, from time to time, various legal actions, including any matters described below, involving product liability, employment, intellectual property and commercial disputes, shareholder related matters, environmental proceedings, tax disputes, and governmental proceedings and investigations, some of which have been settled by the Company. In the opinion of management, such matters are either adequately covered by insurance or otherwise indemnified, or are not expected, individually or in the aggregate, to result in a material, adverse effect on the Company’s financial condition. However, it is possible that the Company’s results of operations, financial position and cash flows in a particular period could be materially affected by these contingencies.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accrues for loss contingencies when it is deemed probable that a loss has been incurred and that loss is estimable. The amounts accrued are based on the full amount of the estimated loss before considering insurance proceeds and do not include an estimate for legal fees expected to be incurred in connection with the loss contingency. The Company consistently accrues legal fees expected to be incurred in connection with loss contingencies as those fees are incurred by outside counsel as a period cost.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 21, 2023, Fortis Advisors, LLC (representative of the security holders of ACell, Inc. (“ACell”)) filed for arbitration against Integra Life Sciences claiming breach of contract related to the earnout consideration from the 2021 acquisition of ACell. Refer below for additional information on the ACell contingent considerations. The Company believes that it has strong defenses to the allegations in the arbitration and intends to defend the matter vigorously.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 12, 2023, a securities class action complaint, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pembroke Pines Firefighters &amp; Police Officers Pension Fund v. Integra LifeSciences Holdings Corporation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 23-cv-20321 (D.N.J.), was filed by a purported stockholder of the Company in the United States District Court for the District of New Jersey (the “Pembroke Litigation”) against the Company and certain of the Company’s current and former executive officers. The Pembroke Litigation, filed on behalf of a putative class of stockholders who purchased or acquired the Company’s common stock between March 11, 2019 and May 22, 2023, inclusive, alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder, on the basis of purportedly materially false and misleading statements and omissions relating to certain quality systems issues identified by the U.S. Food and Drug Administration at the Company’s Boston, Massachusetts manufacturing facility, the Company’s efforts to remediate those issues, and the Company’s forecasts for certain products in its Tissue Technologies segment. The complaint seeks, among other things, compensatory damages, attorneys’ fees, expert fees, and other costs. The Company believes that it has strong defenses to the allegations in the Pembroke Litigation, and intends to defend the matter vigorously.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the fair value of contingent consideration during the three month period ended March 31, 2024 and March 31, 2023 to reflect the change in estimate, additions, payments, transfers and the time value of money during the period.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the opening balances to the closing balances of these Level 3 measurements for the three months ended March 31, 2024 and March 31, 2023 is as follows (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:32.283%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.947%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.096%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.807%"></td><td style="width:0.1%"></td></tr><tr style="height:35pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contingent Consideration Liability Related to Acquisition of:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:39pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Arkis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location in Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derma Sciences</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ACell</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Surgical Innovations Associates (SIA), Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location in Financial Statements</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of January 1, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,755 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,557 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68,700 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration liabilities </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,672 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,596 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69,200 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-Term </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,562 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-Term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,110 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,596 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,672 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,596 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69,200 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:30.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.831%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:7.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.571%"></td><td style="width:0.1%"></td></tr><tr style="height:29pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contingent Consideration Liability Related to Acquisition of:</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:36pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Arkis </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location in Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derma Sciences</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ACell</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Surgical Innovations Associates (SIA), Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location in Financial Statements</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of January 1, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,895 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">230 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,700 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57,607 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,299 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,200)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of March 31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,194 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">230 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,207 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-Term </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,388 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-Term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,806 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">230 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,707 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,194 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">230 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,207 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Arkis BioSciences Inc.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the acquisition of Arkis BioSciences Inc. (“Arkis”), the Company is required to pay the former shareholders of Arkis up to $25.5 million based on the timing of certain development milestones of $10.0 million and commercial sales milestones of $15.5 million, respectively. The Company used a probability weighted income approach to calculate the fair value of the contingent consideration that considered the possible outcomes of scenarios related to each specified milestone. The Company estimated the fair value of the contingent consideration to be $13.1 million at the acquisition date. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Derma Sciences, Inc.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assumed contingent consideration incurred by Derma Sciences, Inc. (“Derma Sciences”) related to its acquisitions of BioD, LLC and the intellectual property related to Medihoney® products. The Company accounted for the contingent liabilities by recording the fair value on the date of the acquisition based on a probability weighted income approach. The Company has already paid $33.3 million related to the aforementioned contingent liabilities. One contingent milestone remains which relates to net sales of Medihoney®™ products exceeding certain amounts defined in the agreement between the Company and Derma Sciences. The potential maximum undiscounted payment amounts to $3.0 million. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">ACell, Inc.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the acquisition of ACell, the Company is required to make payments to the former shareholders of ACell up to $100 million in total for years 2022, 2023, and 2025 based on the achievement by the Company of certain revenue-based performance milestones. The 2022 and 2023 milestones were not achieved, leaving only one contingent milestone remaining. The Company used iterations of the Monte Carlo simulation to calculate the fair value of the contingent consideration that considered the possible outcomes of scenarios related to each specific milestone. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimated the fair value of the contingent consideration to be </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$23.9 million at the acquisition date.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Surgical Innovations Associates, Inc.</span></div>As part of the acquisition of Surgical Innovations Associates, Inc. (“SIA”), the Company is required to pay to the former shareholders of SIA up to $90.0 million for two separate payments, which are dependent on 1) achieving certain revenue-based performance milestones in 2023, 2024, and 2025 (up to $50.0 million in additional payments), as well as 2) the approval by the FDA of the PMA for DuraSorb for certain uses by certain timing targets (up to $40.0 million in additional payments). The Company used iterations of the Monte Carlo simulation to calculate the fair value of the contingent consideration for the revenue-based milestone that considered the possible outcomes of scenarios related to each specific milestone for the revenue based performance milestone. The Company used probabilities of achieving the conditions to calculate the fair value of the contingent consideration for the PMA approval milestone. The Company estimated the fair value of the contingent consideration for the revenue based milestone to be $32.6 million at the acquisition date and $25.0 million for the PMA approval milestone at the acquisition date. <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the opening balances to the closing balances of these Level 3 measurements for the three months ended March 31, 2024 and March 31, 2023 is as follows (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:32.283%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.947%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.096%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.807%"></td><td style="width:0.1%"></td></tr><tr style="height:35pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contingent Consideration Liability Related to Acquisition of:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:39pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Arkis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location in Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derma Sciences</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ACell</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Surgical Innovations Associates (SIA), Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location in Financial Statements</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of January 1, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,755 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,557 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68,700 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration liabilities </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,672 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,596 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69,200 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-Term </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,562 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-Term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,110 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,596 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,672 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,596 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69,200 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:30.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.831%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:7.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.571%"></td><td style="width:0.1%"></td></tr><tr style="height:29pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contingent Consideration Liability Related to Acquisition of:</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:36pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Arkis </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location in Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derma Sciences</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ACell</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Surgical Innovations Associates (SIA), Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location in Financial Statements</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of January 1, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,895 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">230 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,700 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57,607 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,299 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,200)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of March 31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,194 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">230 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,207 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-Term </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,388 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-Term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,806 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">230 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,707 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,194 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">230 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,207 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div> 15755000 2557000 300000 68700000 -83000 39000 0 500000 15672000 2596000 300000 69200000 7562000 0 0 29300000 8110000 2596000 300000 39900000 15672000 2596000 300000 69200000 12895000 230000 3700000 57607000 3299000 0 -2200000 3600000 16194000 230000 1500000 61207000 4388000 0 0 12500000 11806000 230000 1500000 48707000 16194000 230000 1500000 61207000 25500000 10000000.0 15500000 13100000 33300000 1 3000000 100000000 23900000 90000000 2 50000000 40000000 32600000 25000000 false false false false

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